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The effects of neprilysin inhibition in people with advanced chronic kidney disease 
(CKD) are unclear. UK Heart and Renal Protection (HARP)-III aimed to examine the 
effects of sacubitril/valsartan compared with irbesartan, on kidney function, other renal 
and cardiovascular outcomes and safety in CKD. 
 
METHODS:  
UK HARP-III was a randomized trial, including 414 people with CKD with an estimated 
glomerular filtration rate (GFR) of 20 to 60 mL/min/1.73m2. Participants were allocated 
to sacubitril/valsartan or irbesartan. The primary outcome was measured GFR at 12 
months. All analyses were intention to treat.  
 
RESULTS:  
207 participants were allocated sacubitril/valsartan and 207 irbesartan. At 12 months, 
there was no difference in measured GFR among those allocated sacubitril/valsartan 
compared with irbesartan (mean difference -0.1 [SE 0.7] mL/min/1.73m2). The effect of 
sacubitril/valsartan did not differ in a range of prespecified subgroups. There was no 
significant difference in urinary albumin:creatinine ratio (study average difference -9%; 
95% CI -18 to 1) or estimated GFR (mean difference 0.1 mL/min/1.73m2; 95% CI -0.5 
to 0.7; P=0.66) over 12 months between treatments. Sacubitril/valsartan, compared 
with irbesartan, significantly reduced study average systolic and diastolic blood 
pressure by 5.4 (95% CI 3.4-7.4) and 2.1 (95% CI 1.0-3.3) mmHg respectively. 
Concentrations of cardiac biomarkers N-terminal of prohormone brain natriuretic 
peptide and troponin I were by reduced by 18% (95% CI 11-25) and 16% (95% CI 8-
23) respectively. Incidence of serious adverse events (29.5% versus 28.5%; RR 1.07; 
95% CI 0.75-1.53), non-serious adverse reactions (36.7% versus 28.0%; rate ratio 
1.35; 95% CI 0.96-1.90) and renal adverse events were not significantly different 
between randomized treatments. 
 
CONCLUSIONS:  
Over 12 months allocation to sacubitril/valsartan, compared with irbesartan, had no 
significant effects on kidney function or albuminuria, but did significantly reduce blood 
pressure and cardiac biomarkers. It was not associated with any major adverse effects 
in people with advanced CKD.  
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 Chronic kidney disease 
 
Chronic kidney disease (CKD) is defined  by the presence  of structural or functional 
kidney damage present for at least three months.1,2 CKD may present as a pathological 
abnormality or with markers of kidney damage.1 Diagnosis of CKD is based on 
evidence of one or more of the following: estimated glomerular filtration rate (GFR) less 
than 60 mL/min/1.73m2; albuminuria (urine albumin:creatinine ratio [uACR] of 30 mg/g 
[3mg/mmol] or greater); abnormalities in urinary sediment, histology, or imaging 
suggestive of kidney disease or damage; electrolyte or other renal tubular disorders; or 
a history of kidney transplantation.2,3 CKD is classified into five stages according to 
estimated GFR (eGFR). Albuminuria is included in classification systems to enable risk 
stratification of patients in addition to diagnosis of CKD (Table 1).  
 
   Albuminuria category 
   A1 A2 A3 












G1 Kidney damage 
with normal or 
increased eGFR 
≥90 51.2 3.4 0.3 
G2 Kidney damage 
with mild 
decreased eGFR 








30-44 0.6 0.3 0.1 
G4 Severely 
decreased eGFR 15-29 0 0 0.2 
G5 Kidney failure <15 
or on dialysis or 
transplanted 
0 0 0.1 
 
Table 1: Prevalence estimates of chronic kidney disease in the United States by stage 
†eGFR = estimated glomerular filtration rate 





CKD affects between 2% and 17% of the population (depending on the country studied) 
and rates increase substantially with age.5,6 Prevalence data from the United States 
suggest about 5% have moderate CKD (eGFR 30 to 59 ml/min/1.73m2) and about 0.3% 
have more advanced CKD (stage 4 or 5; Table 1).4,6  
CKD is associated with two major hazards: increased risk of progression to end-stage 
kidney disease (ESKD) requiring treatment with renal replacement therapy (dialysis or 
transplantation) and premature morbidity and mortality from cardiovascular disease 
(CVD).7-9 Progressive decline in renal function is not uncommon and each year the 
number of prevalent renal replacement therapy patients in the UK increases.10 There 
are many aetiologies contributing to ESKD including glomerulonephritis, diabetes, 
hypertension and polycystic kidney disease with no cause identified in about 16% of 
cases.10 As renal function declines, associated complications that may develop include 
anaemia, bone and mineral disorders, acid-base disturbances, hypertension and 
dyslipidaemia.2 CKD has a substantial impact on a patient’s quality of life and 
healthcare expenditure, it is therefore a major public health concern.11-13 
 
 Progression of chronic kidney disease 
 
The number of functioning nephrons declines with increasing age. Individuals with 
reduced nephron mass at birth may reach a lower critical mass of nephrons earlier than 
those with larger numbers of functioning nephrons, predisposing to CKD.14,15 Reduced 
nephron mass impedes functional reserve for adaptation following renal insults and/or 
injury that may further decrease functioning nephron mass.14-16  
Following substantial nephron loss, glomerular hyperfiltration and hypertrophy are 
maladaptive compensatory responses that occur in remaining viable nephrons.16-18 In 
animal models of CKD, glomerular hyperfiltration activates the renin-angiotensin 
system (RAS; Figure 1) and alters glomerular haemodynamics.19,20 RAS activation 
raises circulating levels of angiotensin II (ATII) which stimulates aldosterone release, 
inactivates bradykinin, increases release of noradrenaline and decreases nitric oxide 
(NO) activity, all of which contribute to potent systemic and renal vasoconstriction.20-22  
Afferent arteriolar resistance decreases to a greater extent than efferent arteriolar 
resistance and so, glomerular capillary hydrostatic pressure rises.16,23 Remaining 
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nephrons are exposed to increased renal blood flow to maintain an adequate 




Figure 1: Renin-angiotensin system 
 
Over time these changes and the sustained activation of RAS has detrimental effects 
that contribute to the development of intra-glomerular and systemic hypertension as 
well as proteinuria due to increased filtration of plasma proteins.17,19,23 Systemic 
hypertension can be a cause, or consequence of CKD and its prevalence increases 
with falling GFR.24 In healthy individuals, renal blood pressure is controlled by 
autoregulation, but if renal auto-regulation is impaired (e.g. due to reduced nephron 
mass) sustained transmission of raised systemic blood pressure to the kidney 
increases vascular resistance.25 Activation of other vasoactive and inflammatory 
molecules such as endothelin and cyclooxgenase have also been implicated in the 
development of glomerular hypertension.17,26 
 
 Proteinuria and chronic kidney disease 
 
Proteinuria is an important risk factor associated with progression of CKD. Animal 
studies suggest filtration of proteins (such as albumin) through the glomerulus may be 
toxic to the kidneys, stimulating the production of inflammatory and vasoactive peptides 
(including endothelin and ATII), ultimately leading to renal scarring and 
Angiotensinogen 
Angiotensin I 
Angiotensin type 1  
receptor 
Angiotensin II 
Angiotensin type 2 
receptor 






dysfunction.17,27,28 Therefore, the larger the quantity of filtered proteins, the greater the 
extent and severity of the renal injury that arises, hastening the progression of CKD.27,28 
Observational studies and meta-analyses have shown both lower eGFR and increasing 
albuminuria are independently associated with adverse renal outcomes in the general 
population and in high-risk cohorts.29-31 An eGFR of less than 60 ml/min/1.73m2 and 
rising levels of albuminuria have been associated with increased risk of acute kidney 
injury, progressive CKD and ESKD.4,29 However, these findings have been based on 
results from either animal experiments or observational data from humans. 
Increasing albuminuria, independent of eGFR, has been associated with graded 
increases in risk of ESKD without an apparent threshold. Individuals with an eGFR 
above 60 mL/min/1.73m2 and microalbuminuria (uACR greater than 30 mg/g), have 
substantially increased risk of ESKD, compared to those without albuminuria.4 Similar 
risks have been shown in people with diabetes32 or hypertension,24 irrespective of their 
ethnicity.33 
In a meta-analysis of 693,816 people with CKD (including 557,583 with diabetes), a 
30% reduction in albuminuria over 2 years was associated with a 17% (hazard ratio 
[HR] 0.83; 95% confidence interval [CI] 0.74-0.94) reduction in risk of developing 
ESKD.34 An increase in uACR of 43% was associated with a 14% (HR 1.14; 95% CI 
1.06-1.22) increase in risk of cardiovascular mortality.34 
The central role of RAS in the development of intra-glomerular hypertension, systemic 
blood pressure, proteinuria and progression of CKD led to the development of RAS 
inhibitors (angiotensin-converting enzyme inhibitors [ACEi] and angiotensin receptor 









Figure 2: Renin-angiotensin system and sites of therapeutic blockade 
ACE = angiotensin-converting enzyme; ARB = angiotensin receptor blocker; DRI = direct renin inhibitor; 
MRA = mineralocorticoid receptor antagonist 
 
 
 Current treatments for chronic kidney disease 
 
 Renin-angiotensin system blockade  
In animal models of renal disease, RAS inhibitors were shown to reduce systemic and 
intraglomerular pressure, decrease glomerulosclerosis and reduce proteinuria.35-37 
Prevention of glomerular hypertension by RAS blockade was believed to be a key 
mechanism underlying the renoprotective effect of RAS inhibitors (ACEi’s and ARBs).38 
Several clinical trials have consistently demonstrated that ACEi and ARBs reduce risk 
of adverse renal outcomes in patients with diabetic and non-diabetic proteinuric CKD 
(Appendix 1: Summary of trials of targeting blood pressure and albuminuria 
reductions).39-42 The Collaborative Study Group (CSG)-Captopril trial randomized 
people with insulin-dependent diabetes mellitus and proteinuric (500 mg/d or greater) 
CKD (serum creatinine [SCr] 221 µmol/L or lower) to the ACEi captopril (n=207) or 
placebo (n=202).39 Allocation to captopril, compared with placebo, reduced the risk of 
doubling in SCr (the primary outcome) by 43% (25/207 [12%] versus 43/202 [21%] 
respectively; risk reduction [RR] 43% [95% CI 6-65]; P=0.007) and risk of dialysis, 
transplantation or death by 46% (23/207 [11%] versus 42/202 [21%] respectively; RR 
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participants treated with captopril still progressed to ESKD requiring dialysis or 
transplantation over a median duration of 1.7 years.39  
In the Irbesartan in Diabetic Nephropathy Trial (IDNT), irbesartan (an ARB) reduced 
the risk of the primary composite endpoint of doubling of baseline serum creatinine, 
ESKD or death by 20% (HR 0.80; 95% CI 0.66-0.97; P 0.03) compared with placebo 
and, by 23% (HR 0.77; 95% CI 0.63-0.93; P=0.006) compared with amlodipine among 
people with diabetic nephropathy.41 In spite of the reduction in risk of ESKD, 14.2% 
(87/579) of IDNT participants treated with irbesartan still progressed to ESKD during 
2.6 years of follow-up.41 Other trials have shown similar findings.42  
To address this residual risk, it was hypothesised combining ACE inhibitors and ARBs 
for maximal RAS inhibition (“dual blockade”) could be more effective than either agent 
alone at reducing albuminuria,43 risk of progression of CKD to ESKD and cardiovascular 
events.44-46 Randomized trials of dual blockade demonstrated greater reductions in 
albuminuria than either ACEi or ARB alone, but dual blockade did not confer any 
additional renal or cardiovascular protection.43-46  
In the Veterans Affairs Nephropathy in Diabetes (VA NEPHRON-D) trial, 1448 people 
with proteinuric diabetic kidney disease were randomized to receive losartan combined 
with lisinopril or losartan with placebo.46 There was no effect on risk of the primary renal 
outcome (change in eGFR, ESKD, or death) with dual blockade compared with isolated 
RAS blockade (132/724 [18.2%] versus 152/724 [21%] respectively; HR 0.88 [0.70-
1.12]; P=0.30), or on risk of the composite tertiary cardiovascular outcome (risk of 
myocardial infarction, heart failure or stroke; 134/724 [18.5%] versus 136/724 [18.8%] 
respectively; HR 0.97 [95% CI 0.76-1.23]; P=0.79).46  
Furthermore, in VA NEPRON-D dual blockade, compared with isolated RAS blockade, 
was associated with increased risk of adverse events including hyperkalaemia (72/724 
[9.9%] versus 32/724 [4.4%] respectively; HR 2.8 [95% CI 1.8-4.3]; P<0.001) and acute 
kidney injury ([AKI] 130/724 [18.0%] versus 80/724 [11.0%] respectively; HR 1.7 [95% 
CI 1.3-2.2]; P<0.001).46 In the Ongoing Telmisartan Alone and in combination with 
Ramipril Global Endpoint Trial (ONTARGET) comparing ramipril, telmisartan or both, 
requirement for acute dialysis was 2-fold higher in those randomized to combination 
therapy compared with ramipril-alone (28/8502 [0.33%] versus 13/8576 [0.15%]; HR 
2.19 [95% CI 1.13-4.22]; P=0.020).44-46 Similar findings were seen when the direct renin 
inhibitor (DRI; Figure 2), aliskiren, was combined with RAS inhibition as an alternative 
approach to dual RAS blockade.47  
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 Blood pressure lowering 
Hypertension is associated with risk of progression to ESKD and cardiovascular events 
in CKD.48-51 CKD is both a cause of and, can be caused by hypertension. Two previous 
randomized trials in CKD populations did not show ‘intensive’ versus ‘standard’ blood 
pressure lowering targets reduced the risk of ESKD but did suggest a benefit in 
reducing the decline in kidney function in those with baseline proteinuria.52,53  
The African American Study of Kidney Disease and Hypertension (AASK) trial 
randomized hypertensive CKD patients (GFR 20 to 65 mL/min/1.73m2) to either an 
‘intensive’ mean arterial pressure target of 92 mmHg or lower (achieved mean [128/78 
mmHg) or, to a ‘standard’ mean arterial pressure target of 102 to 107 mmHg (achieved 
mean 141/85 mmHg).54 From baseline to four years, there was no difference in the 
mean (SE) decline in GFR between the intensive vs usual treatment arms (2.21 [0.17] 
mL/min/1.73m2/year versus 1.95 [0.17] mL/min/1.73m2/year; P=0.24).54 The risk of the 
secondary renal composite outcome of doubling of serum creatinine, ESKD, or death, 
did not differ between the intensive, compared with standard, blood pressure targets 
during the trial phase (159/540 versus 169/554 respectively; HR 0.88 [95% CI 0.71-
1.09]; P=0.24) or during the longer-term follow-up period ranging between 8.8 to 12.2 
years (123/377 versus 116/382 respectively; HR 0.95 [95% CI 0.74-1.23]; P=0.70).53 
The Modification of Diet in Renal Disease (MDRD) trial randomized 840 patients with 
CKD (study 1: 585 patients with a GFR of 25-55 mL/min/1.73m2 and study 2: 255 
patients with a GFR of 13-24 mL/min/1.73m2) to intensive or standard mean arterial 
blood pressure targets (92 versus 107 mmHg respectively).55 From baseline to 3 years, 
there was no difference in the rate of decline in GFR between intensive compared with 
standard blood pressure lowering in study 1 (10.7 [95% CI 9.1-12.4] mL/min/3 years 
versus 12.3 [95% CI 10.6-14.0] mL/min/3 years respectively) or in study 2 (3.7 [95% CI 
3.1-4.3] mL/min/year versus 4.2 [95% CI 3.6-4.9] mL/min/year respectively).55 In 
longer-term follow-up (mean 6.2 years), intensive blood pressure lowering, compared 
with the standard target, reduced the risk of kidney failure substantially (defined as 
need for dialysis or kidney transplantation; 268/432 versus 286/408 respectively; HR 
0.68 [95% CI 0.57-0.82]; P<0.001).52  
The Systolic Blood Pressure Intervention Trial (SPRINT) compared an ‘intensive’ 
systolic blood pressure target of less than 120 mmHg (achieved blood pressure 
121.4/68.7 mmHg) with a ’standard’ systolic blood pressure of less than 140 mmHg 
(achieved blood pressure 136.2/76.3 mmHg) in 9361 adults at increased 
cardiovascular risk.56 Mean (SD) eGFR amongst the overall cohort was 71.8 (20.7) 
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mL/min/1.73 m2 and in those with CKD (eGFR less than 60 mL/min/1.73m2) at baseline, 
mean (SD) eGFR was 47.9 (9.5) mL/min/1.73m2 and mean (SD) uACR was 42.6 
(165.8) mg/g.56 
Amongst 2646 people with CKD at baseline (eGFR 20 to 60 mL/min/1.73m2) there was 
no difference in the occurrence of the secondary composite renal outcome (reduction 
in eGFR of 50% or more, long term dialysis, or kidney transplantation) between the 
intensive, compared with standard, blood pressure lowering targets (14/1330 [1.1%] 
versus 15/1316 [1.1%] respectively; HR 0.89 [95% CI 0.42-1.87]; P=0.76).56 There was 
no effect on development of albuminuria amongst those with CKD (49/526 [9.3%] 
intensive versus 59/500 [11.8%] standard; HR 0.72 [95% CI 0.48-1.07]; P=0.11) or in 
those without CKD (110/1769 [6.2%] intensive versus 135/1831 [7.4%] standard; HR 
0.81; [95% CI 0.63-1.04]; P=0.10) during the trial.56 
Intensive, compared with standard, blood pressure lowering was associated with a 
substantially increased risk of acute kidney injury (193/4678 [4.1%] versus 117/4683 
[2.5%] respectively; HR 1.66; P<0.001), hypotension (110/4678 [2.4%] versus 66/4683 
[1.4%] respectively; HR 1.67; P=0.001) and electrolyte abnormalities (144/4678 [3.1%] 
versus 107/4683 [2.3%] respectively; HR 1.35; P=0.02).56 
A meta-analysis of 11 trials including 9287 participants with CKD, suggested intensive 
blood pressure lowering reduced the risk of a composite renal failure outcome (50% 
decline in GFR and doubling of the serum creatinine or ESKD) by 17% (HR 0.82; 95% 
CI 0.68-0.98), and reduced the risk of ESKD-alone by 18% (HR 0.79; 95% CI 0.67-
0.93).57 Subgroup analysis showed substantial heterogeneity (P for heterogeneity = 
0.006) in the effect of intensive blood pressure lowering by baseline proteinuria, with a 
27% (HR 0.73; 95% CI 0.62-0.86) reduction in the composite renal failure outcome in 
those with proteinuria but no apparent effect in those without proteinuria (HR 1.12; 95% 
CI 0.67-1.87).57 A meta-analysis including 613,815 participants, showed each 10 
mmHg reduction in systolic blood pressure was associated with a non-significant 5% 
(RR 0.95; 95% CI 0.84-1.07) reduction in risk of ESKD.58  
Strict control of blood pressure and proteinuria is desirable in patients with CKD given 
the results from the MDRD and AASK trials. The Kidney Disease Improving Global 
Outcomes (KDIGO) guidelines previously recommended a blood pressure target of less 
than 130/80 in those with proteinuria or diabetes mellitus (DM).59 In light of more recent 
randomized evidence demonstrating benefits of lower blood pressure targets, the new 
guidance on blood pressure management in people with CKD is likely to recommend a 
systolic blood pressure target of less than 120 mmHg.60 However, the targets will need 
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to be individualised in people who may be at increased risk of harm from more 
aggressive blood pressure lowering, such as the elderly.60  
 
 Sodium-glucose co-transporter 2 inhibition and effects on renal 
outcomes 
Sodium-glucose co-transporter 2 (SGLT2) inhibition has emerged as a new potential 
therapy for prevention of both cardiovascular and renal outcomes in people with 
diabetic kidney disease. SGLT2 is a sodium dependent glucose transporter protein 
located in the first segment of the proximal renal tubule and is responsible for 80-90% 
of filtered glucose reabsorption.61 
SGLT2 inhibition has been shown to reverse the maladaptive changes that occur in the 
kidney with poorly controlled diabetes resulting in reduced glucose and sodium 
reabsorption, thereby increasing distal sodium delivery to the macula densa in the 
kidney.61,62 Increased urinary glucose excretion and natriuresis occurs and local RAS 
activation is suppressed, resulting in activation of tubuloglomerular feedback.  
Tubuloglomerular feedback vasoconstricts the afferent arteriole which reduces renal 
perfusion pressure, intraglomerular hypertension and glomerular filtration rate.61,62 The 
combined effect of all these changes is a reduction in systemic (as well as 
intraglomerular) blood pressure, diuresis, weight loss and reduced circulating glucose 
concentrations.62 
The Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus 
Patients - Removing Excess Glucose (EMPA-REG OUTCOME) trial, was the first large-
scale randomised trial to demonstrate a substantial benefit with SGLT2 inhibition on 
renal and cardiovascular outcomes.63 People with type 2 diabetes mellitus and eGFR 
above 30 mL/min/1.73m2 were randomized to empagliflozin (SGLT2 inhibitor) or 
placebo. Among those with CKD at baseline, mean±SD eGFR was 67.1±7.9 
mL/min/1.73m2 and 40% of the overall cohort had albuminuria.63,64 
Allocation to empagliflozin, compared with placebo, reduced the risk of incident or 
worsening nephropathy by a substantial 39% (525/4124 [12.7%] versus 388/2061 
[18.8%] respectively; HR 0.61 [95% CI 0.53-0.70]; P<0.001).64 Empagliflozin, 
compared with placebo, had a similar effect in people with prevalent CKD (eGFR less 
than 60 mL/min/1.73m2) and/or macroalbuminuria (207/998 [20.7%] versus 161/507 
[31.8%]; HR 0.58 [95% CI 0.47-0.71]; P<0.001).64 Empagliflozin, compared with 
placebo reduced the risk of the post hoc composite renal outcome (doubling of SCr, 
initiation of RRT, or death from renal disease) by 46% (81/4645 [1.7%] versus 71/2323 
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[3.1%]; HR 0.54 [95% CI 0.40-0.75]; P<0.001), with no heterogeneity in the treatment 
effect by baseline albuminuria (P for interaction = 0.51) or eGFR (P for interaction = 
0.18).64 
Empagliflozin produced an acute decline in eGFR in the first month post-randomization 
(mean±SE adjusted eGFR fall 0.82±0.04 mL/min/1.73m2 with 25 mg empagliflozin 
versus 0.01±0.04 mL/min/1.73m2 with placebo).64 Thereafter, the annual rate of decline 
was slower with empagliflozin compared with placebo (0.19±0.11 versus 1.67±0.13 
mL/min/1.73m2 respectively; P<0.001).64 At one month following cessation of 
randomized treatment, empagliflozin, compared with placebo, was associated with 
greater adjusted weekly increases in eGFR (0.55±0.04 mL/min/1.73m2 [with 25 mg 
empagliflozin] versus 0.04±0.04 mL/min/1.73m2 respectively; P<0.001).64  
Since the publication of the EMPA-REG trial results, two additional trials of SGLT2 
inhibition in people with diabetic nephropathy have followed, examining a renal primary 
outcome. The Canagliflozin Cardiovascular Assessment Study (CANVAS) Program 
consisted of two randomized trials (CANVAS and CANVAS-Renal) comparing 
canagliflozin (n=5795) with placebo (n=4347) in people with type 2 diabetes at high risk 
of CV events.65-67 Canagliflozin, compared with placebo, reduced the risk of the pre-
specified renal composite outcome (sustained doubling of SCr, ESKD or death from 
renal disease) in all participants with type 2 diabetes mellitus enrolled in the CANVAS 
Program by 47% (1.5 versus 2.8 per 1000 patient-years; HR 0.53; 95% CI 0.33-0.84) 
with no difference in the treatment effect across a range of subgroups.66 Allocation to 
canagliflozin, compared with placebo, was associated with a slower decline in eGFR 
(between group difference 1.2 mL/min/1.73m²/year; 95% CI 1.0-1.4) and reduced 
albuminuria by 18% (between group difference 18%; 95% CI 16-20).66 
The Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical 
Evaluation (CREDENCE) trial randomized 4401 people with type 2 diabetes and 
proteinuric CKD (uACR 300 to 5000 mg/g and eGFR 30-90 mL/min/1.73m2), to 
canagliflozin (n=2202) or placebo (n=2199).67 Allocation to canagliflozin, compared with 
placebo, reduced the risk of the primary composite outcome (ESKD [dialysis, 
transplantation, or eGFR of less than 15 mL/min/1.73m2], doubling of SCr or, either a 
cardiovascular or renal death) by 30% (245/2202 [11.1%] versus 340/2199 [15.5%] 
respectively; HR 0.70 [95% CI 0.59-0.82]; P=0.00001) with no heterogeneity in the 
treatment effect in a rage of pre-specified subgroups.67 Allocation to canagliflozin, 
compared with placebo, was associated with a slower decline in eGFR (between group 
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difference 1.52 mL/min/1.73m2/year; 95% CI 1.11-1.93) and a 31% (95% CI 26-35) 
reduction in albuminuria.67  
Although results from trials of SGLT2 inhibition have shown significant reductions in 
renal outcomes, these benefits have only been shown in people with diabetic 
nephropathy. For people with non-diabetic CKD, RAS inhibition currently remains the 
cornerstone of treatment to reduce risk of progression to ESKD. Despite treatment with 
RAS inhibition, a substantial residual risk of progression to ESKD remains. Trials of 
SGLT2 inhibition in people with non-diabetic CKD, including The Study of Heart and 
Kidney Protection With Empagliflozin (EMPA-KIDNEY), are currently underway to 
examine whether these drugs have similar effects on renal outcomes to people with 
diabetic nephropathy but, at present there remains an unmet need for more effective 
strategies to address this residual risk.68,69 
 
 Cardiovascular disease in chronic kidney disease  
 
Whereas only a minority of patients with CKD progress to ESKD, cardiovascular 
disease (CVD) is much more common with many patients dying from cardiovascular 
events before the onset of ESKD.8,70-72 In the UK, CVD accounts for about a quarter of 
all deaths amongst those receiving renal replacement therapy and the life expectancy 
for patients with CKD is substantially reduced compared to those of a similar age in the 
general population, even among young patients.8,10  
Risk of CVD in CKD is associated with both “traditional” (including hypertension, 
diabetes, obesity, smoking and dyslipidaemia) and “non-traditional” risk factors which 
are related to manifestations of progressive CKD.60,73-78 Non-traditional risk factors 
include abnormalities in mineral bone disease (including abnormal calcium and 
phosphate balance, hyperparathyroidism, vitamin D deficiency, increases in fibroblast 
growth factor-23 [FGF-23]), inflammation (such as C-reactive protein), anaemia, 
albuminuria and uraemia.4,79-83 
A variety of pathological changes contribute to the excess cardiovascular risk in CKD 
including: atherosclerosis; arteriosclerosis (resulting in non-compliant vasculature, 
increased pulse pressure, left ventricular hypertrophy [LVH] and decreased coronary 
perfusion); hypertension; RAS and sympathetic nervous system hyperactivity; 
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structural heart disease (including LVH and left ventricular dilatation) and; development 
of heart failure (HF).8,71,72,84,85  
As CKD progresses, the manifestation of CVD changes from atherosclerotic disease 
(i.e. myocardial infarction [MI], ischaemic stroke) to non-atherosclerotic disease 
(characterised by arteriosclerosis and structural heart disease).86-88 Among patients 
with advanced CKD (stages 4-5) up to 50% have echocardiographic evidence of 
abnormal cardiac structure which is often clinically asymptomatic.89,90 Non-
atherosclerotic disease manifests clinically as heart failure and has a high incidence of 
sudden cardiac death.8,88  
Observational studies have previously reported ‘U’- or ‘J’-shaped associations between 
blood pressure and cardiovascular risk in people with advanced CKD with an increased 
CVD risk at low to normal blood pressure.24,50,51 This contrasts with the positive log-
linear associations with ischemic heart disease, stroke, and heart failure mortality 
observed amongst apparently healthy adults.91  
The Study of Heart and Renal Protection (SHARP) trial, randomized 9270 patients with 
CKD, without a prior history of myocardial infarction or coronary revascularization, to 
simvastatin and ezetimibe or placebo.75 In post-hoc analyses, amongst the 7278 
participants who reported no previous history of CVD, there was a positive log-linear 
association between increasing systolic blood pressure and risk of CVD risk.92 Each 10 
mmHg increase in usual systolic blood pressure was associated with a 16% (HR 1.16; 
95% CI 1.08-1.25) increase in cardiovascular risk.92  
In the subgroup of patients with an additional troponin I (a cardiac biomarker) 
measurement, in the individuals with a troponin I concentration of 0.01 ng/mL or lower, 
each 10 mmHg increase in systolic blood pressure was associated with a 27% (HR 
1.27; 95% CI 1.11-1.44) increase in cardiovascular risk.92 The effect of systolic blood 
pressure on risk of atherosclerotic and non-atherosclerotic cardiovascular events was 
similar as was the effect in those on dialysis and non-dialysis participants.92 The 
association between diastolic blood pressure and risk of CV events was U-shaped 
irrespective of prior history of CVD or, troponin I result in those without prior CVD.92 
The presence of a positive log-linear association between systolic blood pressure and 
cardiovascular events in patients with advanced CKD at the lowest risk of CVD, 
suggests reverse causality is a possible explanation for the previously observed U or 
J-shaped associations in people with advanced CKD.24,50,51 Long-standing 
hypertension causes changes in cardiac structure and function that lowers blood 
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pressure and simultaneously increases CV risk.93 The results suggest that blood 
pressure may be a causal risk factor for both atherosclerotic and non-atherosclerotic 
CVD in people with CKD, as in other populations.92 Large-scale randomized trials in 
people with CKD are therefore required to assess the effects of intensive blood 
pressure lowering on CVD and renal outcomes to identify new strategies of reducing 
the significant burden of CVD in CKD.  
Observational studies have also shown a log-linear association between albuminuria 
and all-cause or cardiovascular mortality without an apparent threshold effect (on a log-
log scale), independent of eGFR and other cardiovascular risk factors.81,94 In people 
with declining eGFR (below 75 ml/min/1.73m2), even normoalbuminuria (uACR 10 to 
29 mg/g) has been shown to be associated with increased cardiovascular risk 
compared with an eGFR greater than 90 mL/min/1.73m2 and/or uACR less than 10 
mg/g.29,81,94 In individuals with an eGFR of 30-44 mL/min/1.73m2 and 
macroalbuminuria, the risk of cardiovascular mortality increased 6-fold in general 
population (HR 6.10; 95% CI 4.08-9.10) and high-risk cohorts (HR 6.00; 95% CI 4.40-
8.18).81,94 Other studies have shown similar associations, highlighting the significant 
burden of CVD in CKD.24,32,33 
In a meta-analysis of over 267,000 people with a history of hypertension, diabetes, or 
cardiovascular disease (and therefore at an increased risk of CKD), compared with an 
eGFR of 60 mL/min/1.73m2 or above, people with an eGFR of 45 or 15 mL/min/1.73m2 
had increased risk of cardiovascular mortality (eGFR 45 mL/min/1.73m2 HR 1.73 [95% 
CI 1.49-2.00] and eGFR 15 mL/min/1.73m2 HR 3.08 [95% CI 1.89-5.01]).94 In people 
with albuminuria the risk of cardiovascular mortality increased linearly with each log 
increase in albuminuria: compared with albuminuria of 5 mg/g, HR for microalbuminuria 
(30 mg/g) was 1.55 (95% CI 1.30-1.86]) and macroalbuminuria (300 mg/g) 2.59 (95% 
CI 1.95-3.44).94  
 
 Prevention of cardiovascular complications 
 
The excess risk of CVD outcomes and associated mortality in people with CKD 
highlights the need for interventions and therapies that can address this risk. Several 
interventions have been trialled including lipid lowering, RAS blockade, intensive blood 
pressure lowering and SGLT2 inhibition. 
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 Lipid lowering 
The SHARP trial demonstrated lowering low-density lipoprotein (LDL) cholesterol with 
simvastatin plus ezetimibe, compared with placebo, produced a 17% (526/4650 
[11.3%] versus 619/4620 [13.4%] respectively; rate ratio [RR] 0.83 [95% CI 0.74-0.94]; 
P=0.0021) proportional reduction in major atherosclerotic events (defined as non-fatal 
myocardial infarction, or cardiac death, stroke, or arterial revascularisation) in patients 
with CKD including those on dialysis and in those with renal transplants.75  
 
 Renin-angiotensin system blockade 
In the Reduction of Endpoints in Non-Insulin Dependent Diabetes Mellitus with the 
Angiotensin II Antagonist Losartan (RENAAL) trial, there was no difference in CV 
events with losartan compared with placebo (247/751 [32.9%] vs 268/752 [35.2%]; 
P=0.26).42 Similarly, in the IDNT trial, there was no significant reduction in risk of the 
composite cardiovascular endpoint with irbesartan compared with either placebo (RR 
0.91; 95% CI 0.72-1.14; P=0.40) or with amlodipine (RR 1.03; 95% CI 0.81-1.32; 
P=0.78).41  
In the general population, RAS inhibitors reduce the risk of cardiovascular events and, 
meta-analyses have suggested that the mechanism extends beyond reductions in 
blood pressure.95,96 However, randomized trials such as RENAAL and IDNT in patients 
with CKD have not shown RAS inhibition has the same benefits on CV outcomes and 
this may be because they have not been large enough to show such effects.97  
 
 Intensive blood pressure lowering 
Intensive blood pressure lowering on CV outcomes has been trialled in the general 
population and in people with CKD.76 Previous trials in CKD populations did not show 
significant reductions in CV events with intensive blood pressure lowering, but this may 
be because they were not adequately powered to do so (Appendix 2: Table of intensive 
versus standard blood pressure lowering).53,55,98  
The SPRINT trial randomized 9361 to either intensive (n=4678) or standard (n=4683) 
blood pressure lowering (systolic blood pressure less than 120 mmHg versus less than 
140 mmHg respectively).56 The primary outcome was a composite of myocardial 
infarction, acute coronary syndrome, stroke, heart failure, or CV mortality.56 The trial 
was stopped early after median 3.26 years follow-up as allocation to intensive, 
compared with standard, blood pressure lowering reduced the rate of the primary 
33 
 
composite outcome by a highly significant 25% (243/4678 [5.2%] versus 319/4683 
[6.8%]; HR 0.75 [95% CI 0.64-0.89]; P<0.001).56 Allocation to intensive, compared with 
standard, blood pressure lowering reduced all-cause mortality by 27% (155/4678 
[3.3%] versus 210/4683 [4.5%]; HR 0.73; [95% CI 0.60-0.90]; P=0.003).56 
Subgroup analyses from SPRINT assessing the treatment effect of a lower vs higher 
systolic blood pressure target in people with CKD (108/1330 [8.1%] versus 126/1316 
[9.6%] respectively; HR 0.82 [95% CI 0.63-1.07]) compared to those without CKD 
(135/3348 [4.0%] versus 193/3367 [5.7%]; HR 0.70 [95% CI 0.56-0.87]) found no 
significant heterogeneity in risk of the primary outcome between the two groups  (P for 
interaction = 0.32).56 However, the treatment effect was smaller in those with CKD as 
it was not powered to detect an effect in specific subgroups. The SPRINT results 
suggest intensive blood pressure lowering could be of significant benefit in reducing 
CVD outcomes in people with CKD and highlight the need for undertaking adequately 
powered randomized trials of this intervention in people with CKD. 
 
 Sodium-glucose co-transporter 2 inhibition 
The EMPA-REG trial primary outcome was a composite of cardiovascular mortality, 
nonfatal MI, or nonfatal stroke.63 Allocation to empagliflozin, compared with placebo, 
reduced the risk of the primary outcome by 14% (490/4687 [10.5%] versus 282/2333 
[12.1%] respectively; HR 0.86 [95% CI 0.74-0.99]; P for non-inferiority <0.001 and P for 
superiority = 0.04).63 Empagliflozin, compared with placebo, reduced rates of 
hospitalization for heart failure by 35% (126/4687 [2.7%] versus 95/2333 [4.1%] 
respectively; HR 0.65 [95% CI 0.50-0.85]; P = 0.002) and all-cause mortality by 32% 
(269/4687 [5.7%] versus 194/2333 [8.3%] respectively; HR 0.68 [95% CI 0.57-0.82]; 
P<0.001).63  
In CREDENCE, cardiovascular events were studied as secondary outcomes.67 Systolic 
and diastolic blood pressure were lower in those allocated canagliflozin compared with 
placebo (3.30 [95% CI 2.73-3.87] and 0.95 [95% CI 0.61-1.28] mmHg respectively).67 
Canagliflozin, compared with placebo, reduced the risk of cardiovascular mortality or 
hospitalization for heart failure by 31% (179/2202 [8.1%] versus 253/2199 [11.5%] 
respectively; HR 0.69 [95% CI 0.57-0.83]; P<0.001) and, risk of CV mortality, 
myocardial infarction, or stroke by 20% (217/2202 [9.9%] versus 269/2199 [12.2%] 
respectively; HR 0.80 [95% CI 0.67-0.95]; P=0.01).67  
Currently, no treatments have been shown to be beneficial in reducing non-
atherosclerotic CV complications (such as heart failure) associated with CKD in people 
34 
 
without diabetes and so this remains a significant area of unmet clinical need.8 There 
is therefore substantial need for new therapeutic strategies that could improve both the 
risk of progression to ESKD and development of CVD.  
One therapeutic strategy has been to target the natriuretic peptide (NP) system. The 
NP system is a compensatory neurohormonal pathway that counter-regulates RAS and 
the sympathetic nervous system. Therefore, enhancing the activity of NPs, by raising 
circulating levels of NPs, would be a beneficial strategy in disease states in which there 





3 Natriuretic peptide system and neprilysin 
 
 Natriuretic peptides 
 
Natriuretic peptides (NPs) are a family of peptides with short half-lives and similar 
chemical structures.99 In humans, three key NPs exist: atrial (ANP), brain (BNP) and 
C-type (CNP).99,100 ANP and BNP are predominantly synthesised and released from 
atrial and ventricular myocytes respectively in response to cardiac atrial distension from 
raised venous pressure.99,101 CNP is predominantly expressed in endothelial cells in 
response to cytokine and endothelium-dependent agonists and has a major role in 
chondrocyte differentiation and bone formation and also has vasodilatory and anti-
fibrotic effects.102,103 
All three NPs are formed as pre-pro-peptides and the signal peptide is cleaved to form 
pro-peptides. ANP pro-peptide undergoes a further proteolytic cleavage to convert the 
126-amino acid101,104,105 precursor into two smaller peptide fragments,99,102 a 98-amino 
acid N-terminal-fragment (NT-proANP1-98) and the biologically active 28-amino acid 
carboxy-terminal fragment (ANP99-126).99,104,105 Pro-ANP is cleaved by the enzyme corin 
which is expressed in renal and cardiac tissue.106,107 Variations in a minor allele of the 
corin gene (the corin I555 [P568] allele) may be associated with higher levels of blood 
pressure, hypertension and cardiac hypertrophy in African American individuals.107,108  
In the kidney, ANP precursor expression produces a NP called urodilatin (a 32-amino 
acid NP [ANP95-126]) from distal renal tubular cells, which regulates sodium and water 
excretion.99,101,104,109,110 Cardiovascular effects of ANP include inhibition of endothelin 
production, proliferation of smooth muscle cells and myocardial hypertrophy. 
BNP is produced as the pro-hormone pro-BNP1-108. Cleavage by the enzymes corin and 
furin produces the active molecule BNP1-32 and the inactive N-Terminal of prohormone 
BNP1-76 (NT-proBNP).106,111 Circulating levels of NT-proBNP are elevated in heart 
failure and levels of this peptide are used as a biomarker to assess disease activity. 
Specific actions of BNP include: coronary vasodilatation, myocardial relaxation, 
proliferation of cardiac myocytes and inhibition of cardiac fibroblasts, all of which act to 
prevent cardiac remodelling, diastolic dysfunction and heart failure.112 Both ANP and 
BNP also downregulate genes encoding substances regulating fibrosis (e.g. collagen, 
fibronectin) and inflammation (e.g. interleukin [IL]-6, tumour necrosis factor [TNF]-α).112  
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NPs exert their physiological effects via natriuretic peptide receptors (NPRs). Three 
receptors have been identified: NPR-A, -B and -C. Both ANP and BNP predominantly 
act via NPR-A (also known as guanylyl cyclase [GC]-A) and CNP has highest affinity 
for NPR-B (GC-B).99,102 NPs exert their actions through binding to NPR-A and NPR-B 
which activates cyclic guanosine monophosphate (cGMP)-dependent signalling 
(Figure 3).104,113 NPR-C is a clearance receptor for NPs that is not coupled to guanylyl 
cyclase. 
NPs have a range of beneficial actions (Figure 3)81,92-94 and circulating levels of NPs 
are upregulated in disease states such as CKD and heart failure to counteract pathways 
such as RAS and the sympathetic nervous system.  
 
ANP/BNP CNP
















Figure 3: Mechanism of action of natriuretic peptides and neprilysin 
 
 Actions of natriuretic peptides in the kidney 
NPs have several renal (through their actions on glomeruli and tubules) and 
cardiovascular effects that contribute to salt and water homeostasis and blood pressure 
regulation (Figure 3).105,114,115 Urodilatin has direct effects on the distal tubule and 
collecting ducts (acting via a paracrine mechanism) contributing to natriuresis and 
diuresis.104,109,110,116 Urodilatin inhibits sodium reabsorption to a greater extent than ANP 
possibly through higher affinity binding to the NPR-A receptor.116  
ANP = atrial natriuretic peptide 
BNP = brain type natriuretic peptide 
CNP = C-type natriuretic peptide 
NPR = natriuretic peptide receptor 
GC = guanylyl cyclase 
GTP = guanosine triphosphate 
cGMP = cyclic guanosine monophosphate 




ANP increases renal perfusion through pre-glomerular afferent arteriolar vasodilatation 
and post-glomerular efferent arteriolar vasoconstriction which results in increased 
intraglomerular capillary pressure, filtration fraction and GFR.117 Binding of ANP to 
receptors on glomerular mesangial cells, activates guanylyl cyclase receptors which 
counteract ATII-induced contraction of mesangial cells, thereby increasing the capillary 
surface area for filtration and producing a marked diuresis.118,119  
ANP also inhibits the production and actions of angiotensin-II, renin release (which 
reduces RAS activation) and the actions of aldosterone and anti-diuretic hormone 
(ADH) at the collecting duct (Figure 1).101,104,105,120,121 GFR is maintained, despite 
increased distal sodium delivery, by decreased proximal sodium reabsorption and 
increased sodium excretion, giving rise to increased urinary flow rates.120  
Animal models lacking the pro-ANP gene (resulting in an inability to produce ANP) 
develop salt-sensitive hypertension (SSH) compared to the wild-type.122,123 
Heterozygotes with reduced circulating ANP levels can also develop SSH although 
changes in plasma renin activity and dietary salt intake may also contribute.123 Gene 
delivery of ANP (using an adenovirus with the human ANP gene attached [Ad.RSV-
cANP]) to mice with SSH resulted in reduced blood pressure, renal injury, cardiac 
hypertrophy and stroke rates.124,125   
Two single nucleotide polymorphisms (SNP), rs5068 and rs1938358, in the ANP and 
BNP genes (NP precursor A [NPPA] and B [NPPB] genes respectively) are associated 
with increased circulating levels of proANP and proBNP respectively, lower blood 
pressure and risk of hypertension.126 The rs5068 SNP may also be associated with an 
improved metabolic profile.127  
These findings suggest that augmenting circulating levels of NPs could lead to 
improved clinical outcomes in CKD and CVD.  
 
 Raising levels of circulating natriuretic peptides 
Studies of patients with advanced CKD and those receiving haemodialysis 
demonstrated raised ANP levels in these patients compared with healthy controls. 
Release of ANP is believed to be triggered by volume expansion or fluid overload.128-
130  
In dialysis patients, levels of ANP are much higher prior to haemodialysis and 
subsequently fall with ultrafiltration (with net fluid removal).129,130 Therefore, NPs may 
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have a substantial physiological role in the regulation of fluid balance and blood 
pressure in people with CKD. 
In patients with advanced CKD, infusions of ANP were trialled as a method of raising 
circulating levels of NPs with conflicting results. Some studies reported no significant 
increases in GFR and renal plasma flow, whilst others reported the opposite effects 
with no effect on filtration fraction.128 There may be several reasons for the 
inconsistencies including the dose of ANP used in each study the small sample sizes 
in these non-randomized studies and the extremely short follow-up periods.131 
Reductions in blood pressure and plasma renin levels (as a marker of RAS activity) 
were seen despite reduced nephron mass.128,132 In a study of eight patients with 
nephrotic syndrome (proteinuria between 4 to 9 g/24 hours), low-dose and high-dose 
ANP infusions were compared.133 Urinary albumin and sodium excretion increased 
significantly in both groups, with a greater degree of albuminuria developing in those 
given higher doses of ANP.133 Immunoglobulin G (IgG) excretion increased 
proportionally to albumin excretion.133 Similar increases in albuminuria were found in 
studies, where ANP was administered to patients with insulin-dependent diabetes and 
microalbuminuria.132,134 
The increases in albumin excretion may be mediated through enhanced permeability 
of the glomerular filtration barrier, changes in glomerular haemodynamics (resulting in 
increased glomerular capillary hydraulic pressure) and additional relaxation of 
mesangial cells causing an increase in the glomerular filtration surface area.134,135 The 
permeability of the filtration slit membranes attached to podocytes (which possess ANP 
receptors) may also be increased by ANP, allowing albumin and other high molecular 
weight molecules to be filtered more freely.133-135 
Infusions of recombinant ANP (carperitide) and BNP (nesiritide) have been tested in 
patients with cardiac disease. However, their clinical utility in raising NP levels has been 
limited by short bioavailability, a need for parenteral administration, profound 
symptomatic hypotension and a lack of clinical benefit in randomized trials.136,137 
The difficulties with infusions of NPs led to the development of drugs that raise levels 
of NPs by inhibiting the key enzyme responsible for their degradation, neprilysin (also 






Neprilysin (NEP) is a membrane-bound zinc-containing metalloproteinase.99,100 It is a 
90 kDa glycoprotein with widespread tissue distribution (including the brain, vascular 
endothelium, smooth muscle, cardiac myocytes and neutrophils) but has greatest 
abundance in the brush border of proximal renal tubular cells.100,103,121,138 It is believed 
that prevention of breakdown of ANP directly at the brush-border within the kidney 
enhances natriuretic activity by inhibition of sodium reabsorption in the medullary 
collecting duct.   
In addition to NPs, NEP is responsible for processing and degrading a range of other 
vasoactive peptides including ATII, bradykinin, endothelin-1, substance P, 
adrenomedullin and amyloid.121,138-140   
NEP plays an important role in the formation and breakdown of the vasoconstrictor 
endothelin (ET), through conversion of big-ET into endothelin-1 (ET-1), and regulating 
vascular tone.138,140-142 The final step in processing of ET-1 is catalysed by endothelin-
converting enzyme (ECE) which shares sequence homology with NEP. NEP inhibition 
(NEPi) attenuates the activity of ECE-1 which further enhances the activity of ANP.138 
The net action of NEP depends on the balance between vasoconstrictor and 
vasodilatory peptides. 
The wide range of potentially therapeutic actions of NPs and the limitations with some 
methods of raising levels of NPs, led to the development of agents that inhibited NEP.  
 
 Neprilysin inhibition 
 
Short-term studies of orally-active NEP inhibitors (NEPi) in healthy human volunteers, 
demonstrated NEPi resulted in increased urinary and plasma cGMP, plasma ANP 
(suggesting adequate NEPi was achieved), natriuresis and vasodilation with minimal 
RAS activation.143,144 Candoxatrilat was one of the first NEP inhibitors to be produced 
and tested in a range of patients with CKD,145 essential hypertension146,147 and heart 
failure.148  
Candoxatrilat was compared with placebo in 24 patients with normal (mean±SD GFR 
103±8 mL/min), moderately (GFR 64±6 mL/min) and severely (16±2 mL/min) impaired 
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renal function (excluding patients on dialysis) in a cross-over study.145 Compared with 
placebo, candoxatrilat produced substantial elevations in plasma ANP and urinary 
cGMP and, a pronounced natriuresis occurred in all three groups.145  
In contrast to the renal effects noted with NP infusions, no changes in GFR, renal 
plasma flow or blood pressure were seen.145 A marked increase in albuminuria 
emerged in those with severely impaired renal function and may have been due to the 
effects of ANP on renal vasculature, increasing filtration fraction and transglomerular 
albumin transport.128,132,133,145  
Such increases in albuminuria with NEPi, particularly in patients with CKD, would be of 
great concern if they were shown to persist in longer-term studies of NEPi since 
albuminuria has been shown to be associated with increased risk of progression of 
CKD.29-31 However, all of the studies of NEPi included only very small numbers of 
participants that were treated and followed-up and for very short timespans to be able 
to provide reliable information on the effects of NPs in patients with advanced CKD and 
albuminuria. 
In longer term studies, chronic NEPi did not translate into clinically meaningful 
reductions in blood pressure. Since NEPi impairs the degradation of ATII, any blood 
pressure and natriuretic effects were attenuated by compensatory up-regulation of the 
RAS and sympathetic nervous system activity (as well as changes in sodium and 
endothelin).140,147,149  
The beneficial renal and cardiovascular effects of NEPi were shown to be enhanced 
when combined with simultaneous RAS inhibition.104 This led to the development of 
dual NEP/RAS inhibitors to counteract the physiological responses that dampen the 
effects of isolated NEP inhibition.150  
 
 Combined neprilysin and renin-angiotensin converting enzyme 
inhibitors (vasopeptidase inhibitors)  
 
Dual inhibition of NEP and RAS as a single combined treatment was a significant step 
forward in the development of potential treatments for preventing progression of renal 
and cardiovascular disease. Initial combinations consisted of a NEPi with an ACEi 
(working synergistically) and this new class of drugs were termed vasopeptidase 
41 
 
inhibitors (VPIs).151  Many different compounds were produced and trialled in humans 
(Table 2) with omapatrilat the most widely studied drug.139,152,153 
 
Vasopeptidase inhibitor Population studied Year 
Phase II studies 
MDL-100240 Healthy volunteers 2000 
Z13752A Healthy volunteers 2000 
Gemopatrilat Healthy volunteers 2001-2004 
Phase III studies 
Sampatrilat Hypertension 1998-99 




Table 2: Examples of vasopeptidase inhibitors produced and studied in humans 
 
In studies of healthy volunteers, omapatrilat was well tolerated and significant increases 
in urinary excretion of ANP and cGMP were seen compared with ACEi or 
placebo.139,152,153 Omapatrilat produced potent ACE inhibition (decreasing levels of 
angiotensin-II) and reductions in systemic blood pressure.153 Renal effects included 
marked renal vasodilatation (with increased renal blood flow) without associated 
changes in GFR, and decreases in filtration fraction.153  
Evidence for a potential role of VPIs in CKD came primarily from studies of NEPi in 
animal models of renal disease and the results of renal outcomes in trials of NEPi in 
heart failure and hypertension. No clinical outcome trials of VPIs were performed in 
people with CKD. 
In a variety of animal models of hypertension including SSH, stroke-prone 
spontaneously hypertensive rats and renovascular hypertension, combined NEP/RAS 
inhibition resulted in greater reductions in blood pressure and vascular remodelling 
compared with isolated RAS inhibition or control.141,142,154-157    
The VPI AVE7688 was compared to enalapril in a subtotal, or ‘5/6’, nephrectomy model 
with treatment initiated 21 days after nephrectomy when the animals (8 rats in each 
treatment group and 5 normal controls) had developed overt proteinuria and 
hypertension.138 Both treatments led to reductions in proteinuria but serum creatinine 
and proteinuria were much lower in animals treated with AVE7688 than with ACEi-
alone (enalapril).138 The beneficial effects were not thought to be mediated through 
effects on blood pressure as the doses chosen for each drug resulted in similar 
reductions in blood pressure.138  
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Histology specimens showed AVE7688 greatly reduced the percentage of glomeruli 
with sclerotic and tubular changes whereas enalapril only partially reduced such 
changes. AVE7688 increased renal synthesis of NO and decreased synthesis of ET-1 
with reduced renal vasoconstriction and increased renal tubular ANP release. The 
effect on renal NO production was more marked with AVE7688 than enalapril.138  
Other studies have compared the longer-term effects of omapatrilat with ACEi.158,159 In 
one such study, compared with fosinopril or control, omapatrilat led to greater dose-
dependent reductions in blood pressure and proteinuria.158 Both treatments led to 
similar reductions in GFR, glomerulosclerosis and tubulointerstitial fibrosis compared 
with control.158 
In another 5/6 nephrectomy model, treatment was delayed for four weeks’ post-surgery 
allowing the development of hypertension and proteinuria.159 Following similar initial 
reductions in proteinuria between omapatrilat (n=6) and enalapril (n=6), omapatrilat 
resulted in a substantially slower increase in proteinuria than enalapril (despite both 
drugs having similar effects on blood pressure).159 Following surgery, control animals 
(n=15) were euthanized at 12 weeks whilst enalapril-treated rats were euthanized at 32 
weeks due to rapidly rising proteinuria. However, omapatrilat-treated rats were not 
euthanized until 50 weeks at which point levels of proteinuria were similar to pre-
treatment levels. On histology, glomerulosclerosis and tubulointerstitial fibrosis scores 
following 50 weeks of treatment with omapatrilat and 32 weeks of treatment with 
enalapril were similar to those in control animals at 12 weeks.  
In micropuncture studies omapatrilat led to greater reductions in glomerular capillary 
pressure than enalapril.159 These findings suggested that combined NEP/ACE inhibition 
yielded greater renoprotection than ACEi-alone.159  
Similar effects were observed when omapatrilat was compared with isolated RAS 
inhibition in models of diabetic nephropathy. These results were very promising given 
the earlier studies showing NEPi may result in increases in albuminuria.160,161  
It was hoped that the beneficial renal effects seen in animal studies with combined 
NEP/RAS inhibition could translate into greater renal protection in people with 
CKD.158,159 However, animal studies are often poorly predictive of efficacy in humans, 
and no studies were performed with VPIs in people with CKD.162,163  
Some indirect evidence of the renal effects was available from trials of omapatrilat in 
people with heart failure. The Inhibition of Metallo Protease by Omapatrilat in a 
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Randomized Exercise and Symptoms Study of Heart Failure (IMPRESS) trial, 
compared omapatrilat with lisinopril in 573 patients with heart failure.164 Treatment with 
omapatrilat was associated with lower rates of elevated creatinine compared with 
lisinopril (5/289 [1.8%] versus 17/284 [6.1%] respectively; P=0.009), suggesting VPIs 
provided additional renoprotection over ACEi-alone.164  
In the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events 
(OVERTURE) trial of 5770 patients with heart failure, “renal impairment” occurred less 
frequently with omapatrilat than enalapril (196/2886 [6.8%] versus 291/2884 [10.1%] 
respectively) although patients with a serum creatinine greater than 221 μmol/L at 
baseline were excluded.165 The effects on renal function occurred despite omapatrilat 
causing more hypotension than enalapril (564/2886 [19.5%] versus 332/2884 
[11.5%]).165  
The results from these trials supported the animal data suggesting combined NEP/RAS 
inhibition may have favourable effects on renal function and preservation of GFR over 
RASi-alone.  
 
 Vasopeptidase inhibitors and angioedema  
Despite promising effects on kidney function, increasing reports emerged of 
unacceptable rates of angioedema with omapatrilat, compared with isolated RAS 
inhibition, in some cases requiring hospitalisation and mechanical ventilation in the 
most severe cases.164-166  
The Omapatrilat Cardiovascular Treatment versus Enalapril (OCTAVE) trial, 
randomized 25,302 hypertensive patients and compared the effects of omapatrilat with 
enalapril on blood pressure (the primary endpoint) and risk of angioedema (a pre-
specified safety event of special interest).166 At 8 weeks, omapatrilat significantly 
reduced systolic (3.6 mmHg; P<0.001) and diastolic (2.0 mmHg) blood pressure 
compared with enalapril. However, across the 24 week treatment period angioedema 
occurred with greater severity and frequency with omapatrilat than enalapril 
(274/12,609 [2.17%] versus 86/12,557 [0.68%]; relative risk [RR] 3.17; 95% CI 2.52-
4.12; P<0.005).166 Life-threatening angioedema was rare, with two participants 
experiencing airway compromise, one of whom required mechanical ventilation.166 
Rates of angioedema were greater in black participants treated with either omapatrilat 
or enalapril (5.54% and 1.62% respectively) and in current smokers treated with 
omapatrilat (3.93% versus 0.81% with enalapril).166  
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Following the results of the OCTAVE trial, the Food and Drug Administration (FDA) 
review board did not approve omapatrilat and it was withdrawn by the manufacturer.167 
Angioedema is a rare and potentially life-threatening condition caused by a range of 
aetiologies and is a known side effect of treatment with ACE inhibitors. It is seen in 0.1-
0.5% of patients taking ACEi and can occur at any time after initiating treatment with 
these drugs, although most cases occur within the first week following exposure.140,168-
172 Angioedema commonly causes oedema (without urticaria) of the face, tongue and 
throat.172 Very rarely it can cause laryngeal oedema and asphyxiation which may lead 
to death.172 Intestinal oedema can manifest with abdominal pain, nausea, vomiting and 
diarrhoea.167,172  
ACE inhibitor induced angioedema is believed to be mediated by decreased breakdown 
of bradykinin resulting in increased bradykinin levels.167-169,171,173 Bradykinin is a 
mediator of vascular permeability and vasodilatation and is degraded by ACE (Figure 
4).172,174 In an acute episode of angioedema, bradykinin concentrations can increase 
























Figure 4: Production and metabolism of bradykinin 
ACE = angiotensin converting enzyme; APP = aminopeptidase P; DPPIV = dipeptidyl peptidase IV; NEP 
= neprilysin 
 
Given the low incidence of angioedema associated with ACEi, it is believed that 
individuals are more susceptible to developing angioedema if they have an additional 
predisposing risk factor such as smoking (due to reduced NEP and dipeptidyl peptidase 
IV [DPPIV] activity in smokers), black race (due to ACE gene polymorphisms) or 
hereditary angioedema (for example C1 inhibitor deficiency).174,175 With ACE inhibition, 
bradykinin degradation becomes dependent on secondary enzymes (including NEP) 
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for its breakdown (Figure 4) and so combined NEP/RAS inhibition has additive effects 
on circulating bradykinin concentrations.  
Omapatrilat inhibited three key enzymes involved in bradykinin degradation, NEP, ACE 
and aminopeptidase P (APP), which resulted in substantially higher circulating 
bradykinin concentrations and increased risk of angioedema compared with isolated 
ACE inhibition.167,172,174,176 
ARBs have similar cardiovascular and renal effects to ACEi but with minimal effects on 
bradykinin activity (as they are not involved in its metabolism) and are therefore much 
less likely to cause angioedema.171,173 Since NEPi must be combined with simultaneous 
RAS blockade, angiotensin receptor-neprilysin inhibitors (ARNI’s) were developed, 
combining the beneficial effects of RAS inhibition (with an ARB) with NEPi, without 
significantly increasing risk of angioedema (Figure 5).171,177,178  
 













Figure 5: Mechanism of action of angiotensin receptor-neprilysin inhibitors 









Sacubitril/valsartan (previously known as LCZ696) is the first-in-class dual-acting ARNI 
to be developed. It combines two drugs: an ARB moiety, valsartan, and the NEPi pro-
drug sacubitril in a 1:1 molar complex.178  
Sacubitril/valsartan (trade name Entresto®) received expedited approval from the FDA 
for treatment of heart failure with reduced ejection fraction (HFrEF) in the US on 7th 
July 2015179 and from the UK’s National Institute for Clinical Excellence (NICE) in April 
2016.180  
 
 Pharmacokinetics of sacubitril/valsartan 
 
Following oral administration of sacubitril/valsartan, it is rapidly metabolised delivering 
systemic exposure to the two separate moieties. Sacubitril (previously known as 
AHU377), the inactive NEPi, has a relatively short half-life (1.1-3.6 hours) and 
undergoes further rapid conversion by carboxyl esterases (CES) cleaving an ethyl ester 
to form the active NEPi, sacubitrilat (previously known as LBQ657).177,178,181 In in vitro 
studies, this activation primarily occurs in the liver by the hepatic hydrolase CES1.182 
The effect of genetic polymorphisms of CES1 (such as G143E, a loss-of-function 
variant) on systemic exposure to sacubitrilat is unknown but they are not expected to 
have a significant impact.182,183 About 50-70% of sacubitril is excreted in the urine 
predominantly as sacubitrilat and the remainder in the faeces, whereas valsartan 
undergoes hepatic elimination (by bile acids) and is excreted mostly unchanged in 
faeces and only about 10 to 15% in the urine.184  
In multiple-dosing studies in healthy volunteers, valsartan reached peak plasma 
concentrations in 1.6-4.9 hours, sacubitril in 0.6-0.9 hours and the active moiety, 
sacubitrilat, in 1.8-2.7 hours.178 Sacubitril/valsartan was associated with increases in 
plasma cGMP, renin and ATII levels, confirming both NEP and RAS inhibition was 
achieved. Systemic exposure to valsartan following treatment with sacubitril/valsartan 
demonstrated bioequivalence (e.g., the dose of valsartan in sacubitril/valsartan 97/103 
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mg is equivalent to 160 mg of valsartan with similar results for other doses of 
sacubitril/valsartan) and a 40% higher valsartan exposure was achieved than with 
valsartan-alone.178  
Pharmacokinetic studies in individuals with renal impairment revealed the steady-state 
maximum observed concentration (Cmax) increased by ~60% compared with healthy 
volunteers.185 The half-life of sacubitrilat increased from 12 hours in healthy volunteers 
to 21.1, 23.7 and 38.5 hours in those with ‘mild’ (creatinine clearance [CrCl] 50 to 80 
ml/min [n=8]), ‘moderate’ (CrCl 30 to 50 ml/min [n=8]) and ‘severe’ renal impairment 
(CrCl less than 30 ml/min [n=6]) respectively.185  
A lower starting dose of sacubitril/valsartan 24/26 mg has been recommended in 
people with an eGFR of 30 to 60 mL/min/1.73m2 and, for an eGFR less than 30 
mL/min/1.73m2 caution has been advised due to limited exposure in this population.186 
No clinically relevant pharmacokinetic drug-drug interactions have been observed 
between sacubitril/valsartan and a variety of drug classes.187,188  
Several clinical trials including people with hypertension and heart failure have 
assessed the safety and efficacy of sacubitril/valsartan in these populations.  
 
 Effects of sacubitril/valsartan on blood pressure 
 
In spontaneously hypertensive rats, sacubitril/valsartan demonstrated superior blood 
pressure lowering (irrespective of dietary salt consumption) compared with valsartan-
alone or vehicle and ameliorated cardiac hypertrophy,  fibrosis, coronary vascular 
remodelling and endothelial dysfunction.189 
A trial of 1328 people with mild-to-moderate hypertension, compared 
sacubitril/valsartan over 8 weeks with valsartan-alone, sacubitril-alone or placebo. 
Sacubitril/valsartan had superior diastolic blood pressure lowering (primary outcome 
mean diastolic blood pressure reduction 2.17 mmHg; 95% CI 1.06-3.28; P<0.0001) 
compared with valsartan.190 Mean sitting systolic blood pressure was 4.20 (-5.94 to   -
2.46; p<0.0001) mmHg lower with sacubitril/valsartan.  
In single-dose pairwise comparisons, each sacubitril/valsartan dose had greater blood 
pressure lowering than the equivalent dose of valsartan and, the proportional reduction 
in systolic and diastolic blood pressure was greater with increasing sacubitril/valsartan 
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doses (Figure 6). Mean sitting (and ambulatory) pulse pressure was 3.32 (95% CI -5.51 
to -1.13) mmHg lower in people allocated sacubitril/valsartan (2 tablets of 97/103 mg 
daily) versus valsartan (320 mg daily).190 Sacubitril/valsartan was generally well-




Figure 6: Difference in mean sitting systolic and diastolic blood pressure (BP) at 8 weeks 
with maximum sacubitril/valsartan (S/V; n=170) dose compared with full dose valsartan 
(n=163)  
Adapted from Ruilope LM, et al. Lancet 2000190. S/V = sacubitril/valsartan; Val = valsartan 
 
Similar blood pressure effects have been reported in Asian patients (from Japan, China, 
Korea, Taiwan and Thailand) with hypertension, who are generally less responsive to 
isolated RASi as they often have higher salt-intake and are more prone to SSH.191  
The Prospective Comparison of Angiotensin Receptor Neprilysin Inhibitor with 
Angiotensin Receptor Blocker Measuring Arterial Stiffness in the Elderly 
(PARAMETER) trial, randomized 454 people aged over 60 years with systolic 
hypertension and pulse pressure greater than 60 mmHg (suggestive of arterial 
stiffness), to sacubitril/valsartan or olmesartan.192 The primary outcome assessed the 
effect of sacubitril/valsartan on central aortic pressures at 12 weeks.192 
Sacubitril/valsartan, compared with olmesartan, was associated with greater reductions 
in central aortic systolic pressure (12.6 [95% CI -14 to -10.1] mmHg versus 8.9 [95% 
CI -11.1 to -6.7] mmHg respectively), central aortic pulse pressure (6.4 [95% CI -7.7 to 
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-5.1] mmHg versus 4.0 [95% CI -5.3 to -2.6] mmHg respectively; P=0.01) and central 
mean arterial pressure (8.5 [95% CI -10.0 to -7.1] mmHg versus 6.5 [95% CI -8.0 to -
5.0] mmHg respectively) following 12 weeks of treatment.192  
The Effect of Sacubitril-Valsartan vs Enalapril on Aortic Stiffness in Patients With Heart 
Failure and Reduced Ejection Fraction (EVALUATE-HF) trial randomized 464 people 
with HFrEF sacubitril/valsartan (n=231) or enalapril (n=233).193 The primary outcome 
was change in aortic characteristic impedance (Zc; a measure of central aortic stiffness) 
from baseline to 12 weeks.193 
Between baseline and 12 weeks, there was no significant between-group difference in 
Zc in those allocated sacubitril/valsartan compared with enalapril (-2.2 [95% CI -17.6 to 
13.2] dyne×sec/cm5; P=0.78), despite a 6.4 mmHg reduction in brachial systolic blood 
pressure with sacubitril/valsartan compared with only 1.6 mmHg with enalapril 
(between-group difference -4.8 [95% CI -7.6 to -2.1] mmHg; P=0.001).193 
In 8442 patients with HFrEF, at 8 months mean systolic blood pressure was 3.2±0.4 
mmHg lower in patients allocated sacubitril/valsartan compared with enalapril 
(P<0.001).194 Overall throughout the trial a mean reduction in systolic blood pressure 
of 2.70 (95% CI -3.07 to -2.34) mmHg was achieved with sacubitril/valsartan compared 
with enalapril.194 
In a trial of 301 people with heart failure with preserved ejection fraction (HFpEF), at 12 
weeks sacubitril/valsartan reduced systolic and diastolic blood pressure by 9.3 (SD 14) 
mmHg and 4.9 (SD 10) mmHg respectively, compared with 2.9 (SD 17) mmHg and 2.1 
(SD 11) mmHg in people allocated valsartan.195 In a much larger trial of 4822 patients 
with HFpEF, at 8 months sacubitril/valsartan reduced mean systolic blood pressure by 
4.5 mmHg (95% CI 3.6 to 5.4) compared with valsartan.196  
In heart failure trials, the greater blood pressure lowering effect of sacubitril/valsartan 
has not been shown to correlate with the treatment effect. Whether such reductions in 
blood pressure translate into improved renal and CV outcomes in patients with CKD or 
hypertension remains unclear. Apart from in heart failure populations, no large-scale 
randomized clinical outcome trials have been performed with sacubitril/valsartan for 




 Renal effects of sacubitril/valsartan  
 
 Results from in-vitro and animal studies 
In-vitro studies have shown that addition of sacubitrilat to human adrenocortical cells 
enhanced the ability of ANP and BNP to block aldosterone synthesis.197 In another in-
vitro study, addition of sacubitrilat and valsartan (mimicking the ARNI 
sacubitril/valsartan) to cultured renal mesangial cells improved the inhibitory effect of 
valsartan on collagen synthesis in renal mesangial cells.198  
In a rodent model of diabetic nephropathy, rats were treated at 2 or 8 weeks after the 
onset of diabetes with irbesartan (n=8), irbesartan plus NEPi (thiorphan, n=16) or 
vehicle-alone (n=8).199 Irbesartan combined with thiorphan reduced proteinuria (with 
levels normalising at 12 weeks), albuminuria and glomerulosclerosis to a greater extent 
than irbesartan-alone, despite similar reductions in blood pressure.199  
 
 Results from clinical trials of sacubitril/valsartan 
 Effects on renal function 
Data on the effects of ARNI in people with CKD have mostly been extrapolated from 
individuals with an eGFR of 30 to 60 mL/min/1.73m2 participating in trials of heart failure 
or hypertension. Data on the effects of NEPi with sacubitril/valsartan in people with 
CKD, particularly advanced CKD (stage 4 or 5), was scarce since such individuals were 
not included in randomized trials of sacubitril/valsartan.  
The Prospective comparison of ARNi with ARB on Management Of heart failure with 
preserved ejection fraction (PARAMOUNT) trial randomized 301 patients with HFpEF 
to maximum tolerated daily doses of sacubitril/valsartan (97/103 mg twice daily [n=149]) 
or valsartan-alone (320 mg once daily [n=152]).195 42% of PARAMOUNT participants 
had an eGFR less than 60 mL/min/1.73m² at baseline (56/149 [38%] in the 
sacubitril/valsartan arm and 69/152 [45%] in the valsartan arm) and patients with an 
eGFR less than 30 mL/min/1.732 were excluded.195 Mean (SD) eGFR at baseline in 
those allocated sacubitril/valsartan 67 (19.4) mL/min/1.73m² and 64 (21.3) 
mL/min/1.73m² in those allocated valsartan.195  
At the end of the initial 12-week treatment period, mean eGFR did not differ significantly 
between the treatment groups (between-group difference 1.8 mL/min/1.73m2; P=0.14). 
However, at 36 weeks, there was a smaller decline in eGFR in participants randomized 
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to sacubitril/valsartan than valsartan-alone (1.5±13.1 versus 5.2±11.4 mL/min/1.73m² 
respectively; P=0.008) compared with baseline.200  
The Prospective comparison of ARNI with ACEi to Determine Impact on Global 
Mortality and morbidity in Heart Failure trial (PARADIGM-HF) trial, randomized 8442 
patients with HFrEF to maximum doses of sacubitril/valsartan (n=4187) or enalapril 
(n=4212).181,201 Baseline eGFR was 67.7 mL/min/1.73m2, and 36% (1541/4187 [37%] 
allocated sacubitril/valsartan and 1520/4212 [36%] allocated enalapril) of participants 
had an eGFR less than 60 ml/min/1.73m2.167,201 Amongst those with CKD, eGFR was 
49±8 mL/min/1.73m2 at screening.202 The composite renal endpoint, “decline in renal 
function” included time to; i) 50% decline in eGFR relative to baseline eGFR; ii) more 
than 30 mL/min/1.73m2 decline in eGFR from baseline to less than 60 mL/min/1.73m2 
or iii) progression to ESKD.181,201  
Between screening and the end of follow-up, eGFR declined less in people allocated 
sacubitril/valsartan compared with enalapril (7.8 [95% CI 9.6-6.0] versus 10.2 [95% CI 
12.1-8.3] mL/min/1.73m2 respectively).202 The annual rate of decline in eGFR was 
slower with sacubitril/valsartan compared with enalapril (1.61 [95% CI -1.77 to -1.44] 
versus 2.04 [95% CI -2.21 to-1.88] mL/min/1.73m2/year respectively; P<0.001) with no 
heterogeneity in the treatment effect by CKD status at screening (P for interaction = 
0.54).202  
PARADIGM-HF participants with diabetes had a faster rate of decline than those 
without diabetes (2.0 [95% CI 1.9-2.1] versus 1.1 [95% CI 1.1-1.2] mL/min/1.73m2 
respectively; P<0.0001).203 The beneficial effect of sacubitril/valsartan in slowing the 
annual rate of change in eGFR compared with enalapril, was marginally greater 
amongst patients with diabetes than those without diabetes (difference 0.6 
mL/min/1.73m²/year [95% CI 0.4-0.8] versus 0.3 mL/min/1.73m²/year [0.2-0.5] 
respectively; P for interaction = 0.038).203 
There was a non-significant trend towards lower rates of the composite renal endpoint 
in patients treated with sacubitril/valsartan than enalapril (94/4187 [2.2%] versus 
108/4212 [2.6%] respectively; HR 0.86 [95% CI 0.65-1.13]; P=0.28), despite greater 
reductions in blood pressure with sacubitril/valsartan.194 A post-hoc analysis using an 
alternative definition for the composite renal outcome of ESKD or a 50% or greater 
decline in eGFR from baseline, suggested sacubitril/valsartan, compared with enalapril, 
substantially reduced this adverse renal outcome (37/4187 [0.9%] versus 58/4212 
[1.4%] respectively; HR 0.63 [95% CI 0.42-0.95]; P=0.028) with no heterogeneity in the 
effect by CKD status at baseline (P for interaction = 0.97).202  
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Progression to ESKD occurred less frequently with sacubitril/valsartan than enalapril 
(8/4187 [0.2%] versus 16/4212 [0.4%] respectively; P=0.11).194 However, the number 
of ESKD events was small as the trial did not include participants with advanced CKD 
(eGFR less than 30 mL/min/1.73m2) who would be much more likely to progress to 
ESKD, the trial therefore lacked statistical power to assess this outcome.   
The Prospective Comparison of ARNI with ARB Global Outcomes in HF with Preserved 
Ejection Fraction (PARAGON-HF) trial, randomized 4822 patients with HFpEF to 
sacubitril-valsartan 97/103 mg twice daily or valsartan 160 mg twice daily.196 Mean 
eGFR was 62.5±19 mL/min/1.73m2 at baseline and 48.5% (2341/4822) had an eGFR 
of 30-60 mL/min/1.73m2 (patients with an eGFR less than 30 mL/min/1.73m2 were 
excluded).196  
Risk of the secondary renal composite outcome (defined as: [i] death from renal failure; 
[ii] ESKD or; [iii] decline in eGFR of 50% or more from baseline) was halved in patients 
randomized to sacubitril/valsartan compared with valsartan-alone (33/2407 [1.4%] 
versus 64/2389 [2.7%]; HR 0.50 [95% CI 0.33-0.77]).196 
A tabular meta-analysis assessing the effects of combined NEP/RAS inhibition on 
“decline in renal function” in patients with heart failure, suggested this treatment 
combination may be associated with a 32% (risk ratio 0.68; 95% CI 0.51-0.92; P=0.01) 
reduction in the risk of decline in renal function compared with isolated RAS 
inhibition.204 However, there was significant heterogeneity between the trial 
populations, study designs and definitions of the renal outcome between the trials 
(overall P for heterogeneity = 0.10).204 The total number of renal events was also small 
(298 events in 7511 participants allocated combined NEP/RAS inhibition versus 423 
events in 7532 participants allocated isolated RAS inhibition) and the majority of events 
were contributed by just two trials (PARADIGM-HF and OVERTURE).204 
It is hypothesised that the lack of expected decline in GFR despite significant reductions 
in systemic blood pressure in the heart failure trials amongst participants allocated 
ARNIs, may result from afferent arteriolar vasodilation with only a relative efferent 
arteriolar vasoconstriction (due to actions of NPs at this site). This increase in 
intraglomerular capillary hydrostatic pressure enabled GFR to be maintained despite 
low systemic pressure.205 
The data from the heart failure and hypertension trials suggested that combined 
NEP/RAS inhibition may have a beneficial effect on kidney function, however significant 
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uncertainty remained as to the true effects especially in people with advanced CKD, in 
whom this treatment strategy had not been studied.  
 Effects on albuminuria 
In 1328 patients with mild-moderate hypertension, sacubitril/valsartan reduced 
albuminuria more than placebo, but not more than the equivalent dose of valsartan.190 
However, baseline urine albumin:creatinine ratio (uACR) was low (geometric mean 
between 1.1 and 1.5 mg/mmol) in all treatment groups.190 Compared with baseline, at 
8 weeks, sacubitril/valsartan 194/206 mg reduced uACR by 12% (95% CI -25 to 4%; 
P<0.05) and valsartan 320 mg reduced uACR by 10% (95% CI -24 to 8%; P<0.05), 
compared with placebo.190  
In contrast to people with hypertension, albuminuria increased in patients with heart 
failure following treatment with sacubitril/valsartan, although uACR was very low at 
baseline in all treatment groups. In PARAMOUNT, at 36-weeks geometric mean uACR 
increased by 0.5 mg/mmol with sacubitril/valsartan (from 2.4 mg/mmol to 2.9 mg/mmol) 
but remained stable with valsartan (from 2.1 mg/mmol to 2.0 mg/mmol), P for 
difference=0.016.200  
In PARADIGM-HF, uACR was measured in 22% of participants (1872/8442) at 
screening and was re-measured at randomization, one month and eight months post-
randomization.202  Median (interquartile range [IQR]) uACR at screening was 1.0 (0.4-
43.2) mg/mmol and 24% of participants had micro- or macroalbuminuria (median uACR 
in participants with albuminuria 7.55 mg/mmol; 95% CI 2.55-21.8).202 Following 
randomisation, uACR increased by 0.30 (95% CI 0.10-0.50) mg/mmol with 
sacubitril/valsartan and by a similar amount with enalapril.206 At one-month post 
randomization, uACR returned back down to screening levels with enalapril but 
remained significantly higher in those allocated sacubitril/valsartan even at 8 
months.202,206 
The effects of NPs on glomerular haemodynamics that results in increased 
intraglomerular capillary hydrostatic pressure and glomerular permeability may explain 
the rise in albuminuria seen in people with heart failure.205 The effects of 
sacubitril/valsartan on albuminuria in people with heart failure raises uncertainty as to 
the effects of the drug in CKD populations. If sacubitril/valsartan increased albuminuria 
in people with CKD (who often have much higher levels of albuminuria) this would be 
of significant concern given the established link between albuminuria and progression 
of CKD.4,29  
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 Cardiovascular effects of sacubitril/valsartan 
In early heart failure, NP levels increase to counteract salt and water retention. Over 
time the effects of NPs are negated by up-regulation of neurohormonal pathways 
(including RAS and the sympathetic nervous system) which causes further salt and 
water retention. In animal models of cardiac disease, sacubitril/valsartan improved 
cardiac dysfunction and remodelling compared with isolated NEP or RAS 
inhibition.207,208 
 
 Effects on cardiac biomarkers 
In heart failure, NT-proBNP is an important and useful prognostic biomarker as it is not 
degraded by NEP (unlike BNP), so changes in NT-proBNP concentrations can be used 
to assess disease severity in patients treated with NEPi.177,195  
The Comparison of Sacubitril/Valsartan versus Enalapril on Effect on NT-proBNP in 
Patients Stabilized from an Acute Heart Failure Episode (PIONEER-HF) trial, 
randomized 881 patients with acute decompensated heart failure due to HFrEF, to 
sacubitril/valsartan (n=440) or enalapril (n=441).209 Sacubitril/valsartan was associated 
with a significant 46.7% time-averaged reduction in geometric mean NT-proBNP 
concentration (at 4 and 8 weeks versus baseline) compared with a 25.3% reduction 
with enalapril (ratio of change 0.71; 95% CI 0.63-0.81; P<0.001).209 There was no 
heterogeneity in the treatment effect of sacubitril/valsartan on NT-proBNP by eGFR at 
baseline (P for interaction = 0.81) or by any other subgroup.209  
Sacubitril/valsartan reduced mean concentrations of high-sensitivity troponin T (hs-
TnT)  by 16% (P<0.001) and soluble suppression of tumourigenicity-2 (sST2; a marker 
of cardiac stress, stretch and fibrosis and a prognostic marker in ADHF) by 9% 
(P=0.0035) and this reduction emerged by 4 weeks, compared with enalapril.210 
Exploratory analyses suggested sacubitril/valsartan reduced heart failure re-admission 
rates compared with enalapril (35/440 [8.0%] versus 61/441 [13.8%] respectively; HR 
0.56 [95% CI 0.37-0.84]).209 
The PARAMOUNT trial assessed the effects of sacubitril/valsartan on NT-proBNP (as 
a marker of LV wall stress) and troponin-T (as a marker of cardiac myocyte damage) 
concentrations.195 At 12 weeks, sacubitril/valsartan resulted in a significant reduction in 
NT-proBNP (the primary outcome) concentration compared with valsartan (ratio of 
change 0.77 [95% CI 0.64-0.92]; P=0.005) but, the effect was not maintained at 36 
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weeks (0.85; 95% CI 0.65-1.09; P=0·20).195 Ratio of change in hs-TnT between 
sacubitril/valsartan and valsartan was only marginally significant at 12 weeks post-
randomization (0.88; 95% CI 0.77-1.00; P=0.05) compared with 36 weeks (0.86; 95% 
CI 0.75-0.99; P=0.03).211  
The change in NT-proBNP concentrations between the two groups remained significant 
at 12 weeks even after adjustment for blood pressure,195,212 suggesting the effects of 
sacubitril/valsartan on cardiac biomarkers may be independent of any blood pressure 
lowering effects.197,217 There was also no significant heterogeneity in the treatment 
effect on NT-proBNP between individuals with an eGFR greater or less than 60 
mL/min/1.73m2 (P=0.18).195  
Similar results were seen in PARADIGM-HF patients with HFrEF in whom NT-proBNP 
concentrations were significantly lower at 1 and 8 months post-randomization in people 
treated with sacubitril/valsartan compared with enalapril (P<0.0001 for difference 
between the groups at both time points).213 Sacubitril/valsartan did not affect 
concentrations of other cardiac biomarkers (including sS2 or galactin-3 [involved in 
tissue repair, cardiac remodelling, and fibrosis in heart failure]).214 
In EVALUATE-HF, sacubitril/valsartan compared with enalapril, produced greater 
reductions between baseline and 12 weeks in concentrations of NT-proBNP (ratio of 
change 0.67; 95% CI 0.59-0.76; P<0.001), hs-TnT (ratio of change 0.83; 95% CI 0.78-
0.88; P<0.001) and, sST-2 (ratio of change 0.94; 96% CI 0.89-0.98; P=0.006).193 Post-
hoc analyses suggested changes in NT-proBNP concentrations may correlate with 
changes in improvements in Kansas City Cardiomyopathy Questionnaire (KCCQ) 
summary score and LV end diastolic volume index on echocardiography.193 
The data from cardiac biomarker studies suggest that sacubitril/valsartan has beneficial 
effects on cardiac structure and function compared with isolated RAS inhibition. Given 
the manifestation of CVD in CKD (with heart failure and sudden cardiac in advanced 
CKD)88 the data from heart failure populations suggest treatment with 
sacubitril/valsartan could potentially provide a similar degree of benefit in people with 
CKD in reducing the burden of cardiovascular complications in this population, as seen 




 Effects on cardiovascular outcomes 
In early heart failure, NP levels increase to counteract salt and water retention. Over 
time the effects of NPs are negated by up-regulation of neurohormonal pathways 
(including RAS and the sympathetic nervous system) which causes further salt and 
water retention. In animal models of cardiac disease, sacubitril/valsartan improved 
cardiac dysfunction and remodelling compared with isolated NEP or RAS 
inhibition.207,208 
In the PARADIGM-HF trial sacubitril/valsartan, compared with enalapril, produced a 
highly significant 20% (914/4187 [21.8%] versus 1117/4212 [26.5%] respectively; HR 
0.80 [95% CI 0.73-0.87]; P<0.001) reduction in the primary endpoint of death from 
cardiovascular causes or hospitalisation for heart failure.194 The individual components 
of the primary endpoint were reduced by a similar proportion with a 20% reduction in 
cardiovascular mortality (558/4187 [13.3%] versus 693/4212 [16.5%]; HR 0.80 [95% CI 
0.71-0.89]; P<0.001) and a 21% reduction in hospitalisation for worsening heart failure 
(537/4187 [12.8%] versus 658/4212 [15.6%]; HR 0.79 [95% CI 0.71-0.89]; P<0.001).194  
Sacubitril/valsartan reduced all-cause mortality by 16% compared with enalapril 
(711/4187 [17.0%] versus 835/4212 [19.8] respectively; HR 0.84 [95% CI 0.76-0.93]; 
P<0.001). There was no heterogeneity in the treatment effect with sacubitril/valsartan 
on the primary outcome in a range of baseline subgroups including: eGFR above or 
below 60 mL/min/min/1.73m2 (P value for interaction = 0.91), presence or absence of 
diabetes mellitus (P value for interaction = 0.40), systolic blood pressure above or 
below the trial median value (P value for interaction = 0.87).194 
There were 1546 deaths in PARADIGM-HF: 711 deaths amongst participants allocated 
sacubitril/valsartan and 835 amongst those allocated enalapril.215 80.9% (1251/1546) 
of deaths were due to cardiovascular aetiologies; 13.3% amongst participants allocated 
sacubitril/valsartan and 16.5% amongst participants allocated enalapril.215 44.8% of 
cardiovascular deaths were due to sudden cardiac death (defined as an unexpected 
death in an apparently stable patient last seen 24 hours prior to death) and 26.5% were 
due to worsening heart failure.215 Treatment with sacubitril/valsartan, compared with 
enalapril, reduced the risk of sudden cardiac death by 20% (HR 0.80; 95% CI 0.68-
0.94; P=0.008) and death due to worsening heart failure by 21% (HR 0.79; 95% CI 
0.64-0.98; P=0.034).215  
Analyses of the effect of sacubitril/valsartan across a range of systolic blood pressure 
values (less than 110 mmHg and above 140 mmHg) demonstrated a consistent risk 
reduction in the primary outcome even in people with extremely low blood pressure (a 
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population of patients with heart failure at particularly high risk of adverse outcomes), 
compared with enalapril.216 The precise mechanism by which sacubitril/valsartan, 
influences cardiovascular mortality is unknown although suggested mechanisms 
include; counter-regulation of RAS and sympathetic nervous systems, upregulation of 
NP levels and reduced myocardial fibrosis and remodelling.215  
In PARAGON-HF allocation to sacubitril/valsartan, compared with valsartan, 
numerically reduced the number of events for each of the components of the primary 
outcome of the trial (a composite of total hospitalizations for heart failure and 
cardiovascular mortality), but these changes were not statistically significantly (894 
events in 526/2407 versus 1009 events in 557/2389 respectively; Rate Ratio 0.87 [95% 
CI 0.75-1.01]; P=0.06).196 Sacubitril/valsartan (compared with valsartan) had no effect 
on cardiovascular mortality (204/2407 [8.5%] versus 212/2389 [8.9%] respectively; HR 
0.95 [95% CI 0.79-1.16]) or all-cause mortality (342/2407 [14.2%] versus 349/2389 
[14.6%] respectively; HR 0.97 [95% CI 0.84-1.13]).196 
Sacubitril/valsartan was associated with greater improvements in NYHA class from 
baseline to 8 months, compared with valsartan (347/2316 [15%] versus 289/2302 [12.6] 
respectively; Odds Ratio [OR] 1.45 [95% CI 1.13-1.86).196 At 8 months, the mean 
change in KCCQ clinical summary score was 1.0 (95% CI 0.0-2.1) point higher in 
participants allocated sacubitril/valsartan, suggesting reduced symptoms and physical 
limitations compared with valsartan.196 
The similarities in the manifestation of CVD observed in patients with advanced CKD 
and patients with HF raises the hypothesis that treatments proven to be effective in 
heart failure may prove beneficial in CKD populations.  
 
 Safety concerns with sacubitril/valsartan 
 
 Angioedema 
A major safety concern with ARNIs has been of risk of developing angioedema. In 
PARAMOUNT, only one case of angioedema occurred in a patient taking 
sacubitril/valsartan but they were not admitted to hospital.195 In the EVALUATE-HF trial 
only one case of angioedema was reported in a patient allocated enalapril. In 
PIONEER-HF seven cases of angioedema occurred; one case in a participant allocated 
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sacubitril/valsartan and six cases in participants (all of black ethnicity) allocated 
enalapril (RR 0.17; 95% CI 0.02-1.38).193,209,217 
In PARADIGM-HF (the largest trial of sacubitril/valsartan) angioedema rates did not 
differ significantly with sacubitril/valsartan compared with enalapril, and no cases of life-
threatening angioedema with airway compromise occurred (Table 3).  
 
Angioedema severity Sacubitril/valsartan 
(n=4187) (%) 
Enalapril  
 (n=4212) (%) 
P 
value 
No treatment or treated only 
with antihistamines  10 (0.2) 5 (0.1) 0.19 
Treatment with glucocorticoids 
or catecholamines without 
admission to hospital 
6 (0.1) 4 (0.1) 0.52 
Admitted to hospital but no 
evidence of airway compromise 3 (0.1) 1 (<0.1) 0.31 
  
Table 3: Angioedema rates in PARADIGM-HF patients treated with sacubitril/valsartan 
and enalapril  
Table adapted from McMurray, et al. NEJM 2014.194 
 
In PARAGON-HF, sacubitril/valsartan was associated with a significant 0.4% absolute 
excess in cases of angioedema without airway compromise, compared with valsartan 
(14/2407 [0.6%] versus 4/2389 [0.2%]; P=0.02).196 
 
 Renal safety 
In PARAMOUNT, rates of renal serious adverse events were similar between 
sacubitril/valsartan and valsartan (2/149 [1%] versus 3/152 [2%]; P=0.98).195 Overall 
rates of all adverse event reports of ‘renal dysfunction’ (3/149 [2%] versus 7/152 [5%]; 
P=0.34) and ‘hyperkalaemia’ (12/149 [8%] versus 9/152 [6%]; P=0.50) were similar in 
those allocated sacubitril/valsartan and valsartan respectively.195  
Rates of the more specific renal adverse event of ‘worsening renal function’ (defined 
as an increase in serum creatinine of more than 26.5 µmol/l [0.3 g/dL] and/or an 
increase of more than 25% between two time-points), severe hyperkalaemia or 






Adverse event (AE) Sacubitril/valsartan 
(n=149) (%) 
Valsartan 
 (n=152) (%) 
P value 
Worsening renal function 
12 weeks 6 (5) 9 (7) 0.68 
36 weeks 7 (6) 16 (13) 0.08 
Anytime during the trial 16 (12) 25 (18) 0.28 
 
≥50% decline in eGFR 5 (3) 4 (3) 0.98 
Potassium ≥6.0 mmol/L 5 (3) 6 (4) 0.97 
 
Table 4: Renal safety data from PARAMOUNT with sacubitril/valsartan and valsartan-
alone 
Adapted from Solomon, et al. Lancet 2012.195 
 
In the PARADIGM-HF and PARAGON-HF trials, rates of hyperkalaemia occurred less 
frequently with sacubitril/valsartan than enalapril or valsartan respectively (Table 
5).194,196 In PARADIGM-HF, sacubitril/valsartan was associated with significantly fewer 
rises in serum creatinine above 221 µmol/L than with enalapril and, there were fewer 
discontinuations of sacubitril/valsartan for renal impairment compared with enalapril 
(10.7% versus 12.3% respectively; P=0.03).194  
Rates of hyperkalaemia (potassium greater than 5.5 mmol/L) were much lower 
amongst participants allocated sacubitril/valsartan in both PARADIGM-HF and 
PARAGON-HF (Table 5). In PARADIGM-HF participants taking mineralocorticoid 
receptor antagonists at baseline, allocation to sacubitril/valsartan was associated with 
a lower incidence of severe hyperkalaemia (serum potassium above 6.0 mmol/L) 
compared with enalapril (2.2 versus 3.1 per 100 patient-years respectively; HR 1.37 
[95% CI 1.06-1.76]; P = 0.02).218 
 






































63 (1.5) 82 (2.0) 0.10 38 (1.6) 40 (1.7) 0.79 
 
Table 5: Renal adverse events following treatment with sacubitril/valsartan in patients 
with heart failure 
Adapted from McMurray JJ, et al. NEJM 2014194 and Solomon SD, et al. NEJM 2019196 




In PIONEER-HF, there was no difference in rates of worsening renal failure (defined as 
fall in eGFR of 25% or more and a rise in serum creatinine of 44 micromol/L or higher) 
between sacubitril/valsartan compared with enalapril (60/440 [13.6] versus 65/441 
[14.7%] respectively; RR 0.93 [95% CI 0.67 to 1.28]).209 Sacubitril/valsartan, was 
associated with numerically, but not statistically, higher rates of hyperkalaemia (51/440 
[11.6%] versus 41/441 [9.3%] respectively; RR 1.25 [95% CI 0.84-1.84]) and 
symptomatic hypotension (66/440 [15.0%] versus 56/441 [12.7%] respectively; RR 1.18 
[95% CI 0.85-0.64]).209 
The rate at which sacubitril/valsartan is titrated to maximum treatment doses has not 




In PARADIGM-HF, symptomatic hypotension occurred more frequently with 
sacubitril/valsartan than enalapril (588/4187 [14%] versus 388/4212 [9.2%]; P<0.001), 
as did symptomatic hypotension with systolic blood pressure of less than 90 mmHg 
(112/4187 [2.7] versus 59/4212 [1.4%]; P <0.001). Similarly in PARAGON-HF, 
sacubitril/valsartan was associated with a 5% excess in cases of hypotension with a 
systolic blood pressure less than 100 mmHg compared with valsartan (380/2407 
[15.8%] versus 257/2389 [10.8%]; P<0.001).196  
Despite the hypotension, fewer participants allocated sacubitril/valsartan, compared 
with enalapril, discontinued study treatment because of adverse events in PARADIGM-
HF (448/4187 [10.7%] versus 518/4212 [12.3%] respectively; P=0.03) and in 
PARAGON-HF, compared with valsartan (371/2407 [15.4%] versus [387/2389 [16.2%] 
respectively).197,199,216 Importantly, a lower blood pressure associated with 
sacubitril/valsartan did not adversely affect renal function in either trial and in 
PARADIGM-HF sacubitril/valsartan was associated with fewer withdrawals of study 
treatment due to renal impairment (0.7% versus 1.4% with enalapril; P=0.002).194,196,213  
 
 Liver safety 
Rates of liver-related adverse events did not differ between sacubitril/valsartan and 
valsartan in PARAGON-HF (151/2407 [6.3%] versus 178/2389 [7.5%] respectively; 
P=0.11).196 No significant liver-related adverse events were reported in other heart 




There is a theoretical concern that NEP inhibition may affect cognition and lead to the 
development of dementia, as NEP is one of the enzymes involved in the breakdown of 
β-amyloid (Aβ).219 In Alzheimer’s dementia (AD) and cerebral amyloid angiopathy 
(CAA) there is an accumulation of Aβ peptides in the brain.220 Several other amyloid-
degrading enzymes are involved in the degradation of Aβ (including; ACE, ECE-1, 
NEP2 and insulin degrading enzyme) in addition to amyloid transporters (such as 
apolipoprotein E).221 In order for NEP inhibitors to influence Aβ accumulation in the 
brain, the drugs would need to cross the blood-brain barrier. Accumulation of Aβ occurs 
over many years before any clinical manifestations of dementia occur, so studies in 
humans to assess the potential effects of NEP inhibition on the brain would require 
long-term follow-up. 
Due to concerns regarding cognition, studies (a short-term study lasting 2 weeks and 
a long-term study over 39 weeks) were undertaken in cynomolgus monkeys (which 
have greater evolutionarily resemblance to humans than other animals) to assess 
whether sacubitrilat crossed the blood-brain barrier and what, if any, effect 
sacubitril/valsartan had on cerebrospinal fluid concentrations of Aβ isoforms A.222 
Despite very low levels of sacubitril/valsartan in the cerebrospinal fluid compared with 
plasma, sufficient NEP inhibition occurred in the cerebrospinal fluid resulting in a rapid 
rise in Aβ isoforms 1-40, 1-38 and Aβ total due to impaired clearance.222 There was no 
change in brain levels of Aβ isoforms and brain histology showed no treatment-related 
increases in Aβ deposition or plaque formation with the brain or cerebral vasculature.222  
A study similar to that undertaken in monkeys was performed in healthy human 
volunteers.223 The study randomized healthy volunteers to sacubitril/valsartan (n=21) 
or matching placebo (n=22) for 14 days and undertook serial cerebrospinal fluid 
sampling.223 Sacubitril/valsartan did not significantly affect levels of Aβ isoforms 1-42 
and 1-40 (the two isoforms found in amyloid plaques within the brains of patients 
affected with Alzheimer’s) compared with placebo but levels of Aβ 1-38 were 
significantly elevated.223 The clinical relevance of a rise in Aβ 1-38 in the brain or its 
effect on cognitive decline is unknown.  
Due to these concerns, the PARADIGM-HF investigators undertook a detailed review 
of Medical Dictionary for Regulatory Activities (MedDRA) terms reported. Using “broad” 
and “narrow” preferred terms (PTs), no increase in cognition, memory or dementia-
related adverse events with sacubitril/valsartan compared with enalapril was found.224 
The age-adjusted annual rate of broad PT adverse events reports in participants 
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assigned sacubitril/valsartan was 0.95 (95% CI 0.75-1.15) per 100 patient-years group 
compared with 0.98 (95% CI 0.77–1.19) per 100 patient-years in participants assigned 
enalapril.224 
A more detailed sub-study examining the effects of sacubitril/valsartan on cognitive 
function was undertaken in the PARAGON-HF trial. Change in mini mental state 
examination [MMSE] at 2 years was assessed, and the results of this sub-study are 
awaited.225   
 
 Metabolic effects 
In vitro studies showed NPs stimulated lipolysis in adipocytes and, in patients with heart 
failure infusions, of ANP led to increased circulating levels of free fatty acids.226 Excess 
lipid mobilization could potentially cause ectopic fat storage in muscles and in the liver 
resulting in insulin resistance, as seen in type 2 diabetes mellitus.226 
In a large Mendelian randomization study among people without type 2 diabetes 
mellitus or cardiovascular disease, an inverse relationship between levels of NT-
proBNP and risk of type 2 diabetes mellitus was shown, suggesting BNP may have a 
protective role in this disease.227  
In animals with SSH, sacubitril/valsartan, compared with valsartan, did not have any 
effects on insulin, glucose or lipids.189 In a study of 98 people with obesity and 
hypertension, 8 weeks of treatment with sacubitril/valsartan was associated with 
improved insulin sensitivity without significant effects on fasting levels of serum free 
fatty acids despite increased adipose tissue lipolysis.228  
In PARADIGM-HF, at baseline 35% (2907/8274) of participants reported having 
diabetes mellitus.229 Amongst those without a known diagnosis of diabetes mellitus, 
39% (2103/5367) were found to have pre-diabetes (HbA1C between 6.0% and 6.5%) 
and 21% (1106/5367) had “undiagnosed diabetes mellitus” identified by a HbA1C of 
6.5% or greater.229 
In a post-hoc analysis of 3778 PARADIGM-HF participants (of which 1904 were 
allocated sacubitril/valsartan and 1874 allocated enalapril) who at screening had a 
diagnosis of diabetes mellitus or HbA1C of 6.5% or greater (98% of whom had type 2 
diabetes mellitus), at 3 years post-randomization, sacubitril/valsartan was associated 
with a reduction in HbA1C of 0.14% (95% CI -0.23 to -0.06; P=0.0055), compared with 
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enalapril.230 The reduction in HbA1C was only present in individuals reporting presence 
of diabetes at screening and did not correlate with baseline HbA1C level.230 
Participants not on insulin therapy at baseline assigned to sacubitril/valsartan, 
compared with enalapril, had a 29% (114/1904 [7%] versus 153/1874 [10%] 
respectively; HR 0.71 [95% CI 0.56-0.90; P=0.0052) reduction in subsequent initiation 
of insulin therapy and, 23% (HR 0.77; 95% CI 0.58-1.02; P=0.073) lower risk of initiating 
oral hypoglycaemic treatments.230 In patients without diabetes at screening, 
sacubitril/valsartan had no effect on initiation rates of insulin or oral hypoglycaemic 
agents.230 
When risk of the primary outcome (hospitalisation for heart failure or cardiovascular 
mortality) was stratified by eGFR categories, declining eGFR in individuals with 
diabetes was associated with increased risk compared to individuals with normal kidney 
function and no diabetes.229 An eGFR of 30 to 40mL/min in participants with diabetes 
was associated with about a 3-fold increase in risk of the primary outcome (HR 2.87; 
95% CI 2.04-4.06) compared with individuals with normoglycemia. In people with 
diabetes even an eGFR of 90 mL/min or greater was associated with a 25% (HR 1.25; 
95% CI 0.88-1.76) increase in risk of the primary outcome, compared with normal 
kidney function and no diabetes.229 The beneficial effects of sacubitril/valsartan on 
reduction in risk of the primary outcome were unrelated to HbA1C level or diabetes 
status.229 
High-density lipoprotein (HDL) cholesterol concentrations were marginally higher in 
those allocated sacubitril/valsartan, compared with enalapril (overall increase 0.02 
mmol/L [95% CI 0.00-0.03]; P=0.043).230 Both treatments produced a similar reduction 
in triglyceride levels (overall difference 0.01 mmol/L [95% CI -0.09 to 0.07]; P=0.83).230 
Body mass index (BMI) increased by 0.28 (95% CI 0.14-0.41; P<0.0001) kg/m2 in 
people assigned sacubitril/valsartan, compared with enalapril, despite favourable 
effects on other metabolic parameters.230 
 
 Sacubitril/valsartan in CKD and thesis aims 
 
The data from the hypertension and heart failure trials of neprilysin inhibition with ARNIs 
suggests that this treatment may improve cardiovascular and renal outcomes in 
patients with CKD. However, the safety and efficacy of ARNI on renal progression and 
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albuminuria in patients with advanced CKD particularly those with significant levels of 
albuminuria are unknown.  
The key aim of this thesis was to examine the effects of the ARNI sacubitril/valsartan 
in patients with CKD. All prior evidence of the effects of ARNIs in CKD had been 
extrapolated from animal models of CKD and from randomized trials of patients with 
mildly impaired renal function participating in trials of heart failure and hypertension. To 
fill this gap in evidence, a double-blind randomized controlled trial was undertaken to 
reliably test the effects of sacubitril/valsartan in people with CKD. 
The United Kingdom (UK) Heart and Renal Protection (HARP)-III trial compared 
sacubitril/valsartan against irbesartan in 414 patients with CKD stages 3 and 4. The 
trial assessed the short-term safety and efficacy of sacubitril/valsartan in this patient 
population and was the first dedicated test of an ARNI in CKD.  
The primary outcome of UK HARP-III was to compare the effect of sacubitril/valsartan 
with irbesartan (an ARB) on change in measured glomerular filtration rate (mGFR) from 
baseline to twelve months. Secondary aims of the trial examined in this thesis include 
the assessment of the effects of sacubitril/valsartan on urine albumin:creatinine ratio 
and eGFR. Tertiary aims assessed the short-term safety and tolerability of 
sacubitril/valsartan in people with CKD, its effects on blood pressure, rate of change in 







This Chapter describes the design, outcomes and statistical methods of the UK Heart 
and Renal Protection (HARP)-III trial. 
 
 UK HARP-III: a randomized-controlled trial 
 
The UK HARP-III trial was a randomized, double-blind, placebo-controlled, multicentre 
trial comparing NEPi with sacubitril/valsartan with an ARB, irbesartan, in people with 
CKD stages 3 and 4. 
Randomized controlled trials (if appropriately sized) provide the most reliable estimates 
of treatment efficacy.231-233 Most treatments have only moderate effects on outcomes 
and proper randomization allows control of bias, enabling such moderate differences 
in outcomes to be assessed reliably.131,233-237 Randomization ensures that each 
different type of patient entered into the trial will be allocated to each treatment in similar 
proportions, so any confounders (known or unknown) will also be equally distributed 
between the randomized groups.234,235,237 Therefore, only random differences should 
affect the final comparison of treatment effects.234,235   
Effective treatment allocation concealment (as well as proper randomization) is 
essential to prevent imbalances in prognostic factors and biased results.238 The biases 
that could arise with inadequate allocation concealment could be of a similar magnitude 
to the treatment effect and therefore, the observed size of the treatment effect could 
appear much larger or smaller than it actually is or even be completely masked.239-241 
Non-randomized treatments comparisons do not guarantee that any systematic 
differences between patients given each treatment were not just due to chance alone. 
For example, in such studies, foreknowledge of the treatment allocation would result in 
selection bias (i.e. only those participants deemed to have the greatest benefit from the 
treatment would be entered in the trial) and biased reporting of outcomes of 
interest.232,242 As a result, such comparisons could produce the wrong result since the 
potential biases and random error could erroneously show the treatment as being 
beneficial, harmful or having no effect due to differences in outcomes that are unrelated 
to the treatment being tested.131,234,235,242 
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 Trial aims 
 
The UK HARP-III trial aimed to randomize at least 400 participants aged 18 years or 
over with CKD (eGFR of 20 or above and below 60 mL/min/1.73m2) to receive either 
sacubitril/valsartan or irbesartan and, to follow them up for 12 months. The trial protocol 
was amended in May 2015 to extend follow-up from the originally planned 6 months to 
12 months in light of new data that suggested sacubitril/valsartan took longer (about 9 
months) to have full effect.200 Irbesartan was chosen as the comparator as it has a 
license for treatment of proteinuric CKD.243  
The primary aim of UK HARP-III was to assess the difference in effect of 
sacubitril/valsartan, compared with irbesartan, on mGFR (measured using 51Cromium-
ethylenediaminetetraacetic acid [51Cr-EDTA], or 99mTc-diethylenetriaminepentaacetic 
acid [DTPA], or iohexol methods depending on local practice) at 12 months. Secondary 
aims included effects of sacubitril/valsartan on albuminuria and eGFR in people with 
CKD (Table 6). Tertiary aims included assessment of safety and tolerability of 
sacubitril/valsartan and its effects on blood pressure, rate of change in eGFR and 
biomarkers of cardiac damage (troponin I and NT-proBNP) (Table 6). 
 
Primary 
mGFR at 12 months 
Secondary 
• Study average uACR 
• Study average eGFR  
Tertiary 
• Study average systolic and diastolic BP (mmHg) 
• Rate of change of eGFR calculated from creatinine values at Randomization, 1, 3, 6, 
9 and 12 months (overall, and separately for 0-3 months [i.e., Randomization, 1 and 3 
month values] and 3-12 months [i.e., 3, 6, 9 and 12 month values]) using the CKD-
Epidemiology Collaboration formula. Where values from the central laboratory are 
available (randomization, 3, 6 and 12 months) these will be used, but local values will 
be used at 1 and 9 months. 
• Cardiac biomarkers (troponin I and NT-proBNP) at 6 and 12 months 
Table 6: UK HARP-III trial aims 
BP = blood pressure; CKD = chronic kidney disease; eGFR= estimated glomerular filtration rate; mGFR = 
measured glomerular filtration rate; NT-proBNP = N-terminal of the prohormone brain natriuretic peptide; 





 UK HARP-III trial population 
 
Men and women aged 18 years or over with CKD (based on eGFR results for at least 
three months estimated using either the modification of diet in renal disease [MDRD] 
or CKD-Epidemiology Collaboration [CKD-EPI] formulae) were eligible to participate if 
they had: 
• an eGFR of 20 or greater but less than 45 mL/min/1.73m2, OR  
• an eGFR of 45 or greater but less than 60 mL/min/1.73m2 AND a uACR greater 
than 20 mg/mmol (or urine protein:creatinine ratio [uPCR] greater than 30 
mg/mmol) 
 
The original trial protocol required all patients to have a uACR greater than 20 mg/mmol 
irrespective of eGFR. This was subsequently changed by the trial steering committee 
in February 2015 to apply to only those individuals with an eGFR of 45 mL/min/1.73m2 
or greater but less than 60 mL/min/1.73m2 to aid recruitment. In addition to satisfying 
all of the eligibility criteria, patients were only considered as potentially eligible to 
participate if their nephrologist did not believe there was any definite indication for or 
contraindication to sacubitril/valsartan and none of the exclusion criteria were met 
(Table 7).  
The inclusion criteria were kept deliberately broad and simple to enable inclusion of a 
wide range of patients with CKD (in whom the treatment effects are uncertain), ensuring 
that the trial results would be widely generalizable and could illustrate the overall 
treatment effect more reliably in this population (in addition to making recruitment easier 






• Men or women aged ≥18 years (at screening) 
• Established CKD: 
o eGFR ≥20 <45 mL/min/1.73m2 (estimated with the MDRD formula); or 




• ARB therapy contraindicated e.g. bilateral renal artery stenosis 
• Known intolerance of ARB 
• Current treatment with aliskiren (a direct renin inhibitor) 
• Mean systolic blood pressure >180 mmHg at screening visit (or investigator unwilling 
to withdraw ACEi or ARB for another reason) 
• Serum potassium >5.5 mmol/L 
• Patients that currently have nephrotic syndrome (i.e. uPCR >350 mg/mmol [or uACR 
>300 mg/mmol] AND serum albumin <30 g/L) or if patients are currently receiving 
immunosuppression to treat the nephrotic syndrome 
• Functioning renal transplant 
• Acute coronary syndrome, stroke or transient ischaemic attack in 3 months prior to 
screening 
• Known chronic liver disease or alanine aminotransferase (ALT) / aspartate 
aminotransferase (AST) >2x upper limit of normal (ULN) at screening 
• History of angioedema (drug-related or otherwise) 
• Use of unlicensed investigational medicinal product in previous month 
• Pregnancy, lactating women, or women with child-bearing potential (refusing a reliable 
method of contraception) 
• Medical history that might limit the patient’s ability to take study treatments for the 
duration of the study (e.g. severe respiratory disease, or recent history of alcohol or 
substance misuse or history of cancer or evidence of spread in last 5 years other than 
non-melanoma skin cancer) 
 
Table 7: UK HARP-III trial inclusion and exclusion criteria 
ACEi = angiotensin converting enzyme inhibitor; ARB = angiotensin receptor blocker; eGFR = estimated 
glomerular filtration rate; uACR = urine albumin:creatinine ratio; uPCR = urine protein:creatinine ratio 
 
 
 Trial design  
 
The trial design and detailed information regarding the study schedule are 






Figure 7: UK HARP-III trial design overview  








































































































































































 Central coordination of the trial 
 
 Trial organisation 
The University of Oxford was the trial sponsor. The Central Coordinating Office (CCO) 
for UK HARP-III was based at the Clinical Trial Service Unit & Epidemiological Studies 
Unit (CTSU), University of Oxford. At each local study site, a senior nephrologist was 
designated as the local lead investigator (LLI) and local research nurses (local 
research coordinator [LRC]) worked together with the LLI to identify, recruit and 
follow-up study participants.  
 Staff training 
Prior to initiating recruitment, LRCs received training in the study procedures and the 
web-based data capture system at the CCO. The web-based system enabled direct 
entry and recording of data to avoid any data transcription errors. Research staff 
conducting trial visits and procedures undertook a series of exercises following the 
training to confirm that they understood the study protocol and procedures and were 
confident with using the web-based study information technology (IT) system. 
Additional training was provided if indicated.  
The LLIs and LRCs were provided with all materials relevant to the study procedures 
to enable them to perform the daily study-related tasks, including a Manual of 
Operations. 
During the recruitment phase, regular teleconferences were arranged for the research 
nurses to provide additional advice and support and to answer any general/non-
urgent queries. In addition, annual meetings were held for the research nurses to be 
updated on study procedures and progress.  
 Data management 
The UK HARP-III study IT system, Cello, was a web-based direct data entry system. 
CCO staff used the system to manage drug supply, track adverse events, and for 
central monitoring of the study. All access required a unique username and password, 
and any changes to data required the user to enter their username and password as 
an electronic signature. Staff access was restricted according to their role in the study. 
 Trial treatments 
The manufacturer of sacubitril/valsartan (Novartis) provided both study treatments 
and their matching placebos. Cases of study treatment were shipped at appropriate 
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intervals to the local centres (guided by remaining supplies at local sites) at the 
request of administrators at the CCO. Study treatment packs consisted of two bottles: 
one containing active or placebo tablets of sacubitril/valsartan and the other 
containing active or placebo capsules of irbesartan. 
Study treatments were stored at or below 25°C (with regular temperature monitoring) 
and LRCs were trained on how to issue study treatments as guided by Cello. Issue 
of study treatments required the entry of a verification code from the study treatment 
pack to ensure that the correct treatment pack was selected for the participant, at 
sites where LRCs issued study treatment themselves. At those sites where LRCs 
were not permitted to issue study treatment, it was stored and issued from the local 
site pharmacy, but the verification code check was not available. Local pharmacy staff 
were responsible for ensuring that the correct pack was issued to the participant by 
manually checking the verification code against the issuing information provided by 
Cello.  
 
 Local clinical centres 
At each of the local study sites, a local clinical centre (LCC) was established. LCC 
staff were responsible for assisting with obtaining local research approval, conducting 
the trial procedures according to the study protocol, dealing with routine enquiries 
from patients and their families or other personnel and obtaining and providing the 
relevant information for study outcomes (e.g. laboratory and mGFR results). 
The LLI was responsible for trial oversight at the LCC and ensuring that the study 
protocol was adhered to. The LLI could delegate duties (specified on the delegation 
of duties log) to other staff members (e.g. permitting study nurses to take informed 
consent and perform all trial visits) but retained overall responsibility for all aspects of 
the study conducted at the LCC. LCCs were established at 24 sites (Appendix 2: 
Supplementary material) across the UK. 
I travelled to several sites to address any issues local staff had with establishing the 
LCC (for example, concerns relating to issuing study treatment). The visits increased 
awareness of the trial amongst clinical staff and encouraged participant recruitment 




 Identification and invitation 
UK HARP-III piloted a new method of recruiting participants into renal trials to test 
whether such methods enabled faster and more efficient recruitment.  
Local site study staff were advised to identify potentially eligible patients primarily 
from electronic hospital databases. Study staff could supplement this with 
identification of patients from lists of clinic attendees, consultant referrals and patients 
self-referring (for example, from having viewed the study poster [Appendix 3: study 
poster] or visiting the study website). Once identified, a brief check of suitability for 
participation was performed using hospital medical records for any obvious reason 
for ineligibility before patients were invited. 
Potentially eligible patients were then sent a copy of the invitation letter and 
Participant Information Leaflet (PIL; Appendix 4) or provided with this in clinic on 
behalf of the LLI. Study staff then telephoned these individuals about a week later to 
discuss the trial with them in detail, answer any questions or concerns they might 
have and to check whether they were interested in participating.  
Interested individuals were offered an appointment to attend a screening visit and 
some basic demographic information was entered into the study IT system after 
obtaining verbal consent. 
 
 Screening visit 
At the screening visit, eligibility was checked by asking questions pertaining to the 
inclusion and exclusion criteria (Table 7) and answers were recorded directly into the 
screening case report form in the study database. If any of the exclusion criteria were 
met and patients were deemed ineligible the visit ended at this point. For eligible 
patients, after written informed consent was obtained, information regarding relevant 
medical history (including primary renal diagnosis, cardiovascular disease, and 
presence of diabetes mellitus) and current medications (including total daily doses of 
all anti-hypertensive medications) was recorded. Blood pressure was measured three 
times after sitting for at least 5 minutes (using an Omron M6 automated digital 
sphygmomanometer) in addition to height and weight, and these measurements were 
recorded in the visit form. 
 Consent  
Patients who appeared eligible to participate had the study explained to them by the 
LRC using the Participant Information Leaflet (Appendix 3) as a basis for discussion. 
73 
 
Patients were offered the opportunity to discuss the trial further with their family or 
friends, General Practitioner or usual nephrologist, and those patients who wished to 
do so were asked to attend at a later date for a repeat screening visit. Patients who 
were unlikely to be willing or able to continue taking study treatments and, comply 
with attendance at study follow-up visits for entire the duration of the trial were 
discouraged from participating. Consent was also sought for the storage of blood and 
urine samples. 
 Biological samples  
Blood and urine samples were collected at the screening visit and sent to the local 
laboratory for analysis to confirm eligibility for the trial. Participants provided a random 
urine sample in clinic for quantification of albuminuria and were given a container to 
collect a first morning void urine sample on the day of the randomization visit. 24 hour 
urine collections are the gold standard method for measuring urine albumin excretion 
and verifying the presence of microalbuminuria.244 However, measurement of 
albuminuria in first morning void urine samples have been shown to have high 
agreement with albuminuria quantified from a 24 hour collection, much less 
intraindividual variability and, are much more practical.244 Random spot urine 
collections are associated with significant variation and are therefore not 
recommended.244  
If the results of biological samples collected at screening were deemed to be 
inaccurate, and therefore did not meet the eligibility criteria, the result could be 
repeated once, and the latest result was used to confirm eligibility. If the eGFR result 
was 60 or greater but less than 70 ml/min/1.732 on the sample sent at screening, such 
patients were eligible to continue in run-in if all other eligibility criteria were met. 
 
 Pre-randomization run-in  
Following the screening visit, any current ACEi and/or ARB therapy that the patient 
was taking was stopped and the participant entered the single-blind placebo pre-
randomization run-in period which lasted between four and seven weeks prior to 
randomization. Participants were issued with a run-in treatment pack containing an 
eight-week supply of study treatment and advised to take one tablet of placebo 
sacubitril/valsartan and one capsule of placebo irbesartan daily. Participants were 
also provided with a study treatment information sheet (STIL; Appendix 5). 
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The results of blood and urine samples along with the clinical data collected at 
screening were reviewed by the LLI (or another nephrologist approved by the LLI) to 
approve the participant as suitable for randomization, if appropriate. Those 
participants not eligible for the trial on the basis of results of samples taken at 
screening, or for any other reason in the opinion of the LLI, were telephoned by 
research staff daily and informed. They were advised to stop the study run-in 
treatment and restart any ACEi and/or ARB treatment that was withdrawn at 
screening.  
If raised BP was a concern during run-in, then the LLI or the participants’ usual 
nephrologist was advised to titrate up existing antihypertensive medications (if 
possible) or to start additional treatment but to avoid ACEi, ARB or DRI. The choice 
of additional antihypertensive medication remained at the discretion of the local 
nephrologist.  
Participants could withdraw from run-in at any time prior to randomization. 
Participants who did not withdraw returned between four and seven weeks later to 
have their GFR measured (using 51Cr-EDTA, 9mTc-DTPA or iohexol) and attend for 
the randomization visit. The results of the mGFR test were not required to determine 
eligibility for randomization, as this was based on the eGFR at screening. Copies of 
the mGFR result were sent back to the CCO for confirmation of the result by CCO 
clinical study staff blind to treatment allocation. 
In willing participants, a voluntary 24-hour urine collection was undertaken 24-48 
hours prior to the randomization visit for quantification of albumin and sodium 
excretion (but this was not required for determining eligibility for randomization).  
The aims of the pre-randomization run-in were: (i) to allow a ‘wash-out’ of any ACEi 
prior to potential treatment with NEPi (in light of the risk of angioedema when the two 
treatments are combined); (ii) to allow a comparison of the acute effects of study 
treatments on GFR; and (iii) to improve compliance by excluding people less likely to 
adhere with study treatment and thereby reduce the rate of post-randomization 
discontinuation of study treatments and consequently improve the trial’s statistical 
sensitivity.245-248 
 Randomization 
At the randomization visit, participant’s eligibility and willingness to participate was re-
confirmed. Participants were asked about any serious adverse events since their 
screening visit and compliance with study treatment was checked. Study treatments 
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were required to be taken on average at least six days per week (over 80% of the 
time) for compliance to be regarded as satisfactory. Pill counts were not performed at 
any study visits as these are unreliable and tend to overestimate adherence with 
treatment.233,249-251 Non-study medications were also checked and updated. Blood 
pressure and weight were measured and recorded. 
Participants were not eligible for randomization if: systolic blood pressure was less 
than 110 mmHg (or less than 130 mmHg if they had symptoms of hypotension); or if 
the LLI was concerned about hypotension); or if they reported an adverse event that 
they believed to be related to their (placebo) run-in treatment. The protocol was 
amended in February 2015 (Section 6.2.1.1) to allow inclusion with this lower cut-off 
(110 mmHg) for blood pressure at randomization, with no upper limit (previously set 
as systolic blood pressure of 180 mmHg) as blood pressure would be controlled with 
active study treatment following randomization. 
Participants who: remained willing and eligible; tolerated the run-in medications; were 
willing to comply with taking study treatments; and attend follow-up visits for the trial 
duration (a further 12 months) were eligible to be randomized.  
Participants were randomized 1:1 by Cello which prevented any foreknowledge of 
treatment allocation affecting the decision to enter a patient into the trial (i.e. selection 
bias which would result in patients being systemically different between the treatment 
two arms).234,235,238 Random allocation of treatment ensured that each participant that 
entered into the trial had a similar chance to being allocated to either treatment and 
in similar numbers in each group.235  
Effective treatment allocation concealment (as well as proper randomization) is 
essential to prevent imbalances in prognostic factors and biased results.238 The 
biases that could arise with inadequate allocation concealment could be of a similar 
magnitude to the treatment effect and therefore, the observed size of the treatment 
effect could appear much larger or smaller than it actually is or even completely 
masked.239-241 
A minimization algorithm was used to ensure that the treatment groups were balanced 
with respect to prognostically important factors that could impact the treatment affect 
in patients with CKD,252,253 particularly predictors of renal progression (measured at 
screening) including: age, sex, systolic blood pressure, eGFR, uACR and presence 
of diabetes mellitus.252-254 
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 Randomized treatment and blinding 
At the end of the randomization visit, run-in treatment was collected, and participants 
were issued with a treatment pack containing two bottles of study treatments: one 
containing tablets of sacubitril/valsartan 97/103 mg or placebo and the other 
containing capsules of irbesartan 150 mg or placebo. As both treatments differed in 
their appearance (i.e. tablets and capsules) a “double-dummy” approach was used to 
ensure both participants and all study staff remained blind to treatment allocation to 
minimize bias (such as ascertainment, recall and detection bias).131 The two treatment 
arms that participants were randomized to were as follows: 
• Sacubitril/valsartan plus placebo irbesartan 
OR 
• Irbesartan plus placebo sacubitril/valsartan 
Participants were initially advised to take one tablet and one capsule daily (i.e. either 
sacubitril/valsartan 97/103 mg and placebo irbesartan or placebo sacubitril/valsartan 
and irbesartan 150 mg) for the first two weeks post-randomization.  
The participant’s usual nephrologist and GP were then informed that the participant 
had been randomized into the UK HARP-III trial and advised to avoid any ACEi, ARB 
or DRI for the duration of the trial (if possible). If their managing doctor felt that the 
participant should be started on any ACEi, ARB or DRI treatment during the course 
of the trial, they were advised to discuss this first with the LLI or with a CCO clinician, 
following which the participant could stop their allocated study treatment but would 
continue to attend all remaining follow-up visits. Managing nephrologists were asked 
not to alter antihypertensive therapy during the first four weeks after randomization 
unless absolutely necessary on clinical grounds. 
 Blood and urine samples 
Blood and urine samples were collected for local analysis of creatinine, electrolytes 
(sodium and potassium), liver function tests (alanine aminotransferase [ALT] or 
aspartate aminotransferase [AST] and bilirubin) and uACR. Participants also had 
additional venous blood collected into an EDTA-containing polyethylene tube which 
was kept refrigerated until processing on the same day. The sample was then 
centrifuged at 1500g and the plasma aliquoted into three 2 mL cryovials, and 
additionally two 2 mL cryovials were filled with urine. These samples were then frozen 
and stored at or below -20°C locally, prior to transfer for analysis (at the end of the 




Analyte Time point Randomization 3 months 6 months 12 months 
EDTA plasma samples 
    











    
Urine samples 
    
uACR X x x x 
 
Table 8: Planned central laboratory blood and urine analyses 
NT-proBNP = N-terminal of the prohormone brain natriuretic peptide; urine albumin:creatinine ratio 
 
 
 Forced titration at 2 weeks post-randomization 
At 2 weeks post-randomization, participants were asked to attend either their local 
study centre or general practice to have a blood sample taken to check their renal 
function and potassium. If the results were satisfactory, participants were instructed 
to increase the dose of study treatments to the maximum dose, taking one tablet twice 
daily and two capsules once daily (i.e. either sacubitril/valsartan 97/103 mg twice daily 
and placebo irbesartan once daily or placebo sacubitril/valsartan twice daily and 
irbesartan 300 mg once daily ). If based on these results or due to some other concern 
(such as hypotension) the LLI believed it was inappropriate to titrate the study 
medications, the participant was advised to remain on the lower dose of study 
treatments.    
 
 Follow-up visits (1, 3, 6, 9 and 12 months) 
Study follow-up visits were scheduled at 1, 3, 6, 9 and 12 months post-randomization, 
at which LRCs systematically sought information on adverse events, symptoms of 
hepatitis and whether the participant had required dialysis since their previous study 
visit. The visits could be undertaken up to two weeks either side of the scheduled visit 
date.  
 Adverse events and compliance with trial treatment 
At each study visit, details of all serious adverse events and non-serious adverse 
events that the participant believed to be related to study treatment or leading to its 
discontinuation were recorded directly into the study IT system. Any serious adverse 
events that were considered to be due to study treatment, were discussed 
immediately with a CCO clinician, as such events may have required expedited 
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reporting. An estimation of adherence with study treatment was made from direct 
questioning of participants and pill counts were not performed.233,249-251 
 Physical measurements 
The participants weight and blood pressure were measured at every study visit. Blood 
pressure was measured and recorded three times after the participant had been 
seated for at least five minutes (using an Omron M6 automated digital 
sphygmomanometer). Blood pressure was controlled according to the current Kidney 
Disease Improving Global Outcomes (KDIGO) guidelines for managing blood 
pressure in patients with CKD.59 Blood pressure measurements recorded on visit 
forms were monitored by CCO clinicians and if there was a concern, LRCs were 
contacted and advised to discuss this with their LLI or the participants usual 
nephrologist. The choice of any additional (or withdrawal of) anti-hypertensive 
treatment remained at the discretion of the responsible clinician if required. 
 Blood and urine samples 
At every follow-up visit samples were taken for local measurement of creatinine, 
electrolytes (sodium and potassium), liver function tests (ALT or ALP and bilirubin) 
and uACR. Results of these samples were to be entered into the study IT system 
within 2 working days and were reviewed daily by a CCO clinician, who provided 
advice on any abnormal results including any potassium more than 5.5 mmol/L, ALT 
more than twice the upper limit of normal or a fall in eGFR more than 25% from the 
previous value.  
At the specified visits (3, 6 and 12 months), participants also had an additional blood 
sample collected in an EDTA-containing tube which was centrifuged and the plasma 
aliquoted into three cryovials, with two cryovials filled with urine and these samples 
were then frozen at or below -20°C locally, prior to transfer for analysis in the Wolfson 
laboratory (Table 8).  
Participants were provided with a container at the previous visit (randomization, 1, 3, 
6 and 9 months) and asked to bring a first morning void urine sample with them to 
every clinic visit. If they did not bring a first morning void sample, a random sample 
was provided by the participant when they attended the study clinic. The samples 
were then transported to the coordinating centre’s Wolfson laboratory for analysis and 
long-term storage.  
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 Central laboratory methods 
Creatinine was assayed in the central laboratory on a Beckman Coulter AU680 
analyser using a kinetic alkaline picrate method and calibrated using material 
traceable to isotope dilution mass spectrometry (using the National Institute of 
Standards and Technology Standard Reference Material 967); troponin I was 
measured by immunoassay on an Architect system and NT-proBNP by immunoassay 
on an Elecsys system.255 All analyses were undertaken at the coordinating centres’ 
Wolfson Laboratory, University of Oxford.  
 Issuing trial treatment 
Participants were reminded at every study visit regarding the importance of avoiding 
the use of any non-study ACEi, ARB or DRI and, asked to inform local study staff or 
to contact the CCO if any such treatment was prescribed. At the 3, 6 and 9 month 
visits, participants were re-issued a further supply of their randomized study treatment 
(as each treatment bottle contained 105 days’ supply). Participants were asked to 
return their previously allocated supplies back to the LRC. 
 Final follow-up and mGFR 
All participants were requested to have a second GFR measured using 51Cr-EDTA, 
9mTc-DTPA or iohexol (with the same method being used for all measurements in 
trial participants at that centre) depending on local practice, even if they had 
previously stopped study treatment. In most cases this was performed on the same 
day as their final follow-up visit but if this were not possible, it was arranged during 
the two-week period prior to their scheduled final follow-up visit. Copies of the mGFR 
test result were sent back to the coordinating centre for confirmation of the result by 
clinical trial staff blind to treatment allocation to ensure an unbiased assessment of 
the primary outcome data.  
Once participants had completed the final visit, a letter was sent to the usual 
nephrologist and GP (and a copy provided to the participant in clinic) informing them 
of this and with advice on restarting any prior ACEi and/or ARB 48 hours after the last 
dose of study treatment (to prevent any risk of angioedema with overlap of NEPi and 
ACEi). Participants and study staff were also asked to report any serious adverse 




 Early recall visits 
At any point following randomization prior to the final follow-up visit, an ‘early recall 
visit’ (i.e. additional trial visits outside of the scheduled timeline) could be arranged. 
This could be done at the request of the participant (e.g. if they are experiencing 
troublesome symptoms) or on the advice of CCO or local trial staff (e.g. on the basis 
of the local blood results taken at a preceding trial visit). Abnormal potassium, 
creatinine, or ALT/AST results in samples taken from a trial visit prompted an early 
recall to enable repeat checking. 
 Modifying or discontinuing trial treatment 
Participants were encouraged to adhere to trial treatments throughout the study. 
However, the LLI could decide to discontinue trial treatment at any time in the 
interests of the participant’s health and well-being. For example, trial treatment may 
be temporarily or permanently discontinued for a particular participant if one of the 
following criteria were met: 
• serious adverse events thought likely to be due to trial treatment (suspected 
serious adverse reaction [SSAR]). This usually resulted in permanent 
discontinuation of study treatments unless the investigator and CCO agreed that 
there was justification to continue or restart the study treatment 
• participant started a contraindicated medication (i.e. ACEi, ARB or DRI) for the 
duration of use of the contraindicated medication 
• conditions or procedures in which study treatments may be contraindicated (e.g. 
diagnosis of severe bilateral renal artery stenosis) 
• pregnancy 
• any other situation where, in the opinion of the participant’s own doctors or the 
clinic staff, continuing trial treatments would not be in the participant’s best 
interest  
 
In addition, the participant themselves may have decided not to continue trial 
treatments. If trial treatment was discontinued, the participant was still followed-up for 
the duration of the trial in the usual way (wherever possible). Complete follow-up of 
such data was essential as all planned analysis employed the ‘intention-to-treat’ (ITT) 
principle.236,256 Participants who could not tolerate the full dose of their allocated 
treatment (i.e. sacubitril/valsartan 97/103 mg twice daily or irbesartan 300 mg once 
daily) could halve their dose. If appropriate, participants were encouraged to increase 
their dose again once any symptoms had resolved.  
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 Withdrawal from the trial 
Participants had the right to withdraw from the trial at any time and for any reason 
(without prejudice to his or her future medical care by the physician or at the institution 
where they are usually cared for) and were not obliged to give reasons for doing so. 
If participants were no longer willing to attend trial clinics, then they were asked if they 
would be willing to continue follow-up by telephone and/or relevant data (e.g. eGFR) 
collected directly from their medical records, unless participants withdrew consent for 
this as well. If participants withdrew their consent from all forms of follow-up, they 
were asked to confirm this in writing and the local investigator was asked to complete 
a “Withdrawal of Consent” form to confirm this. 
 
 Statistical analysis 
 
A summary of the main details of the statistical analysis plan are presented below. 
Further details are provided in the published Data Analysis Plan (Appendix 1: 
Supplementary material). 
 
 Sample size calculation 
The primary aim of the trial was to compare the change in mGFR between 
sacubitril/valsartan and irbesartan from the baseline value to final follow-up. This 
could be done most efficiently through use of an analysis of covariance (ANCOVA) 
which compared mean follow-up mGFR between the two treatment groups after 
adjustment for baseline mGFR (and of any random imbalances in baseline 
measurements that occurred between the treatment groups despite 
randomization).233,257-259 ANCOVA has greater statistical power to detect treatment 
effects than other methods.233,258 
Assuming a between person standard deviation in mGFR of 15 mL/min/1.73m2 and 
a correlation between an individual’s baseline and follow-up mGFR of 0.8, 
randomization of 400 participants would provide 80% power (at 2p=0.05) to detect a 
difference in mGFR at final follow-up of 3 mL/min/1.73m2 (the chosen minimum 
clinically meaningful difference), even if 15% of participants discontinued study 
treatment after randomization.  
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 Intention to treat analysis (ITT) 
Analyses of all outcomes were performed using the ITT, i.e. all comparisons 
compared outcomes among all participants randomized to receive sacubitril/valsartan 
97/103 mg twice daily versus all those randomized to receive irbesartan 300 mg once 
daily, regardless of whether or not the participant ever actually took the study 
treatment or the duration that they took it for.234,236,256 ITT analyses avoids introducing 
systematic errors relating to differences between participants who deviated from one 
treatment compared with the other and, in doing so, provides a more reliable 
assessment of whether there is any true difference between the treatments being 
tested and their effects on the outcomes of interest (compared with for example ‘on-
treatment’ analysis).233,234,236,238  
 
 Methods of analysis 
 Analysis of Covariance (ANCOVA) 
Comparisons of continuous variables (listed in Table 9) between the allocated 
treatment arms were performed using ANCOVA adjusted for each patient’s value at 
randomization.258 If continuous variables were not normally distributed then 
appropriate transformations (for example log transformation) were made.260,261  
 
Categorical variables Continuous variables 
Sex† 
Ethnicity†  
CKD stage*  
Prior cardiovascular disease† 
Prior diabetes mellitus†  
Non-trial medications*  
Renin-angiotensin system inhibitor use† 




Systolic blood pressure*  
Diastolic blood pressure*  
Weight*  
Height†  
CKD Epidemiology Collaboration formula 
eGFR*  
Urine albumin:creatinine ratio*  
Potassium*  
Aspartate aminotransferase or Alanine 
aminotransferase* 
Albumin* 
24-hour sodium excretion 
24-hour albumin excretion 
Measured glomerular filtration rate 
N-terminal of the prohormone brain 
natriuretic peptide ‡ 
Troponin I‡ 
 
Table 9: Continuous and categorical data in UK HARP-III 
*Repeated at every follow-up visit. †Recorded at screening. ‡Measured centrally on samples at the time-




 Repeated measures analyses of biomarkers 
In cases where more than one value was available at follow-up of a biomarker (Table 
8), a comparison of the mean value of the biomarker was performed at each follow-
up time using ANCOVA adjusted for the baseline value of the biomarker (to reduce 
variance and bias).233,237,262 
 Imputation of missing data  
As all analyses were performed according to the ITT principle, in cases where there 
was data missing for primary and secondary outcomes, data was imputed (unless the 
participant had died prior to the relevant time-point). For each of the continuous 
outcomes missing post-randomization results were imputed, using 20 imputed 
datasets (generation of 10 or more imputed datasets have been shown to provide 
95% or greater efficiency without significant change in the precision of the 
results),263,264 with results across the imputations combined using the method of 
Rubin.263  
Multiple imputation generated a plausible range of values that approximated the 
missing value and took into account the variability in the results between the imputed 
datasets and the uncertainty with the missing results.263-265 It therefore allowed all 
participants to be included in the analysis, even those with missing data.264  
Multiple imputation is superior to other methods of handling missing data. Use of only 
“complete-cases” (i.e. observations with no missing data), would lead to substantially 
biased results since complete-cases may be very different to those who are not.264-
267 In addition, missing data across several variables would result in a substantial 
proportion of the sample population being excluded resulting in significant loss of trial 
power, precision in estimates and misleading conclusions.264-266  
Single versus multiple imputation would also have been inferior as the imputed value 
is inserted and analysed as if it was the actual value observed.266,267 However, single 
imputation underestimates the uncertainty in the imputed values and so the variance 
becomes progressively and inappropriately smaller and artificially increases the 
precision of the estimate and the likelihood of a type 1 error.266  
Last observation carried forward is another single imputation technique that has been 
used in which the missing value is assumed, incorrectly, to have remained unchanged 
from that previously recorded and therefore, the last recorded value is used to replace 
the missing value.266,267 This approach can also significantly underestimate the result 
and is therefore misleading and not generally used.266,267 
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The multiple imputation procedure used in UK HARP-III trial analyses took into 
consideration each participant’s key baseline characteristics (Appendix 1: 
Supplementary data, section 3), treatment allocation and any intermediate follow-up 
values of the biomarker, where available.  
 Imputation of the primary outcome data 
Participants with a missing randomization mGFR value had their eGFR value at 
randomization imputed in place of the missing result. Participants without a final 
mGFR, had the missing mGFR result imputed using multiple imputation. For any 
participants who progressed to ESKD and commenced chronic dialysis during the 
trial, a value of 0 was imputed for their 12-month mGFR.  
Technical reasons can lead to spurious measured GFR results which would not be 
apparent until after the participant had been randomized into the trial and initiated on 
randomized treatment (or when they stopped taking randomized treatment at the end 
of the trial). The differences between each mGFR value and its corresponding 
creatinine-based eGFR value (collected at the same timepoint as the mGFR test) was 
calculated and the distribution of the differences were inspected prior to any unblinded 
analyses being performed. Where the difference between the mGFR result and the 
central eGFR was more extreme than the 1st or 99th centile of the distribution of 
differences, the value of mGFR was set to missing in those cases. Multiple imputation 
was used to calculate missing mGFR values. The results from the multiple imputation 
analyses were compared with those from equivalent “complete-case” analyses, but 
primary emphasis was placed on the results after multiple imputation. 
  
 Analysis of tertiary outcome: rate of change in eGFR 
The rate of decline in eGFR in those randomized to sacubitril/valsartan and irbesartan 
was assessed using creatinine measurements analysed on central samples collected 
at randomization, 3, 6 and 12 months and using local creatinine results collected at 1 
and 9 months.  
Missing values for eGFR were imputed using multiple imputation and participants with 
the poorest fitting slopes (defined as participants with the mean deviation from their 
own fitted slope in the top 1% of the distribution [of mean deviations across all 




 Allowance for multiplicity of comparisons 
The primary outcome was assessed without adjustment for multiplicity. For secondary 
and particularly the tertiary and exploratory analyses, allowance in their interpretation 
was made for multiple hypothesis testing,236,256 taking into account the nature of 
events (including timing, duration and severity) and evidence from other studies. In 
addition to the pre-specified comparisons, many other analyses were performed with 
due allowance for their exploratory and, perhaps, data-dependent nature.268  
Conventionally, two-sided P-values less than 0.05 are often described as “significant”. 
But, the larger the number of events on which a comparison is based and the more 
extreme the P-value (or, analogously, the further the confidence interval is from zero) 
after any allowance has been made for the nature of the particular comparison (i.e. 
primary, secondary or tertiary; pre-specified or exploratory), the more reliable the 
comparison and, hence, the more definite any finding will be considered.268 
 
 Tests for heterogeneity 
The sample size was powered to detect the overall difference in treatment effect 
between the two groups and therefore the numbers of patients within any subgroups 
would be inadequate to produce a result that could reliably estimate the treatment 
effect in any such subgroup (which would require a substantially larger sample 
size).238,268,269  When a number of different subgroups are considered, chance alone 
may lead to there being an apparent lack of effect (or even a magnified or weakened 
effect) in several subgroups in which the treatment effect is really only about the same 
as that observed overall.268-270 In such circumstances, “lack of direct evidence of 
benefit” is not “good evidence of lack of benefit”, and any obvious significant overall 
result would provide substantial indirect evidence of benefit in some small subgroups 
where the actual results, if they were taken in isolation, were not conventionally 
significant (or could even be harmful).236,256,270 Therefore, unless the proportional 
effect in some specific subgroup is clearly very different from the overall observed 
result, the true treatment effect in that subgroup is best estimated indirectly by 
applying the proportional effect observed among all patients in the trial to the absolute 
risk of the event observed among control patients in that category.268,270   
To account for this, tests for heterogeneity of the proportional effect observed in 
subgroups were used (with allowance for multiple comparisons) to determine whether 
the proportional effects in specific subgroups were clearly different from the overall 
estimated treatment effect.236,256,268 If, however, three or more patient categories could 
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be arranged in some meaningful order (e.g. age at randomization: less than 60; 60 or 
greater but less than 70; 70 or above) then assessment of any trend was made. For 
subgroups based on continuous variables (Table 9), approximate similar sized 
divisions (such as by tertiles) were used, using natural cut-offs to define categories 
(e.g. systolic blood pressure less than 140 mmHg as opposed to less than 138.7 
mmHg). These cut-offs were defined exactly prior to any unblinding of results. 
 
 Trial governance and approvals 
 
The Ethics Committee meeting at which the UK HARP-III trial was reviewed took 
place at the Nottingham Research Ethics Committee (REC)-2 panel on 25th 
November 2013. I attended the meeting with the Chief Investigator. REC approval 
(13/EM/0434) was granted on 17th December 2013. UK HARP-III acquired Medicines 
and Healthcare Products Regulatory Agency (MHRA) approval (Clinical Trial 
Authorisation [CTA] 21439/0243/001-0001) and, obtained local NHS research and 
development (R&D) committee and Administration of Radioactive Substances 
Advisory Committee (ARSAC) approvals at all 24 sites across the UK prior to initiation 
of the trial. The trial manager coordinated the submission of all approvals via the 
centralised Integrated Research Application System (IRAS).  
UK HARP-III was registered with the International Standard Randomized Controlled 
Trial Number (ISRCTN) registry (ISRCTN11958993) prior to recruitment of the first 
participant. All clinical trials require registration with ISRCTN so that there is 
transparency of the whole trial, from development of the protocol through to 
publication of trial results and this is stipulated by organisations such as the World 
Health Organisation (WHO) and the International Committee of Medical Journal 
Editors (ICMJE). ICJME stipulates that clinical trials will not be published unless they 
are registered with a clinical trials registry.  
The European Trials Agency (EMA) mandates additional registration with the 
European Union Drug Regulating Authorities Clinical Trials (EudraCT) database in 
accordance with the European Clinical Trials Directive 2001/20/EC for all Clinical 
Trials of Investigational Medicinal Products (CTIMPs).271 The trial was registered with 
the EudraCT database following ethics committee approval of the first version of the 
protocol and given a unique identification number, EudraCT 2013-004205-89. No 
additional ethics, regulatory or other approvals were required to undertake this thesis.  
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6 Trial Management 
 
 Study coordination 
 
The UK HARP-III trial was coordinated by the CCO based at CTSU, University of 
Oxford. The University of Oxford was the trial sponsor (Figure 13). Oversight of the 
trial and its progress was provided by the Trial Steering Committee (TSC) and safety 
and efficacy data were closely monitored by an independent Data Monitoring 

















Figure 13: Trial coordination structure  
CCO = Central coordinating office; DMC = Data Monitoring Committee; LCC = Local Coordinating 
Centre; SOP = Standard Operating Procedure; TSC = Trial Steering Committee 
  
CCO 
- Trial planning and organisation of TSC meetings  
- Contractual issues with LCCs and budget 
administration 
- Design and maintenance of UK HARP-III trial IT 
systems  
- Safety monitoring  
- Report to regulatory authorities and ethics committee 
- Manage trial drug treatments 
DMC 
- Review unblinded interim trial data in 
accordance with the trial protocol  
- Advise the TSC if, in their opinion, the 
unblinded randomized data provided 
sufficient evidence for early termination 
of the trial or modification of the protocol 
for safety reasons 
TSC 
- Agree final trial protocol  
- Review trial progress and agree 
changes to the protocol and SOPs to 
facilitate the trials progress and 
successful completion  
- Review new evidence that was relevant 
to UK HARP-III  
- Review and approve trial reports for 
publication   
LCC LCC LCC LCC LCC 
LCCs 
- Obtain local Research Governance approval (assisted by 
the CCO)  
- Provide access to appropriate hospital computer systems 
for identification and recruitment of suitable participants 
- Conduct clinic procedures in accordance with the trial 
protocol and SOPs  
- Deal with routine enquiries from participants and their 
families 
- Obtain relevant information to confirm trial endpoints 
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 Central coordination of the UK HARP-III trial 
 
The conduct of a large, multicentre trial like UK HARP-III, requires a multi-disciplinary 
team including amongst others: clinicians, trial managers, administrators, nurses, 
statisticians, and computer programmers.  
The CCO was responsible for overall trial management, establishing local trial sites, 
ensuring the trial protocol was implemented correctly, data collected were complete 
and accurate and, that the results were analysed in accordance with the published 
trial DAP. The CCO carefully monitored the safety of all trial participants and CCO 
clinicians provided advice to healthcare staff regarding their clinical management and 
safety concerns. CCO staff managed the delivery of supplies of all study equipment 
including study treatments, central sample collection kits, blood pressure machines 
and all study documentation. 
I had a central role within the UK HARP-III CCO team and worked closely with the 
Chief Investigator of the trial, Professor Richard Haynes and, the two Principal 
Investigators, Professor Colin Baigent and Professor Martin Landray, who maintained 
overall responsibility for the trial. The Chief Investigator was responsible for the 
design and overall conduct of UK HARP-III. 
I helped prepare documents for regulatory approvals and supported and supervised 
the trial administrative team with setting up local study sites. I liaised with 
nephrologists, local research and development staff, pharmacists and nurses at these 
local sites to resolve issues that arose during site set-up (and throughout the trial) to 
ensure that the trial could be undertaken at the site.  
 
 Trial documentation 
The CCO generated all study documents required for conducting the trial. The CCO 
supplied local sites with all documents and materials at the start of the trial prior to 
recruitment beginning at the site. Additional materials required to conduct trial 
procedures and tasks were provided throughout the trial as required.  
 Trial protocol 
The Chief Investigator was responsible for preparation of the protocol and all 
subsequent revisions. I assisted with refinements and revisions of the trial protocol, 
the final version of which was approved by the TSC. 
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During the recruitment phase, the trial eligibility criteria were reviewed by the TSC 
and amended, to improve the number of patients that were eligible for the trial and 
the overall rate of recruitment. Many patients that were expected to be eligible for the 
trial based on previous renal function and proteinuria results were failing at the 
screening visit due to ineligible lab results such as a potassium greater than 5.2 
mmol/L (for example due to a haemolysed sample) or albuminuria results that were 
slightly out of range for eligibility (having previously been expected to be in the range 
for eligibility). The TSC agreed the following changes to the protocol to increase the 
number of patients eligible at screening: 
- Individuals with an eGFR of 20 to 45 mL/min/1.73m2 were eligible regardless 
of the level of albuminuria (previously all participants were required to have a 
uACR greater than 20 mg/mmol) 
- Individuals with an eGFR of 45 to 60 mL/min/1.73m2 were only eligible if they 
also had a uACR greater than 20 mg/mmol 
- potassium criteria for exclusion at screening changed from 5.2 to 5.5 mmol/L 
Additionally, some participants who were eligible at screening became ineligible at 
randomization as their blood pressure had fallen below 130/80 at the visit. In many 
cases this was due to over-treatment of blood pressure during the run-in phase when 
RAS inhibitors had been withdrawn. To avoid drop-out at randomization, the blood 
pressure criteria for eligibility at randomization were modified so participants 
remained eligible unless systolic blood pressure was below 110 mmHg at 
randomization in asymptomatic patients (or below 130/80 if participants were 
symptomatic at this level).  
In June 2015, new data emerged suggesting sacubitril/valsartan may take up to 9 
months to have full effect on renal function.200 The TSC agreed an extension in the 
duration of trial follow-up from 6 to 12 months. Ethics committee and regulatory 
approval was obtained, and all participants were provided with an updated PIL 
explaining the rationale for the extension to trial follow-up and invited to continue the 
trial for an additional 6 months. All participants agreeing to the extended follow-up 
were re-consented to formally document their agreement to extended follow-up. The 
TSC also provided comments and approvals for all trial publications including the trial 
rationale/baseline and main results publications.255,272 
 Standard Operating Procedures and internal operating procedures  
Under the guidance of the Chief Investigator, I produced the Local Clinical Centre 
Manual of Operations which outlined the study protocol, providing detailed 
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descriptions of all trial procedures to enable LRCs at LCCs to perform all trial visits 
and procedures. The manual included a guide on how to perform actions in the trial 
database, Cello. 
I drafted an SOP outlining the procedures for sample collection, transport, storage 
and central analysis of blood and urine samples collected at local sites. I provided 
feedback on other trial SOPs including the reporting of adverse events. 
I wrote the Data (or Statistical) Analysis Plan (DAP) for the trial with a team of 
statisticians and clinicians (Appendix 1: Supplementary material).272 The DAP was 
approved by the TSC and published prior to the unblinding of any trial participants 
and, before any unblinded analyses were performed.272 Statisticians at the 
coordinating centre provided all statistical support for the trial and performed all trial 
analyses. 
I wrote an internal operating procedure (IOP) outlining the responsibilities of trial 
clinicians working on the trial including daily review of all adverse events and 
laboratory results, dealing with LRCs and patient queries and, procedures for 
unblinding trial participants if necessary. 
 Participant-facing documents 
I was responsible for drafting several of the participant-facing trial documents prior to 
submission for the necessary regulatory approvals and throughout the trial, including 
the study poster (Appendix 3), PIL (Appendix 4), study treatment information sheet 
(STIL; Appendix 5), participant reminder card (Appendix 7) and study participation 
card (Appendix 8). I provided feedback on the participant letters to GPs and their local 
nephrologists, which informed the responsible clinician of the participants’ 
involvement in the trial. I worked closely with the Chief Investigator to draft, review 
and revise all trial documentation. 
 
 Local clinical centres (LCC) 
I travelled to several LCCs to address any issues local staff had with establishing the 
LCC (for example, concerns relating to issuing study treatment). The visits increased 
awareness of the trial amongst clinical staff and encouraged participant recruitment 
through the use of the pre-screening method.  
As an LCC clinician for Oxford University Hospitals NHS Foundation Trust, I worked 
closely with the LRCs to recruit patients and to provide clinical support for all follow-
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up visits when required. I provided clinical advice throughout the trial, for example, on 
BP management, abnormal laboratory results and assisted with collecting blood 
samples for mGFR tests.   
 
 Participant recruitment 
 
During the recruitment phase, weekly emails were sent to local sites to monitor 
numbers of participants pre-screened, invitations sent out and the response rates 
from potential participants. This regular contact encouraged LRCs to continue to 
recruit patients and provided an opportunity to offer additional assistance if needed 
during the recruitment phase. The weekly emails allowed sites with slower recruitment 
rates to be identified much earlier and provide them with any additional support more 
swiftly. 
Sites with poor recruitment rates (determined by numbers of patients invited and 
registered in the study database at monthly intervals) were contacted regularly and 
recruitment was discussed with the study nurses and LLIs to resolve any concerns 
regarding recruitment. At some sites, study nurses found it difficult to find time to 
make the follow-up telephone calls to patients after invitations were sent out, 
particularly at sites where nurses worked less than full-time or if the research nurse 
was single-handedly coordinating the trial).  
All sites were offered additional funding to cover a research assistant to support LRCs 
with making initial telephone calls to patients to ask whether they were interested in 
participating in the trial. This reduced the number of calls study nurses needed to 
make to patients by removing this element of their workload. Sites that utilised this 
resource found that their recruitment rates improved trial efficiency.  
If despite these additional supportive measures being implemented sites could not 
recruit (or recruit adequate numbers) of participants, they were closed prior to 
randomizing any participants. Enrolling fewer sites that were able to recruit larger 
numbers of participants prevented the quality of the trial data at the site being 
compromised and avoided the costs of monitoring multiple sites with small numbers. 
To further encourage LRCs to utilise pre-screening and to improve nurses’ confidence 
with the method, I helped produce a video entitled ‘Transforming Renal Trial 
Recruitment’. The short video demonstrated the successful implementation of pre-
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screening in a large international cardiovascular trial.273 The video outlined what pre-
screening entails, the experiences of two UK HARP-III trial participants and a 
research nurse describing her experience of the trial and pre-screening. The video 
included feedback regarding pre-screening from other UK HARP-III nurses across the 
UK. The video helped allay concerns from LRCs regarding telephoning patients after 
sending invitation letters and, demonstrated how successful and more effective pre-
screening was compared with other methods of recruitment. 
I drafted a monthly newsletter which outlined new information relating to the trial, 
study procedures and recruitment progress. At the end of recruitment, I drafted a 
newsletter that was sent to all randomized participants informing them of trial 
progress, safety information and what to expect on completion of the trial. 
A ‘league’ table of recruitment by site was included in the monthly newsletters at the 
request of local research coordinators. Sites were ranked by numbers of patients 
screened in the preceding month and, sites with the highest recruitment rates were 
highlighted in the newsletter. The table encouraged sites to recruit larger numbers of 
participants.  
To increase the rate of overall trial recruitment, five additional LCCs were established. 
Four of these centres were subsequently closed prior to randomization of any 
participants due to recruitment difficulties.  
At the end of the recruitment phase, I produced a questionnaire to collect information 
from all local clinical centres (Appendix 6) about the methods of recruitment used to 
recruit participants for UK HARP-III. Information was collected on the catchment size 
of the population covered by the local renal unit, the principal method(s) for identifying 
potentially eligible patients and whether follow-up phone calls were made. The 
responses enabled analysis of the utility of ‘pre-screening’ compared with ‘traditional’ 
methods of recruiting trial participants (e.g. consultant referrals or manually searching 




I led the trial team daily to ensure the smooth-running of the trial. I managed all clinical 
queries from research nurses at local sites and provided advice and support with 
administrative queries from sites. I supervised and assisted the team with managing 
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the trial email account and drafting responses to sites as needed. I answered all 
clinical and some of the administrative telephone queries. 
I reviewed weekly study progress reports to ensure that adequate treatment and 
follow-up compliance was maintained, blood results were entered on time and 
outstanding trial actions had been completed at sites. I supported the trial team with 
chasing outstanding tasks and contacting LRCs and LLIs where required. I also 
reviewed and approved minutes of weekly trial meetings prior to dissemination to the 
remainder of the CCO UK HARP-III team.  
As the trial progressed, I took over leading and running the trial training days for new 
staff including administrative staff, research nurses and trial monitors. This involved 
working with a trial administrator to coordinate and organise the agenda, speakers, 
dates for training and delivering the training. I led the administrative team in preparing 
mock exercises for the newly trained staff to complete following the training days. 
Once the individuals had completed the exercises, I reviewed the responses to 
confirm that they understood the trial procedures and were competent with using the 
IT system.  
I worked with the administrative team to coordinate the retrieval and transport of 
central blood and urine samples back from local sites to the central laboratory (the 
Wolfson laboratory) based in Oxford. All central samples were stored and analysed 
(with the exception of pharmacokinetic analyses) in the Wolfson laboratory. 
I assisted with drafting reports for TSC and DMC meetings and drafted abstracts and 
manuscripts for oral presentations and journal publications relating to the UK HARP-
III trial (Appendices 1, 9 and 10).255,272,274 
 
 Trial database and data management 
 
The UK HARP-III trial IT system, Cello, was a web-based electronic data capture 
system. The bespoke system was developed by programmers based at the 
coordinating centre and modelled on databases created for data collection in other 
large randomized trials led by the coordinating centre. I worked with the Chief 
Investigator and the IT system leads to design a system that would comply with the 
trial protocol and clinical requirements to enable participant data to be captured real-
time and entered directly into the trial database. 
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The specification for the design and functionality of Cello was written by a computer 
systems analyst and was updated as dictated by the required functionality of the 
database. The specification document facilitated the programming and testing of the 
database prior to the live database being released for use. I attended weekly 
meetings with the IT team during database development and helped with testing prior 
to the database going live. I identified and reported issues with the functionality of the 
database that required fixing throughout the trial.  
The web-based system enabled direct data entry into Cello during study visits. The 
trial protocol did not permit any data to be recorded on paper (or elsewhere) and 
transcribed into the database at a later time. Direct data entry had several 
advantages: it allowed checks at the time of data entry to avoid data transcription 
errors improving the reliability of the trial data; ensured that the study database and 
data collection was as complete as possible at the end of the trial and; improved 
efficiency with running the trial.  
All access to the database required a unique electronic username and password, and 
all new information and any changes to existing data required the user to enter their 
username and password as an electronic signature. This ensured an audit-trail could 
be maintained and monitored and so only those individuals with a Cello account could 
access confidential participant data.  
Access within Cello was restricted according to an individual’s role in the study both 
at the coordinating centre and at local sites. For example, CCO clinicians could review 
the full breadth of clinical data including laboratory results, adverse events, visit forms 
and treatment records. However, CCO administrators could not access any clinical 
information. Similarly, at local sites, only the LLI and any designated clinicians with 
overall responsibility for participants could approve participants for randomization. A 
web-based system provided flexibility with performing study visits as they could be 
performed from any location with internet access.  
Research nurses managed all aspects of the trial using Cello, including booking study 
visits, completion of case report forms, entering local laboratory and mGFR results, 
recording adverse events and issuing study treatment. A task list was built into Cello 
to remind LRCs of outstanding tasks for participants. The task list enabled me and 
CCO administrators to monitor outstanding actions at sites. A task would not be 
removed from the list of outstanding actions until it had been completed (for example, 
a follow-up appointment made, or blood results entered). 
95 
 
Cello allowed CCO staff to perform a wide range of trial procedures including 
monitoring and ordering of drug supplies for sites, reviewing safety parameters (such 
as adverse event data and local laboratory results), monitoring reports of compliance 
with study treatment and follow-up. The outstanding actions and participant progress 
reports helped ensure study visits occurred within the specified timeframes, for 
example before participants ran out of study treatment.  
 
 Teaching and training 
 
Before recruitment could begin, all local coordinating centre received training with 
performing study procedures and using Cello. I had a central role in the organisation 
and delivery of the training.  
I led the one-day training sessions at the CCO which educated staff about the UK 
HARP-III trial rationale and methodology. I arranged training dates, organised 
speakers and delivered much of the teaching to research staff (including doctors, 
nurses, study monitors and administrators). Throughout the trial, additional ‘refresher’ 
training was available if required, both on-site at the CCO and remotely using web-
based conferencing.  
A series of short presentations were delivered, covering: 
• rationale, design and conduct of the UK HARP-III trial, as described in the 
protocol and this document 
• eligibility criteria and recruitment method 
• study treatment handling, distribution and storage 
• general features of clinical trials, including discussion of International 
Conference on Harmonisation Good Clinical Practice (ICH GCP) guidelines and 
the practical procedure for obtaining valid informed consent  
• collection, processing and transfer to the coordinating centre of samples for 
central analysis  
• adverse event reporting 
• administrative information (e.g. documentation, finance, local coordinating 




The presentations were followed by practical demonstrations of the IT system, Cello 
and how trial procedures are performed within Cello. Copies of all training slides were 
provided to the research staff and were available in Cello for reference. Study nurses 
were provided with laptops on which they could familiarise themselves with Cello 
using a demonstration version of the system. These ‘practical’ sessions were led by 
me and other CCO clinical staff working on the UK HARP-III trial. 
I developed a set of training exercises that local research staff were required to 
complete following the training session to demonstrate they understood the study 
procedures and were competent in using Cello. Test/dummy patients were created in 
the demonstration version of Cello. A range of trial activities were assessed including 
receipt of study drug, performing follow-up visits, entering laboratory results and 
reporting adverse events (serious adverse events, suspected serious adverse 
reactions and non-serious adverse reactions).  
On review, if the exercises were not completed satisfactorily, then additional training 
was provided as deemed necessary. Following satisfactory completion of the training 
exercises, an electronic signature (username and password) was issued allowing 
newly trained research staff to use the ‘live’ version of Cello.  
During the recruitment phase, regular teleconferences were arranged by the lead 
CCO monitor and me to provide LRCs with an additional opportunity to gain advice 
and support with the trial and have non-urgent queries addressed. Local research 
nurses were also to share their experiences with research nurses from other sites. 
Annual meetings were held for LRCs at which they were updated on trial progress, 
study procedures and any new information to support them with conducting the trial 
locally (such as information relating to changes in the trial protocol and the importance 
of follow-up of all participants as per ITT analyses). An annual UK HARP-III 
collaborators’ meeting was held to inform all staff of future plans for the trial and 
offered an opportunity for all LLIs and LRCs to meet and discuss and/or feedback any 




 Trial monitoring 
 
Several types of monitoring took place in the UK HARP-III trial. CCO staff coordinated 
central and local monitoring of study data and procedures. A team of research nurses 
performed all on-site local trial monitoring (on behalf of the CCO) in accordance with 
the trial Monitoring SOP. The TSC provided monitoring and advice on trial progress 
and an independent DMC regularly reviewed the unblinded interim analyses of all 
serious adverse events and trial data including all blood and urine results and 
compliance with study follow-up visits and randomized treatment. 
The key trial team comprised of administrators, clinicians (including myself) and study 
monitors, attended a weekly meeting to discuss and review: trial progress, issues at 
LCCs, study amendments, sample collections, supplies of blood kits and study 
treatments at local sites. The meeting was led by me and the trial manager, Rejive 
Dayanandran. Central monitoring reports were also reviewed and planning of staff 
training days, trial newsletters and study meetings were also discussed. 
 
 Central monitoring 
 Recruitment 
Recruitment rates across all sites were closely monitored by the CCO to ensure that 
recruitment progressed rapidly and to identify any difficulties sites may be having with 
recruiting patients. A weekly report was generated of numbers of patients screened 
by sites. The report was reviewed at the weekly trial management team meeting. The 
web-based system had in-built monitoring reports, one such report allowed ‘real-time’ 
review of future screening appointments at sites to track recruitment progress. The 
weekly emails sent to all sites requesting recruitment data allowed recruitment 
tracking so that sites recruiting more slowly could be contacted to discuss any 
concerns or difficulties they may be experiencing.  
Copies of all signed participant consent forms were returned to the CCO for review 
by CCO nurses for any irregularities or errors. Sites were informed of any errors and 
requested to make corrections to the consent forms as required. The lead CCO 
monitor for UK HARP-III held regular meetings with local site monitors to discuss any 
concerns and issues at sites, to plan monitoring visits and discuss trial progress. 
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 Key data 
Sites were asked to provide paper copies of all baseline and final mGFR results to 
allow verification of the primary outcome data. The result entered into Cello was 
checked against the paper report and any data errors were recorded as a data query 
for correction at the end of the trial, prior to data analyses and unblinding of participant 
data. Common errors in mGFR results included entry of results not adjusted for body 
surface area and incorrect procedure dates. 
 Compliance 
The web-based data capture system produced reports to follow participants’ progress 
at each site and the reports were reviewed weekly. The reports provided information 
on a participants’ remaining drug supply, and helped CCO staff to ensure compliance 
with study procedures, including: booking study visits at scheduled times (before drug 
supplies ran out), compliance with study visits, issuing of study drugs and compliance 
with study medications and laboratory and mGFR results entry. The reports were 
linked to the ‘task-list’ in Cello and helped prevent follow-up visits being missed, 
thereby maintaining compliance with follow-up and randomized study treatment. If a 
participant’s follow-up method changed (for example, to follow-up by telephone or 
through medical records) then the reports prompted CCO staff to contact LCC staff 
when a face-to-face study visit would have been scheduled, to collect and upload the 
available data. I regularly reviewed these reports to ensure that no participant follow-
up was missed, particularly for those participants whose follow-up method had 
changed.  
In order to track compliance with study treatment, I maintained a list of all participants 
stopping study medications either temporarily or permanently, including the reasons 
for stopping. The lists enabled me to prompt and encourage LCC staff to re-introduce 
study treatments in those participants in whom it was appropriate to do so. This 
helped prevent large numbers of participants stopping randomized treatment 
completely, which would have had a significant impact on study power. Wherever 
possible, study nurses were encouraged to restart full dose study treatments, if this 
was not appropriate (or possible) then participants remained on the lower (half) dose 
of study treatment.  
At the time of final follow-up, additional reports were generated to ensure that final 
study visits and mGFR tests were scheduled and performed on time (specifically 
before the participant ran out of study treatment). The report identified outstanding 
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mGFRs results that were not recorded in the study database or for which the paper 
result had not been received. 
 Data errors 
Documentation of all data errors and anomalies such as laboratory results being 
recorded with incorrect dates or values, were maintained within a ‘data queries’ 
spreadsheet. All queries were reviewed by CCO clinical staff and a decision was 
made as to whether a data correction was required. At the end of the trial a bespoke 
software programme (“ERATO”) developed by CCO programmers, was used make 
any required data corrections. For example, all mGFR results entered in the study 
database were compared against the paper copy of the report and any errors were 
reported in the data queries spreadsheet with a link to the correct information (and 
supporting evidence), creating an audit trail. This process occurred prior to the 
unblinding of any participant data or study analyses being performed).  
 
 Local on-site monitoring 
Shortly after local sites began to recruit and screen patients, an on-site monitoring 
visit was arranged by a CCO trial monitor. The purpose of this visit was to help staff 
to resolve any local problems with the trial, ensure the trial was being conducted in 
accordance with the trial protocol and to check the accuracy, completeness and 
quality of the data entered into Cello. In UK HARP-III, as in other trials led by the 
CCO, trial monitors sat in on and observed trial visits to ensure that the well-being of 
participants was being respected and that GCP and regulatory standards were being 
complied with, for example by reviewing the consent-taking process. The clinical trial 
monitors checked paper copies of local laboratory results, mGFR results and 
participant data against that recorded in the web-based system to verify the accuracy 
of the data recorded in Cello, as this data was the source data for the trial.   
At site monitoring visits, trial monitors visited the local hospital pharmacy to review 
the conditions where study treatments were stored, ensure that drug issuing 
procedures were being complied with and, an accurate drug accountability and 
temperature logs were being maintained.  
The trial monitor prepared a report following the monitoring visit and submitted it for 
review by senior CCO staff. The timing and frequency of further monitoring visits were 
arranged according to the results of both central and local monitoring of all the trial 
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data for each site. The site monitors and lead CCO monitor voiced their concerns to 
the Chief Investigator and to me if there were discrepancies in the delivery of the trial 
at LCCs. For example, concerns regarding the timing of entry of blood results in 
relation to completion of a study visit form and whether the results were ‘genuine’ or 
if the timeline or sequence of events was plausible to be in keeping with the stipulated 
trial procedures.  
 
 Clinical and participant safety monitoring 
 CCO monitoring 
I led the management of the clinical and safety monitoring of participant results with 
assistance from other CCO clinicians. All laboratory results and adverse events 
recorded in Cello were reviewed daily, blinded to treatment allocation. All significant 
clinical safety events were reported to and discussed with the Chief Investigator and 
sites were provided with the appropriate advice on management.  
All local laboratory results required entry in Cello within 48 hours of a trial visit being 
completed and were reviewed and ‘signed-off’ by a CCO clinician using a unique 
electronic signature to verify that they had been reviewed. I signed all results entered 
in Cello on a daily basis. If there were any abnormalities or concerns with the results, 
then I contacted LCC staff and advised them of the appropriate course of action to be 
taken. For example, if there were any abnormal potassium or creatinine results, I 
contacted LRCs by email and advised them on the timing of repeat samples and the 
management of the abnormal result. For any results needing more urgent action (for 
example, serum potassium greater than or equal to 6.0 mmol/L or significant rises 
serum in creatinine), LRCs were contacted by telephone and advised on the 
management and a follow-up email documenting the advice was sent. I maintained a 
list of all abnormal results and regularly updated these once results had been 
repeated, to ensure the abnormal results had been actioned and resolved. 
If any irregularities in laboratory results were seen for example, suspected implausible 
results or values, then these were queried with the local site and a data query 
recorded where appropriate. I reviewed all such data queries and any concerning 
patterns of abnormalities were raised with the monitoring team and discussed with 
the local site as required. 
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I reviewed all trial visit follow-up forms to monitor participants’ blood pressure during 
clinic visits. If mean blood pressure rose above targets (as per the current KDIGO 
guidelines on management of blood pressure in CKD)59 or appeared unusually low, 
LRCs were advised to discuss with their LLI or the participants’ usual nephrologist, 
particularly if any home blood pressure readings were of a similar range. The 
management of blood pressure was left to the discretion of local nephrologists 
however, I (and other CCO clinicians) provided advice if requested or required, in 
particular to prevent study treatment from being withheld, reduced or withdrawn 
unnecessarily. This also provided an opportunity to check that participants requiring 
re-supply of randomized treatment had this re-issued correctly. 
I reviewed all reported adverse events (serious and non-serious) daily. No further 
information was sought for serious adverse events not believed to be related to study 
treatment unless the event was reported as life-threatening or resulted in death. No 
additional information was sought for non-serious adverse reactions unless deemed 
a potential event of particular interest, for example a fall which may have resulted 
from postural hypotension caused by study treatment.  
All suspected serious adverse events required discussion with a CCO clinician prior 
to being entered into the study database. I contacted all LRCs to collect additional 
detailed information on all suspected serious adverse event reports, including a 
thorough history of the event, results of any relevant investigations and, current 
medication history so that a report of the event could be compiled. All suspected 
serious adverse event reports were discussed with the Chief Investigator and sent for 
review by the DMC unblinded to study treatment allocation. All clinicians and staff 
working on the trial remained blind to randomized treatment allocation.  
I dealt with all clinical queries from local sites and study participants and provided 
advice as required. Less urgent clinical queries were received and managed by email 
and urgent queries were addressed by telephone. During working hours, LRCs could 
contact the study office with any clinical (or administrative) concerns that they wished 
to discuss with a clinician. For queries outside office hours or those from participants, 
the CCO provided a 24 hour, 7 days per week clinical service via a freephone 
telephone contact that was covered by a clinician at all times, to support all sites, 
healthcare staff and study participants. I wrote a short guide to assist clinicians that 
did not routinely work on the UK HARP-III trial. The guide covered the management 
of significant clinical events of relevance such as the management of symptomatic 
hypotension, angioedema or hyperkalaemia. 
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 Independent DMC monitoring 
The independent DMC regularly reviewed all the unblinded interim analyses of all 
serious adverse events and trial data including all blood results and compliance with 
follow-up and trial treatment. In light of these analyses and any other information 
considered relevant, the DMC provided advice to the TSC if, in their view, the 
randomized comparisons in the study provided both (i) “proof beyond reasonable 
doubt” that for all, or some specific types of, patients use of sacubitril/valsartan was 
clearly indicated or clearly contraindicated; and (ii) evidence that might be reasonably 
expected to influence materially the patient management of many clinicians who were 
already aware of the results of other relevant trials.  
It was the responsibility of the TSC to then decide whether to modify the trial or to 
seek additional data (where relevant). Unless this happened, the TSC, collaborators, 
trial participants, and all trial staff (except those who provided the confidential 









 Recruitment method 
At the end of the recruitment phase, local sites were sent a recruitment questionnaire 
to complete (Appendix 6). Sites were asked to report their primary method of 
recruitment, any alternative methods used to recruit, the size of the catchment area 
served by their renal unit and the number of CKD patients cared for by their unit.  
Sites recruiting participants using the preferred method of recruitment for UK HARP-
III as recommended by the CCO (i.e. pre-screening potentially eligible participants 
using electronic hospital databases, sending out batches of invitations and 
telephoning patients about a week later) recruited larger numbers of participants and, 
more rapidly than sites using ‘traditional’ methods of recruitment (e.g. awaiting 
consultant referrals or approaching patients attending renal clinics; Figure 8). 
Of the 24 UK HARP-III sites, 13 sites (total catchment population 11.1 million people) 
used the pre-screening method for recruitment and 11 sites (total catchment 
population 15.3 million people) primarily used traditional methods of recruitment. The 
median (IQR) screening rate was 21.9 (13.5-40.4) participants per million population 
per year (pmp py) at sites primarily using pre-screening methods compared with 14.1 
(8.4-27.4) pmp py at sites primarily using traditional recruitment methods (P=0.20 by 






Figure 8: Numbers of participants screened using the pre-screening and traditional 
methods of recruitment  
 
Between November 2014 and March 2016, 620 patients were screened at 24 sites 
across the UK. Of the 620 participants screened, 566 (91%) entered the pre-





















































Figure 9: Flow of participant through the UK HARP-III trial 
 
 Ineligibility at screening 
54 participants were ineligible at the screening visit. The reasons for ineligibility are 
outlined in Table 10. The main reason for ineligibility was out of range historic 
laboratory results, particularly potassium and uACR. Due to the drop-out at screening, 
the TSC amended the potassium threshold for exclusion from greater than 5.2 mmol/L 




Reason for ineligibility during the Screening visit* N (%) 
Ineligible medical history  
Contraindication to angiotensin receptor blocker 5 (9%) 
Previous adverse reaction to angiotensin receptor blocker 3 (6%) 
On immunosuppression for nephrotic syndrome 4 (7%) 
Known chronic liver disease 4 (7%) 
Previous angioedema 6 (11%) 
Taken an unlicensed investigational medicinal product in last month 1 (2%) 
Medical condition that might limit the participant's ability to take study  
treatment for the duration of the study 11 (20%) 
  
Ineligible based on laboratory measurements available at the time of the 
screening visit  
eGFR out of range 7 (13%) 
uACR ≤20 mg/mmol (or uPCR ≥30 mg/mmol) 10 (19%) 
Potassium too high** 11 (20%) 
Serum albumin <<30 g/L and uACR >300 mg/mmol (or uPCR >350 mg/mmol) 2 (4%) 
Alanine or aspartate transferase 2 x the upper limit of normal 1 (2%) 
  
Ineligible based on blood pressure at the screening visit  
Mean systolic blood pressure >180 mmHg 5 (9%) 
  
Declined to consent 5 (9%) 
  
Total ineligible at screening visit 54 
 
Table 10: Reasons for ineligibility for UK HARP-III during the screening visit 
eGFR = estimated glomerular filtration rate; uACR=urinary albumin:creatinine ratio; uPCR=urinary 
protein:creatinine ratio. *More than one reason may apply.  
**Threshold for exclusion for potassium was changed from >5.2 to >5.5 in March 2015 (protocol version 
6). 
 
 Pre-randomization run-in 
 
138 participants were withdrawn from the pre-randomization run-in phase prior to 
attending the randomization visit (reasons for withdrawal are outlined in Table 11). 
The most common reason for withdrawal from run-in was blood and urine samples 
taken at the screening visit not meeting the eligibility criteria in 43% of cases (Table 
11). Blood pressure related adverse events were not a cause of withdrawals from run-
in. Participants thought unlikely to tolerate or comply with study medications and/or 
scheduled study visits for the duration of the trial were encouraged to withdraw (Table 
11). 
Overall, 152 (27%) of the 566 participants that entered the pre-randomization run-in 




Reason for withdrawal from placebo run-in* N (%) 
Adverse event  
SAE (unrelated) 3 (2%) 
NSAR 7 (5%) 
Subtotal: Any adverse event 10 (7%) 
  
Participant died during run-in** 1 (1%) 
  
Other reason  
Ineligible screening lab result 59 (43%) 
Unable to attend clinic 5 (4%) 
Concerns about tablets 13 (9%) 
Difficulty taking tablets 3 (2%) 
Doctor advice 13 (9%) 
Trial administration problem 11 (8%) 
Undergoing investigations 1 (1%) 
Family circumstances 1 (1%) 
Travel problem 5 (4%) 
Patient wishes 16 (12%) 
Subtotal: Any other reason 127 (92%) 
  
Total drop-out during run-in 138 
 
Table 11: Reasons for withdrawal from pre-randomization run-in 
NSAR=non-serious adverse reaction; SAE=serious adverse event.  
*More than one reason may apply. **This participant died of pneumonia. 
 
Four participants were withdrawn from run-in due to a serious adverse event 
(including myocardial infarction, septic shock and two cases of pneumonia [one of 
which was fatal]). These events were not related to run-in study treatment (Table 12).  
Seven participants reported non-serious adverse reactions believed to be related to 
the placebo run-in study medication. Individuals reporting non-serious adverse 
reactions were not eligible for randomization. 
Overall, adverse events during run-in were uncommon. 7% of participants 
experienced at least one adverse event during a mean of 33.7 person-days of follow-





Adverse events during Run-in Placebo run-in 
Entered run-in 566 
Total person-days follow-up 19065 
Mean person-days follow-up 33.7 
  
Cardiovascular causes  
Stroke 0 (0%) 
Transient ischaemic attack 0 (0%) 
Other vascular hypertensive disorders 6 (1%) 
Cardiac event 1 (0%) 
Other vascular 1 (0%) 
Subtotal: Any cardiovascular 9 (2%) 
  
Non-cardiovascular causes  
Cancer 0 (0%) 
Infection 4 (1%) 
Respiratory 3 (1%) 
Other non-cardiovascular 24 (4%) 
Subtotal: Any non-cardiovascular 29 (5%) 
  
Total: Any adverse event 37 (7%) 
 
Table 12: Any adverse event during pre-randomization run-in  
 
 Ineligibility at randomization 
 
428 patients attended the randomization visit and 14 were ineligible for randomization 
(reasons outlined in Table 13). The commonest reason for this was mean systolic 





Reasons for ineligibility at randomization* N (%) 
Consent not confirmed 0 (0%) 
Compliance ≤80%** 0 (0%) 
Mean systolic blood pressure too low† 9 (64%) 
Mean systolic blood pressure >180mmHg$ 1 (7%) 
Female ≤55 years and unwilling to use reliable contraception 0 (0%) 
 
Medical History  
Related adverse event reported (serious or not) 3 (21%) 
Contraindicated medication started 1 (7%) 
  
Total drop-out at randomization visit 14 
 
Table 13: Reasons for ineligibility at randomization  
*More than one reason may apply.  
**Compliance was estimated from direct questioning of participants and pill counts were not performed. 
Compliance of 80% or less was classified as having taken study treatment on at least six days per week 
on average. 
†Threshold changed in March 2015 (protocol version 6). $Removed in March 2015 (protocol version 6). 
 
 
 Baseline characteristics 
 
414 participants were randomized into the UK HARP-III trial: 207 to 
sacubitril/valsartan and 207 to irbesartan. Baseline characteristics were similar 
between the two groups (Table 14). 
The mean age at randomization among the whole cohort was 62.8 (SD 13.7) years. 
Participants allocated sacubitril/valsartan were slightly younger than those allocated 
irbesartan (mean [SD] age 62.0 [14.1] versus 63.6 [13.4] years respectively). 72% 
were male and 91% of participants were white (Table 14). Representation from ethnic 
minority groups was low with only 4% South Asian, 2% black and 3% of participants 
from other ethnic groups.  
Overall, 40% of participants reported having diabetes mellitus, 13% coronary heart 












Demographics    
Age at randomization (years) 62.0 (14.1) 63.6 (13.4) 62.8 (13.7) 
<50 37 (18%) 36 (17%) 73 (18%) 
≥50 to <70 97 (47%) 99 (48%) 196 (47%) 
≥70 73 (35%) 72 (35%) 145 (35%) 
Sex    
Male 148 (71%) 150 (72%) 298 (72%) 
Female 59 (29%) 57 (28%) 116 (28%) 
Ethnicity    
White 186 (90%) 191 (92%) 377 (91%) 
Black 3 (1%) 4 (2%) 7 (2%) 
South Asian 11 (5%) 7 (3%) 18 (4%) 
Other 7 (3%) 5 (2%) 12 (3%) 
    
Medical history    
Prior disease    
Coronary heart disease 21 (10%) 33 (16%) 54 (13%) 
Cerebrovascular disease 16 (8%) 15 (7%) 31 (7%) 
Peripheral vascular disease 22 (11%) 22 (11%) 44 (11%) 
Heart failure 8 (4%) 7 (3%) 15 (4%) 
Diabetes mellitus 81 (39%) 83 (40%) 164 (40%) 
    
Renal diagnosis*    
Cause of kidney disease    
Glomerular disease 60 (29%) 51 (25%) 111 (27%) 
Tubulointerstitial disease 18 (9%) 32 (15%) 50 (12%) 
Diabetic kidney disease 36 (17%) 47 (23%) 83 (20%) 
Hypertensive/renovascular  
Disease 18 (9%) 24 (12%) 42 (10%) 
Other systemic diseases  
affecting the kidneys 1 (0%) 2 (1%) 3 (1%) 
Familial/hereditary  
Nephropathies 30 (14%) 13 (6%) 43 (10%) 
Other known causes 5 (2%) 4 (2%) 9 (2%) 
Unknown 39 (19%) 34 (16%) 73 (18%) 
    
Medication history    
Medication    
Antiplatelet therapy 64 (31%) 75 (36%) 139 (34%) 
Oral anticoagulant 13 (6%) 15 (7%) 28 (7%) 
Diuretic 79 (38%) 85 (41%) 164 (40%) 
Calcium channel blocker 104 (50%) 103 (50%) 207 (50%) 
Beta blocker 50 (24%) 62 (30%) 112 (27%) 
Alpha blocker 58 (28%) 55 (27%) 113 (27%) 
LDL-lowering agent 126 (61%) 137 (66%) 263 (64%) 
Use of RAS blockade at screening visit 
Yes 173 (84%) 166 (80%) 339 (82%) 
No 34 (16%) 41 (20%) 75 (18%) 
 
Table 14A: Baseline characteristic of UK HARP-III participants randomized  
Values are n (%), mean (SD), geometric mean (approx. SE) or median (IQR). RAS=Renin-angiotensin 











Physical measurements    
Systolic blood pressure (mmHg) 146 (16) 146 (16) 146 (16) 
<140 76 (37%) 85 (41%) 161 (39%) 
≥140 to <160 93 (45%) 84 (41%) 177 (43%) 
≥160 38 (18%) 38 (18%) 76 (18%) 
Diastolic blood pressure (mmHg) 81 (11) 80 (11) 81 (11) 
<80 96 (46%) 105 (51%) 201 (49%) 
≥80 to <90 68 (33%) 58 (28%) 126 (30%) 
≥90 43 (21%) 44 (21%) 87 (21%) 
Body mass index (kg/m²) 30 (6) 31 (6) 30 (6) 
<25 35 (17%) 33 (16%) 68 (16%) 
≥25 to <30 74 (36%) 73 (35%) 147 (36%) 
≥30 95 (46%) 100 (48%) 195 (47%) 
Not available 3 1 4 
    
Medication history    
Medication    
Antiplatelet therapy 64 (31%) 75 (36%) 139 (34%) 
Oral anticoagulant 13 (6%) 15 (7%) 28 (7%) 
Diuretic 79 (38%) 85 (41%) 164 (40%) 
Calcium channel blocker 104 (50%) 103 (50%) 207 (50%) 
Beta blocker 50 (24%) 62 (30%) 112 (27%) 
Alpha blocker 58 (28%) 55 (27%) 113 (27%) 
LDL-lowering agent 126 (61%) 137 (66%) 263 (64%) 
Use of RAS blockade at screening visit 
Yes 173 (84%) 166 (80%) 339 (82%) 
No 34 (16%) 41 (20%) 75 (18%) 
 
Laboratory measurements 
CKD-EPI estimated glomerular filtration rate at randomization (mL/min/1.73m²) 
Mean (SD) 35.4 (11.0) 35.5 (11.0) 35.5 (10.9) 
<30 79 (38%) 77 (37%) 156 (38%) 
≥30 to <45 86 (42%) 91 (44%) 177 (43%) 
≥45 41 (20%) 39 (19%) 80 (19%) 
Not available 1 0 1 
Urine albumin:creatinine ratio at randomization (mg/mmol) 
Geometric mean (approx. SE) 34 (5) 34 (5) 34 (3) 
Median (IQR) 52 (11-162) 56 (11-146) 54 (11-153) 
<3 30 (14%) 28 (14%) 58 (14%) 
≥3 to <30 43 (21%) 45 (22%) 88 (21%) 
≥30 134 (65%) 134 (65%) 268 (65%) 
24-hour urinary sodium excretion during run-in (mg/24 hours) 
Geometric mean (approx. SE) 2245 (183) 2585 (187) 2400 (132) 
Median (IQR) 2484 (1794-3795) 2875 (1932-4232) 2680 (1817-3910) 
Not available 100 110 210 
 
Table 15B: Baseline characteristic of UK HARP-III participants randomized  
Values are n (%), mean (SD), geometric mean (approx. SE) or median (IQR).  




 Renal characteristics 
The commonest causes of CKD were glomerular disease (27%), diabetic kidney 
disease (20%) and CKD due to unknown aetiology (18%). Mean (SD) systolic blood 
pressure was 146 (16) mmHg and diastolic blood pressure 81 (11) mmHg at 
randomization (between 4 and 7 weeks after withdrawal of prior ACEi or ARB or both). 
Mean CKD-EPI eGFR was 35.5 (SD 10.9) mL/min/1.73m2. 38% of participants had 
advanced CKD with an eGFR less than 30 mL/min/1.73m2, 43% had an eGFR of 30 
to 45 mL/min/1.73m2 and 19% had an eGFR of 45 to 60 mL/min/1.73m2.   
The geometric mean uACR (approximate SE) was 34 (3) mg/mmol and median (IQR) 
uACR was 54 (11-153) mg/mmol. 14% of participants had normoalbuminuria, 21% 
had microalbuminuria and 65% had macroalbuminuria (Table 14). 82% of participants 
were taking RAS blockade (either ACE inhibitor, ARB or both) at screening. 
204 participants provided a 24-hour urine collection (107 participants allocated 
sacubitril/valsartan and 97 allocated irbesartan). Median (IQR) urinary sodium 
excretion during run-in (following 4 to 7 weeks without any treatment with RAS 
blockade) was 2484 (1794-3795) mg/24 hours in participants randomized to 
sacubitril/valsartan and 2875 (1932-4232) mg/24 hours in those randomized to 
irbesartan. 
 
 Risk of progression of to end stage renal disease 
Risk of progression to ESKD was calculated using a validated 4-variable risk equation 
that utilizes age, sex, eGFR and uACR.275 The median 5-year risk of progression of 
ESKD (using characteristics ascertained at randomization) was 16.5%. 62% of 





Figure 10: Five-year risk of progression to End-stage kidney disease among UK HARP-
III participants  
 
 Compliance with follow-up 
 
Compliance with trial visits was excellent with very few missed follow-up visits (Table 
15). If participants were unable to attend in person for a face-to-face visit, then follow-






who started the 
follow-up period* 
Follow-up status 
Withdrew Died Completed** Missed 
1 month 414 0 1 404 9 
3 months 412 2 0 408 2 
6 months 409 1 0 401 7 
9 months 399 2 0 393 4 
12 months 397 0 1 394 2 
 
Table 16: Compliance with trial follow-up visits following randomization in UK HARP-III 
*Not including those who died or withdrew consent in an earlier follow-up period, or (for the 9- and 12-
month rows) the 9 participants who did not consent to extending follow-up from 6 to 12 months.             
**Mainly includes survivors who have completed follow-up but may also include those who completed 
follow-up and subsequently died or withdrew consent for further follow-up during the same period. 
 
At one site, four participants missed the 1-month study visit. On investigation, the 
participants involved had been reviewed in a trial clinic by the LRCs however, the visit 
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constituted a significant study protocol violation and the LRCs received additional 
training and monitoring. All safety blood and urine samples had been collected and 
analysed at the time of the visit, so there were no safety concerns for the participants 
involved because of the ‘missed’ follow-up visits.  
Nine participants declined consent to continue participation in the trial beyond the 
originally planned six-month trial period following randomization when the trial 
extended follow-up to 12 months. These individuals had their final mGFR and final 
follow-up visit at 6 months following randomization.  
Only three participants withdrew their consent following randomization for all further 
follow-up during the trial. Two participants died during follow-up; one due to a 
pulmonary embolism and the other due to sepsis, neither of these cases were related 
to randomized treatment.  
 
 Compliance with study treatment 
 
Compliance with study treatments was estimated from direct questioning of 
participants and pill counts were not performed. Adequate treatment compliance was 
classified as having taken over 80% of study treatment on at least six days per week 
on average. 
 
 Compliance with full dose study treatment 
Compliance with full dose study treatments (either sacubitril/valsartan 97/103 mg 
twice daily or irbesartan 300 mg once daily) was broadly similar in both groups 
throughout the trial (Table 16). At three months, compliance with full dose study drugs 
was 85% in the sacubitril/valsartan arm and 86% in the irbesartan arm. At nine 
months, this had fallen to 75% in those allocated sacubitril/valsartan and 78% in those 
allocated irbesartan and at 12 months compliance rates were 76% and 79% 
respectively (Table 16). 
 
 Compliance with any dose of study treatment 
Compliance with study drugs (either full dose or less than full dose e.g. half dose of 
study treatment in those unable to tolerate the full dose) at 3 months post-
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randomization was high with 91% of participants taking sacubitril/valsartan and 90% 
taking irbesartan (Table 16). At final follow-up, compliance with study treatment had 
fallen to 82% in participants allocated sacubitril/valsartan and 84% in those allocated 









Number (%) taking at least 80% 
of the full dose of study 
treatment since last study visit 
Number (%) taking at least 80% 
of any dose of study treatment 
since last study visit 
Sacubitril/valsartan Irbesartan Sacubitril/valsartan Irbesartan 
1 month 414 172 (83%) 183 (88%) 189 (91%) 195 (94%) 
3 months 413 176 (85%) 177 (86%) 188 (91%) 187 (90%) 
6 months 411 162 (79%) 169 (82%) 177 (86%) 179 (87%) 
9 months 401 150 (75%) 157 (78%) 168 (84%) 169 (84%) 
12 months 399 151 (76%) 158 (79%) 164 (82%) 168 (84%) 
 
Table 17: Compliance with randomized treatment in UK HARP-III 
*Not including those who died or withdrew consent in an earlier follow-up period, or (for the 9 and 12 
month rows) the 9 participants who did not consent to extend follow-up from 6 to 12 months. 
 
 Reasons for stopping randomized treatment 
Over the 12-month trial duration, 44 (21%) participants stopped sacubitril/valsartan 
and 42 (20%) stopped irbesartan (P=0.90). Non-serious adverse reactions were the 
main reason for stopping randomized treatment in both groups (sacubitril/valsartan 












Serious adverse event (SAE)    
Angioedema 1 (0%) 0 (0%)  
Hyperkalaemia 0 (0%) 2 (1%)  
Acute kidney injury 1 (0%) 1 (0%)  
Abnormal liver function test 0 (0%) 0 (0%)  
Gastrointestinal disorders 1 (0%) 0 (0%)  
Infections and infestations 1 (0%) 0 (0%)  
Neoplasms benign, malignant and 
unspecified (including cysts and polyps) 0 (0%) 0 (0%)  
Pregnancy, puerperium and perinatal 
conditions 0 (0%) 1 (0%)  
Renal and urinary disorders 0 (0%) 1 (0%)  
Respiratory, thoracic and mediastinal 
disorders 0 (0%) 1 (0%)  
Surgical and medical procedures 0 (0%) 2 (1%)  
Subtotal: Any SAE 4 (2%) 8 (4%) 0.38 
    
Non-serious adverse reaction (NSAR)    
Hypotensive disorder 6 (3%) 2 (1%)  
Hyperkalaemia 4 (2%) 0 (0%)  
Acute kidney injury 1 (0%) 3 (1%)  
Abnormal liver function test 0 (0%) 0 (0%)  
Cardiac disorders 0 (0%) 1 (0%)  
Gastrointestinal disorders 3 (1%) 1 (0%)  
General disorders and administration site 
conditions 1 (0%) 2 (1%)  
Metabolism and nutrition disorders 1 (0%) 0 (0%)  
Musculoskeletal and connective tissue 
disorders 1 (0%) 0 (0%)  
Nervous system disorder 4 (2%) 3 (1%)  
Respiratory, thoracic and mediastinal 
disorders 1 (0%) 1 (0%)  
Skin and subcutaneous tissue disorders 2 (1%) 0 (0%)  
Subtotal: Any NSAR 24 (12%) 13 (6%) 0.08 
    
Other reason    
Unable to attend clinic 2 (1%) 1 (0%)  
Concerns about tablets 0 (0%) 2 (1%)  
Doctor advice 8 (4%) 9 (4%)  
Withdrew consent 5 (2%) 6 (3%)  
Participants wishes 1 (0%) 2 (1%)  
Subtotal: Any other reason 16 (8%) 21 (10%) 0.49 
    
Total: stopped for any reason 44 (21%) 42 (20%) 0.90 
 




Symptomatic hypotension related to study treatment (resulting in a reduction in the 
dose of trial treatment taken) was more frequently reported in participants randomized 
to sacubitril/valsartan compared with irbesartan (6 versus 2 cases respectively), as 
was hyperkalaemia (4 versus 0 cases respectively). However overall, there was no 
significant difference in reasons for stopping full dose study treatments between the 
sacubitril/valsartan compared with irbesartan (44/207 [21%] versus 42/207 [20%] 
respectively; P=0.90).  
Similarly, there were no differences in the reasons for participants completely 
stopping all of their study treatments between sacubitril/valsartan, compared with 
irbesartan (33/207 [16%] versus 34/207 [16%] respectively; P=1.00; Table 18 [a 













Serious adverse event (SAE)    
Angioedema 1 (0%) 0 (0%)  
Hyperkalaemia 0 (0%) 1 (0%)  
Acute kidney injury 1 (0%) 1 (0%)  
Abnormal liver function test 0 (0%) 0 (0%)  
Gastrointestinal disorders 1 (0%) 0 (0%)  
Infections and infestations 1 (0%) 0 (0%)  
Neoplasms benign, malignant and 
unspecified (including cysts and polyps) 0 (0%) 0 (0%)  
Pregnancy, puerperium and perinatal 
conditions 0 (0%) 1 (0%)  
Renal and urinary disorders 0 (0%) 1 (0%)  
Respiratory, thoracic and mediastinal 
disorders 0 (0%) 1 (0%)  
Surgical and medical procedures 0 (0%) 2 (1%)  
Subtotal: Any SAE 4 (2%) 7 (3%) 0.54 
    
Non-serious adverse reaction (NSAR)    
Hypotensive disorder 2 (1%) 2 (1%)  
Hyperkalaemia 4 (2%) 0 (0%)  
Acute kidney injury 1 (0%) 3 (1%)  
Abnormal liver function test 0 (0%) 0 (0%)  
Cardiac disorders 0 (0%) 1 (0%)  
Gastrointestinal disorders 3 (1%) 1 (0%)  
General disorders and administration site 
conditions 1 (0%) 2 (1%)  
Metabolism and nutrition disorders 1 (0%) 0 (0%)  
Musculoskeletal and connective tissue 
disorders 1 (0%) 0 (0%)  
Nervous system disorder 3 (1%) 2 (1%)  
Respiratory, thoracic and mediastinal 
disorders 0 (0%) 1 (0%)  
Skin and subcutaneous tissue disorders 2 (1%) 0 (0%)  
Subtotal: Any NSAR 18 (9%) 12 (6%) 0.34 
    
Other reason    
Unable to attend clinic 2 (1%) 1 (0%)  
Concerns about tablets 0 (0%) 1 (0%)  
Doctor advice 3 (1%) 4 (2%)  
Withdrew consent 5 (2%) 6 (3%)  
Participants wishes 1 (0%) 2 (1%)  
Subtotal: Any other reason 11 (5%) 15 (7%) 0.54 
    
Total: stopped for any reason 33 (16%) 34 (16%) 1.00 
 
Table 19: Reasons for completely stopping randomized study treatment 
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 Primary outcome: Effect of sacubitril/valsartan on rate of 
change in measured glomerular filtration rate at 12 months 
 
Mean (SE) mGFR at baseline was 34.0 (0.8) mL/min/1.73m² in the sacubitril/valsartan 
group and 34.7 (0.8) mL/min/1.73m² in the irbesartan group (Table 19).  
A total of 404 baseline mGFR results were used and the 10 missing baseline mGFR 
values were replaced by the baseline eGFR result. At 12 months, 371 mGFR results 
were available. A value for the 12-month mGFR was imputed for 41 participants, 
including the 9 participants that did not consent to continue follow-up beyond 6 
months, allowing ITT analyses.  
At 12 months mean (SE) mGFR decreased from 34.0 to 29.8 (0.5) mL/min/1.73m² in 
those allocated sacubitril/valsartan and from 34.7 to 29.9 (0.5) mL/min/1.73m² in 
those allocated irbesartan: between-group difference in mGFR of 0.1 (SE 0.7) 





















Randomization 404  10 34.0 (0.8) 34.7 (0.8)   
12 months 371 2 41 29.8 (0.5) 29.9 (0.5) -0.1 (0.7) 0.86 
 
Table 20: Primary outcome: Effect of sacubitril/valsartan on rate of change in measured 
glomerular filtration rate at 12 months  
mGFR = measured glomerular filtration rate. †Values are absolute differences in arithmetic means (SE).  
 
A pre-specified sensitivity analysis excluding all participants with missing 12-month 
mGFR results (i.e. “complete-case analysis”) was also performed to verify the result 
observed using multiple imputation. Complete case analysis yielded a between-group 






















Randomization 404  10 34.0 (0.8) 34.7 (0.8)   
12 months 371 2 0 29.8 (0.5) 30.2 (0.5) -0.4 (0.7) 0.55 
 
Table 21: Pre-specified sensitivity analysis of the effect of randomization to 
sacubitril/valsartan on measured glomerular filtration rate as 12 months, excluding 
participants with missing measured glomerular filtration rate values at 12 months 
mGFR = measured glomerular filtration rate. *Values are absolute differences in arithmetic 
means (SE). 
 
 Effect of sacubitril/valsartan on mGFR in pre-specified subgroups 
There was no difference in the treatment effect of sacubitril/valsartan on mGFR at 12 





Figure 11: Effect of sacubitril/valsartan on measured glomerular filtration rate at 12 
months in a range of pre-specified sub-groups 
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 Effect of sacubitril/valsartan on secondary outcomes 
 
 Effects of sacubitril/valsartan on estimated glomerular filtration rate 
(eGFR) 
eGFR was measured on central samples at randomization, 3, 6 and 12 months and 
results from local laboratory samples were used for the 1 and 9-month eGFR values. 
At each time point, there was no difference in mean eGFR between participants 
randomized to either sacubitril/valsartan or irbesartan (Figure 12). Study average 
eGFR in participants allocated to sacubitril/valsartan was 32.3 (SE 0.2) and irbesartan 




Figure 12: Effect of randomization to sacubitril/valsartan on estimated glomerular 
filtration rate 




An acute fall in eGFR was seen on eGFR measurements at one-month post-
randomization. This fall reflects the renal haemodynamic changes resulting in a 
reduction in intraglomerular pressure that occurs with initiation of RAS blockade.276 
 
 Effect of sacubitril/valsartan on urinary albumin:creatinine ratio (uACR) 
uACR was measured in central samples at randomization, 3, 6 and 12 months. 
Sacubitril/valsartan, compared with irbesartan, had no overall effect on albuminuria 
but, was associated with a non-significant mean reduction of 9% (95% CI -18 to 1%; 




















Randomization 414 0 34.1 (4.6) 33.9 (4.5)   
3 months 396 18 17.0 (1.0) 17.8 (1.0) -4% (-19 to 12%) 0.58 
6 months 394 20 15.6 (1.0) 18.4 (1.1) -15% (-28 to 0%) 0.06 
12 months 378 36 16.4 (1.2) 17.6 (1.3) -6% (-23 to 14%) 0.52 
Study 
average   16.3 (0.6) 17.9 (0.7) -9% (-18 to 1%) 0.08 
 
Table 22: Effect of randomization to sacubitril/valsartan on urinary albumin:creatinine 
ratio at 3, 6 and 12 months 
†Values are percentage changes in geometric means (95% CI) for urinary albumin:creatinine ratio.  
 
A post-hoc analysis was performed to assess whether the treatment effect of 
sacubitril/valsartan on albuminuria varied by subgroup (Table 23). In most subgroups 
examined, there was no significant difference in the effect of sacubitril/valsartan on 
albuminuria. 
The effect of sacubitril/valsartan on albuminuria appeared to differ by underlying 
cause of kidney disease (P=0.01). However, even a highly significant P-value of 0.01 
is not good evidence of variation in treatment on albuminuria due to the post-hoc 
nature of the analyses.236,256,268 Furthermore, the result is likely to be the result of 





Geometric mean uACR  








(n=207) χ² statistic 
P 
 value 
Age (years)    0.59 0.44 
≤60 15.2 (0.9) 17.6 (1.1) -13% (-27 to 3%)   
>60 17.0 (0.8) 18.1 (0.8) -6% (-17 to 7%)   
Sex    1.50 0.22 
Male 16.5 (0.7) 18.8 (0.8) -12% (-23 to -1%)   
Female 16.0 (1.1) 15.8 (1.1) 1% (-17 to 23%)   
Prior diabetes    1.09 0.30 
Yes 17.5 (1.0) 20.5 (1.2) -15% (-28 to 0%)   
No 15.6 (0.7) 16.4 (0.8) -5% (-16 to 9%)   
Prior vascular disease    1.30 0.25 
Yes 18.8 (1.4) 22.5 (1.5) -16% (-32 to 2%)   
No 15.6 (0.7) 16.3 (0.7) -4% (-15 to 8%)   
Systolic blood pressure 
(mmHg)    1.06 0.30 
≤140 16.9 (1.0) 17.4 (1.0) -3% (-17 to 15%)   
>140 16.0 (0.8) 18.3 (0.9) -13% (-24 to 0%)   
Diastolic blood pressure 
(mmHg)    4.00 0.05 
≤80 17.4 (0.9) 17.2 (0.9) 1% (-13 to 17%)   
>80 15.3 (0.8) 18.7 (1.0) -18% (-29 to -5%)   
Body mass index (kg/m²)    0.21 0.64 
≤30 15.6 (0.8) 17.3 (0.9) -10% (-22 to 4%)   
>30 17.1 (0.9) 18.1 (1.0) -6% (-19 to 10%)   
Baseline mGFR 
(mL/min/1.73m²)    0.04 0.85 
≤30 18.2 (1.0) 19.9 (1.2) -8% (-22 to 8%)   
>30 15.0 (0.7) 16.7 (0.8) -10% (-21 to 3%)   
Baseline uACR (mg/mmol)    0.17 0.68 
≤30 2.4 (0.2) 2.6 (0.2) -7% (-23 to 13%)   
>30 48.5 (2.1) 54.7 (2.4) -11% (-21 to -0%)   
Baseline 24 hour urinary sodium 
excretion (mg/24 hours) 
 
1.68 0.19 
≤2680 15.5 (1.1) 14.7 (1.2) 6% (-14 to 30%)   
>2680 12.7 (1.0) 14.6 (1.1) -13% (-30 to 7%)   
Use of RAS blockade at 
screening    4.10 0.04 
Yes 16.3 (0.7) 16.9 (0.7) -4% (-14 to 8%)   
No 16.6 (1.5) 22.9 (2.0) -27% (-43 to -7%)   
Cause of kidney disease    15.95 0.01 
Glomerular disease 14.7 (1.0) 13.8 (1.0) 6% (-13 to 30%)   
Tubulointerstitial disease 19.9 (2.5) 17.7 (1.7) 12% (-18 to 53%)   
Diabetic kidney disease 18.9 (1.7) 19.4 (1.5) -2% (-23 to 23%)   
Hypertensive/renovascular 
disease 14.7 (1.8) 21.9 (2.4) -33% (-52 to -7%)   
Familial/hereditary 
nephropathies 15.3 (1.5) 20.1 (3.2) -24% (-47 to 10%)   
Other known causes* 20.4 (4.3) 11.3 (2.4) 81% (0 to 225%)   
Unknown 16.3 (1.4) 21.6 (2.0) -25% (-41 to -3%)   
All participants 16.3 (0.6) 17.9 (0.7) -9% (-18 to 1%)   
 
Table 23: Post-hoc exploratory analysis analysing the effect of allocation to 
sacubitril/valsartan on study average urinary albumin:creatinine ratio in a range of 
subgroups 
mGFR = measure glomerular filtration rate; RAS = renin angiotensin system; uACR = urinary 
albumin:creatinine ratio. *Includes other systemic kidney diseases.  
†Values are percentage differences in geometric means (95% CIs).  
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 Effect of sacubitril/valsartan on tertiary outcomes 
 
 Effect of randomization to sacubitril/valsartan on change in estimated 
glomerular filtration rate slopes 
There was no significant difference in the rate of decline in eGFR at 12 months in 
those allocated sacubitril/valsartan compared with irbesartan. Mean (SE) reduction in 
eGFR with sacubitril/valsartan was 0.22 (0.03) mL/min/1.73m²/month and with 
irbesartan was 0.25 (0.03) mL/min/1.73m²/month (P=0.42; Table 24).   
The rate of decline was further analysed to assess whether there was any difference 
between the acute slope (randomization to 3 months) and chronic slopes (3 months 
to 12 months). The rate of change in eGFR was fastest in the first three months 
following randomization with a mean (SE) decline in eGFR of 0.68 (0.12) 
mL/min/1.73m²/month in those allocated sacubitril/valsartan and 0.61 (0.10) 












Pre-specified analyses     
Randomization to 12 months 409 -0.22 (0.03) -0.25 (0.03) 0.42 
Randomization to 3 months 410 -0.68 (0.12) -0.61 (0.10) 0.63 
3 months to 12 months 409 -0.11 (0.05) -0.16 (0.04) 0.44 
Post-hoc analyses     
Randomization to 1 month 409 -2.55 (0.34) -1.89 (0.31) 0.15 
1 month to 12 months 409 -0.12 (0.04) -0.17 (0.03) 0.33 
 
Table 24: Effect of randomization to sacubitril/valsartan on rate of change in estimated 
glomerular filtration rate slopes 
CKD-EPI = Chronic kidney disease Epidemiology Collaboration. eGFR = estimated glomerular filtration 
rate.  
 
Additional post-hoc analysis showed most of the decline in eGFR occurred within the 
first month following initiation of trial treatments. The rate of decline in eGFR was 
faster in those allocated sacubitril/valsartan compared with irbesartan (mean [SE] 
decline in eGFR 2.55 [0.34] versus 1.89 [0.31] mL/min/1.73m²/month; P=0.15; Table 
24). Beyond one month following randomization, the rate of change in eGFR slopes 
between 1 and 12 months and 3 and 12 months, was similar for both treatments 
(Table 24).  
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 Effect of sacubitril/valsartan on blood pressure 
Both systolic blood pressure and diastolic blood pressure were significantly lower in 
participants randomized to sacubitril/valsartan than irbesartan throughout trial follow-
up (Table 25). Overall, mean systolic blood pressure was 5.4 (95% CI -7.4 to -3.4; P 
<0.001) mmHg lower, and mean diastolic blood pressure 2.1 (95% CI -3.3 to -1.0; P 
<0.001) mmHg lower in participants randomized to sacubitril/valsartan compared with 
irbesartan (Table 25).   
The largest reduction in blood pressure was observed at 3 months. 
Sacubitril/valsartan reduced systolic blood pressure and diastolic blood pressure by 
7.3 (95% CI -10.3 to -4.3; P<0.001) mmHg and 2.6 (95% CI -4.3 to -0.9; P=0.003) 










Mean (SE) (mmHg) 
Difference in 







Systolic blood pressure 
Randomization 414 0 146 (1.1) 146 (1.1)   
1 month 402 12 129 (1.1) 132 (1.1) -3.5 (-6.5 to -0.6) 0.02 
3 months 405 9 129 (1.1) 137 (1.1) -7.3 (-10.3 to -4.3) <0.001 
6 months 396 18 128 (1.1) 135 (1.1) -6.9 (-10.0 to -3.7) <0.001 
9 months 387 27 130 (1.2) 134 (1.2) -4.0 (-7.3 to -0.8) 0.02 
12 months 381 33 128 (2.5) 133 (2.2) -4.4 (-10.9 to 2.1) 0.18 
Study average  129 (0.8) 134 (0.7) -5.4 (-7.4 to -3.4) <0.001 
       
Diastolic blood pressure 
Randomization 414 0 81 (0.8) 80 (0.8)   
1 month 402 12 73 (0.6) 74 (0.6) -0.8 (-2.5 to 0.9) 0.37 
3 months 405 9 73 (0.6) 76 (0.6) -2.6 (-4.3 to -0.9) 0.003 
6 months 396 18 72 (0.6) 75 (0.6) -2.5 (-4.2 to -0.8) 0.005 
9 months 387 27 73 (0.6) 74 (0.6) -1.8 (-3.6 to -0.1) 0.04 
12 months 381 33 72 (1.6) 75 (1.3) -2.2 (-6.2 to 1.9) 0.29 
Study average  73 (0.5) 75 (0.4) -2.1 (-3.3 to -1.0) <0.001 
 
Table 25: Effect of randomization to sacubitril/valsartan on systolic and diastolic blood 
pressure 




 Effect of sacubitril/valsartan on cardiac biomarkers 
Concentrations of NT-proBNP and troponin I were similar in both treatment groups at 
baseline. Allocation to sacubitril/valsartan, compared with irbesartan, was associated 
with an 18% (95% CI -25 to -11%; P<0.001) reduction in NT-proBNP and 16% (95% 
CI -23% to -8%; P<0.001) reduction in troponin I concentration (Table 26).  
The greatest reduction in concentrations of both biomarkers were seen at 6 months 
post-randomization to sacubitril/valsartan. At 6 months, allocation to 
sacubitril/valsartan, compared with irbesartan, was associated with 20% (95% CI -29 
to -11%) lower NT-proBNP concentrations and 19% (95% CI -27 to -10%) lower 



















N Terminal Pro B-type Natriuretic Peptide (ng/L) 
Randomization 414 0 254.5 (22) 250.9 (22)   
6 months 395 19 175.6 (7.2) 219.7 (8.9) -20% (-29 to -11%) <0.001 
12 months 379 35 210.2 (11) 247.5 (12) -15% (-26 to 2%) 0.02 
Study average  188.7 (6.0) 230.4 (7.3) -18% (-25 to 11%) <0.001 
       
Troponin I (ng/mL) 
Randomization 414 0 7.3 (0.5) 7.5 (0.5)   
6 months 395 19 5.4 (0.2) 6.6 (0.2) -19% (-27 to -10%) <0.001 
12 months 379 35 6.3 (0.4) 7.1 (0.4) -11% (-24 to 4%) 0.14 
Study average 
 
5.7 (0.2) 6.8 (0.2) -16% (-23 to -8%) <0.001 
 
Table 26: Effect of randomization to sacubitril/valsartan on cardiac biomarkers 
†Values are percentage changes in geometric means (95% CI).  
 
Additional post-hoc analyses showed that the effect of sacubitril/valsartan on NT-
proBNP did not differ by any particular baseline characteristic (Table 27). However, 
the effect of troponin I appeared to be differ significantly with BMI. Sacubitril/valsartan, 
compared with irbesartan, appeared to have a significantly larger effect on those with 
a BMI greater than 30, resulting in a 28% (-37 to -18%; P<0.001) reduction in troponin 






Geometric mean NT-proBNP  











statistic P value 
Age (years)    1.22 0.27 
≤60 160.9 (8.4) 208.2 (12) -23% (-33 to -10%)   
>60 208.3 (8.3) 242.9 (9.5) -14% (-23 to -4%)   
Sex    0.95 0.33 
Male 186.2 (7.0) 221.5 (8.1) -16% (-24 to -7%)   
Female 194.9 (12) 255.6 (16) -24% (-35 to -10%)   
Prior diabetes    1.98 0.16 
Yes 212.8 (11) 240.0 (12) -11% (-23 to 2%)   
No 174.7 (7.1) 224.2 (9.1) -22% (-30 to -13%)   
Prior vascular disease    1.40 0.24 
Yes 212.0 (14) 235.6 (14) -10% (-24 to 7%)   
No 181.7 (6.7) 228.3 (8.7) -20% (-28 to -12%)   
Systolic blood pressure (mmHg)   0.00 0.97 
≤140 188.0 (9.8) 229.3 (11) -18% (-29 to -6%)   
>140 189.1 (7.6) 231.3 (9.6) -18% (-27 to -8%)   
Diastolic blood pressure (mmHg)   1.49 0.22 
≤80 204.9 (9.4) 236.2 (10) -13% (-23 to -2%)   
>80 174.4 (7.8) 224.5 (10) -22% (-31 to -12%)   
Body mass index (kg/m²)    0.46 0.50 
≤30 179.8 (7.7) 224.7 (9.8) -20% (-29 to -10%)   
>30 192.0 (9.0) 225.8 (10) -15% (-25 to -3%)   
Baseline mGFR (mL/min/1.73m²)   0.25 0.62 
≤30 217.7 (11) 260.7 (13) -17% (-27 to -4%)   
>30 169.5 (7.1) 212.4 (8.6) -20% (-29 to -11%)   
Baseline uACR (mg/mmol)    0.25 0.62 
≤30 201.2 (11) 239.3 (13) -16% (-28 to -2%)   
>30 181.4 (7.1) 226.2 (8.9) -20% (-28 to -11%)   
Baseline 24 hour urinary sodium excretion 
(mg/24 hours)   1.44 0.23 
≤2680 206.0 (13) 241.6 (17) -15% (-29 to 3%)   
>2680 162.9 (11) 224.5 (15) -27% (-40 to -13%)   
Use of RAS blockade at screening   0.23 0.63 
Yes 185.7 (6.5) 223.6 (7.9) -17% (-25 to -8%)   
No 204.4 (16) 260.3 (19) -21% (-36 to -3%)   
Cause of kidney disease    6.62 0.36 
Glomerular disease 170.9 (10) 221.3 (14) -23% (-35 to -8%)   
Tubulointerstitial disease 185.8 (20) 225.5 (18) -18% (-37 to 7%)   
Diabetic kidney disease 228.5 (17) 231.4 (15) -1% (-19 to 20%)   
Hypertensive/renovascular 
disease 175.3 (18) 227.7 (21) -23% (-42 to 1%)   
Familial/hereditary 
nephropathies 174.1 (15) 249.8 (33) -30% (-49 to -5%)   
Other known causes§ 203.8 (37) 183.2 (33) 11% (-33 to 84%)   
Unknown 201.7 (15) 252.9 (20) -20% (-35 to -1%)   
All participants 188.7 (6.0) 230.4 (7.3) -18% (-25 to -11%)   
 
Table 27: Post-hoc assessment of the effect of sacubitril/valsartan on NT-proBNP 
mGFR = measure glomerular filtration rate; NT-proBNP = N-Terminal pro B-type Natriuretic Peptide; 
RAS = renin angiotensin system; uACR=urinary albumin:creatinine ratio. †Values are percentage 





Geometric mean troponin I  









(n=207) χ² statistic P value 
Age (years)    0.52 0.47 
≤60 5.3 (0.3) 6.0 (0.3) -12% (-24 to 2%)   
>60 6.0 (0.2) 7.3 (0.3) -18% (-26 to -8%)   
Sex    0.29 0.59 
Male 5.9 (0.2) 7.1 (0.3) -17% (-25 to -8%)   
Female 5.3 (0.3) 6.0 (0.4) -13% (-26 to 4%)   
Prior diabetes    0.00 0.98 
Yes 5.9 (0.3) 7.1 (0.4) -16% (-27 to -3%)   
No 5.6 (0.2) 6.6 (0.3) -16% (-25 to -6%)   
Prior vascular disease    0.20 0.65 
Yes 6.7 (0.4) 8.2 (0.5) -18% (-30 to -3%)   
No 5.4 (0.2) 6.3 (0.2) -14% (-22 to -5%)   
Systolic blood pressure (mmHg)   0.21 0.65 
≤140 5.8 (0.3) 6.7 (0.3) -14% (-25 to -1%)   
>140 5.7 (0.2) 6.9 (0.3) -17% (-26 to -7%)   
Diastolic blood pressure (mmHg)   0.17 0.68 
≤80 6.0 (0.3) 7.0 (0.3) -14% (-24 to -3%)   
>80 5.5 (0.2) 6.6 (0.3) -17% (-27 to -6%)   
Body mass index (kg/m²)    12.79 <0.001 
≤30 6.1 (0.3) 6.1 (0.3) -1% (-12 to 11%)   
>30 
5.4 (0.3) 7.5 (0.3) 
-28% (-37 to -
18%)   
Baseline mGFR (mL/min/1.73m²)   0.90 0.34 
≤30 5.9 (0.3) 7.4 (0.4) -20% (-31 to -9%)   
>30 5.6 (0.2) 6.4 (0.3) -13% (-23 to -3%)   
Baseline uACR (mg/mmol)    0.00 0.97 
≤30 5.5 (0.3) 6.5 (0.4) -16% (-28 to -2%)   
>30 5.9 (0.2) 7.0 (0.3) -16% (-24 to -6%)   
Baseline 24 hour urinary sodium excretion (mg/24 hours)  0.02 0.89 
≤2680 5.8 (0.4) 6.9 (0.5) -16% (-30 to 1%)   
>2680 6.2 (0.4) 7.3 (0.5) -14% (-29 to 3%)   
Use of RAS blockade at screening   0.00 0.95 
Yes 5.7 (0.2) 6.8 (0.2) -16% (-23 to -7%)   
No 5.9 (0.5) 7.0 (0.5) -16% (-32 to 3%)   
Cause of kidney disease    2.11 0.91 
Glomerular disease 5.3 (0.3) 6.4 (0.4) -18% (-30 to -3%)   
Tubulointerstitial disease 6.0 (0.6) 7.0 (0.6) -14% (-34 to 12%)   
Diabetic kidney disease 6.0 (0.5) 7.2 (0.5) -16% (-31 to 2%)   
Hypertensive/renovascular 
disease 6.2 (0.6) 6.2 (0.6) -1% (-25 to 31%)   
Familial/hereditary 
nephropathies 6.2 (0.5) 8.3 (1.1) -25% (-45 to 1%)   
Other known causes§ 6.0 (1.1) 7.2 (1.3) -17% (-50 to 37%)   
Unknown 5.4 (0.4) 6.5 (0.5) -17% (-33 to 2%)   
All participants 5.7 (0.2) 6.8 (0.2) -16% (-23 to -8%)   
 
Table 28: Post-hoc assessment of the effect of sacubitril/valsartan on troponin I 
mGFR = measure glomerular filtration rate; RAS = renin angiotensin system; uACR = urinary 
albumin:creatinine ratio. §Includes other systemic kidney diseases. †Values are percentage differences 
in geometric means (95% CI).  
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 Pharmacokinetic analyses 
Data from 87 participants who had taken their last dose of sacubitril/valsartan 
between 10 and 16 hours previously were used to assess the effects of determinants 
of drug metabolism and drug levels. Median (IQR) concentrations of each metabolite 
were: sacubitril 2 (1-5) ng/mL, sacubitrilat 11700 (8700-15900) ng/mL and valsartan 
975 (522-1910) ng/mL. 
Concentrations of sacubitrilat (the active form of sacubitril) increased significantly with 
decreasing kidney function. Each 10 mL/min/1.73m2 reduction in mGFR was 
associated with a 1485 (95% CI 572 to 2397) ng/mL higher sacubitrilat concentration 
(P=0.002; Table 28). The median (IQR) concentration of sacubitrilat in participants 
with an mGFR of 30 mL/min/1.73m2 or below was 16,700 (10500-19400) ng/mL 






Table 29: Associations between baseline characteristics and sacubitril/valsartan 
metabolite values at the 3 month visit 
ACR = albumin:creatinine ratio; BSA = body surface area; mGFR = measured glomerular filtration rate. 
Models adjusted for all characteristics shown in table and additionally for time since last dose. *White 
ethnicity used as reference category. Race was not prescriptive for inclusion in the models. †Males used 
as a reference category. 
 
Characteristic 
Sacubitril Sacubitrilat Valsartan 




Absolute change in 







Age, per decade 
higher 22% (1 to 48%) 0.04 889 (-30 to 1808) 0.06 14% (-2 to 33%) 0.09 
Race*  0.78  0.71  0.22 
Black   -60% (-95 to 252%)  -4856 (-15440 to 5729)  -63% (-94 to 112%)  
Other -44% (-89 to 175%)  539 (-7208 to 8286)  5% (-71 to 276%)  
South Asian 7% (-71 to 297%)  1947 (-3684 to 7578)  -59% (-84 to 5%)  
Sex† -25% (-67 to 71%) 0.48 -4413 (-8444 to -381) 0.03 -37% (-67 to 23%) 0.18 
BSA, per 0.1 m² 
higher -32% (-64 to 31%) 0.25 -3327 (-6500 to -154) 0.04 -23% (-54 to 31%) 0.34 
Weight, per 5 kg 
higher 20% (-20 to 78%) 0.37 1915 (-25 to 3854) 0.05 13% (-18 to 56%) 0.44 
mGFR 
(unadjusted for 
BSA), per 10 
mL/min/1.73m² 
lower -17% (-32 to 1%) 0.06 1485 (572 to 2397) 0.002 -3% (-17 to 13%) 0.65 
Log ACR, per 5-
fold increase -7% (-24 to 13%) 0.44 -622 (-1590 to 346) 0.21 -14% (-27 to 1%) 0.07 
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 Safety outcomes with sacubitril/valsartan 
 
 Effect of sacubitril/valsartan on serious adverse events (SAEs) 
There were two deaths during the trial, one due to pulmonary embolism in a 
participant randomized to sacubitril/valsartan and the other due to sepsis in a 
participant randomized to irbesartan. Neither of these deaths were believed to be 
related to study treatment (Table 29). 
One case of angioedema occurred in a participant randomized to sacubitril/valsartan 
(Table 29). However, this was an expected adverse reaction with sacubitril/valsartan 
and the participant did not seek medical attention. Only one serious adverse event of 
significant hypotension was reported in each treatment group (Table 29).  
Requirement for temporary dialysis was similar in both treatment groups (2 
participants randomized to sacubitril/valsartan and 3 participants randomized to 
irbesartan: Table 29). Only two participants progressed to ESKD requiring long-term 
dialysis; both were randomized to irbesartan. There was no numerical excess in 
numbers of cases of any other non-fatal serious adverse events. Overall rates of all 
serious adverse events did not differ significantly between those allocated  
sacubitril/valsartan, compared with irbesartan (61/207 [29.5%] versus 59/207 (28.5%) 
respectively; rate ratio [RR] 1.07 [95% CI 0.75-1.53]; P=0.70) (Table 29A&B). 
 
 Sacubitril/valsartan (n=207) 
Irbesartan 
(n=207) Rate ratio (95% CI) 
P 
value 
Fatal SAEs     
Cardiovascular causes     
Coronary 0 (0.0%) 0 (0.0%)   
Other cardiac 0 (0.0%) 0 (0.0%)   
Other vascular 0 (0.0%) 0 (0.0%)   
Subtotal: Any cardiovascular 0 (0.0%) 0 (0.0%)   
Non-cardiovascular causes     
Cancer 0 (0.0%) 0 (0.0%)   
Infection 0 (0.0%) 1 (0.5%)   
Respiratory* 1 (0.5%) 0 (0.0%)   
Hepatic* 0 (0.0%) 0 (0.0%)   
Other medical 0 (0.0%) 0 (0.0%)   
Non-medical 0 (0.0%) 0 (0.0%)   
Subtotal: Any non-cardiovascular 1 (0.5%) 1 (0.5%)   
Subtotal: Uncategorized/unknown 0 (0.0%) 0 (0.0%)   
Total: Any fatal SAE 1 (0.5%) 1 (0.5%)   
 
Table 30A: Effect of randomization to sacubitril/valsartan on serious adverse events 
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 Sacubitril/valsartan (n=207) 
Irbesartan 
(n=207) Rate ratio (95% CI) 
P 
value 
Non-fatal SAEs     
Angioedema 1 (0.5%) 0 (0.0%)   
Hypotension 1 (0.5%) 1 (0.5%)   
Dialysis 2 (1.0%) 3 (1.4%)   
  
Other SAE (by MedDRA* System, Organ, Class [SOC] category)  
Respiratory, thoracic and mediastinal  
Disorders 6 (2.9%) 6 (2.9%)   
Infection and infestations 16 (7.7%) 15 (7.2%)   
Blood and lymphatics system 2 (1.0%) 2 (1.0%)   
Cardiac disorders 6 (2.9%) 5 (2.4%)   
Ear disorders 0 (0.0%) 0 (0.0%)   
Endocrine disorders 2 (1.0%) 0 (0.0%)   
Eye disorders 2 (1.0%) 1 (0.5%)   
Gastrointestinal disorders 5 (2.4%) 6 (2.9%)   
Hepatobiliary disorders     
Bile duct and gallbladder disorders 1 (0.5%) 1 (0.5%)   
Liver/other hepatobiliary 0 (0.0%) 0 (0.0%)   
Immune system disorders 0 (0.0%) 0 (0.0%)   
Metabolism and nutrition disorders     
Diabetes/glucose 3 (1.4%) 1 (0.5%)   
Other metabolism/nutrition 7 (3.4%) 6 (2.9%)   
Musculoskeletal and connective tissue  
Disorders 3 (1.4%) 0 (0.0%)   
Cancer 4 (1.9%) 5 (2.4%)   
Neoplasms benign, malignant and  
unspecified (including cysts and polyps) 2 (1.0%) 3 (1.4%)   
Nervous system disorders     
Stroke or TIA 1 (0.5%) 1 (0.5%)   
Other neurological 2 (1.0%) 2 (1.0%)   
Psychiatric disorders 0 (0.0%) 0 (0.0%)   
Renal and urinary disorders 10 (4.8%) 5 (2.4%)   
Skin and subcutaneous tissue disorders  
(excluding angioedema) 1 (0.5%) 0 (0.0%)   
Vascular disorders (excluding hypotension) 




(14.0%)   
Investigations 8 (3.9%) 13 (6.3%)   
Surgical and medical procedures  
(excluding dialysis) 18 (8.7%) 14 (6.8%)   
Miscellaneous medical** 13 (6.3%) 8 (3.9%)   
Non-medical (including trauma) 7 (3.4%) 5 (2.4%)   
Total: Any non-fatal SAE 61 (29.5%) 59 (28.5%) 1.07 (0.75-1.53) 0.70 
     
Total: Any SAE 61 (29.5%) 59 (28.5%) 1.07 (0.75-1.53) 0.70 
 
Table 31B: Effect of randomization to sacubitril/valsartan on serious adverse events 
*MedRA = Medical dictionary for Regulatory Activities; SAE = serious adverse event; TIA=Transient 
ischaemic attack. *Excluding cancer and infection. **Made up of System Organ Class categories: 
Congenital, familial and genetic disorders, General disorders and administration site conditions, and 
Pregnancy, puerperium and perinatal conditions. 
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 Effect of sacubitril/valsartan on non-serious adverse reactions 
(NSARs) 
Non-serious adverse reactions (reported by trial participants or study nurses as being 
related to study treatments) of hypotension, hyperkalaemia and acute kidney injury 
were considered to be adverse events of special interest. These events might result 
in withdrawal of the study treatment and have significant impact on kidney function in 
people with CKD. 
Rates of non-serious adverse reactions of hypotension with sacubitril/valsartan were 
more than double that with irbesartan (17/207 [8.2%] versus 7/207 [3.4%] 
respectively; RR 2.36 [95% CI 1.06-5.26]; P=0.04; Table 30). There were more cases 
of hyperkalaemia with sacubitril/valsartan compared with irbesartan (6/207 [2.9%] 
versus 1/207 [0.5%] respectively; RR 4.23 [95% CI 0.96-18.61]; P=0.06). Rates of 
AKI were similar between sacubitril/valsartan and irbesartan (3/207 [1.4%] versus 
6/207 [2.9%] respectively; RR 0.51 [95% CI 0.14-1.90]; P=0.32).   
Cases of gastrointestinal disorders (for example nausea, vomiting, diarrhoea) were 
more frequently reported in participants allocated sacubitril/valsartan than irbesartan 
(18/207 [8.7%] versus 10/207 [4.8%] respectively), as were skin and subcutaneous 
tissue disorders including pruritus (18/207 [8.7%] versus 6/207 [2.9%] respectively; 
Table 30).  
Overall, rates of non-serious adverse reactions were similar between 
sacubitril/valsartan and irbesartan (76/207 [36.7%] versus 58/207 [28.0%] 







Rate ratio (95% CI) P 
value 
Hypotension 17 (8.2%) 7 (3.4%) 2.36 (1.06-5.26) 0.04 
     
Hyperkalaemia 6 (2.9%) 1 (0.5%) 4.23 (0.96-18.61) 0.06 
     
Acute kidney injury 3 (1.4%) 6 (2.9%) 0.51 (0.14-1.90) 0.32 
     










Rate ratio (95% CI) P value 
Other NSAR (by MedDRA System, Organ, Class [SOC] category)   
Respiratory, thoracic and    
mediastinal disorders 4 (1.9%) 4 (1.9%)   
Infection and infestations 2 (1.0%) 1 (0.5%)   
Blood and lymphatics system 1 (0.5%) 0 (0.0%)   
Cardiac disorders 0 (0.0%) 2 (1.0%)   
Ear disorders 1 (0.5%) 2 (1.0%)   
Endocrine disorders 0 (0.0%) 0 (0.0%)   
Eye disorders 0 (0.0%) 1 (0.5%)   
Gastrointestinal disorders 18 (8.7%) 10 (4.8%)   
Hepatobiliary disorders     
Bile duct and gallbladder  
Disorders 0 (0.0%) 0 (0.0%)   
Liver/other hepatobiliary 0 (0.0%) 0 (0.0%)   
Immune system disorders 0 (0.0%) 0 (0.0%)   
Metabolism and nutrition  
disorders  
(excluding hyperkalaemia)     
Diabetes/glucose 0 (0.0%) 0 (0.0%)   
Other  
metabolism/nutrition 3 (1.4%) 1 (0.5%)   
Musculoskeletal and  
connective tissue disorders 6 (2.9%) 5 (2.4%)   
Cancer 0 (0.0%) 0 (0.0%)   
Neoplasms benign, malignant  
and unspecified (incl. cysts  
and polyps) 0 (0.0%) 0 (0.0%)   
Nervous system disorders     
Stroke or TIA 0 (0.0%) 0 (0.0%)   
Other neurological 20 (9.7%) 18 (8.7%)   
Psychiatric disorders 0 (0.0%) 1 (0.5%)   
Renal and urinary disorders   
(excluding acute kidney injury) 2 (1.0%) 2 (1.0%)   
Reproductive system and  
breast disorders 2 (1.0%) 3 (1.4%)   
Skin and subcutaneous tissue  
disorders (excluding  
angioedema) 18 (8.7%) 6 (2.9%)   
Vascular disorders (excluding  
hypotension) 1 (0.5%) 0 (0.0%)   
Other medical 6 (2.9%) 7 (3.4%)   
Investigations 3 (1.4%) 1 (0.5%)   
Surgical and medical  
procedures 0 (0.0%) 0 (0.0%)   
Miscellaneous medical** 8 (3.90%) 12 (5.8%)   
Non-medical (including  
trauma) 0 (0.0%) 0 (0.0%)   
Total: Any non-serious adverse 
reaction* 76 (36.7%) 58 (28.0%) 1.35 (0.96-1.90) 0.08 
 
Table 33B: Effect of sacubitril/valsartan on non-serious adverse reactions 
NSAR=non-serious adverse reaction. TIA=Transient ischaemic attack. *Excluding angioedema. **Made 
up of SOC categories: Congenital, familial and genetic disorders, General disorders and administration 
site conditions, and Pregnancy, puerperium and perinatal conditions. 
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 Effect of sacubitril/valsartan on biochemical safety parameters 
 Renal safety data 
Overall, rates of hyperkalaemia (potassium result of 5.5 mmol/L or higher) were not 
significantly different; 32% (66/207) participants allocated sacubitril/valsartan 
compared with 24% (50/207) allocated irbesartan, experienced hyperkalaemia 
(P=0.10; Table 31). 
Moderate hyperkalaemia (potassium between 6.0 and 6.5 mmol/L) occurred in 10% 
(20/207) participants allocated sacubitril/valsartan compared with 3% (7/207) 
allocated irbesartan. There was no difference in rates of severe hyperkalaemia 
(potassium 6.5 mmol/L or higher) between sacubitril/valsartan vs irbesartan (2/207 
[1%] with versus 5/207 [2%] respectively; Table 30).  
Similarly, there was no difference in reduction in CKD-EPI eGFR of 25% or greater 
compared with eGFR at randomization. This degree of decline in eGFR occurred in 
34% (71/207) of participants allocated sacubitril/valsartan compared with 32% 









Potassium (mmol/L)    
≥5.5 to <6.0 44 (21%) 38 (18%)  
≥6.0 to <6.5 20 (10%) 7 (3%)  
≥6.5 2 (1%) 5 (2%)  
Total: Any hyperkalaemia 66 (32%) 50 (24%) 0.10 
    
CKD-EPI eGFR    
≥25% reduction in CKD-EPI eGFR 71 (34%) 67 (32%) 0.75 
 
Table 34: Effect of sacubitril/valsartan on renal safety outcomes 
CKD-EPI = Chronic kidney disease Epidemiology Collaboration; eGFR = estimated glomerular filtration 
rate. *Based on local laboratory measurements.  
 
 Liver safety data 
No cases of significant liver enzyme derangement were observed with either 






(n=207) Irbesartan (n=207) 
ALT/AST >10x ULN 0 (0%) 0 (0%) 
Consecutive ALT/AST >3x ULN 0 (0%) 0 (0%) 
ALT/AST >3x ULN and bilirubin  ≥2x ULN 0 (0%) 0 (0%) 
 
Table 35: Effect of sacubitril/valsartan on liver safety outcomes 
ALT = alanine transaminase; AST = aspartate transaminase; ULN = upper limit of normal.  
*Based on local laboratory measurements 
 
Two participants developed abnormalities in liver enzymes which did not meet the 
criteria for liver enzyme derangement outlined in Table 32. One participant had an 
isolated rise in ALT 6x ULN which was believed to be due to acute decompensated 
heart failure. The liver enzymes normalized without any specific treatment despite 
continuing the study treatments. 
The second participant developed an ALT rise of 2.7x ULN and an associated bilirubin 
rise of more than 4x ULN due to cholecystitis and biliary sepsis. Study treatments 
were discontinued as the participant simultaneously developed significant AKI. 







The UK HARP-III trial is the first randomized trial to examine the effects of ARNI with 
sacubitril/valsartan on kidney function in patients with advanced CKD. Trials of 
sacubitril/valsartan in patients with heart failure and hypertension have excluded 
patients with advanced CKD (particularly those with an eGFR less than 30 
mL/min/1.73m2).190,192,194,196  
The UK HARP-III trial demonstrated twelve months of treatment with 
sacubitril/valsartan had similar effects on kidney function to irbesartan in patients with 
CKD. In contrast to patients with heart failure, no significant effect on albuminuria was 
observed. Sacubitril/valsartan substantially reduced blood pressure, cardiac 
biomarker concentrations and, had similar tolerability without any major safety 
concerns to irbesartan. 
 
 Recruitment successes and challenges 
 
The pre-screening method (pre-screening potentially eligible participants and 
telephoning them about a week later) used for recruiting patients into UK HARP-III 
proved very successful. Screening rates were numerically much higher (21.9 patients 
per million population per year) at sites primarily using pre-screening methods 
compared with sites primarily using traditional recruitment methods of recruitment 
(14.1 patients per million population per year). This method of recruitment has been 
extremely successful in other large randomized trials in cardiovascular disease and 
diabetes, with telephone reminders following initial invitation increasing recruitment 
by 6% (95% CI 3% to 9%).273,277-280 Trials using ‘traditional’ methods of recruitment 
have reported much slower rates of recruitment.278,281   
Successful trial recruitment is pivotal to the outcome of a trial. Poor recruitment can 
substantially increase trial costs or cause premature trial discontinuation resulting in 
an underpowered trial which could incorrectly show a statistically non-significant 
result and risk the trial treatment or intervention being inappropriately withdrawn.282 If 
trial follow-up were lengthened to account for poor or slow recruitment, participants 
could be exposed to potentially hazardous or ineffective treatments for longer 
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durations or conversely result in substantial delays in demonstrating any clinical 
benefit.280  
There are several reasons that contributed to the success of the recruitment method 
used in UK HARP-III. CCO staff made regular (weekly) contact with study nurses to 
enquire about recruitment progress at local sites. CCO staff collected and recorded 
information on the numbers of invitations sent, numbers of patients telephoned and 
those agreeing to participate each week. Sites recruiting more slowly were contacted 
to discuss potential reasons for this. A monthly newsletter was produced containing 
a ‘league’ table of recruitment performance by site, allowing local study staff to 
compare their own recruitment progress with other sites. Enhanced communication 
with sites and provision of site-specific feedback has been shown to increase 
numbers of participants in clinical trials and reduce the duration of recruitment,280 and 
such approaches have proven to be successful in other trials.278  
The UK HARP-III trial eligibility criteria were broad and simple to encourage the 
recruitment of a wide range of participants. This strategy ensures trial results are 
widely generalizable and provide more reliable information regarding the safety and 
efficacy of treatments such as sacubitril/valsartan.282  
Renal units from across England, Scotland and Wales were invited to participate in 
the trial ensuring that the diverse range of CKD patients managed across the UK were 
eligible to participate, with the trial conducted within the usual clinical setting. Trial 
populations do not necessarily need to be ‘representative’ of the population from 
which they are recruited for trial results to be widely generalizable.282 Adequate 
randomization and balance of potential confounders between the treatment arms is 
essential to enable the proportional effects of the treatment on various outcomes to 
studied and applied to the wider population of interest.282 
Baseline characteristics in UK HARP-III were well-balanced between both treatment 
groups. Participants were mainly white and male. Cardiovascular disease was 
present in about 10% and diabetes mellitus in 40% of participants. The aetiology of 
CKD amongst participants was similar to that seen in UK renal units.283 Blood 
pressure was slightly higher (146/81) than expected for patients with CKD managed 
in secondary care. However, pre-study RAS inhibition (taken by 82% of participants) 
was stopped at screening resulting in a slight rise in blood pressure during the pre-
randomization run-in prior to initiation of randomized study treatment. The majority of 
participants had CKD stage 3 or 4 and over two-thirds had macroalbuminuria, 
139 
 
representing a population at risk of progression of CKD. This was verified by 
assessment of risk of progression to ESRD using an established risk equation which 
showed two-thirds of UK HARP-III participants had a 5 year risk of at least 10%, and 
their overall lifetime risk was probably much higher, although current equations do 
not calculate such risk.275 
The number of female and elderly (aged 70 years or older) participants recruited to 
UK HARP-III was lower than males and younger counterparts respectively which has 
been seen in many cancer and cardiovascular disease trials.56,284-286 However, it is 
not clear whether such individuals were not invited to participate in UK HARP-III by 
local centres or whether they were more likely to decline to participate compared with 
male counterparts as this information was not collected centrally.  
The numbers of participants recruited from ethnic minority groups were low although 
similar to those recruited in trials in other disease areas. Several UK HARP-III 
participating centres were based in areas with large populations of ethnic minority 
groups and in these centres, translators were readily available for routine medical 
appointments and study visits to prevent language barriers hindering trial 
participation. The participant information sheets and study documentation (such as 
study posters, consent forms, study website) were only published in the English 
language therefore, non-English speaking patients may have been disadvantaged but 
English language was not an entry requirement for eligibility in UK HARP-III.   
Low rates of participation amongst ethnic minorities have been reported in other large 
randomized trials and,64,287,288 in trials of sacubitril/valsartan.190,192,194 
Underrepresentation of individuals from ethnic minorities could have potential 
implications for assessment of effects of genetic variability in metabolism and 
treatment tolerance.289,290 Factors that have been described as potential contributors 
to underrepresentation of ethnic minorities in medical research include: increasing 
participant age; sex; fear and mistrust in medical research/researchers; lack of 
awareness about medical research; language barriers; socioeconomic factors; 
concerns regarding drug side effects and; cultural and religious beliefs.285,291-293  
In future large clinical trials, to ensure recruitment of people from ethnic minority 




 Tolerability and compliance with sacubitril/valsartan 
 
Sacubitril/valsartan had similar tolerability and compliance to irbesartan throughout 
the trial. The use of a single-blind placebo run-in phase is a recognised method for 
improving compliance by identifying those participants that may be unwilling or unable 
to comply with study treatments and/or follow-up for the study duration. If such 
patients were randomized it is likely that they would discontinue study treatments or 
attendance at follow-up visits post-randomization, which could have a significant 
impact on the trial’s statistical power.245,246  
The trial steering committee monitored the reasons for drop out during run-in. The 
majority of participants withdrawn from run-in had ineligible laboratory results on 
samples taken at screening. In view of this, the Trial Steering Committee (TSC) 
recommended a change in the study protocol allowing results that did not fulfil the 
trial eligibility criteria to be repeated once more for confirmation of eligibility. This 
reduced drop-out from run-in due to ineligible laboratory results.  
Drop-out at randomization was higher than expected. On cessation of prior RAS 
blockade at screening, some participants were initiated on additional blood pressure 
lowering medication causing blood pressure to fall below the level for eligibility at 
randomization (greater than 130/80). The TSC recommended the lower limit for 
systolic blood pressure be reduced to less than 110 mmHg (or below 130 mmHg if 
the patient had symptomatic hypotension). These changes to the eligibility criteria 
improved the efficiency of the trial without adversely affecting the reliability of the trial 
results or compromising patient safety.  
Compliance with study follow-up visits was excellent throughout the trial, with very 
few missed follow-up visits. As per intention to treat analyses, all patients were asked 
to continue to attend for study follow-up (either in person, by telephone or by use of 
their medical records) even if they stopped study treatments. To facilitate this, I 
telephoned all study nurses when informed of participants with a change in their study 
treatment or follow-up method and/or when reviewing completed study follow-up 
forms. A log of all such participants was maintained and I regularly contacted LRCs 
to review compliance of affected individuals and encourage maximum compliance 
wherever possible. Participants indicating that they no longer wished to continue with 
study follow-up visits were contacted to reiterate the importance of ongoing trial 
follow-up despite stopping study treatments. 
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The initial trial power calculation assumed randomization of 360 participants would 
provide 80% power (at 2p=0.05) to detect a clinically meaningful difference in mGFR 
of 3 mL/min/1.73m2, even if 10% of participants discontinued study treatment after 
randomization. During the trial, post-hoc data from the PARAMOUNT trial suggested 
it may take up to 9 months for the effects of sacubitril/valsartan on renal function to 
emerge.294 The TSC therefore recommended increasing trial follow-up to 12 months. 
The revised power calculation took into account any change in compliance with study 
treatment over an extended period of follow-up and so randomization of 400 
participants provided similar power even if 15% of participants discontinued study 
treatment. 
Throughout the trial, rates of discontinuation of study treatments were similar at each 
follow-up time-point. At 12 months, about 80% of participants were still taking some 
study treatment and the proportion taking full dose sacubitril/valsartan or irbesartan 
dropped by similar amounts in each treatment group. Reasons for discontinuing 
sacubitril/valsartan were similar to other trials.190,194,195  
In PARADIGM-HF, overall rates of discontinuation of sacubitril/valsartan were 
significantly lower than enalapril (746/4187 [17.8%] versus 833/4212 [19.8%] 
respectively; HR 0.89 [95% CI 0.80-0.98]; P=0.016).202 In participants with CKD the 
rates of study treatment discontinuation were similar in both treatment groups 
(324/2745 [24%] sacubitril/valsartan versus 355/5654 [25%] enalapril; HR 0.97 [95% 
CI 0.84-1.13]; P=0.72) and, did not differ significantly from those without CKD (P for 
interaction = 0.18).202 Renal reasons accounted for fewer discontinuations of 
sacubitril/valsartan than enalapril amongst the overall trial population (27/4189 [0.9%] 
versus 59/4212 [1.4%] respectively; HR 0.49 [95% CI 0.31-0.76]; P=0.002).  
In UK HARP-III, there were numerically (though not statistically significantly) more 
cases of hypotension resulting in a reduction in the dose of sacubitril/valsartan. This 
was not surprising given the effect of the drug on blood pressure and hypotension did 
not produce any excess in discontinuations of sacubitril/valsartan, compared with 




 Effects of sacubitril/valsartan on renal function 
 
At 12 months, sacubitril/valsartan had a similar effect to irbesartan on mGFR. The 
effect of sacubitril/valsartan on mGFR was not modified by any particular baseline 
characteristic (including: age; sex; presence of diabetes; previous vascular disease; 
severity of renal impairment; albuminuria; urinary sodium excretion at baseline; prior 
use of RAS blockade; BMI; blood pressure or; cause of underlying renal disease), 
suggesting the drug has similar effects across the broad range of patients with CKD 
studied in UK HARP-III.  
Animal studies of neprilysin inhibition with omapatrilat (vasopeptidase inhibition) 
showed similar effects on renal function to those in UK HARP-III. In a variety of animal 
models of renal disease, treatment with omapatrilat was not associated with 
significant differences in GFR compared with animals treated with ACE inhibition 
alone.158,159 In contrast, histology specimens from these animals showed combined 
NEP/RAS inhibition, was associated with substantial reductions in glomerulosclerosis 
and tubulointerstitial fibrosis compared with isolated RAS inhibition, suggesting 
greater renoprotection with the addition of NEP inhibition.138,158,159,161  
Animal studies that compared ARBs combined with NEP inhibition (mimicking ARNIs) 
with isolated RAS inhibition (with an ARB), reported similar GFR and histological 
findings to studies with vasopeptidase inhibitors.199,295 Although animal models are 
poorly predictive of drug efficacy in humans, these data were encouraging and 
provided a rationale for the potential use of NEP inhibition in people with CKD to 
preserve kidney function.162,163  
The animal data suggest that the duration of the UK HARP-III trial may have been too 
short to detect a clinically meaningful effect on kidney function. Sacubitril/valsartan 
may also need to be given for a much longer duration to allow the histological findings 
seen in animal studies to translate into biochemical and clinical efficacy in humans. 
Trials examining the effects of isolated RAS (compared with placebo and/or other 
antihypertensive treatment) on ESKD in people with diabetic nephropathy, showed it 
may take 15-18 months for the effects on this outcome to emerge.41,42 The effects of 
isolated RAS inhibition on doubling in serum creatinine were observed earlier, at 
around 12 months.41,42 
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The results from the PARADIGM-HF trial suggested sacubitril/valsartan may have 
smaller effects on renal function than those in the PARAMOUNT trial and, that the 
effects may take longer to emerge.200,202 In patients with CKD, combined NEP/RAS 
inhibition may need to be initiated at much earlier stages of kidney disease, prior to 
the development of substantial renal fibrosis, nephron loss and hyperfiltration causing 
albuminuria, to have an influential effect on kidney function. The UK HARP-III trial 
was not intended (and the trial duration was too short) to determine any longer-term 
effects of ARNIs on renal outcomes such as progression to ESKD in people with CKD. 
The renal function results from the UK HARP-III trial contrast to those in trials of heart 
failure populations. In PARAMOUNT, patients with HFpEF randomized to 
sacubitril/valsartan, had a slower decline in eGFR following 36 weeks treatment 
compared with valsartan (1.5±13.1 versus 5.2±11.4 mL/min/1.73m2 respectively; 
P=0.008).200 However, PARAMOUNT participants had a higher eGFR (mean 65.5 
[SD 20.4] mL/min/1.73m2) compared with UK HARP-III participants and only 42% had 
CKD (defined as an eGFR less than 60 mL/min/1.73m2) at baseline.195,200  
In PARADIGM-HF, allocation to sacubitril/valsartan resulted in a slower rate of decline 
in eGFR between screening and the end of follow-up, compared with enalapril (1.61 
[95% CI -1.77 to -1.44] versus 2.04 [95% CI -2.21 to -1.88] mL/min/1.73m2/year 
respectively; P<0.001).202 The effect on eGFR was similar in patients with and without 
CKD at baseline (P for interaction = 0.54).202 Post-hoc analyses suggested 
sacubitril/valsartan may have a greater effect on slowing the rate of decline in renal 
function, in people with diabetes compared to those without diabetes.203  
In UK HARP-III there was no heterogeneity in the treatment effect by diabetes status. 
The lack of effect of sacubitril/valsartan on GFR seen in UK HARP-III may result from 
differences in the mechanisms of progression of kidney disease in people with heart 
failure compared with those with more advanced and/or proteinuric CKD. Neprilysin 
inhibition raises circulating levels of natriuretic peptides (NPs) which causes systemic 
vasodilatation and reduces systemic blood pressure and renal blood flow.158,161  
In people with heart failure, cardiac function is probably a more important determinant 
of kidney function than in people with proteinuric CKD. Therefore, any changes in 
cardiac structure and function related to neprilysin inhibition, may have a greater 
impact on kidney function in patients with heart failure than with CKD.200  
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 Glomerular haemodynamics in normal health 
The kidney receives about a quarter of the circulating blood volume and filters about 
a fifth of this every minute.296,297 Renal blood flow is provided by the renal artery, a 
branch of the abdominal aorta. This further subdivides into segmental arteries which 
become interlobar arteries and, in turn develop into arcuate arteries.21,296 Afferent 
arterioles branch off from arcuate arteries and supply blood to the glomerulus of 
Bowman’s capsule via the afferent arteriole which forms a capillary network.21,296,297  
Efferent arterioles take blood away from the glomerulus and subdivide into peritubular 
capillaries, which then form the venous system which takes blood away from the 
kidney via the renal vein.21,296 Renal blood flow is regulated by changes in the 
resistances of the renal artery and vein.21,296 Renal blood flow (RBF) is calculated 
from renal plasma flow (RPF) and haematocrit using the formula:297 
RBF =           RPF 
     (1-haematocrit) 
GFR is the amount of fluid filtered from the glomerulus into Bowman’s capsule 
(expressed as mL/min). GFR is determined from the capillary filtration coefficient (Kf), 
hydrostatic pressure in glomerular capillaries (PGC) and Bowman’s space (PBC), the 
oncotic pressures of blood in the glomerular capillaries blood (πGC) and Bowman’s 
space (πBC) and, glomerular plasma flow rate, using the formula:21,296 
GFR = Kf ([PGC - PBC] – [πGC - πBC]) 
Glomerular capillary hydrostatic pressure is determined by afferent and efferent 
arteriolar resistance and the pressure within the renal artery.21 GFR depends on net 
filtration pressure (which is usually between 10-16 mmHg), the surface area available 
for filtration and permeability of the glomerular basement membrane.21 In healthy 
individuals, renal plasma flow (determined by the formula: [renal arterial pressure 
minus renal venous pressure] divided by total renal vascular resistance) is about 600-
650 mL/min and GFR is between 100-140 mL/min.296  
Filtration fraction (FF) is the fraction of renal plasma flow (RPF) filtered across the 
glomerulus and therefore the composition of renal tubular blood flow.297,298 It is 
calculated using the formula:297  





GFR and renal blood flow are tightly regulated by “autoregulation”, independent of 
renal perfusion pressure, between 80-180 mmHg.299 Autoregulation is mediated by 
tubuloglomerular feedback and the sympathetic nervous system.299-301 The 
sympathetic nervous system innervates juxtaglomerular cells in the macula densa in 
the distal nephron to regulate renin release.302 Sympathetic nerves also innervate 
proximal tubular cells and afferent and efferent arterioles with preferential regulation 
of afferent arteriolar vessel tone.300,301  
If renal perfusion pressure increases, sodium reabsorption in the proximal tubule falls 
leading to greater sodium delivery to the macula densa.302 The increased sodium load 
triggers afferent arteriolar vasoconstriction and reduced renin release.300,301 Single 
nephron blood flow falls due to increased vascular resistance (due to reduced renal 
blood flow) and urinary sodium excretion.299 The net effect of these changes is a 
reduction in single nephron GFR to maintain constant GFR and renal blood flow.299 
When GFR is reduced, tubular fluid flow rate and sodium delivery falls and renin 
release increases causing arteriolar vasodilatation, arise in glomerular capillary 
hydrostatic pressure and an increase in GFR.296,302 Renin acts on angiotensinogen to 
convert this into angiotensin I which is then converted to ATII by ACE. ATII acting on 
efferent arterioles produces vasoconstriction and in the adrenal cortex it stimulates 
the release of aldosterone from the adrenal glands.297 Increased sympathetic activity 
augments proximal tubular sodium reabsorption and reduces urine volume.301,302  
Changes in vessel diameter of the afferent or efferent arterioles alters glomerular 
hydrostatic pressure which drives ultrafiltration. Afferent arteriolar vasoconstriction 
decreases renal blood flow and GFR.297 Efferent arteriolar vasoconstriction also 
reduces renal blood flow, but increases glomerular capillary hydrostatic pressure and 
filtration fraction.297  
There are several neurohormonal determinants of glomerular haemodynamics. 
Efferent arteriolar vasoconstriction is augmented by ATII, endothelin-1, thromboxane 
A2 and reactive oxygen species.21,296,303 Mediators of afferent arteriolar vasodilatation 
include NPs, nitric oxide (which increases renal plasma flow and GFR), 
prostaglandins (which vasodilate afferent and efferent arterioles increasing renal 
plasma flow) and bradykinin.21,296,303 In addition to regulation of NPs, NEP is 
responsible for processing and breakdown of vasoactive peptides including 
prostaglandin, nitric oxide, bradykinin, ATII and endothelin-1. NPs result in 
natriuresis, diuresis, RAS inhibition (including suppression on renin and aldosterone 
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release) and reductions in systemic blood pressure.304 NPs preferentially vasodilate 
the afferent arteriole to increase renal blood flow and augment glomerular capillary 
hydrostatic pressure and GFR. GFR may also be regulated through possible effects 
of NPs on glomerular permeability and on contractile elements in mesangial cells 
resulting in altered glomerular filtration surface area.135  
 
 Glomerular haemodynamics and renin-angiotensin system in 
progressive heart failure 
In studies of patients with severe heart failure, individuals with mild renal impairment 
(GFR between 60 and 70 mL/min/m2) associated with reduced cardiac output, 
exhibited compensatory increases in ultrafiltration (filtration fraction) which preserves 
GFR and intracapillary pressure, despite reductions in renal blood flow.205,305,306 
Patients with the most severely impaired cardiac function and, consequently GFR 
(around 40 mL/min/min2), exhibited much smaller increases in filtration fraction.305  
In heart failure renal blood flow is reduced to a greater amount proportionally than 
cardiac output.306 In mild to moderate heart failure, filtration fraction of renal blood 
flow increases allowing a constant GFR to be maintained.307,308 As heart failure 
progresses and systemic blood pressure falls, GFR becomes much more dependent 
on renal blood flow and perfusion pressure.305 In order to maintain GFR, RAS 
activation produces marked efferent arteriolar vasoconstriction relative to the afferent 
arteriole mediated by ATII. This increases post-glomerular resistance and capillary 
hydrostatic pressure in spite of overall decreased renal perfusion pressure.205,305,307   
In the most severe and advanced heart failure there is excessive renal afferent 
arteriolar vasoconstriction due to overwhelming activation of RAS, sympathetic 
nervous system and counterregulatory activation of neurohormonal responses 
including upregulation of the NP system and renal prostaglandin release (producing 
a vasodilatory response).305,309 These mechanisms are aimed at increasing pre-
glomerular resistances to maintain systemic blood pressure and prioritise delivery of 
circulating blood volume back to the heart and brain.308 
Activation of the sympathetic nervous system stimulates sodium reabsorption and 
renin release which further amplifies the production and actions of ATII resulting in 
predominant afferent arteriolar vasoconstriction.310 The combined effects of afferent 
and efferent arteriolar vasoconstriction reduces renal blood flow and intraglomerular 
pressure further.290,292 The net effect of all the changes described is a fall in filtration 
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fraction and GFR.307,309 ATII release also stimulates aldosterone and ADH production 
which further increases circulating blood volume through sodium and water retention 
in response to renal hypoperfusion and reduced circulating plasma volume in an 
attempt to sustain cardiac output and renal perfusion.308 
 Effect of renin-angiotensin system inhibition on glomerular 
haemodynamics in heart failure 
RAS inhibition in heart failure makes GFR dependent on systemic blood pressure. 
RAS inhibition reduces systemic blood pressure and helps to reverse afferent 
arteriolar vasoconstriction and decrease post-glomerular resistance by blocking ATII-
mediated efferent arteriolar vasoconstriction.305,310 These changes result in 
predominant efferent arteriolar vasodilatation.298 Capillary hydrostatic pressure is 
reduced which lowers filtration fraction and GFR falls (detectable as a rise in serum 
creatinine).205,305,310  
In randomized trials of RAS inhibition in heart failure, post hoc analyses have not 
demonstrated adverse outcomes associated with this acute reduction in GFR.311 
Additionally, RAS inhibition did not reduce rates of long term decline in kidney function 
(over a 3 year follow-up period), compared with placebo.312  
Results from randomized trials assessing the effects of RAS inhibition on kidney 
function in people with heart failure contrast to those with diabetic nephropathy or 
other proteinuric kidney diseases.39-41 It is hypothesised that reduction in proteinuria 
with RAS inhibition is an important mechanism by which progressive decline in kidney 
function is prevented in people with CKD.312 However, kidney disease associated with 
heart failure is not typically a proteinuric condition, therefore beneficial effects of RAS 
inhibitors may be less pronounced, particularly effects on decline in kidney function 
mediated through an effect on proteinuria.312 
 Effect of neprilysin inhibition on glomerular haemodynamics in heart 
failure 
The addition of neprilysin inhibition to RAS inhibition, raises circulating NP 
concentrations which further reduces systemic blood pressure that is transmitted to 
the renal circulation as a significant reduction in renal perfusion pressure.143 In animal 
models, ANP has been shown to produce vasodilatation of afferent arterioles, 
reducing pre-glomerular resistance, whilst simultaneously vasoconstricting efferent 
arterioles and increasing post-glomerular resistance.117  
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NEP inhibition has been shown to be associated with both upregulation and 
downregulation of endothelin-1.199 The degree of NEP inhibition is likely to determine 
whether a predominant vasodilatory or vasoconstrictive effect on renal and systemic 
vasculature occurs. NPs also reduce sympathetic nervous system activity further 
enhancing the afferent arteriolar vasodilatory effects.313  
 Effect of angiotensin receptor-neprilysin inhibition on glomerular 
haemodynamics in heart failure 
The combined actions of inhibition of RAS and NEP on efferent arterioles results in a 
relative vasoconstriction and an increase in post-glomerular resistance.205,308 The 
overall effect of NPs on renal blood flow and GFR depends on the balance of afferent 
arteriolar vasodilatation and efferent arteriolar vasoconstriction.313 Therefore, GFR 
will vary accordingly dependent on the actions of NPs on glomerular haemodynamics. 
In heart failure populations, combined NEP/RAS inhibition produces a rise in 
intracapillary hydrostatic pressure which increases filtration fraction in spite of 
considerably reduced systemic blood pressure and allows GFR to be 
maintained.205,313  
 
 Glomerular haemodynamics in CKD 
Progressive CKD is associated with loss of functioning glomeruli and nephrons with 
resulting glomerular hyperfiltration.14,23 In an attempt to minimise reductions in GFR 
that would otherwise occur due to reduced overall nephron mass, single nephron 
GFR increases due elevations in glomerular capillary hydrostatic pressure and 
decreased pre- and post-glomerular arteriolar resistances.16,23,299 There is structural 
and functional hypertrophy of remaining nephrons which leads to the development of 
progressive proteinuria, tubulointerstitial fibrosis, glomerulosclerosis (which further 
increases glomerular permeability and proteinuria) and glomerular hypertension (with 
or without secondary systemic hypertension).14,23,299 There is gradual loss of cortical 
glomeruli by global sclerosis and loss of glomerular capillaries with formation of direct 
connections between afferent and efferent arterioles (“aglomerular arterioles”).314  
 Effects of renin angiotensin system inhibition on glomerular 
haemodynamics in CKD 
In animal models of CKD, micropuncture studies demonstrated treatment with ACE 
inhibitors substantially lowered systemic blood pressure and glomerular capillary 
hydrostatic pressure, resulting in significant reductions in proteinuria, 
glomerulosclerosis and hyperfiltration.35,315,316 These findings were seen even after 
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ACE inhibition was delayed until the development of systemic hypertension.35,315,316 
In contrast, other antihypertensive agents that did not affect glomerular capillary 
pressure, were not associated with additional renoprotection.315,316 Control of 
glomerular hypertension was deemed to be an essential mechanism for slowing the 
progression of renal disease. 
In randomized clinical trials, long-term RAS inhibition significantly reduced the risk of 
progression to ESKD compared with placebo or other antihypertensive drug 
classes.39-41,54 Following initiation of RAS inhibitors, there is an acute drop in GFR 
which is due to their haemodynamic effects, mediated by blocking the actions of ATII 
on the efferent arteriole which causes efferent arteriolar vasodilatation and so 
reducing glomerular capillary hydrostatic pressure.317  Post-hoc analyses of trials of 
RAS inhibition, suggested that this acute reversible decline may be an indicator of 
subsequent rate of longer term decline in kidney function with a larger acute decline 
being associated with a slower long term rate of GFR decline (independent of blood 
pressure and albuminuria).317 However, given the post-hoc nature of these analyses, 
comparisons of non-randomized changes in GFR were must interpreted with caution. 
 Possible effect of neprilysin inhibition on glomerular haemodynamics 
in CKD 
In animal models of CKD, micropuncture studies showed combined NEP/RAS 
inhibition resulted in significantly greater reductions in glomerular capillary hydrostatic 
pressure compared with isolated RAS blockade.138,159 The reductions may be in part 
due to preferential vasodilation of the afferent arteriole by NPs producing natriuresis, 
diuresis, vasodilatation and inhibition of RAS. These combined actions also 
significantly reduce systemic blood pressure and renal perfusion pressure. Greater 
lowering of glomerular capillary hydrostatic pressure with combined NEP/RAS 
inhibition translated into significantly decreased glomerulosclerosis, tubulointerstitial 
fibrosis and proteinuria compared with isolated RAS inhibition.138,159  
 
 Differences in effects on GFR with ARNIs between people with heart 
failure and those with CKD 
Differences in the effects of ARNIs in people with CKD and heart failure are likely to 
be mediated through differences in the underlying mechanisms affecting renal 
haemodynamics. In heart failure, the overall effect of ARNIs is to increase capillary 
hydrostatic pressure to either maintain or increase GFR in the presence of reduced 
renal perfusion pressure. However, in CKD a reduction in capillary hydrostatic 
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pressure is the proposed mechanism by which RAS inhibitors confer their beneficial 
effects in slowing the rate of decline in GFR and progression of CKD.  
NPs act directly on afferent arterioles and by blocking sympathetic activity to produce 
afferent arteriolar vasodilatation. They may also produce relaxation of mesangial cells 
to increase the surface area for filtration. As CKD progresses, the numbers of 
functioning nephrons decrease due to sclerosis, fibrosis and atrophy. However, this 
is quite different to the mechanism of renal impairment seen in people with CKD 
compared to those with heart failure.  
It is plausible that once a certain degree of scarring, fibrosis and nephron loss has 
developed, kidneys of people with CKD are less responsive to the actions of NPs. 
Renal autoregulatory mechanisms are also likely to be impaired in CKD resulting in a 
decline in filtration fraction as opposed to a compensatory increase seen in people 
with heart failure.309 Therefore, the size of the effect of NEP inhibition on kidney 
function could be much smaller in people with CKD compared to those with heart 
failure. 
Animal models of cardiac disease, including CVD in CKD, have also suggested 
combined NEP/RAS inhibition may attenuate cardiac remodelling and improve 
cardiac function by limiting cardiac fibrosis and hypertrophy.207,208,318 Over time, 
improvements in cardiac function may significantly enhance renal blood flow and 
GFR.298  
The results from the UK HARP-III trial suggest that neprilysin inhibition with 
sacubitril/valsartan has similar efficacy to isolated RAS inhibition in maintaining renal 
function, at least in the short-term. However, a much larger trial and, of longer duration 
than UK HARP-III is required in people with advancing CKD, to address whether 
sacubitril/valsartan can preserve kidney function and the degree to which it can be 
maintained long-term, as suggested by the data among people with heart failure. 
 
 Effects of sacubitril/valsartan on albuminuria 
 
Sacubitril/valsartan, compared with irbesartan, was associated with a non-significant 
reduction in albuminuria and a marginal trend towards lower levels of albuminuria at 
every follow-up visit. Although, the reduction in albuminuria did not reach statistical 
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significance, is it still of huge importance that albuminuria did not rise during the 12 
month trial duration in a CKD population. This contrasts with uACR changes among 
patients with HFpEF where albuminuria increased by 50% in those allocated 
sacubitril/valsartan compared with valsartan and, by 20% in those with HFrEF 
allocated sacubitril/valsartan compared with enalapril.200,202 
The UK HARP-III albuminuria results were similar across a broad range of pre-
specified subgroups including: age; sex; blood pressure; presence of diabetes; prior 
vascular disease; BMI; kidney function; urinary sodium excretion and; prior use of 
RAS blockade. The effect of sacubitril/valsartan appeared to differ by underlying 
cause of CKD however, the source of heterogeneity in this subgroup was a 33% 
reduction in albuminuria seen in people with hypertensive or renovascular disease. 
This result is likely to be a chance finding arising as a consequence of multiple 
hypothesis testing and should be interpreted with caution given the overall result of 
no effect of sacubitril/valsartan on albuminuria.236,256,268,319,320  
The albuminuria results from UK HARP-III are also not consistent with the findings 
from animal models of renal disease, in which combined NEP/RAS inhibition led to 
substantially lower levels of albuminuria compared with isolated RAS inhibition, 
despite similar reductions in blood pressure.159 In these animal models, the 
subsequent rate of rise in albuminuria to pre-treatment levels was much slower 
compared with isolated RAS inhibition, suggesting a delay in progression to ESKD 
mediated by mechanisms beyond blood pressure reduction.159 The reductions in 
albuminuria may have contributed to the improvements in renal structure and levels 
of pro-inflammatory cytokines and vasoactive peptides producing greater reductions 
in glomerulosclerosis, tubulointerstitial fibrosis and atrophy seen on histology from 
animals treated with combined NEP/RAS inhibition compared with isolated RAS 
inhibition.138,158,159,161,295 
In a randomized trial of 1328 patients with mild-moderate hypertension, full dose 
treatment with sacubitril/valsartan reduced uACR levels by 12% (95% CI -25 to 4%) 
compared with baseline, but not more than the equivalent dose of valsartan (mean 
reduction in uACR of 10% [95% CI -24 to 8%]).190 Although, albuminuria was 
extremely low in these participants at baseline and within the normal range, it is 
reassuring that the UK HARP-III results are consistent with these. 
The effect of sacubitril/valsartan on albuminuria in UK HARP-III contrasts with results 
from heart failure populations. In people with HFpEF and HFrEF, sacubitril/valsartan 
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was associated with significant increases (although within the normal range) in 
albuminuria, compared with isolated RAS inhibition.195,200,202,206 In PARAMOUNT, 
allocation to sacubitril/valsartan was associated with an increase in geometric mean 
uACR of 51.8% at 36 weeks compared with baseline but, remained stable in those 
allocated valsartan (difference in means of 0.9 mg/mmol at 36 weeks; P for difference 
= 0.016).200 In PARADIGM-HF, albuminuria was higher in those allocated 
sacubitril/valsartan, compared with enalapril (difference in means of 0.3 mg/mmol).202 
If similar proportional increases in albuminuria with sacubitril/valsartan had been 
observed in people with proteinuric CKD, this would be of considerable concern since 
albuminuria has been shown to be associated with increased risk of progression to 
ESKD.4,29,31,321   
Differences in the acute effects of sacubitril/valsartan on albuminuria between people 
with proteinuric CKD and those with heart failure may be mediated by the additional 
actions of NPs in the kidney. In animal models and patients with diabetes, ANP 
infusions were associated with increases in glomerular pressure, filtration fraction, 
urinary albumin excretion and changes in glomerular permeability.134,135,322,323  
When NEP inhibition is combined with RAS inhibition, the additional reductions in 
systemic blood pressure and renal perfusion pressure result in preferential pre-
glomerular arteriolar vasorelaxation and relative vasoconstriction of post-glomerular 
arterioles.205 The resultant changes reduce glomerular resistance  which increases 
capillary hydrostatic pressure in spite of an overall reduction in systemic blood 
pressure and renal perfusion pressure.135,205 The changes in glomerular 
haemodynamics, permeability and renal arterial tone induced by NPs, further 
increases filtration fraction and GFR.135,205 GFR may also be increased through 
possible effects of NPs on relaxation of mesangial cells resulting in an increased 
glomerular filtration surface area.135 When such effects are combined with the direct 
effects of NPs on glomerular permeability, transcapillary albumin leak is increased, 
manifesting as increases in albuminuria.135  
It is hypothesised that the aetiology of the increase in albuminuria, which normalises 
on withdrawal of sacubitril/valsartan in people with heart failure but not in those with 
proteinuric CKD, may be mediated by changes in renal haemodynamics and the 
balance of neurohormonal peptides.135,202 People with CKD develop irreversible 
glomerular damage and resultant hyperfiltration which is not the mechanism 




 Effects of sacubitril/valsartan on blood pressure 
 
In UK HARP-III, sacubitril/valsartan significantly reduced systolic and diastolic blood 
pressure compared with irbesartan. Blood pressure was significantly lower with 
sacubitril/valsartan at every time-point except at 12 months, when the observed 
difference between the two treatments in blood pressure was no longer significant. 
The average number of additional anti-hypertensive medications taken by 
participants did not change throughout the trial.  
In animal studies of combined NEP/RAS inhibition, mean arterial pressure was 
reduced by a similar degree to isolated RAS-inhibition.138,159 Despite this, at each level 
of mean arterial pressure combined NEP/RAS inhibition reduced glomerular capillary 
pressure to a greater degree than isolated RAS inhibition resulting in increased renal 
plasma flow and reduced filtration fraction.159,324 The actions of NPs and vasoactive 
peptides on renal haemodynamics may have afforded superior renoprotection.    
Blood pressure reductions, similar to those in UK HARP-III, with sacubitril/valsartan 
compared with isolated RAS inhibition, have been demonstrated in trials of patients 
with hypertension and heart failure.190-192,194,195 In patients with hypertension, full dose 
treatment with sacubitril/valsartan was associated with reductions in mean sitting 
systolic and diastolic blood pressure of 6.01 (95% CI -9.01 to -3.02) mmHg and 2.70 
(95% CI -4.61 to 0.80) mmHg respectively, compared with the equivalent valsartan 
dose (320 mg).190 The blood pressure reductions in UK HARP-III are consistent with 
the reductions achieved in this hypertension trial despite UK HARP-III participants 
only taking on average one other antihypertensive medication in addition to study 
treatment.  
In the PARAMETER trial of 454 elderly patients with hypertension and arterial 
stiffness, compared with olmesartan, sacubitril/valsartan reduced central aortic 
systolic pressure by 3.7 mmHg (P=0.010), central aortic pulse pressure by 2.4 mmHg 
(P<0.012), mean 24-hour ambulatory brachial and central aortic systolic pressure by 
4.1 and 3.6 mmHg (P<0.001).192 In 114 patients with hypertension and raised pulse 
pressure, 52 weeks treatment with sacubitril/valsartan reduced left ventricular mass 
index more than olmesartan (mean difference 3.27 [95% CI 6.21-0.34] g/m2; P=0.029) 
and central pulse pressure (mean difference 3.50 [95% CI -6.15 to -0.85] mmHg; 
P=0.010).325 There was no significant difference in central aortic blood pressure.325 
These results suggest sacubitril/valsartan may have additional benefits on vascular 
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remodelling.192 Progressive CKD is associated with vascular stiffening and 
calcification, so any effects ARNIs may have on vascular remodelling could be hugely 
beneficial to patients with CKD.192  
Observational studies have shown raised blood pressure to be an independent risk 
factor for developing ESKD and the risk increases with rising blood pressure.49,326 In 
people with advanced CKD, higher blood pressure is associated with faster rates of 
decline in GFR.49,327,328 However, individual randomized trials of intensive blood 
pressure lowering in patients with advanced CKD have not shown this strategy to 
prevent progression of renal disease.54,55  
A meta-analysis of intensive blood pressure lowering (including 9287 patients with 
CKD) suggested this intervention reduced the risk of the composite renal failure 
outcome (50% decline in GFR and doubling of the serum creatinine or ESKD) by 18% 
(HR 0.82; 95% CI 0.68-0.98) and, reduced the risk of ESKD-alone by 21% (HR 0.79; 
95% CI 0.67-0.93).57 Subgroup analysis found significant heterogeneity in the effect 
of intensive blood pressure lowering by baseline proteinuria, with a 27% (HR 0.73; 
95% CI 0.62-0.86) reduction in the composite renal failure outcome in those with 
proteinuria and no apparent benefit in those without proteinuria (HR 1.12; 95% CI 
0.67-1.87; P for heterogeneity = 0.006).57  
A meta-analysis of 44,989 participants showed no reduction in risk of ESKD with 
intensive blood pressure lowering (RR 0.90; 95% CI 0.77-1.06) but, did reduce the 
risk of progression of albuminuria by 10% (95% CI 3-16).329 A much larger meta-
analysis including 613,815 participants, showed each 10 mmHg reduction in systolic 
blood pressure was associated with a non-significant 5% (RR 0.95; 95% CI 0.84-1.07) 
reduction in risk of ESKD.58 At present it remains unclear whether the combined 
effects of a greater blood pressure lowering effect and reductions, albeit small, in 
albuminuria achieved with sacubitril/valsartan in UK HARP-III, could translate into 
reductions in risk of progression of CKD.  
CKD is also a cause of hypertension which is associated with increased risk of 
cardiovascular disease.8 Observational analyses have demonstrated that even 
among people with CKD at lowest probability of risk of CVD, each 10 mmHg rise in 
usual systolic blood pressure resulted in a 27% (HR 1.27; 95% CI 1.11-1.44) increase 
in cardiovascular risk.92 The association between systolic blood pressure and risk of 
CVD events was similar for atherosclerotic (HR 1.25; 95% CI 1.06-1.48) and 
nonatherosclerotic events (HR 1.31; 95% CI 1.09-1.57).92 
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Meta-analyses in people with mild-to-moderate CKD have shown lowering blood 
pressure reduces cardiovascular risk in this population.330 In a meta-analysis of 
152,290 participants, including 30,295 with an eGFR less than 60 mL/min/1.73m2, 
each 5 mmHg reduction in systolic blood pressure was associated with a 17% (HR 
0.83; 95% CI 0.76-0.90) reduction in rates of major CV events (defined as stroke, 
coronary heart disease, heart failure and cardiovascular mortality). The effects were 
similar amongst people with CKD and an eGFR between 45 and 59 mL/min/1.73m2 
(HR 0.86; 95% CI 0.78-0.95) and those with an eGFR less than 45 mL/min/1.73m2 
(HR 0.86; 95% CI 0.73-1.02) with no heterogeneity in the effect compared with people 
with an eGFR of 60 mL/min/1.73m2 or greater (P for heterogeneity = 0.93).330  
A further meta-analysis of 613,815 participants, including 8769 participants with CKD, 
showed a similar 16% (RR 0.84; 95% CI 0.73-0.96) reduction in risk of major 
cardiovascular events in people with CKD but, a larger proportional reduction in 
people without CKD (RR 0.68; 95% CI 0.62-0.75; P for heterogeneity = 0.012).58 Each 
10 mmHg reduction in systolic blood pressure was associated with a non-significant 
5% (RR 0.95; 95% CI 0.84-1.07) reduction in the effect on the renal composite 
outcome (defined as ESKD leading to initiation of dialysis, transplantation, or death).58 
In animal models of cardiovascular disease, treatment with sacubitril/valsartan 
reduced aortic fibrosis and markers of cardiac hypertrophy and fibrosis (fibroblast 
growth factor [FGF]-23 and NT-proBNP), and improved markers of cardiac oxidative 
stress and inflammation, to a greater degree than isolated RAS inhibition.207,208,318 The 
blood pressure lowering effects observed in these animal studies and from heart 
failure trials suggest sacubitril/valsartan could help reduce the risk of cardiovascular 
events observed in patients with CKD. 
 
 Effects of sacubitril/valsartan on cardiac biomarkers 
 
As CKD progresses, the manifestation of CVD changes from predominately 
atherosclerotic disease, for example myocardial infarction and ischaemic stroke, to 
non-atherosclerotic disease, characterised by arteriosclerosis (due to the 
development of vascular calcification) and structural heart disease (for example LVH 
and increased LV mass) which manifests clinically similar to heart failure with a high 
incidence of sudden cardiac death.9,72,86-88,331  
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The utility of cardiac biomarkers including troponin and NT-proBNP in patients with 
CKD and ESKD has been questioned as their concentrations may be affected by the 
degree of renal impairment due to impaired renal clearance (particularly NT-proBNP), 
as well as underlying cardiac disease and volume status.332,333 However, studies have 
shown that even after adjustment for eGFR and albuminuria, these biomarkers 
remain independent predictors of CVD (symptomatic and asymptomatic) in patients 
with CKD.334,335 Furthermore, NT-proBNP is not metabolised by neprilysin (unlike 
BNP) so levels are not affected by NEP inhibition and can be used as a measure of 
cardiac disease and dysfunction in patients treated with sacubitril/valsartan.336 
In people with CKD, troponin has been shown to predict the development of heart 
failure337 and correlate with left ventricular (LV) mass338-340 and cardiac function.341 
Troponin I concentrations have been used to risk stratify individuals with CKD without 
a known history of CVD. In 7278 patients with CKD without CVD, increasing baseline 
troponin I was strongly associated with future CVD risk.92 Compared with people with 
an undetectable troponin I concentration (0.01 ng/mL or less) individuals with 
substantially elevated troponin I (greater than 0.03 ng/mL) had nearly a 3-fold 
increase in CVD risk  (HR 2.82; 95% CI 2.42-3.28).92  Raised troponin-I was 
associated with increased CVD risk in both non-dialysis and dialysis patients.92 
NT-proBNP  has been used a marker of LV mass,334,339 LV hypertrophy,334,339,340 LV 
systolic function339 and heart failure in CKD.337 In the general population, NT-proBNP 
is used for the diagnosis, management342 and prognosis of heart failure343,344 and 
increasing concentrations have been associated with adverse cardiovascular and 
mortality outcomes.344-346 NT-proBNP and troponin have both been used to predict 
risk of mortality and cardiovascular events in the CKD and ESKD population as well 
as in the general population.333,346,347 
Elevated concentrations of both these biomarkers may also be predictive of an 
increased risk of progression of CKD (HR  per SD increase in log high sensitivity 
troponin 1.11 [95% CI 1.01-1.22] and, HR per SD increase in log NT-proBNP 1.24 
[95% CI 1.13-1.36])337,348 and, risk of adverse cardiovascular outcomes in people with 
CKD even after adjustment for eGFR.349-351 
In UK HARP-III, sacubitril/valsartan significantly reduced concentrations of NT-
proBNP by 18% (95% CI -25 to -11%; P<0.001) and troponin I by 16% (95% CI -23% 
to -8%; P<0.001), compared with irbesartan. Similar reductions in these biomarkers 
have also been seen shown in patients with HFpEF,195,211 HFrEF and hypertension 
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treated with sacubitril/valsartan.192 The reductions in circulating concentrations of NT-
proBNP and troponin with sacubitril/valsartan in patients with CKD in UK HARP-III 
are most likely related to the actions of increasing  concentrations of circulating NPs 
with NEP inhibition resulting in: natriuresis; diuresis; inhibition of RAS and 
sympathetic nervous system activation and; possible anti-fibrotic and anti-
hypertrophic effects on the heart.99  
The cardiac biomarker results from UK HARP-III raise the hypothesis that, as in heart 
failure trial populations,194,195 sacubitril/valsartan may have beneficial effects on 
cardiac structure and function and subsequently cardiovascular outcomes in patients 
with CKD. Since CVD mortality increases as CKD progresses,9 if sacubitril/valsartan 
had similar cardiovascular effects in people with CKD to those seen in PARADIGM-
HF, sacubitril/valsartan could substantially improve CVD outcomes in CKD.194  
In trials of heart failure, the greater blood pressure lowering effects seen with 
sacubitril/valsartan did not correlate with the treatment effect on cardiovascular 
outcomes.194,196 These results suggest that the beneficial cardiovascular effects seen 
with sacubitril/valsartan in patients with CKD may be mediated through additional 
mechanisms beyond just blood pressure lowering. However, the blood pressure and 
biomarker results with sacubitril/valsartan (compared with isolated RAS inhibition) in 
UK HARP-III are hypothesis generating and provide a rationale to support a much 
larger cardiovascular outcomes trial in people with CKD.  
 
 Pharmacokinetics of sacubitril/valsartan in CKD  
 
Pharmacokinetic analyses were undertaken to assess the determinants of plasma 
concentrations of metabolites of sacubitril/valsartan in individuals with advanced 
CKD. The only significant determinant of sacubitrilat concentration was kidney 
function. Each 10 mL/min reduction in mGFR, resulted in 1485 ng/mL higher serum 
concentrations of sacubitrilat (the active form of sacubitril; P=0.002). Sacubitrilat is 
predominantly renally excreted, so it is not surprising that impaired or declining renal 
function results in higher sacubitrilat concentrations compared with people with 
normal kidney function.184,185  
In a pharmacokinetic study of sacubitril/valsartan in 24 people with CKD, higher 
steady-state serum concentrations of sacubitrilat correlated with the degree of renal 
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impairment.185 In UK HARP-III, higher concentrations of sacubitrilat may have 
contributed to the lower blood pressure seen in those allocated to sacubitril/valsartan. 
Reassuringly, there was no excess of side effects such as derangements in liver 
function or angioedema in a population with advanced CKD and higher sacubitrilat 
concentrations. 
 
 Safety of sacubitril/valsartan 
 
Sacubitril/valsartan, compared with irbesartan, did not generate any major safety 
concerns in people with progressive CKD. Rates of fatal and non-fatal serious 
adverse events were similar and importantly there were no excess serious adverse 
events of angioedema, hypotension or requirement for dialysis with 
sacubitril/valsartan compared with irbesartan.  
 
 Angioedema 
Only one adverse event of angioedema occurred during the trial, in a participant 
allocated sacubitril/valsartan. This resolved spontaneously without any treatment and 
the participant did not seek any medical attention. When the adverse event was 
reported, I contacted the participant to collect additional detailed information relating 
to the event to compile an adverse event report. I advised the participant to stop all 
study treatment immediately and to restart their pre-trial ARB. The participant 
continued to attend follow-up visits for the remainder of the trial. The event report was 
sent to the DMC, the trial sponsor, the University of Oxford, and the manufacturer of 
sacubitril/valsartan (Novartis). Only the DMC were provided with the unblinded 
treatment allocation.  
Similar safety data have been demonstrated in other trials of sacubitril/valsartan.190,194 
In PARADIGM-HF, there was no difference in the rates of angioedema between 
sacubitril/valsartan and enalapril (19/4187 versus 10/4212 events respectively).194 
However, in PARAGON-HF, angioedema rates were significantly higher in those 
allocated sacubitril/valsartan compared with valsartan (14/2407 [0.6%] versus 4/2389 
[0.2%]; P=0.02) but no participants developed airway compromise.196 In UK HARP-III 
there were not enough events of angioedema to fully assess what the effect of 
sacubitril/valsartan on angioedema in people with CKD might be. A much larger trial 
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and of longer duration of exposure to sacubitril/valsartan would be required to allow 
a more comprehensive assessment of the adverse event profile in CKD. 
 
 Hypotension 
There were only two SAEs of hypotension with one occurring in each treatment group. 
Rates of non-serious hypotension were significantly higher with sacubitril/valsartan 
than with irbesartan (8.2% versus 3.4% respectively). This resulted in a small non-
significant excess in numbers of participants allocated sacubitril/valsartan having their 
study treatment dose halved, compared with irbesartan (3% versus 1%). Importantly, 
there was no difference in the proportions of participants stopping sacubitril/valsartan 
completely. The reduction in study treatment dose was satisfactory to control 
symptoms of hypotension and maintain compliance with study treatment. 
Trials in heart failure populations, comparing sacubitril/valsartan with isolated RAS 
inhibition have similarly shown higher rates of symptomatic hypotension (588/4187 
[14%] versus 388/4212 [9.2%] respectively; P<0.001) including symptomatic 
hypotension with a systolic blood pressure of less than 90 mmHg (112/4187 [2.7%] 
versus 59/4212 [1.4%] respectively; P<0.001).194 However, as in UK HARP-III, 
hypotension rarely resulted in discontinuation of sacubitril/valsartan.194  
 
 Renal safety  
 Hyperkalaemia 
In UK HARP-III, sacubitril/valsartan had no significant effect on overall rates of 
hyperkalaemia (any potassium result of 5.5 or higher), compared with irbesartan. 
There was a slight numerical excess in the rates of moderate hyperkalaemia 
(potassium between 6.0 to 6.4 mmol/L) in participants allocated sacubitril/valsartan, 
compared with irbesartan. However, rates of severe hyperkalaemia (potassium 6.5 
mmol/L or above) with sacubitril/valsartan were similar to irbesartan. 
Only one serious adverse event related to hyperkalaemia was reported in UK HARP-
III, in a participant assigned irbesartan. Non-serious adverse events of hyperkalaemia 
believed by the participant to be related to study treatment were reported in 2% of 
participants assigned sacubitril/valsartan and resulted in withdrawal of study 
treatment in all cases. 
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The potassium results from UK HARP-III contrast with those in heart failure trials of 
sacubitril/valsartan. Rates of hyperkalaemia with a potassium greater than 6.0 
mmol/L were significantly lower with sacubitril/valsartan compared with enalapril 
(181/4187 [4.3%] versus 236/4212 [5.6%] respectively; P=0.007)194 or valsartan 
(75/2386 [3.1%] versus 101/2367 [4.3%] respectively; P=0.04).196 
The lower rates of hyperkalaemia in heart failure trials may relate to greater diuretic 
use (likely loop diuretics) and higher eGFR compared with UK HARP-III participants. 
Loop diuretics act in the thick ascending limb in the kidney (where about 25% of the 
filtered sodium is normally reabsorbed) and macula densa to inhibit the sodium-
potassium-chloride-2 cotransporter which exchanges sodium and chloride ions for 
potassium.352,353 This impedes sodium reabsorption and increases distal tubular 
sodium concentration causing a natriuresis and resultant osmotic diuresis.352,353 In 
PARADIGM-HF 80% of participants in each treatment group were taking diuretics.194 
In UK HARP-III only about 40% of participants were taking diuretics and with 
worsening renal function there is a greater susceptibility to hyperkalaemia due to 
impaired potassium excretion and development of metabolic acidosis.353  
Treatment with sacubitril/valsartan provides additional aldosterone and RAS inhibition 
compared with isolated RAS inhibition. Therefore, in patients with CKD in whom GFR 
is reduced, it is not surprising that UK HARP-III participants had higher serum 
potassium concentrations, perhaps as a result of greater RAS inhibition with 
sacubitril/valsartan compared with equivalent doses of irbesartan.  
 Acute kidney injury 
In UK HARP-III, there was no difference in rates of acute kidney injury (defined as a 
25% or greater reduction in CKD-EPI eGFR) between those allocated 
sacubitril/valsartan and those allocated irbesartan. The UK HARP-III results are in 
keeping with the renal safety data from other trials of sacubitril/valsartan among 
people with heart failure and hypertension, in which no excess of renal adverse 
events occurred.194,196,202 
In the PARADIGM-HF trial, elevations in serum creatinine (creatinine 2.5 mg/dL [220 
micromoles/L] or greater) occurred less frequently in participants allocated 
sacubitril/valsartan compared with enalapril (139/4187 [3.3%] versus 188/4212 [4.5%] 
respectively; P=0.007).194 However, there was no difference in rates of more 
substantial reductions in serum creatinine (greater than 3.0 mg/dL [266.4 mg/mmol]) 
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in participants allocated sacubitril/valsartan, compared with enalapril (63/4187 [1.5%] 
versus 83/4212 [2.0%] respectively; P=0.10).194  
Overall, rates of discontinuation of study treatment due to renal adverse events were 
lower with sacubitril/valsartan than enalapril (29/4187 [0.7%] versus 59/4212 [1.4%] 
respectively; HR 0.49 [95% CI 0.3-10.76]; P=0.002).202 Amongst people with CKD, 
significantly fewer participants allocated sacubitril/valsartan discontinued treatment 
for a renal cause, compared with enalapril (15/4187 [1.1%] versus 36/4212 [2.6%]; 
HR 0.43 [95% CI 0.24-0.80] respectively; P=0.008; P for interaction = 0.52).202 
It is not surprising that occurrence of acute kidney injury was low in UK HARP-III or 
in other trials of sacubitril/valsartan. In UK HARP-III, 85% of participants were taking 
RAS-inhibition at screening and similar numbers in heart failure trials. The study 
populations selected included participants known to tolerate RAS blockade, reducing 
the risk of acute kidney injury (which can arise with RAS inhibition). The participants 
selected for the trials were generally well and stable with regards their heart failure or 
CKD. Finally, the effects on sacubitril/valsartan on renal haemodynamics particularly 
preferential relaxation of the afferent arteriole maintaining GFR despite reductions in 
systemic blood pressure and renal perfusion pressure induced by NPs, coupled with 
the effects of NPs on other vasoactive and neurohormonal substances are likely to 
have reduced the risk of acute kidney injury and renal adverse events. 
 
 Liver impairment 
In UK HARP-III, no hepatic adverse events including transaminitis or more significant 
liver injury (e.g. fulminant hepatic failure) were observed with either 
sacubitril/valsartan or irbesartan. The safety data from UK HARP-III are extremely 
encouraging since the clearance of valsartan is predominantly via enterohepatic 
circulation. This route also accounts for about 35-50% of the clearance of sacubitrilat, 
concentrations of which significantly increased with decreasing kidney function.184  
Randomized trials in hypertension and heart failure populations have not reported 
any excess cases of liver enzyme impairment or injury in participants allocated to 
sacubitril/valsartan compared with isolated RAS inhibition.190,192,194,195 In PARAGON-
HF, liver‑related adverse event reports were similar between sacubitril/valsartan and 
valsartan (151/2407 [6.3%] versus 178/2389 [7.5%] respectively; P=0.11).196 
The safety data from UK HARP-III provide important information regarding the use of 
sacubitril/valsartan in people with CKD. The results suggest sacubitril/valsartan could 
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potentially be safely prescribed in patients with a lower eGFR (down to 20 
ml/min/1.73m2) than currently licenced (eGFR greater than 30 ml/min/1.73m2).186 This 
would enable a greater proportion of patients with CKD and/or heart failure (and who 





The UK HARP-III trial was a phase II, randomized trial of 414 participants with CKD 
with a short duration of follow-up (12 months) and exposure to sacubitril/valsartan. 
The trial had adequate power to examine the short-term effects of sacubitril/valsartan 
on kidney function however, the duration of follow-up and sample size was insufficient 
and, moreover the trial was not designed to assess clinical outcomes, such as risk of 
progression to ESKD or CV events in people with CKD.  
The choice of the comparator, irbesartan, could have influenced the interpretation of 
the renal function results. Irbesartan was chosen as the comparator as it is licenced 
for the treatment of proteinuric kidney disease following the results of randomized 
trials showing that it reduced rates of progression of nephropathy compared with 
placebo or other antihypertensive medications.41,354 However, valsartan is the ARB 
that is combined with sacubitrilat to form the trial drug sacubitril/valsartan. Both 
Irbesartan and valsartan have some differences in their bioavailability, half-life, affinity 
for the angiotensin-type 1 receptor and metabolism,355,356 which may affect their anti-
hypertensive and renal haemodynamic properties and contributed to the observed 
lack of effect on renal function.355-357 It is more likely that the overall effects of both 
drugs are comparable and these differences are unlikely to translate into any material 
effect on kidney function. 
The results of the effects of sacubitril/valsartan on blood pressure and cardiac 
biomarkers, although of significant interest, should only be regarded as hypothesis 
generating as these were exploratory outcomes and the trial was not powered to 
detect differences in such outcomes. A large-scale clinical outcomes trial would be 
required to adequately examine the CV and renal effects of sacubitril/valsartan in 




 Future prospects for angiotensin receptor-neprilysin 
inhibition in CKD 
 
The UK HARP-III trial demonstrated ARNI with sacubitril/valsartan may offer a new 
therapeutic strategy to address the excess CVD risk in patients with CKD. The 
substantial reductions in blood pressure and cardiac biomarkers (troponin I and NT-
proBNP), compared with isolated RAS-inhibition, were similar to those seen in heart 
failure trials.194,195 If the reductions in blood pressure and cardiac biomarkers were of 
a similar magnitude to the reductions in CVD outcomes in people with CKD as in the 
general population, ARNIs could significantly improve the outlook for people with 
CKD. This is of particular importance since the manifestations of CVD associated with 
progressive CKD are similar to heart failure with vascular stiffness and 
arteriosclerosis rather than atherosclerotic disease.72,86-88 
 
Sacubitril/valsartan did not demonstrate an effect on kidney function in people with 
CKD over 12 months, compared with isolated RAS inhibition. Importantly, there was 
no increase in albuminuria seen in patients with CKD, 65% of whom had 
macroalbuminuria, unlike in patients with heart failure.194,195 The effects on kidney 
function and albuminuria are likely mediated via the actions of NPs on haemodynamic 
changes within the kidney.135,205,305-309 In animal models these changes have 
translated into substantial reductions in histological features associated with 
progression of CKD, however the long-term effects of this in humans in 
uncertain.138,158,159   
 
In people with diabetic nephropathy, randomized trials of SGLT-2 inhibition have 
demonstrated significant reductions in both cardiovascular (including cardiovascular 
mortality and fatal and non-fatal cardiovascular events) and renal outcomes (including 
progression to ESKD and renal mortality).64,65,67 Effects of SGLT-2 inhibition in people 
with advanced non-diabetic CKD are currently unknown although trials are currently 
ongoing in this population to assess effects on CVD and renal outcomes.68 Even if 
these trials show significant reductions in renal and cardiovascular outcomes, there 
is still an argument for a potential role of ARNI in CKD for cardiovascular benefit to 
treat any residual risk given ARNIs act at a different site to SGLT-2 inhibitors in the 




The UK HARP-III trial results suggest that ARNI may have a much bigger effect on 
reductions in CVD outcomes in people with CKD than renal outcomes. The data 
support the need for a large-scale randomized clinical outcomes trial of ARNIs in 
people with CKD to assess primarily effects on CVD outcomes and any assessment 




The UK HARP-III trial is the first randomized trial to examine the effects of 
sacubitril/valsartan on kidney function in people with advanced CKD. UK HARP-III 
has shown that, 12 months of treatment with sacubitril/valsartan had similar effects to 
irbesartan on kidney function. Importantly, unlike in the heart failure population, 
sacubitril/valsartan had no adverse effect on albuminuria.  
Sacubitril/valsartan significantly lowered blood pressure and concentrations of 
cardiac biomarkers troponin I and NT-proBNP, compared with irbesartan, suggesting 
that the drug could provide substantial benefit on cardiovascular outcomes (a major 
cause of morbidity and mortality in people with CKD) in people with advanced and 
progressive CKD, as in heart failure trials with this drug. Importantly, 
sacubitril/valsartan had similar tolerability to irbesartan, and no major safety concerns 
were observed. 
There is currently an unmet clinical need for interventions that could both reduce the 
risk of progression of CKD to ESKD and CVD in people with CKD, especially non-
diabetic renal disease. The results of UK HARP-III provide a strong rationale for 
undertaking a large-scale outcomes trials examining the effects of ARNI on 
cardiovascular outcomes in people with CKD. The trial did not exclude a potential 
benefit on kidney function and so effects of sacubitril/valsartan on progression of CKD 
to ESKD would also need to be considered in any future large-scale clinical outcomes 
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Appendix 1:  
Trials of renin-angiotensin system blockade and renal outcomes. 
























Renin-angiotensin system blockade 
AASK 
(2002)(1) 
1,094 African Americans aged 
18-70, GFR 20-65 mL/min/1.732 
with hypertensive 
nephrosclerosis 
Ramipril (n=436) Metoprolol (n=441) 54.4 47 vs 32 RR 22%  
(-10 to 45) 
P=0.16 
GFR event, ESRD, or death 
= 126 




1,094 African Americans with 
hypertensive nephrosclerosis 
Ramipril l217 Amlodipine 441 54.5 32 vs 47 RR 59%  
(36 to 74) 
P<0.001 
GFR event, ESRD, or death 
= 56 




1,094 African Americans with 
hypertensive nephrosclerosis 
Metoprolol (n=441) Amlodipine 212 54.9 NA RR 59%  
(36 to 74) 
P<0.001 
GFR event, ESRD, or death 
= 155 




11,140 aged >55 years with 
type 2 diabetes, & history of 
major CVD or ≥1 other risk 




Placebo (n=5,571) 66 NA  New or worsening 






583 with CKD (Cr 133-354 
µmol/L + 24hr estimated CrCl 
30-60 ml/min) 
Benazepril (n=300) Placebo (n=283) 51 1 vs 1 NA Doubling of SCr or need for 




8,531 aged ≥35 years with type 
2 diabetes, microalbuminura, 










ESRD or doubling of SCr 





422 Chinese aged 18-70 with 
CKD, SCr 133-442 μmol/L & 
CrCl 20-70 ml/min/1.73m2; non-
diabetic renal disease; & 
proteinuria (>0.3 g/d)  
Benazepril 
Group 1 n=104 
Placebo 
Group 2 only n=112 
44.8 NA NA Doubling of SCr, ESRD or 





409 aged 18-49 with IDDM and 
diabetic retinopathy, urine 
protein >500 mg/d & SCr <221 
µmol/L 
Captopril (n=207) Placebo (n=202) 34.5 20 vs 31 NA Dialysis, transplant or death 
=  
23 vs 42 




1715 >35 years with type 2 
diabetes, hypertension (sitting 
SBP >135 mmHg, DBP > 85 
mmHg), Urine protein ≥900 
mg/d). SCr 88-265 µmol/L in 





(A; n=567) and 
placebo  
(P; n=569) 
58.9 I = 82 
A = 104 
P = 101 
I vs P  
HR 0.83 (0.62-
1.11) P=0.19  
I vs A =  
HR 0.76 (0.57-
1.02) P=0.06 
A vs P  
HR 1.09 (0.82-
1.43) P=0.56  
Doubling in SCr, ESRD, or 
death = 644 in total: 
 
I = 189 
A= 233 
P = 222 
I vs P  
HR 0.81 (0.67-
0.99) P=0.03 
I vs A =  
HR 0.76 (0.63-
0.92) P=0.005 
A vs P  
HR 1.07 (0.89-
1.29) P=0.47  
























25,620, >55 years with 
atherosclerotic vascular disease 
or diabetes with end-organ 
damage. SCr <265 µmol/L 
Telmisartan n=8542 Ramipril  n=8576 66.4 51 vs 48 HR 1.07  
(0.72-1.58) 
P=0.747 
                                                                                                                                                                            
Dialysis, doubling in SCr, 
death 






25,620, >55 years with 
atherosclerotic vascular disease 
or diabetes with end-organ 




Ramipril (n=8576) 66.4 63 vs 48 HR 1.33 (0.92-
1.94) 
P=0.133 
Dialysis, doubling in SCr, 
death 






566 Japanese & Chinese aged 
30-70, with T2 diabetes; UACR 
>33.9 mg/; SCr 88.40-221.00 
μmol/l in women and 106.08-
221.00 μmol/l in men.  
Olmesartan (n=282) Placebo (n=284) 59.2 74 vs 78 HR 1.08 (0.78-
1.49) 
Dialysis, doubling in SCr, 
death 
Renal composite outcome 







352 Aged 18-70 with 166 in 
Stratum 2, CrCl 20-70 
mL/min/1.73m2 and persistent 
proteinuria, not received ACEi 









49.3 17 v 29 NA Doubling of SCr or ESRD  






352 Aged 18-70, with 186 in 
Stratum 1, CrCl 20-70 
mL/min/1.73m2 and persistent 
proteinuria, not received ACEi 









49.7 9 vs 18 RR 2.72  
(1.22-6.08) 
 
Decline in GFR per month 
(mL/min) 
0.26 [SE 0.05] vs 




1,513 Aged 31-70, type 2 
diabetes and UACR >300 mg/g 
and SCr 115-265 µmol/L. 
Losartan   Placebo 60 147 vs 
194 
RRR 28%  
(11-42%) 
P=0.002 
Doubling of SCr, ESRD, or 
death 






360 Chinese aged 18-70, with 
non-diabetic proteinuric CKD. 
SCr 133-442 µmol/L & CrCl 20-










Doubling of SCr, ESRD, or 
death 




Effects of blood pressure lowering interventions on risk of end-stage renal disease and other renal outcomes 
 
AASK = African American Study of Kidney Disease and Hypertension; ADVANCE = The Action in Diabetes and Vascular disease: Preterax and Diamicron-MR Controlled Evaluation; AIPRI = 
Angiotensin converting enzyme inhibition in renal insufficiency; ALTITUDE = The Aliskiren Trial in Type 2 Diabetes Using Cardiorenal Endpoints; CSG-Captopril = Collaborative Study Group - 
Captopril trial; IDNT = Irbesartan in Diabetic Nephropathy; ONTARGET = Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial; ORIENT = Olmesartan Reducing 
Incidence of Endstage Renal Disease in Diabetic Nephropathy Trial; REIN = Ramipril Efficacy in Nephropathy; RENAAL = Reduction of Endpoints in Non-Insulin Dependent Diabetes Mellitus 
(NIDDM) with the Angiotensin II Antagonist Losartan; ROAD = Renoprotection of Optimal Antiproteinuric Doses; TRANSCEND = Telmisartan Randomized Assessment Study in ACE Intolerant 
Subjects with Cardiovascular Disease; VA-NEPHRON = Veterans Affairs Nephropathy in Diabetes. 
ACEi = angiotensin converting enzyme inhibitor; CAD = coronary artery disease; CKD = chronic kidney disease; CrCl = creatinine clearance; CVD = cardiovascular disease; DBP = diastolic blood 
pressure; eGFR = estimated glomerular filtration rate; GFR = glomerular filtration rate; ESRD = end-stage renal disease; HR = hazard ratio; IDDM = insulin-dependent diabetes mellitus; MAP = 






















360 Chinese aged 18-70, with 
non-diabetic proteinuric CKD. 






51.5 NA RR 47%  
(3.6-76.9) 
P=0.046 
Doubling of SCr, ESRD, or 
death 
13 vs 26 
RR 53%  




5,926 with intolerance to ACEi 
and CAD, PVD or stroke, or 
diabetes with end-organ 
damage without evidence of 
heart failure 




of 38%  




1,448 Veterans with type 2 
diabetes, UACR ≥300 mg/g and 






64.6 27 vs 43 HR 0.66 (0.41-
1.07)  
P=0.07 
eGFR decline, ESRD, or 
death 





Effects of blood pressure lowering interventions on risk of end-stage renal disease and other renal outcomes 
 
 














Clinical composite and No 





AASK (2002)(1) 1,094 African Americans 




control (MAP <92 
mmHg) with Ramipril 
(n=540)  
STANDARD (MAP 




54.6 83 vs 88 RR 6%  
(-29 to 31)  
P=0.72 
GFR event, ESRD, or death 
= 340 





385 Children (3-18 years), 
GFR 15-80 & 24-hr MAP 






Ramipril for a 
CONVENTIONAL 
BP target (n=196) 
11.5 22 vs 34 NA 50% decline in GFR or 
ESRD =  






585 Aged 18-70, GFR 25-
55mL/min/1.732, a MAP 
(calculated as 2/3 of DBP + 
1/3 of SBP) of ≤125 mmHg 
and a dietary protein intake  
>0.9g/kg body weight/d. 
LOW BP (MAP ≤92 
mmHg if ≤60 years or 
≤98 mmHg if >60 
years) AND Usual 
protein (1.3g/kg/day)  
(n=145) diet OR  
Low protein diet 
(0.58g/kg/day)(n=140) 
USUAL BP (MAP 
≤107 mmHg if ≤60 
years or ≤113 
mmHg if >60 years) 
AND Usual protein 
diet (1.3g/kg/day) 
(n=145) OR Low 
protein diet (n=140) 
52 MDRD 
1+2 Low 
vs Usual = 
61 vs 66 
HR 0.76  
(0.52-1.10)  
P=0.15 
Rate of decline in GFR 
(slope)  
GFR slope = 
10.7 
(9.1-12.4) 





255 Aged 18-70, GFR 13-24 
mL/min/1.732 & MAP ≤125 
mmHg, irrespective of protein 
intake. 
 
LOW BP (MAP ≤92 
mmHg if ≤60 years or 
≤98 mmHg if >60 
years) AND Low 
protein diet (n=67) 
OR Very Low protein 
diet (0.28g/kg/day ) 
(n=65) 
USUAL BP (MAP 
≤107 mmHg if ≤60 
years or ≤113 
mmHg if >60 years) 
(n=123) AND 
Low protein diet 
(n=62) OR Very Low 
protein diet (n=61) 
52 MDRD 
1+2 Low 
vs Usual = 
61 vs 66 
HR 0.76  
(0.52-1.10) 
P=0.15  
Rate of decline in GFR 
(slope) 
GFR slope =  
3.7  
(3.1-4.3) mL/min 






840 Aged 18-70, with GFR 
13-55 mL/min/1.732, MAP 
<125 mmHg & dietary protein 
intake >0.9g/kg body 
weight/d. 
LOW BP target (MAP 
≤92 mmHg; 
equivalent to BP 
<125/75 mmHg if ≤60 
years and ≤98 mmHg 
if >60 years) AND 
usual, low or very low 
protein diet (n=432)   
USUAL BP target 
(MAP ≤107 mmHg; 
equivalent to BP of 
140/90 mmHg if ≤60 
years and ≤113 
mmHg if >60 years) 
AND usual, low or 
very low protein diet 
(n=408) 
52 268 vs 
286 
HR 0.68  
(0.57-0.82) 
P>0.001 
ESRD or all-cause mortality 







Effects of blood pressure lowering interventions on risk of end-stage renal disease and other renal outcomes 
AASK = African American Study of Kidney Disease and Hypertension; ESCAPE = Effect of Strict Blood Pressure Control and ACE Inhibition on the Progression of Chronic Renal Failure in 
Paediatric Patients; MDRD = Modification of Diet in Renal Disease; REIN = Ramipril Efficacy in Nephropathy; SPRINT = Systolic Blood Pressure Intervention Trial. 
ACEi = angiotensin converting enzyme inhibitor; ADPKD = autosomal dominant polycystic kidney disease; CKD = chronic kidney disease; CrCl = creatinine clearance; CV = cardiovascular; CVD = 
cardiovascular disease; DBP = diastolic blood pressure; eGFR = estimated glomerular filtration rate; GFR = glomerular filtration rate; ESRD = end-stage renal disease; HR = hazard ratio; IDDM = 














Clinical composite and No 







338, Aged 18-70, non-diabetic 
nephropathy & persistent 
proteinuria, not received ACEi 
for >6 weeks. Proteinuria 1-3 
g/d included if CrCl <45 
mL/min/1.73m2; proteinuria >3 
g/d included if CrCl <70 
mL/min/1.73 m2. 
INTENSIVE BP 
control to <130/80 
mmHg (n=169) 
CONVENTIONAL 
BP control (DBP <90 
mmHg irrespective 
of SBP) (n=169) 
53.9 38 vs 34 HR 1.00  
(0.61-1.64)  
P=0.99 










75 Aged 20-60, with ADPKD 
and left ventricular 
hypertrophy,  














2,646 with CKD, hypertension 
and 1 other CV risk factor 
INTENSIVE BP 
control  
SBP <120 mmHg 
(n=1,330) 
CONVENTIONAL 
BP control  
SBP <140 mmHg 
(n=1,316) 
67.9 6 vs 10 HR 0.57  
(0.19-1.54)  
P=0.27 
eGFR reduction ≥50%, 
dialysis, or transplantation 







6,677 without CKD, and  
hypertension and 1 other CV 
risk factor  
INTENSIVE BP 
control  
SBP <120 mmHg  
(n= 3,332) 
CONVENTIONAL 
BP control - SBP 
<140 mmHg (n = 
3,345) 
67.9 NA NA ≥30% reduction in eGFR to 
<60 ml/min/1.73m2 
137 vs 27 
HR 3.49 (2.44-
5.10) P<0.001 
Toto (1995)(22) 87 Aged 25-73, without 
diabetes with hypertension 
(DBP 95 mmHg), and GFR 70 
m/min/1.73m2 
STRICT BP control  




DBP 85-95 mmHg 
(n=35) 
55.7 7 vs 2 NA Rate of decline in GFR 
mI/min/1.73m2/year 
-0.31±0.45  
(-1.73 to +1.95) 
vs  
-0.05±0.50  
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irbesartan in patients with chronic kidney disease: United
Kingdom Heart and Renal Protection (HARP)- III—rationale,
trial design and baseline data
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ABSTRACT
Background. Patients with chronic kidney disease (CKD) are at
risk of progression to end-stage renal disease and cardiovascular
disease. Data from other populations and animal experiments
suggest that neprilysin inhibition (which augments the natriuret-
ic peptide system) may reduce these risks, but clinical trials
among patients with CKD are required to test this hypothesis.
Methods. UK Heart and Renal Protection III (HARP-III) is a
multicentre, double-blind, randomized controlled trial compar-
ing sacubitril/valsartan 97/103 mg two times daily (an angioten-
sin receptor–neprilysin inhibitor) with irbesartan 300 mg one
time daily among 414 patients with CKD. Patients ≥18 years of
age with an estimated glomerular filtration rate (eGFR) of ≥45
but <60 mL/min/1.73 m2 and urine albumin:creatinine ratio
(uACR) >20 mg/mmol or eGFR ≥20 but <45 mL/min/1.73 m2
(regardless of uACR) were invited to be screened. Following a
4- to 7-week pre-randomization single-blind placebo run-in
phase (during which any current renin–angiotensin system inhi-
bitors were stopped), willing and eligible participants were ran-
domly assigned either sacubitril/valsartan or irbesartan and
followed-up for 12 months. The primary aim was to compare
the effects of sacubitril/valsartan and irbesartan on measured
GFR after 12 months of therapy. Important secondary outcomes
include effects on albuminuria, change in eGFRover time and the
safety and tolerability of sacubitril/valsartan in CKD.
Results. Between November 2014 and January 2016, 620
patients attended a screening visit and 566 (91%) entered the
pre-randomization run-in phase. Of these, 414 (73%) partici-
pants were randomized (mean age 63 years; 72% male). The
mean eGFR was 34.0 mL/min/1.73 m2 and the median uACR
was 58.5 mg/mmol.
Conclusions. UK HARP-III will provide important informa-
tion on the short-term effects of sacubitril/valsartan on renal
function, tolerability and safety among patients with CKD.
Keywords: cardiovascular disease, chronic kidney disease, ne-
prilysin, progression
INTRODUCTION
Chronic kidney disease (CKD) affects between 2 and 17% of the
general population (depending on the country) [1, 2] and is as-
sociated with increased risks of progression to end-stage renal
disease (ESRD) andmorbidity andmortality from cardiovascu-
lar disease (CVD) [3, 4]. Renin–angiotensin system (RAS) inhi-
bitors [angiotensin-converting enzyme inhibitors (ACEis) and
angiotensin receptor blockers (ARBs)] have been shown to re-
duce the risk of ESRD in patients with proteinuric CKD [5–8],
but despite such treatments, patients remain at significant risk
of progression to ESRD and CVD.
The natriuretic peptide (NP) system is a neurohormonal sys-
tem that has a variety of potentially beneficial functions, includ-
ing natriuresis, diuresis, vasodilatation and counterregulation
of RAS [9, 10]. The NP system can be augmented by inhibiting
the main enzyme responsible for degrading NPs, namely
neprilysin [or neutral endopeptidase (NEP)] [10]. NEP is
a membrane-bound zinc-containing metalloproteinase [11]© The Author 2016. Published by Oxford University Press on behalf of ERA-
EDTA. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/4.0/),
which permits unrestricted reuse, distribution, and reproduction in any medium,
provided the original work is properly cited.
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that also degrades other peptides, including angiotensin II,
bradykinin, endothelin and substance P [12]. However, isolated
NEP inhibition (NEPi) leads to reflex RAS activation, and inhi-
bits angiotensin II breakdown (counteracting any potentially
beneficial effects) and therefore NEPi must be combined with
RAS inhibition.
As NEPi and ACEi both inhibit bradykinin degradation,
their combination is associated with substantially elevated
bradykinin levels that cause unacceptable rates of angioedema
[13]. ARBs do not inhibit bradykinin degradation and can be
safely combined with NEPi [creating a new class of drugs called
angiotensin receptor–neprilysin inhibitors (ARNis)]. Sacubi-
tril/valsartan (previously known as LCZ696) is the first drug
in this new class, combining valsartan with sacubitril
[(AHU377) a prodrug that is metabolized via esterases to the
active NEPi sacubitrilat (LBQ657)]. Sacubitril/valsartan 97/
103 mg provides equivalent plasma concentrations of valsartan
as oral valsartan 160 mg [14].
In a 5/6 nephrectomy model, treatment with combined
NEP/RAS inhibition was associated with greater reductions in
proteinuria and glomerulosclerosis compared with RAS inhib-
ition alone [15, 16]. Micropuncture studies also demonstrated
NEPi led to greater reductions in capillary glomerular pressure
[15]. Among patients with heart failure, trials comparing sacu-
bitril/valsartan with either ACEi or ARB have suggested that the
estimated glomerular filtration rate (eGFR) of patients allocated
sacubitril/valsartan declined less than those assigned ACEi or
ARB [17, 18]. Sacubitril/valsartan also reduced blood pressure
more than equivalent doses of valsartan in trials among patients
with elevated blood pressure [19]. Trials in heart failure popu-
lations suggest NEPi might increase albuminuria [18, 20], but
this effect was not observed in patients with hypertension
[19] and baseline albuminuria was very low in all these trials.
Overall, these data raise the hypothesis that treatment with an
ARNi may be superior to either ACEi or ARB alone in slowing
the progression of CKD.
The United Kingdom (UK) Heart and Renal Protection III
(HARP-III) trial (ISRCTN11958993) was designed to provide
information on the short-term efficacy (in terms of effect on
renal function), tolerability and safety of sacubitril/valsartan
among patients with CKD. The trial will also assess the effects
of sacubitril/valsartan on albuminuria, blood pressure and bio-
markers of kidney and cardiac damage.
MATERIALS AND METHODS
Study design
UK HARP-III is a double-blind, multicentre, randomized
controlled trial comparing sacubitril/valsartan 97/103 mg two
times daily versus irbesartan 300 mg one time daily among at
least 400 participants ≥18 years of age with stages 3 and 4
CKD. Irbesartan 300 mg was selected as the comparator, as it
has been shown to reduce the risk of ESRD among patients
with diabetic kidney disease and is licensed for the treatment
of proteinuric CKD [6, 21]. Participants were randomly allo-
cated to receive sacubitril/valsartan or irbesartan and will be
followed up for 1 year (Figure 1). The primary aim of UK
HARP-III is to assess the effect of sacubitril/valsartan 97/103
mg two times daily versus irbesartan 300 mg one time daily
on measured glomerular filtration rate (mGFR) at 12 months.
Important secondary outcomes include the effect on urine al-
bumin:creatinine ratio (uACR) and eGFR. All the secondary
and tertiary assessments are shown in Figure 2 and further de-
tails are available in the data analysis plan (see Supplementary
data). A summary of substantial amendments to the protocol is
provided in the Supplementary data.
Eligibility
To fulfil the inclusion criteria, patients need to be ≥18 years
of age and have either an eGFR ≥45 but <60 mL/min/1.73 m2
with a uACR >20 mg/mmol or eGFR ≥20 but <45 mL/min/























1.73 m2 (regardless of uACR). The exclusion criteria were de-
signed to identify patients for whom the safety of sacubitril/val-
sartan or irbesartanmay have been a concern. The full eligibility
criteria are shown in Figure 3.
Study enrolment and randomization
Identification and invitation. After relevant ethics [Notting-
ham Research Ethics Committee 2 (13/EM/0434)] and regula-
tory approvals had been obtained, sites were established in UK
renal units. Site staff identified potentially eligible patients from
hospital electronic databases, mailed these individuals an invi-
tation letter and a copy of the patient information sheet and
called them ∼1 week later to discuss the trial in more detail, an-
swer any questions they might have and to see whether they
were interested in participating. Those individuals interested
in participating were invited to attend a screening visit.
Screening. At the screening visit, eligibility was assessed and
written informed consent was obtained from eligible indivi-
duals. All data were recorded directly into a bespoke Internet-
based electronic case report form system. Relevant details of
their medical history (including primary renal diagnosis, pres-
ence of diabetes mellitus and prior CVD) were recorded by
trained research nurses and their height, weight and blood pres-
sure were measured. Blood pressure was measured and re-
corded three times using an Omron M6 automated digital
sphygmomanometer after sitting for at least 5 minutes. Willing
and eligible patients entered the pre-randomization run-in
phase. Samples of blood and urine were sent to the local hos-
pital laboratory for confirmation of eligibility. If the results
were considered inaccurate (e.g. haemolysed sample) by the
local study staff the samples could be repeated once, but if the
results did not confirm eligibility the participant was withdrawn
from the run-in phase.
Pre-randomization run-in. The aims of the pre-
randomization run-in phase were (i) to ‘wash out’ any ACEi
prior to introduction of NEPi, (ii) to allow a comparison of
the acute effects of the study treatments on GFR and (iii) to re-
duce the rate of post-randomization discontinuation of study
treatment and to produce a consequent improvement in the
trial’s statistical sensitivity [22]. Following the screening visit,
any current ACEi and/or ARB that the participant was taking
was stopped and the participant entered the 4- to 7-week single-
blind pre-randomization run-in phase, during which they were
asked to take one placebo sacubitril/valsartan tablet and one
placebo irbesartan capsule once daily. If elevated blood pressure
became a concern during the run-in phase, local investigators
were advised to titrate up or start additional anti-hypertensive
medications, but to avoid an ACEi, ARB or direct renin inhibi-
tor (DRI). The choice of additional anti-hypertensive therapy
remained at the discretion of the responsible clinician. Partici-
pants could withdraw from the trial for any reason during this
run-in phase. Participants who did not withdraw returned 4–7
weeks later and had their GFR measured and attended a ran-
domization visit. GFR was measured using a standard
51Cr-EDTA technique, although if this was not available at
the site, other methods (99mTc-DTPA or iohexol) could be
used with the agreement of the coordinating centre. In willing
participants, a 24-hour collection of urine for albumin and so-
dium quantification was also obtained.
Randomization visit. Participants were not eligible for ran-
domization if themean of their second and thirdmeasurements
of systolic blood pressure was <110 mmHg (or <130 mmHg
with symptoms of hypotension) or if they reported an adverse
event they believed to be related to their run-in treatment. Par-
ticipants who remained willing and eligible were then randomly
allocated in a 1:1 ratio to receive either sacubitril/valsartan or
irbesartan. Participants were randomized by an Internet-based
system using aminimization algorithm to ensure balance of im-
portant predictors of renal progression, including age, sex, sys-
tolic blood pressure, eGFR, uACR and the presence or absence
of diabetes mellitus.
At the randomization visit, run-in treatment was collected
and willing and eligible participants were issued two bottles
of study treatments: one containing sacubitril/valsartan 97/
103 mg or placebo tablets and the other containing irbesartan
150 mg or placebo capsules (therefore a double-dummy tech-
nique to protect blinding). Participants were initially instructed
to take one tablet and one capsule daily in the morning (i.e. ei-
ther sacubitril/valsartan 97/103 mg plus placebo irbesartan or
placebo sacubitril/valsartan plus irbesartan 150 mg). Blood
and urine samples were collected for the local analysis of cre-
atinine, electrolytes, liver function tests and uACR and others
were prepared for central analysis (Table 1).
Post-randomization follow-up
Randomization is now complete and all participants are in
follow-up. In order to check potassium and renal function
after starting study treatment, participants attend their study
clinic or local primary care physician at 2 weeks after random-
ization for a blood sample. If these results are satisfactory, study
treatments are increased to either sacubitril/valsartan 97/103
mg two times daily plus two capsules of placebo irbesartan
one time daily or one tablet of placebo sacubitril/valsartan
two times daily plus irbesartan 300 mg one time daily.























Follow-up assessments. Study follow-up visits are scheduled
at 1, 3, 6, 9 and 12 months after randomization. At all visits,
study staff systematically seek the information on all serious ad-
verse events, any non-serious adverse events considered by par-
ticipants to be related to study treatment; and on symptoms of
hepatitis. Compliance with study treatment is assessed and par-
ticipants unable to tolerate the maximum dose of study treat-
ments are encouraged to continue on the lower dose of study
drug (i.e. sacubitril/valsartan 97/103 mg or irbesartan 150 mg
daily) for the remainder of the trial. If relevant, a reason for dis-
continuation or dose reduction is recorded. Participants pre-
scribed contraindicated medications (ACEi, ARB or DRI)
have their randomized treatment stopped. Weight and blood
pressure are measured (three times after sitting for at least 5
minutes) at all visits. In both treatment groups, blood pressure
is to be controlled according to the Kidney Disease: Improving
Global Outcomes guidelines [23], with the initiation and choice
of additional anti-hypertensive treatment being at the discre-
tion of the responsible clinician. Within the 2 weeks before
their 12-month visit participants have their second GFR meas-
urement (using the same method as at baseline). Copies of
results of both measurements of GFR are sent to the coordinat-
ing centre so the results entered by site staff can be verified by
clinical study staff blind to the treatment allocation.
Biological samples and safety monitoring. At each follow-
up visit, blood and urine samples are sent to the local hospital
laboratory for creatinine, electrolytes, liver function tests (bili-
rubin, alanine or aspartate transaminase and alkaline phosphat-
ase) and uACR. In addition, at the 3-, 6- and 12-month visits,
samples are also taken for central analysis. EDTA samples are
centrifuged and the plasma aliquoted into Cryovials, which
are stored locally (with Cryovials of urine) at or below −20°C
prior to transfer to the central laboratory in Oxford, UK,
where they are stored at−80°C. Themain plasma analytes mea-
sured at the central laboratory are creatinine, cardiac and in-
flammatory biomarkers and the urine analytes include
albumin and markers of tubular damage and function [includ-
ing kidney injury molecule 1, neutrophil gelatinase-associated
lipocalin, β2-microglobulin and retinol binding protein;
Table 1]. Participants are asked not to take their morning
dose of study treatment on the day of their 3-month visit (at























this visit only) and the date and time of the last dose is recorded,
as these samples are to be used for pharmacokinetic analyses.
The results of local samples are entered into the trial data-
base once available and reviewed daily by a trained clinician
at the coordinating centre. If the potassium is >5.5 mmol/L, ala-
nine or aspartate transaminase >2× the upper limit of normal or
if the eGFR has fallen >25% from the previous value, then the
trial protocol provides advice on further tests and study treat-
ment (see Supplementary data).
Monitoring
Prior to starting recruitment, study staff received training in
the study procedures and the web-based data collection system
at the coordinating centre. Recruitment rates, adherence to trial
procedures and completeness of follow-up data are monitored
closely by staff at the coordinating centre. All sites have at least
one on-site monitoring visit, with further visits as indicated by
the results of central monitoring of the data. An independent
data monitoring committee (see Supplementary data) regularly
reviews unblinded interim analyses of all relevant data.
Statistical considerations
Sample size. The chief aim of this study is to compare mGFR
between the two treatment groups at the final follow-up visit.
Analysis of covariance (ANCOVA) compares mean follow-up
mGFR between treatment groups after adjustment for baseline
mGFR [24]. Assuming a between-person standard deviation
(SD) in mGFR of 15 mL/min/1.73 m2 and a correlation be-
tween an individual’s baseline and follow-up mGFR of 0.8, ran-
domization of 400 participants will provide at least 80% power
(at 2 P = 0.05) to detect a difference inmGFR at the final follow-
up (adjusted for baseline values) of 3mL/min/1.73 m2 (the cho-
sen minimum clinically meaningful difference), even if 15% of
participants discontinue allocated study treatment [20].
Statistical analysis. All analyses will involve comparing out-
comes during the scheduled treatment period among all those
participants allocated at randomization to receive sacubitril/
valsartan 97/103 mg two times daily versus all those allocated
to receive irbesartan 300 mg one time daily [i.e.
intention-to-treat (ITT) analyses] [25, 26]. Comparisons of
continuous outcomes (including the primary outcome) be-
tween the allocated treatment arms will be performed using
ANCOVA adjusted for each patient’s value at baseline [27]. If
continuous outcomes are not normally distributed, then appro-
priate transformations (e.g. log transformation) will be made.
Multiple imputation techniques will be used to account for
any missing data in the primary and secondary outcomes
[28]. Further details are provided in the data analysis plan
(see Supplementary data).
RESULTS
Study sites were established in 24 renal units in theUK. Between
November 2014 and January 2016 a total of 620 patients at-
tended the study screening visits and 566 (91%) entered the pre-
randomization run-in (Figure 4).
Pre-randomization run-in
A total of 138 participants withdrew from the pre-
randomization run-in before attending a randomization visit
(Table 2A). The most common medical reason for withdrawal
from run-in was that the results from blood and urine samples
taken at the screening visit did not confirm the participant’s eli-
gibility (Table 2A). Adverse events were uncommon and four
participants were withdrawn because of a serious adverse
event (myocardial infarction, septic shock and two cases of
pneumonia).
In addition, 14 individuals attended a randomization visit
but were not eligible to be randomized: the most common rea-
son for this was their blood pressure being too low (Table 2B).
Overall, 152 (27%) of the 566 individuals who entered the pre-
randomization single-blind placebo run-in phase were not sub-
sequently randomized.
Baseline characteristics of randomized participants
A total of 414 people were randomized (Figure 4). The mean
age was 63 (SD 14) years and 298 (72%) were male (Table 3).
The mean systolic blood pressure was 146 (SD 16) mmHg at
randomization (i.e. after 4–7 weeks of withdrawal of any prior
ACEi or ARB). Based on results from the local laboratories, the
mean eGFR was 34.0 (SD 10.6) mL/min/1.73 m2 and the me-
dian uACR was 58.5 (interquartile range 12.5–156.3) mg/
mmol. Central laboratory assays will be conducted at the end
of the study. About half of randomized participants had either
glomerular [111 (27%)] or diabetic [83 (20%)] kidney disease
and 165 (40%) patients reported diabetes mellitus at baseline.
The median 5-year risk of ESRD (calculated using a validated
risk calculator [29] was 16.5%, and 62% of participants had a
5-year risk >10%.









Creatinine ▪ ▪ ▪ ▪
Albumin ▪ ▪ ▪
Troponin-I ▪ ▪ ▪
NT-proBNP ▪ ▪ ▪
CRP ▪ ▪ ▪




▪ ▪ ▪ ▪
KIM-1 ▪ ▪ ▪
NGAL ▪ ▪ ▪
cGMP ▪ ▪ ▪




NT-proBNP, N-terminal prohormone brain natriuretic peptide; CRP, C-reactive protein;
IL-6, interleukin 6; KIM-1, kidney injury molecule 1; NGAL, neutrophil
























The UK HARP-III trial has recruited 414 participants with
CKD and will provide information on the short-term effects
of sacubitril/valsartan on the change in kidney function
(using mGFR) and the tolerability and safety of the drug com-
pared with irbesartan in people with CKD. The trial will also
provide information on the effects of sacubitril/valsartan on al-
buminuria, blood pressure and other biomarkers of both kidney
and cardiac function. These results are important because sacu-
bitril/valsartan has now entered routine clinical practice as a
treatment for heart failure with reduced ejection fraction
(HFrEF) [30], and many of these patients also have CKD.
Moreover, NEPi has the potential to be a useful treatment for
CKD itself.
Large randomized trials of interventions to slow the progres-
sion of CKD are required since currently available treatments
do not prevent ESRD in all patients with CKD. Although
ACEis and ARBs reduce the risk of progression of proteinuric
diabetic and non-diabetic kidney disease, their effect (like most
medical treatments) is moderate. For example, in proteinuric
diabetic kidney disease, irbesartan reduced the risk of ESRD,
doubling of creatinine or death from any cause by 20% com-
pared with placebo {hazard ratio [HR] 0.80 [95% confidence
interval (CI) 0.66–0.97]; P = 0.02}, but this composite outcome
still occurred in nearly one-third of those allocated irbesartan
(and 14% reached ESRD) during the mean 2.6 years of follow-
up [6]. Other strategies to reduce the risk of renal progression
have either been ineffective, hazardous or both [31–33]. Nepri-
lysin inhibition appears to be effective in rat models of CKD
[15, 16, 34], but these are poorly predictive of efficacy in hu-
mans [35, 36]. In addition, sacubitril/valsartan has been
shown to increase albuminuria in trials among patients with
heart failure (who typically have very low baseline albuminuria)
[18, 20]. NPs (particularly atrial NP) cause afferent arteriolar
vasodilatation [37, 38] that may lead to increased intraglomer-
ular pressure and hyperfiltration, which would be detrimental
to the kidney. However, NEPi also disturbs degradation of other
F IGURE 4 : Trial profile: flow of participants through the trial. *Indicates that participants may have more than one reason.
Table 2. Reasons for (A) withdrawal during run-in and (B) ineligibility at a
randomization visit
(A) n (%)
Number entering run-in 566
Adverse event
Serious adverse event 4 (3)
Non-serious adverse reaction 7 (5)
Other reason
Ineligible on laboratory results sent at screening visit 59 (43)
Participant wishes 16 (12)
Medical advice 13 (9)
Other non-medical reason 39 (28)
Total withdrawn during Run-in 138 (100)
(B)
Number attending randomization visit 428
Adverse event
Serious adverse event 0 (0)
Non-serious adverse reaction 3 (21)
Other reason
Blood pressure too low 9 (64)
Other 2 (14)























vasoactive peptides, so the net effect of NEPi on glomerular
haemodynamics is uncertain, and in rat models at least, it ap-
pears to be favourable [15, 16, 34]. NPs may alter glomerular
permeability and/or tubular reabsorption of protein, which
may lead to albuminuria without hyperfiltration, the conse-
quences of which are uncertain. UK HARP-III is the first trial
of NEPi in humans with CKD and the measurements of GFR,
albuminuria and other markers of kidney function and damage
will help to resolve these uncertainties.
Most patients with CKDdo not progress to ESRD [39], but are
at high risk of CVD [4]. Lowering low-density lipoprotein choles-
terol has been shown to clearly reduce the risk of atherosclerotic
vascular disease inCKD [40].However, as renal function declines,
the pattern of CVD changes from atherosclerotic disease (i.e.
myocardial infarction, ischaemic stroke) to non-atherosclerotic
disease (characterized by arteriosclerosis and structural heart dis-
ease, which manifests clinically similarly to heart failure, with a
high incidence of sudden cardiac death) [4, 41–43], but effective
treatments for non-atherosclerotic disease are not yet available.
Lowering blood pressure in patients with CKD appears to reduce
the risk of awide variety of cardiovascular events, but residual risk
remains [44]. The similarities in the manifestation of non-
atherosclerotic disease observed in CKD and heart failure suggest
that treatments that are effective in heart failure may well also be
effective at reducing cardiovascular risk among patients with
CKD. In the Prospective Comparison of ARNI with ACEI to
Determine Impact on Global Mortality and Morbidity in Heart
Failure (PARADIGM-HF) trial, sacubitril/valsartan reduced the
risk of cardiovascular mortality or hospitalization for heart failure
by 20% [HR 0.80 (95% CI 0.73–0.93) P < 0.001] compared with
enalapril, with similar effects observed among participants with
and without CKD at baseline [45]. These data suggest that
NEPi would be an ideal candidate to test among patients with
CKD. Nevertheless, most patients with CKD have a normal ejec-
tion fraction [41, 43], and treatments that improve outcomes in
HFrEF do not necessarily improve outcomes in patients with
heart failure with preserved ejection fraction [46, 47], so direct
evidence is needed. NEPi has improved cardiac biomarkers
(e.g. troponin, N-terminal prohormone brain NP in trials in
heart failure [18, 48], so the effects of NEPi on these cardiac bio-
markers in people with CKD will also be of interest.
NEPi has the potential to improve both renal and cardiovas-
cular outcomes among patients with CKD. The UK HARP-III
trial will provide important information on the efficacy, safety
and tolerability of sacubitril/valsartan in people with CKD. Re-
sults are anticipated in 2017.
SUPPLEMENTARY DATA
Supplementary data are available online at http://ndt.oxford-
journals.org.
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South Asian 18 (4)
Other 12 (3)
Prior disease
Coronary heart disease 55 (13)
Cerebrovascular disease 31 (7)
Peripheral arterial disease 44 (11)
Heart failure 17 (4)
Diabetes 165 (40)












Not available 4 (1)
Medication
Antiplatelet therapy 138 (33)
Oral anticoagulant 28 (7)
Diuretic 164 (40)
Calcium channel blocker 207 (50)
β-blocker 112 (27)
α-blocker 112 (27)
LDL-lowering agent 263 (64)
Prior use of ACEi or ARB
Yes 339 (82)
No 75 (18)




Not available 5 (1)
Urine albumin:creatinine ratio (mg/mmol) 58.5 (12.5–156.3)
<3 48 (12)
≥3–< 30 88 (21)
≥30 251 (61)
Not available 27 (7)
Primary renal diagnosis
Glomerular disease 111 (27)
Tubulointerstitial disease 50 (12)
Diabetic kidney disease 83 (20)
Hypertensive/renovascular disease 42 (10)
Other systemic diseases affecting the kidneys 3 (1)
Familial/hereditary nephropathies 43 (10)
Miscellaneous renal disorders 9 (2)
Unknown 73 (18)
Recorded at randomization visit unless otherwise stated. Values are given as n
(%), mean ± SD or median (interquartile range).
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The purpose of this Data Analysis Plan is to provide a clear definition of the main 
randomized analyses to be reported in the primary report of the UK HARP-III trial results, 
before unblinding of the treatment allocation. The nature of further analyses and the content 
of subsequent publications cannot be specified in detail but, where appropriate, the general 
analytical approach is set out.  
 Outcomes in UK HARP-III 2.
 
2.1 Primary outcome 
The primary outcome is mean measured glomerular filtration rate (mGFR; adjusted for body-
surface area) at 12 months. Glomerular filtration rate (GFR) will be measured using a 51Cr-
EDTA or other approved technique. 
 
2.2 Secondary outcomes 
The secondary outcomes are: 
 Mean urine albumin:creatinine ratio (uACR) at 3, 6 and 12 months from centrally 
analysed urine samples 
 Estimated GFR (eGFR) at 3, 6 and 12 months from centrally analysed plasma 
samples using the Chronic Kidney Disease-Epidemiology Collaboration (CKD-EPI) 
formula 
 Metabolites of sacubitril/valsartan measured in blood samples taken at 3 months 
 
2.3 Tertiary outcomes 
The tertiary outcomes are: 
 Systolic and diastolic blood pressure (mmHg) at 1, 3, 6, 9 and 12 months 
 Markers of renal damage (kidney injury molecule-1 [KIM-1] and neutrophil gelatinase-
associated lipocalin [NGAL]) at 6 and 12 months 
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 Markers of renal tubular function (β2-microglobulin and retinol binding protein) at 6 
and 12 months  
 Urine cyclic guanosine monophosphate (cGMP) excretion at 6 and 12 months 
 Cardiac biomarkers (troponin I and N-terminal prohormone brain natriuretic peptide 
[NT-proBNP]) at 6 and 12 months 
 Rate of change of eGFR calculated from creatinine values at Randomization, 1, 3, 6, 
9 and 12 months (overall, and separately for 0-3 months [ie, Randomization, 1 and 3 
month values] and 3-12 months [ie, 3, 6, 9 and 12 month values]) using the Chronic 
Kidney Disease Epidemiology Collaboration (CKD-EPI) formula (see section 4.4.). 
Where values from the central laboratory are available (randomization, 3, 6 and 12 
months) these will be used, but local values will be used at 1 and 9 months 
 
 Baseline characteristics 3.
 
In order to assess balance of baseline characteristics between randomized arms, the 
following variables recorded at randomization will be presented for each of the 
sacubitril/valsartan and irbesartan groups:  
 Age 
 Sex 
 Past medical history (prior diabetes mellitus, prior vascular disease) 
 Blood pressure (systolic and diastolic separately) 
 Body mass index 
 Baseline mGFR 
 Baseline albuminuria  
 Baseline 24 hour urinary sodium excretion (top versus bottom half) 
 Current/recent medication (including any renin-angiotensin system [RAS] blockade) 
 Cause of kidney disease (glomerular, tubulointerstitial, diabetic, 
hypertensive/renovascular, other systemic diseases, familial/hereditary, other known 




 Comparisons of sacubitril/valsartan versus irbesartan 4.
 
All comparisons will involve comparing outcomes during the scheduled treatment period 
among all those participants allocated at randomization to receive sacubitril/valsartan 97/103 
mg twice daily versus all those allocated to receive irbesartan 300mg once daily (i.e. 
“intention-to-treat” [ITT] analyses).1, 2 
 
4.1 Primary assessment  
Mean mGFR at 12 months will be compared between all participants allocated 
sacubitril/valsartan and all participants allocated irbesartan. Estimates will be made by 
analysis of covariance (ANCOVA) after adjustment for each participant’s baseline mGFR. 
Missing or implausible mGFR values will be handled as described in section 6.1.3.  
 
4.2 Secondary assessments of the primary outcome 
Mean mGFR at 12 months (the primary outcome) among sacubitril/valsartan-allocated and 
irbesartan-allocated participants will be compared separately by the following baseline 
characteristics: 
 Age (≤60; >60 years) 
 Sex (Female, Male) 
 History of diabetes mellitus (Yes, No) 
 History of vascular disease (Yes, No) 
 Systolic blood pressure (≤140; >140 mmHg) 
 Diastolic blood pressure (≤80; >80 mmHg) 
 Body mass index (top versus bottom half) 
 Baseline mGFR (≤45; >45 mL/min/1.73m2) 
 Baseline uACR (≤30 mg/mmol; >30 mg/mmol) 
 Baseline 24 hour urinary sodium excretion (top versus bottom half, ignoring 
participants with missing values) 
 Use of RAS blockade at screening (Yes, No) 




4.3 Assessment of secondary outcomes 
Mean uACR (or an appropriate transformation of uACR) and eGFR at 3, 6 and 12 months 
will be compared between all participants allocated sacubitril/valsartan and all participants 
allocated irbesartan using ANCOVA to adjust for baseline values. This will be done both 
separately at the three follow-up time points and overall (using the mean of the 3, 6 and 12 
month values). 
 
Pharmacokinetic analyses will also be conducted using measurements of sacubitril/valsartan 
metabolite trough concentrations measured at 3 months after randomization (see section 
6.1.4).  
 
4.4 Assessment of tertiary outcomes 
Mean values of tertiary outcomes (or mean of an appropriate transformation of the outcome) 
at 6 and 12 months will be compared between all participants allocated sacubitril/valsartan 
versus all patients allocated irbesartan. ANCOVA will be used to estimate the mean value 
adjusted for the baseline value. As systolic and diastolic blood pressure are also measured 
at 1, 3 and 9 months, analyses of these outcomes will also be done separately for the 1, 3 
and 9 month follow-up visits, as well as overall (using a weighted average of the 1, 3, 6, 9 
and 12 month values). 
For each participant, linear regression will be used to estimate the rate of change in eGFR 
from the available creatinine values. The validity of making such a linearity assumption will 
be assessed by examining the residuals. The participants with the most poorly fitting slopes 
(defined as participants with the mean deviation from their own fitted slope in the top 1% of 
the distribution [of mean deviations across all participants]) will be excluded. The mean rate 
of change in eGFR will then be compared between participants allocated sacubitril/valsartan 
versus patients allocated irbesartan. 
Any other comparisons of the tertiary outcomes will also be between all participants 
allocated sacubitril/valsartan versus all participants allocated irbesartan but will be 
exploratory only (with due allowance in the interpretation for multiplicity and the retrospective 




 Safety and tolerability outcomes 5.
The safety and tolerability of sacubitril/valsartan will be assessed from the following 
information. The analyses of these data are described in section 6.1.5. 
 
5.1 Serious adverse events (SAEs) 
All SAEs, regardless of whether the SAE is considered related to study treatment, will be 
recorded, and subdivided by outcome (fatal/non-fatal). The numbers and proportions of 
participants with SAEs in each group (sacubitril/valsartan and irbesartan) will be described. 
Particular SAEs of interest include: 
 Angioedema 
 Hypotension 
 Need for dialysis (recorded on electronic case report form) 
 
5.2 Reported reasons for stopping study treatment 
All reasons for stopping treatment will be recorded and listed in relevant categories by 
treatment allocation. All adverse events, including non-serious adverse events, that cause 
participants to discontinue study treatment will be recorded and grouped by treatment 
allocation according to MedDRA version 14.0 primary system organ class. The numbers and 
proportions of participants in each treatment group with non-serious adverse events and 
serious adverse events that result in discontinuation of study treatment will be described. In 




 Deterioration in renal function 





5.3 Biochemical safety data 
The biochemical safety data collected will include kidney and liver related outcomes, in 
particular: 
 Potassium (≥5.5 <6.0; ≥6.0 <6.5; ≥6.5 mmol/L) 
 25% reduction in eGFR since randomization  
 ALT/AST >10x upper limit of normal (ULN) 
 ALT/AST >3x ULN and bilirubin ≥2x ULN 
 Consecutive ALT/AST >3x ULN (ie, two consecutive measurements at least 3 
days apart) 
 
 Details of analyses 6.
 
6.1 Methods of analysis 
 
6.1.1 ANCOVA 
Comparisons of continuous outcomes (eg, mGFR, uACR, systolic and diastolic blood 
pressure and any other biomarkers or physical measurements) between the allocated 
treatment arms will be performed using ANCOVA adjusted for each patient’s value at 
randomization.3 If continuous outcomes are not normally distributed then appropriate 
transformations (e.g. log transformation) will be made.  
 
6.1.2 Repeated measures 
Where more than one follow-up value of a biomarker is available, comparisons of the mean 
values of the biomarker will be conducted at each follow-up time using ANCOVA adjusted for 
each participant’s baseline value of the biomarker. In addition, a weighted average of all the 
follow-up values (with weights proportional to the amount of time between visits) will be 
calculated for each participant and the mean values compared using ANCOVA adjusted for 




6.1.3 Imputation of missing data 
All analyses will be done according to the intention-to-treat principle and hence, where 
missing, primary and secondary outcome data will be imputed. For each of the continuous 
outcomes (eg, mGFR, uACR) missing post-randomization results will be imputed using 
multiple imputation, using 20 imputed data sets, with results across imputations being 
combined using the methods of Rubin.4 The imputation procedure will take into 
consideration each participant’s key baseline characteristics (listed in section 3), treatment 
allocation and any intermediate follow-up values of the biomarker, where available. For 
patients who commence chronic dialysis during the study and for whom it is not possible to 
measure GFR at study end, a value of 0 will be imputed for the final mGFR. Values will be 
imputed for patients who die prior to their second mGFR. The results from these analyses 
will be compared with those from equivalent “complete-case” analyses, but primary 
emphasis will be placed on the results after multiple imputation. All multiple imputation 
analyses will be implemented using the multiple imputation procedure in SAS version 9.3 
(SAS Institute, Cary NC), using the expectation-maximization algorithm (which assumes a 
multivariate normal distribution) to impute values. For any continuous variables with missing 
baseline values, the mean among those with observed values will be imputed. 
 
6.1.3.1 Participants who refused consent for 12 months follow-up 
A small number of participants who had been randomized before the protocol was amended 
to extend follow-up from 6 to 12 months refused consent for 12 months follow-up. These 
participants will have a mGFR performed at 6 months. Multiple imputation will be used to 
impute 12 month mGFR values for these participants, including all available information on 
GFR at 6 months in the imputation model. 
 
6.1.3.2 Implausible mGFR values 
Technical issues can cause GFR measurements to give spurious results, but this is typically 
not apparent until after the participant has already been randomized and started their 
randomized allocation (or stopped taking study treatment at the end of the trial). The 
differences between each mGFR value and its corresponding creatinine-based eGFR value 
(ie, the value based on a blood sample taken at the same timepoint as the mGFR) will be 
calculated, and the distribution of these differences inspected before any unblinded analyses 
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are performed. Based on this inspection a threshold will be determined (eg, 95 or 99% 
centiles) such that any values that fall outside this threshold are ignored. Multiple imputation 
will be used to handle any missing values of mGFR generated. 
 
6.1.4 Pharmacokinetic assessments  
 
The objective of pharmacokinetic analyses is to quantify the determinants of plasma 
concentrations of metabolites of sacubitril/valsartan (including LBQ657 [sacubitrilat], the 
active metabolite of sacubitril [AHU377]). 
A single trough plasma sample for pharmacokinetic analysis is collected at the 3 month visit 
(including time since last drug dosage). This will be sent to a third party laboratory (WuXi 
AppTec, Shanghai, China) for measurement of sacubitril, valsartan and LBQ657. 
Participants will be included in analyses from these analyses if they were allocated and 
taking sacubitril/valsartan at the 3 month visit and the plasma sample was taken between 10 
to 16 hours after the last dose. Plasma concentrations of sacubitril, valsartan and LBQ657 
will be tabulated by baseline mGFR (unadjusted for body surface area). In addition, 
appropriate population pharmacokinetic modelling techniques will be used to identify the 
determinants of the plasma concentration of each metabolite. The variables to be assessed 
will include baseline mGFR (unadjusted for body surface area), time since last dose, 
albuminuria, age, sex, body surface area and weight. 
 
6.1.5 Safety analyses 
All participants randomized to sacubitril/valsartan will be compared with all participants 
randomized to irbesartan, regardless of whether a participant received all, some or none of 
their allocated treatment (ie, ITT).1, 2 A participant may contribute to more than one 
assessment if they have events of more than one type (e.g. non-fatal hypotension followed 
by angioedema).  
 
For reasons for stopping and safety biochemical outcomes, the effect of allocated treatment 
on the number of randomized participants with at least 1 event will be compared using 




For the time-to-event analyses of adverse events, the effect of allocated treatment will be 
evaluated using survival analytic methods on the time to first event during the entire study 
period. For each outcome, the log-rank method will be used to estimate the average event 
rate ratio comparing all those allocated sacubitril/valsartan with all those allocated 
irbesartan.2 Estimates of event rate ratios will be shown with 95% confidence intervals and 
their associated log-rank p-values. In all analyses, two-sided p-values (2P) <0.05 will be 
considered statistically significant (after any adjustment for multiple testing [see section 6.2]). 
 
6.2 Allowance for multiplicity of comparisons 
The primary outcome will be assessed without adjustment for multiplicity. For secondary and 
particularly the tertiary and exploratory analyses, allowance in their interpretation will be 
made for multiple hypothesis testing,1, 2 taking into account the nature of events (including 
timing, duration and severity) and evidence from other studies. In addition to the pre-
specified comparisons, many other analyses will be performed with due allowance for their 
exploratory and, perhaps, data-dependent nature. Conventionally, two-sided P-values <0.05 
are often described as “significant”. But, the larger the number of events on which a 
comparison is based and the more extreme the P-value (or, analogously, the further the 
confidence interval is from zero) after any allowance has been made for the nature of the 
particular comparison (i.e. primary, secondary or tertiary; pre-specified or exploratory), the 
more reliable the comparison and, hence, the more definite any finding will be considered. 
 
6.3 Tests for heterogeneity 
When a number of different subgroups are considered, chance alone may lead to there 
being no apparent effect in several subgroups in which the effect of treatment really is about 
the same as is observed overall. In such circumstances, “lack of direct evidence of benefit” is 
not good “evidence of lack of benefit”, and clearly significant overall results would provide 
strong indirect evidence of benefit in some small subgroups where the results, considered in 
isolation, are not conventionally significant (or, even, perhaps, slightly adverse).1, 2 Hence, 
unless the proportional effect in some specific subcategory is clearly different from that 
observed overall, the effect in that subcategory is likely to be best estimated indirectly by 
applying the proportional effect observed among all patients in the trial to the absolute risk of 




Tests for heterogeneity of the proportional effect observed in subgroups will be used (with 
allowance for multiple comparisons) to determine whether the proportional effects in specific 
subcategories are clearly different from the overall effect.1, 2 If, however, three or more 
patient categories can be arranged in some meaningful order (e.g. age at randomization: 
<50, ≥50<60, ≥60) then assessment of any trend will be made. For subgroups based on 
continuous variables (e.g. blood pressure, kidney function), approximate similar sized 
divisions (such as by tertiles) may be used, using natural breaks to define categories (e.g. 
systolic blood pressure <140 mmHg rather than <138.7 mmHg). These breaks will be 




1. Peto R, Pike MC, Armitage P, et al. Design and analysis of randomized clinical trials 
requiring prolonged observation of each patient. I. Introduction and design. Brit J Cancer 
1976; 34: 585-612. 
2. Peto R, Pike MC, Armitage P, et al. Design and analysis of randomized clinical trials 
requiring prolonged observation of each patient. II. analysis and examples. Brit J Cancer 
1977; 35: 1-39. 
3. Vickers AJ, Altman DG. Statistics notes: Analysing controlled trials with baseline and 
follow up measurements. Brit Med J 2001; 323: 1123-4. 






Safety monitoring procedures 
 
1. Abnormal potassium 
 
a. Potassium >5.5 <6.0 mmol/L 
 Confirm potassium in non-haemolyzed sample 
 Inform Local Lead Investigator (LLI) within 72 hours 
 Dietary advice to avoid potassium-rich food and drink 
 Review non-study medications (including over-the-counter medications) and stop 
potassium-sparing medications if possible 
 Consider checking for acidosis and correcting if present 
 Repeat potassium measurement within 7 days 
 If potassium remains >5.5 <6.0 mmol/L, discuss frequency of potassium 
monitoring with LLI (and coordinating centre if required) 
 If potassium ≤5.5 mmol/L, return to routine follow-up 
 
b. Potassium ≥6.0 mmol/L 
 Confirm potassium in non-haemolyzed sample 
 Inform LLI immediately 
 Discontinue study treatments 
 Dietary advice to avoid potassium-rich food and drink 
 Review non-study medications (including over-the-counter medications) and stop 
potassium-sparing medications if possible  
 Consider checking for acidosis and correcting if present 
 Repeat potassium measurement within no more than 3 days (ideally 1-2 days if 
potassium >6.5 mmol/L)  
 If <6.0 mmol/L, restart study treatment and discuss frequency of potassium 
monitoring with LLI (and coordinating centre if required) 
 If ≥6.0 mmol/L remain off all study treatment permanently 
 
2. Unexpected changes in estimated glomerular filtration rate (eGFR) 
If the eGFR falls by more than 25% between study visits (in particular, during the titration 
period in the first month after randomization) the LLI should be informed so that alternative 
causes of deterioration may be investigated (e.g. hypovolaemia, obstruction, non-study 
medications). The eGFR should be re-measured within 7 days (fewer days if a larger fall) in 
case of measurement error. If necessary the dose of study treatment can be modified, 
ideally after discussion with the coordinating centre. 
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3. Abnormal alanine aminotransferase (ALT) or  aspartate aminotransferase (AST) 
ALT or AST (xULN) Symptoms1/bilirubin Action Follow-up 
monitoring 
≤3 Not relevant None Repeat at next study 
visit 
>3 ≤5 Absent and 
Bilirubin <2x ULN 
Inform LLI 
Repeat in 1 week: 
investigate for 
cause** if still >3 
At LLI’s discretion 
>5 ≤8 Absent and 
Bilirubin <2x ULN 
Inform LLI 
Repeat in 2-4 
days: investigate 
for cause** if still 
>3 
Repeat ALT/AST, 
ALP and bilirubin until 
resolution (frequency 
at LLI’s discretion) 
If >5 for >2 weeks, 
stop study treatment 
>8 Absent and 
Bilirubin <2x ULN 
Inform LLI 
Repeat in 2-4 






ALP and bilirubin until 
resolution (frequency 
at LLI’s discretion) 
If >5 for >2 weeks, 
stop study treatment 
>3 Present or  







ALP and bilirubin until 
resolution (frequency 
at LLI’s discretion) 
Consider restart if 
alternative cause 
found 
ULN = upper limit of normal; LLI = local lead investigator;  
                                                          
1
 Symptoms of liver disease e.g. malaise, fatigue, abdominal pain, nausea, vomiting, jaundice 
** 




Substantial amendments to the study protocol 
Version Date Original text Amended text Rationale 
5.0 04/09/2014 Version approved by ethics 
committee and regulatory 
agency prior to recruitment 
beginning 
   
5.1 19/11/2014  First morning void urine samples will be collected at each 
study visit for local and central analysis 
First morning urine samples reduce intra-individual variability 
compared with random urine samples  
6.0 09/03/2015 
Inclusion criteria: 
eGFR ≥20 <60 mL/min/1.73m
2
 
and urine albumin:creatinine 
ratio >20 mg/mmol 
 
Exclusion criteria: 
Serum potassium > 5.2 mmol/L 
Systolic BP <130 mmHg at 
Randomization 
Inclusion criteria: 
eGFR ≥20 <45 mL/min/1.73m
2
; or 
eGFR ≥45 <60 mL/min/1.73m
2
 and urine albumin:creatinine 
ratio >20 mg/mmol 
 
Exclusion criteria: 
Serum potassium > 5.5 mmol/L 
Systolic BP <110 mmHg (or <130 mmHg with symptoms of 
orthostatic hypotension) at Randomization 
To facilitate recruitment and avoid unnecessary exclusion of 
participants 
7.0 11/05/2015 Follow-up duration 6 months 
 
Follow-up duration 12 months 
 
New data from heart failure population suggested that the full 




8.0 25/01/2016 Original sample size 360 
participants (based on 
assumption that 10% might 
discontinue study treatment) 
Sample size increased to at least 400 participants  To allow for up to 15% of participants to discontinue study 
treatment 
1. Voors AA, Gori M, Liu LC, et al. Renal effects of the angiotensin receptor neprilysin inhibitor LCZ696 in patients with heart failure and preserved ejection fraction. Eur J Heart Fail 2015; 17: 
510-7. 
Appendix 3:  
UK HARP-III trial study poster. 
UK HARP-III 
UK Heart and Renal Protection Study 
Some people with chronic kidney disease will develop end stage renal disease 
requiring long-term dialysis or transplantation. UK HARP-III is a national study being 
coordinated by the University of Oxford which is investigating a new treatment to slow 
the progression of kidney disease and the development of circulatory problems such as 
heart attacks and strokes. 
If you have kidney disease (but are not on dialysis or have a transplant), then                
UK HARP-III could be suitable for you. 
 
LCZ696  
LCZ696 is a new drug  with two actions: one half is an “angiotensin receptor blocker” 
which is a drug commonly used in heart and kidney disease. (Such drugs include 
valsartan, losartan and irbesartan.) 
The other half of the drug prevents the breakdown of certain proteins (“natriuretic 
peptides”) in the bloodstream. There is some evidence to suggest that preventing the 
breakdown of these proteins may have beneficial effects on protecting the kidney. This 
might slow the rate of progression of kidney disease and delay the need for dialysis or 
transplantation. There may also be beneficial effects on the heart and blood vessels. 
UK HARP-III is comparing LCZ696 with irbesartan (a commonly used angiotensin 
receptor blocker) to investigate whether LCZ696 might improve outcomes for people 
with chronic kidney disease. 
Do you have Chronic Kidney Disease 
and are you interested in research? 
Where can I find out more about 
UK HARP-III 
Further details are available on our website: 
www.harp3trial.org 
 
Or you can speak to a member of the study 
team: 
 
What do I do if I am interested 
in taking part? 
 
Please contact the study team who will be 
able to tell you if you are suitable for the 
study. 
 
Thank you for your interest. 
UK HARP3 Poster V1.0_2013-10-28 
Appendix 4:  
UK HARP-III trial participant information leaflet. 
HARP-III PIS V 3.0 2015-05-11 
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UK Heart And Renal Protection (UK HARP-III) Trial 
LCZ696 in chronic kidney disease: a pilot study 
An invitation to join a research study 
 
We would like to invite you to take part in an important study about kidney disease. The study could 
provide doctors with much better information about how to reduce the illness worsening in 
thousands of patients around the world. 
Please take the time to read this information leaflet before making a decision about whether or not 
to join this study. It is important that you know why the research is being done, and what it might 
mean for you. Feel free to discuss this information with family and friends. Please contact us if there 
is anything more you would like to know. 
What is the purpose of the study? 
The study is called the UK HARP-III trial. It is investigating whether a new drug (LCZ696) has the 
potential to protect kidneys better than current standard treatment.  
Chronic kidney disease affects about 1 in 10 adults. The illness can worsen over time. This means 
that some people eventually need to have dialysis or a kidney transplant.  
There are treatments that can slow the rate of kidney decline. However, despite such treatment 
some people still need transplantation or dialysis. Two commonly-used treatments are: 
 “ACE inhibitors” (you may be familiar with them as their drug names end with the letters “-
pril”. And, 
 Angiotensin receptor blockers (the drug names end in “-sartan”) 
LCZ696 is a new treatment which has two actions: one half of the drug is the same as an angiotensin 
receptor blocker (valsartan). The other half of the drug is a “neprilysin inhibitor” which prevents the 
breakdown of certain proteins in the blood. Blocking their breakdown might slow the progression of 
kidney damage and delay the need for dialysis and transplant. These drugs may also benefit the 
heart and blood circulation.  
Why have I been invited? 
Your medical records suggest that you may be suitable because you have chronic kidney disease. We 
have informed your kidney consultant about the study and they are happy for us to discuss it with 
you. If you take part your GP will be informed.  
Do I have to take part? 
No. Participation is entirely up to you. If you agree to take part we will ask you to sign a form to 
show that you have consented. You are free to withdraw at any time, without giving a reason. This 
will not affect the standard of care you receive. 
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Who is running and who is funding the study? 
UK HARP-III is being led by experienced medical scientists at the University of Oxford who carried 
out the important Study of Heart and Renal Protection (SHARP). This study showed the benefits of 
lowering “bad” cholesterol in people with chronic kidney disease and resulted in changes to medical 
practice around the world. Treatment for this study is provided free by Novartis (a pharmaceutical 
company), which also contributes to the cost of running of the study, by a grant to the University of 
Oxford. The results will be analysed by scientists at the University of Oxford independently of 
Novartis.  
What will happen to me if I take part? 
You will need to participate in UK HARP-III for about 13 months. You will be asked to attend about 
seven hospital appointments, some of which may coincide with your routine renal outpatient 
appointments. In addition, we will measure your kidney function very precisely on two occasions 
during the study. 
Getting started At your first visit to the HARP-III clinic a trained researcher (usually a nurse) will ask 
you about your medical history. They will explain the study to you and you will be given plenty of 
opportunity to ask questions. The researcher will take your blood pressure and a sample of blood 
and urine. If you are interested in the study, you will be asked to sign a form agreeing to take part. 
We will write to your GP about your participation in the study.  You will then be provided with a 
supply of the study tablets and asked to take two a day. This visit will take about 45 minutes. 
You may be asked to stop some of your current blood pressure treatment (because the study 
treatment will replace them). Over the course of the next few weeks you will have the chance to try 
out the study tablets. This will allow you and the UK HARP-III doctors and nurses to be sure the 
routine of taking these particular tablets agree with you. You will be given a container and asked to 
collect a sample of your urine on the morning of your next visit and bring it with you to the study 
clinic. Towards the end of this period you may also be asked to collect your urine for 24 hours, but 
this optional and you can still participate even if you don’t want to do this.  
After 4 to 7 weeks After at least 4 weeks of taking the study tablets you will be asked to attend a 
second appointment to see if you would like to continue.  We will measure your kidney function very 
precisely (see below). Your blood pressure will be checked and we will ask for another blood sample. 
Your height and weight will also be recorded at this visit. If you have had no problems with the study 
treatments during the first few weeks and are happy to continue, you will be asked to commit to the 
study for another 12 months. This visit will take about 30 minutes. 
At this appointment your treatment for the rest of the study will be decided “at random” (like the 
toss of a coin). You will be given two drugs (one, an active treatment and the other a ‘dummy’ 
placebo). These will be either active LCZ696 and placebo irbesartan, or placebo LCZ696 and active 
irbesartan. Irbesartan is an angiotensin receptor blocker and is commonly used to treat kidney 
disease. The initial dose is one tablet of each treatment once daily. 
You have as much chance of receiving LCZ696, as you do of receiving the standard treatment, 
irbesartan. You will not know which treatment you receive, nor will your GP or the UK HARP-III staff. 
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However, this information would be made available to your doctor and other medical staff if this 
was medically necessary. 
Further visits You will be asked to have a blood test after about two weeks to check your potassium 
level. This can be done at your GP surgery or your renal clinic. The dose of your study treatment will 
then increase to the full dose (two tablets of active treatment and two tablets of placebo once daily). 
You will be asked to attend five further appointments (about 1, 3, 6, 9 and 12 months later) to see 
how you are getting on. You will be asked to bring a urine sample collected on the morning of each 
of these visits to the clinic (in a container provided at the previous visit). Your blood pressure will be 
checked and a blood sample will be taken at each visit. At the final visit you will also have a second 
precise measurement of your kidney function. Each visit will last about 30 minutes. 
In the unlikely event that your blood test results are of concern (for example, if your potassium level 
was high) you may be asked to attend an extra visit. We would repeat the blood test and further 
checks would be done. With regular check-ups from the UK HARP-III specialist nursing team, you can 
be assured of the best possible follow-up care and attention. If any problems emerge for you while 
you are on the study, your consultant and GP will be informed. 
Blood and urine samples 
 
The blood and urine samples that you provide will be tested locally to check that the study 
treatments are not having any adverse effects.  We need about 4 teaspoons of blood on each 
occasion. Some of the samples will also be sent to the central laboratory in Oxford University. This 
allows us to see whether the effects of the treatments vary between different types of people taking 
part. We will also look to see if the treatments affect other markers of kidney function.  
We will also ask for permission to store your blood and urine samples long-term. These samples will 
not have your name on. This will help with other kidney studies and research into other diseases.  
Measuring kidney function 
In routine clinical practice, your doctors estimate kidney function by looking at the level of a 
substance called creatinine in the blood. This is sufficient for clinical purposes, but in the UK HARP-III 
study we need to measure kidney function more precisely. This involves having an injection of a very 
small amount of a substance (which in some hospitals may be radioactive) and then a number of 
blood samples in the 4-5 hours that follow (this may take longer at certain hospitals). This allows us 
to measure how quickly your kidneys remove this substance from your blood. This test is routinely 
used in the NHS when kidney function needs to be measured precisely. If used, the amount of 
radioactivity is very small (equivalent to about ten days of normal background radiation or less in the 
UK), so represents a negligible risk to your health. 
Travel expenses 
We are happy to reimburse reasonable expenses for travelling to your UK HARP-III appointments. 
Please make sure you ask about this at the clinic. 
What will I have to do? 
For UK HARP-III to produce the best results, it is important that people stay in the study for its 
duration if possible. You will need to attend the UK HARP-III clinic seven times during the 13-14 
months of the study. Extra appointments can also be arranged if you are worried about the study 
tablets. However, you can withdraw from the study at any time.  
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You will be asked to take either a drug called irbesartan or the new treatment, LCZ696. Scientists do 
not know which treatment is best. You may be asked to stop some of your current medications 
because the study treatment will replace them. We will discuss this with you at your appointment.  
 
We will ask you to provide blood and urine samples and to give permission for them to be stored for 
future tests.  We will also ask about your health. Your blood pressure will be measured at every visit. 
At some visits extra measurements will be taken, including your height and weight. 
What are the benefits of taking part in this study? 
You may be helping yourself, but you will most certainly be helping doctors and scientists improve 
treatment for people who have chronic kidney disease and who may be at risk of needing dialysis or 
a transplant. If successful, results from this study will help to design a larger trial of LCZ696 which 
could reliably show whether LCZ696 is better than current treatment in slowing the progression of 
chronic kidney disease. 
Are there any risks? 
Most treatments have side-effects which some people may experience and others do not. If you do 
experience any side effects while on the UK HARP-III study they will be noted, so that scientists can 
learn from you. You can withdraw from the study if you wish. 
 Irbesartan is generally very well-tolerated. It has been tested in thousands of people and is 
taken by hundreds of thousands of people worldwide. It lowers blood pressure so it can cause 
dizziness. Other side-effects include nausea, muscle pain and fatigue. Like all “angiotensin 
receptor blockers” it can raise potassium levels in the blood and you will be monitored for this. 
 LCZ696 is an unlicensed drug and is being tested in this study. Over 8,000 people have taken 
LCZ696 in other trials and it is generally well-tolerated. It also lowers blood pressure so can 
cause dizziness and fatigue. Rarely it may cause swelling of the mouth and face (angioedema), 
but it does not appear to do this more frequently than “ACE inhibitors” which are a very 
commonly used medication in people with chronic kidney disease. It is very important that you 
do not take LCZ696 with an ACE inhibitor (e.g. ramipril, lisinopril). The treatment can raise 
potassium levels in the blood and you will be monitored for this. One patient who received 
LCZ696 had an allergic reaction which included abnormal liver function tests. At this stage, 
scientists cannot rule out the possibility of there being side effects (such as diarrhoea or muscle 
pains), or effects on other blood tests. 
 
A large trial of LCZ696 in patients with heart problems recently showed that LCZ696 reduced 
admissions to hospital with heart problems or dying of circulatory problems. In this population 
the treatment was well-tolerated and there were no concerning safety problems. UK HARP-III is 
testing LCZ696 in a different group of patients i.e. people with chronic kidney disease. 
Throughout the study you would be carefully monitored by our nursing team for possible side 
effects. At every visit, the study staff would discuss any new information about the drug with 
you. 
 
There is nothing to suggest that stopping the tablets will cause you harm. If you do experience side 
effects, you may choose, or be advised by your doctor, to stop the tablets provided by the study.  
If you do experience unexpected symptoms after joining the study you can contact your UK HARP-III 
nurse, or a study doctor on Freefone 0800 585323 (available 24 hours a day, 7 days a week). 
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What are the other possible disadvantages of taking part? 
The study includes two precise measurements of your kidney function which may involve an 
injection of a small amount of radioactive material. The dose of radioactivity is small (equivalent to 
ten days of natural background radiation or less in the UK) and poses a negligible risk to health. 
Before participating you should check whether doing so will affect any insurance that you have and 
seek advice if necessary.  
For women Irbesartan should not be taken by pregnant or breast-feeding women. The effects of 
LCZ696 on pregnancy and the unborn child and breast-feeding are not known therefore such 
individuals would not be eligible to participate in the study. Women who could become pregnant 
must use effective and reliable methods of contraception1 (listed in the footnote below) during the 
course of this study and for 7 days after the end of the study (i.e. after stopping study treatment).   
If you become pregnant during the trial (or wish to do so), you should tell your study nurse or doctor 
immediately so appropriate action can been discussed. 
What happens when the study stops? 
You and your doctors will be informed of the study results when they become available. LCZ696 does 
not have a license in the UK currently so it will not be available once the study is complete. However 
this study will help design a larger trial of LCZ696 in people with chronic kidney disease which could 
lead to it becoming available. At the end of the study you will go back to any treatment that you 
stopped. Your doctor will advise you about this. 
What if there is a problem? 
If you have any concerns about any possible side-effects of treatment or any complaint about the 
way you have been dealt with during the study, please call the study team on Freefone 0800 585323. 
More detailed information is given in Part 2. 
 
  
                                                          
1
 Highly effective methods of contraception include; injectables, the combined oral contraceptive pill (if taking the 
combined pill, you must have been taking a stable dose for at least 3 months before entering the study), an intrauterine 
device, vasectomised partner, or true sexual abstinence (this does not include periodic abstinence measures such as 
calendar, ovulation, symptothermal or post-ovulation methods). 




When you provisionally agree to take part in the study some of your usual medications may be 
stopped and you will start two study treatments daily.
Basic investigations (blood, urine, blood pressure, height , weight).
EARLY PHASE – 4-7 WEEKS
During this period you will have the chance to try the study treatments out and ensure the 
routine of taking these particular tablets suit you. You will also be asked to undertake a 
voluntary 24 hour urine collection (if you decline this it will not affect your eligibility to 
participate in the study). 
SECOND APPOINTMENT
If you are happy to continue with the study tablets for the duration of the trial, you will receive 
a further supply study medications. 
Blood pressure, blood and urine tests taken.
A precise measurement of your kidney function checked.
2 WEEKS LATER
Blood test only at your GP or Renal clinic to check 
potassium level
FOLLOW-UP APPOINTMENTS
1, 3, 6, 9 and 12 months after second appointment, check ups will take place to monitor blood 
and urine tests and check blood pressure. General health will also be reviewed.
FINAL APPOINTMENT (at 12 months)
General health, blood pressure, blood and urine tests will be re-checked.




Participants stop study medications and study clinic visits. Pre-study usual medications 
maybe started by your doctor. Continued follow-up with renal clinic as planned.
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Part 2: Further details for patients who want them 
What if relevant new information becomes available? 
Sometimes during the course of a research project, new information becomes available about the 
treatments that are being studied. If this happens, your study doctor will tell you about it and discuss 
whether you want to or should continue in the study. If you decide not to carry on, your doctor will 
make the necessary arrangements. On receiving new information your doctor might consider it to be 
in your best interests to stop the study treatments. They will explain the reasons and arrange for 
your care to continue. If the study is stopped for any other reason, you will be told why and your 
continuing care will be arranged. 
What if I don’t want to carry on with the study? 
You are free to withdraw at any time. If you wish to discontinue your study treatment we would 
advise you to do this in consultation with your doctor so they can arrange other suitable treatment. 
We would still like to see you in the study clinic, even if you are not taking the study tablets, so that 
we can ensure the study’s results are as reliable as possible. 
For women Women who could become pregnant must continue to use effective methods of 
contraception for 7 days after stopping study treatment (or  the end of the study.)  
What if there is a problem? 
You retain all the usual rights of an NHS patient. 
 
The University of Oxford has appropriate insurance in place in the unlikely event that you suffer any 
harm as a direct consequence of your participation in this trial. 
 
If you have a concern about any aspect of the study you can speak with the researchers. They can be 
contacted on a 24-hour Freefone number: 0800 585323 or you may contact the University of Oxford 
Clinical Trials and Research Governance (CTRG) office on 01865 572224 or the head of CTRG, email 
ctrg@admin.ox.ac.uk. If you remain unhappy and wish to complain formally, you can do this through 
the NHS Complaints Procedure. Details can be obtained from the Patient Advice and Liaison Service 
at your hospital. 
Will my taking part be kept confidential? 
Yes, absolutely. If you accept this invitation, your basic contact details will be recorded so your first 
appointment can be made (and these details could only be seen by your local research team and 
staff working in the coordinating centre in Oxford). Nurse monitoring staff from the coordinating 
centre in Oxford may occasionally ask your permission to be present during your clinic visit to ensure 
procedures are being properly followed. The coordinating centre will seek information from your 
doctors and from NHS and other central registries about any serious illnesses that may occur. This 
requires your name, date of birth and NHS number. All information received will be used, in 
confidence, only for medical research purposes and for routine regulatory and audit purposes. 
Responsible members of the University of Oxford or the host NHS Trust may be given access to data 
for monitoring and/or audit of the study to ensure we are complying with regulations. Anonymised 
data collected during the study may be sent to Novartis (the company funding the trial). 
 
Blood samples are sent to a laboratory at the University of Oxford for analysis. They are identified by 
a unique number linked in the computer to other study information. In the laboratory they are not 
linked to your name. The information used for scientific analysis will not include any details that 
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identify you. Any information from stored samples will not be provided to you, your doctors, or 
anybody else. In particular, having these samples stored and subsequently tested would not affect 
your ability to obtain insurance. 
What will happen to the results of the research study? 
It is intended to present the results at a major medical conference and publish them in an 
appropriate medical journal. No patient will be individually identified in any report or publication. 
How is this study organised? 
Scientists and doctors consider the questions being asked by UK HARP-III to be important because 
they could improve treatment for people who have chronic kidney disease. Scientists at the 
University of Oxford are coordinating the study with the collaboration of many doctors and nurses 
from around the country. The study design has been reviewed and agreed by independent Research 
Ethics Committee (Nottingham 2 Research Ethics Committee, reference 13/EM/0434). These 
committees check whether the health question being asked is important enough to warrant a study, 
and that the study is being carried out in an independent, honest and professional manner. 
 
An independent committee also watches over the study and keeps an eye on results. This committee 
could stop the study early if important new evidence emerged that had an impact on the need for 
the study to continue.  
 
Independent studies such as UK HARP-III are costly to run. Treatment for the study is provided free 
by Novartis, which also contributes to the cost of running of the study, by a grant to the University of 
Oxford. However, UK HARP-III is conducted independently of Novartis and the study information will 
be collected, analysed and published independently of the source of funding. 
Thank you 
Thank you for your interest in this study. Our aim is to make your participation an interesting and 
worthwhile experience, while helping us and others to improve the treatment of people who have 
chronic kidney disease. 
 
Questions about the study should be directed to the coordinating centre in Oxford  
By phone: 
24-hour Freefone service: 0800 585323 
By post: 
UK HARP-III, Clinical Trial Service Unit (CTSU), Richard Doll Building, University of Oxford, Roosevelt 




Or visit our website: 
www.harp3trial.org 
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Other medications 
 
At each visit the study nurse will check that any other medications you are taking 
are compatible with both LCZ696 and irbesartan. However, it is important that 
any doctor treating you (including your GP) knows that you are taking part in UK 
HARP-III so any prescription they give you will also be compatible. They may call 
Freefone 0800 585323 if they have any queries. 
 
Throughout the study duration, Angiotensin Converting Enzyme (ACE) inhibitors, 
Angiotensin Receptor Blockers (ARBs) and Direct renin inhibitors such as 
aliskiren (Rasilez), should not be taken with your UK HARP-III study treatment at 
any time. Examples of these medications are listed below. 
 
 ACE inhibitors  ARBs 
Lisinopril (Zestril, Carace Plus, 
Zestoretic) 
Losartan potassium (Cozaar, Cozaar-
Comp) 
Ramipril (Tritace, Triapin) Valsartan (Diovan, Co-Diovan, Exforge) 
Perindopril (Coversyl, Coversyl 
Arginine Plus) 
Irbesartan (Aprovel, CoAprovel  
Enalapril (Innovace, Innozide) Candesartan cilexetil (Amias) 
Captopril (Captoten) Telmisartan (Micardis, Micardis Plus) 
Cilazapril (Vascace) Olmesartan (Olmetec, Sevikar, Sevikar 
HCT, Olmetec Plus) 
Fosinopril Eprosartan (Teveten) 
Quinapril (Accupro, Accuretic) Azilsartan (Edarbi) 
Trandolapril (Gopten, Tarka)  
Imidapril hydrochloride (Tanatril)  
Moexipril hydrochloride (Perdix)  
 
Questions about the study treatments may be directed to the coordinating centre 
in Oxford 
UK HARP-III, Clinical Trial Service Unit (CTSU) 
Richard Doll Building, University of Oxford 
Roosevelt Drive, OXFORD, OX3 7LF 
 
Tel: 0800 585323 (Freefone) or +44 (0)1865 765615 (from outside UK) 
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Throughout the study you will be provided with two types of study treatment: 
 Tablets of LCZ696 200 mg or matching placebo (“dummy”) 
 Capsules of irbesartan 150 mg or matching placebo 
Initial Run-in phase 
After your first study visit you will enter the “Run-in phase”. You will be issued 
with a pack of Type F Run-in Treatment containing two bottles of study 
treatment, one labelled as bottle A and one as bottle B. 
i. Bottle A will contain an 8 week supply of tablets of LCZ696 200 mg or 
placebo and will be identified by a blue label. 
ii. Bottle B will contain an 8 week supply of capsules of irbesartan 150 mg or 
placebo and will be identified by a white label. 
Long-term phase 
At your second study visit, if you proceed into the long-term part of the study you 
will be randomly allocated to receive tablets containing either LCZ696 200 mg or 
matching placebo tablets.  If you are allocated active tablets of LCZ696 you will 
also receive placebo irbesartan capsules, and if you are allocated to receive 
placebo tablets of LCZ696 you will then receive active irbesartan capsules. 
 
At your second visit, and your 3, 6 and 9 month visits, you will be issued with a 
pack of Type R Randomised Treatment with two bottles of study treatment 
containing your random allocation, one labelled as bottle X and one as bottle Y. 
i. Bottle X will contain a 3 month supply of tablets of LCZ696 200 mg or 
placebo and will again be identified by a blue label. 
ii. Bottle Y will contain a 3 month supply of capsules of irbesartan 150 mg or 
placebo and will again be identified by a white label. 
This leaflet contains important information relating to your UK HARP-III study 
treatment. Please read all the information contained in this leaflet very carefully. If you 
have any questions about your study treatment, please feel free to call a UK HARP-III 
study nurse or doctor on:  Freefone 0800 585323 
 
Please keep this information leaflet in a safe place for future reference. 














 During the Run-in phase, following your first visit, you should take 1 tablet 
daily from bottle A (LCZ696 or placebo) and 1 capsule daily from bottle B 
(irbesartan or placebo).  
 For the first 2 weeks after your second visit you should take 1 tablet daily 
from bottle X (LCZ696 or placebo) and 1 capsule daily from bottle Y 
(irbesartan or placebo).  
 Your study nurse will have arranged for you to have a blood test done 
towards the end of this 2 week period. This is important so please contact 
your study nurse or the UK HARP-III office if you cannot make this 
appointment. 
 After 2 weeks, you should start taking 1 tablet twice daily from bottle X 
(LCZ696 or placebo) and 2 capsules once daily from bottle Y (irbesartan or 
placebo), unless advised otherwise. 
 
Suggested treatment schedule: 
 
 Morning Evening 
Bottle X (LCZ696 or placebo) 1 tablet 1 tablet 
Bottle Y (Irbesartan or placebo) 2 capsules Nil 
 
 
 If you forget to take either type of tablet or capsule at your usual time, you 
may still take it later the same day. However, if you miss a whole day or 
LCZ696 200 mg or matching placebo tablets 
and 
Irbesartan 150 mg or matching placebo capsules 
 
 Oral use. 
 Do not store above 25°C. 
 Protect from moisture. 
 Keep out of the sight and reach of children. 
 For clinical trial use only. 
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more, do not make up for the missed tablets or capsules. Instead, leave them 
in the bottle and continue from the day you restart. 
 If you think you will reach the end of your bottles before your next clinic visit 
or if you lose your study treatment, please contact your study nurse or call 
the UK HARP-III office and we will arrange for replacement treatment to be 
provided. 
 Please return unused tablets and capsules at each clinic visit. 
 For women: if you become pregnant while taking the study tablets please 
stop them immediately and inform your local study nurse or call Freefone 





Both LCZ696 and irbesartan may cause raised potassium levels in your blood. This 
will not cause symptoms so it is important that you attend your UK HARP-III study 
visits so that this can be checked. Please inform your study nurse or the UK HARP-
III office if you cannot attend your study visit. 
 
Both LCZ696 and irbesartan may lower your blood pressure. If you feel light-
headed or dizzy on standing, please inform your study nurse or the UK HARP-III 
office. We can arrange for you to see your study nurse in the next few days for a 
review if we think it is necessary. 
 
Further information about side effects of LCZ696 is given in the UK HARP-III 
Participant Information Leaflet. If any new information arises during the course 
of the study staff will discuss this with you. Updated information will also be 
available on the study website (www.harp3trial.org). 
 
If you develop any symptoms that you think are related to your study medication, 
please contact your study nurse or call Freefone 0800 585323 for further advice. 
Should any side effect of the study treatment become intolerable for you, you 
would, of course, be free to stop either type of study tablet at any time. 
 
If at any time you develop vomiting or diarrhoea, please temporarily stop all 
study treatment until the symptoms have settled. 
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Possible side effects 
Appendix 6:  
UK HARP-III trial recruitment questionnaire. 
UK HARP-III Recruitment Survey 
 
Site Name or number: 
 
Dear UK HARP-III Nurses, 
 
Many thanks for all your hard work and efforts with recruiting patients for UK HARP-III and getting us across the finish 
line. As you know, in UK HARP-III we were also piloting new methods to recruit patients into the trial.  
 
We recognise that each site has different ways of delivering clinical research and as such not all sites had the 
resources/databases to follow our proposed method of recruitment. However, we would be very grateful if you could 
complete this short feedback form on the methods you used to recruit patients for UK HARP-III, as this would help us plan 
future large-scale trials in nephrology.  
 
Many thanks and best wishes, 
 
The UK HARP-III Team 
 
Identification of eligible participants 
 
What was the principal method you used to identify potentially patients? (tick one) 
 Consultant referral         ☐   
 Manually searching clinic lists         ☐  
 Using an IT search of your unit’s renal database (if you have one)   ☐ 
 Using a search of some other database/spreadsheet of patients attending clinics  ☐  
 Patients self-referring (e.g. from seeing a poster in out-patients)    ☐  
 Other, please specify         ☐ 
            
 
Were there any other methods that you use to identify potentially patients? (tick as many as appropriate) 
 Direct consultant referral        ☐    
 Manually searching clinic lists         ☐  
 Using an IT search of your unit’s renal database (if you have one)    ☐  
 Using a search of some other database/spreadsheet of patients attending clinics  ☐  
 Patients self-referring (e.g. from seeing a poster in out-patients)    ☐  
 Other, please specify         ☐ 
 
 
For all those patients who were potentially eligible, who did the pre-screening to help exclude those patients likely not to 
be eligible? 
 Local study doctor/patients usual nephrologist       ☐ 
 Study nurse          ☐ 






What was the main method by which potentially eligible patients received their UK HARP-III invitation and patient 
information sheet? 
 Provided in clinic by LLI/Study nurse or usual nephrologist    ☐  
 Posted to participant using mail-merge tools provided     ☐ 
 Posted without using mail-merge        ☐  
 Other, please specify          ☐  
 
 
If you used the mail-merging tools provided, did you do this yourself or did you have administrative help to do this? 
 Did it yourself           ☐   
 Administrative and/or clerical support        ☐    




Were you able to contact patients after they received their invitation to participate? 
 Yes            ☐   
 No            ☐  
 
Who made the follow-up phone calls? (tick as many as appropriate) 
 Study nurse          ☐ 
 Admin support          ☐ 
 Local study doctor         ☐ 
 
How easy did you find making the calls and speaking to potentially eligible patients?  
 Very easy           ☐   
 Easy            ☐  
 Neither easy nor difficult        ☐   
 Difficult           ☐    
 Very difficult           ☐    
 
General information on your renal unit 
 
Does your renal unit have an electronic database of all CKD renal patients (not just those on dialysis/transplant)? 
 Yes            ☐    
No            ☐    
      
Approximately how many patients does your renal unit care for:  
With CKD (not on RRT)    
With a transplant 
On dialysis (HD and PD) 
In total  
 






Appendix 7:  
UK HARP-III trial participant reminder card. 
UK HARP-III Coordinating Centre (CTSU) 
Richard Doll Building 
University of Oxford 
Old Road Campus 
Oxford, OX3 7LF 
 
24-hour Freefone: 0800 585323 
e-mail: harp3@ctsu.ox.ac.uk 
Preparation for Final Visit 
Shortly before your final study visit the study 
nurse will arrange for you to have another test 
to measure your kidney function (measured 
GFR).   
This appointment is on  
Date: ___________Time: ________________ 









If you need to change an appointment please 





12 month (final) visit 
 
The appointment for your final visit to the 
study clinic is: 
_______________________________  
On the morning of your appointment please 
collect a sample of the urine you pass first 
thing, and bring it to your appointment in the 
small specimen pot provided. Also, please bring 
back all your study treatment bottles. 
 
If necessary, please make an appointment with 
your GP prior to this visit to ensure you have a 
supply of any tablets you stopped taking when 
you entered the study. Your nurse will advise 
you on this and when to restart them. NB 
please do not restart them before your final 
visit. 
“Remember to contact the study nurse 
if any of your regular medications are 
changed or new tablets are started.” 
UK HARP-III Participant Reminder Card V2.0_2015-05-11 
UK HARP-III 
UK Heart and Renal Protection 
6 and 9 month visits 
On the morning of each of these appointments 
please collect a sample of the urine you pass 
first thing, and bring it to your appointment in 
the small specimen pot provided.  
 
The appointment for your 6 month visit to the 
study clinic is:  
_____________________________________  
The appointment for your 9 month visit to the 
study clinic is:  
_____________________________________  
 
After these study clinic visits if your blood tests 
are satisfactory and you are not experiencing 
any problems you will continue to take one 
tablet from Bottle X twice a day and two 
capsules from Bottle Y once a day.  
What to take to every study visit 
 All bottles of study tablets 
 A list of all your regular medications 
 Sample of urine you pass first thing in the 
morning 
 Details of any illnesses or hospital             
admissions since your last study visit 
After this visit, initially you should take one 
tablet from the Bottle X and one capsule 
from the Bottle Y that have been provided 
today. 
Two weeks after this visit you need to have a 
blood test either at the renal clinic or your GP, 




If the test results are satisfactory you will need 
to start taking the full dose of the study 
tablets: one tablet from Bottle X twice a 
day and two capsules from Bottle Y once a 
day.  
After Screening (1st Visit) 
Your study nurse will have explained to you that 
we would like you to stop taking the following 
blood pressure medication during the study: 
_______________________________________ 
Instead you need to take one tablet from Bottle 
A and one capsule from Bottle B once daily. 
 
If you have agreed to provide a 24-hour urine 
sample this needs to be collected 2 days 
before your next appointment, so start on: 
 
______________________________________ 




It does not matter how much or little urine is 
passed each time, as long as it is all collected. 
Completely empty your bladder first thing in the 
morning and discard that urine, but note the 
time e.g. 06:15. 
For the next 24 hours (during the day and 
night) collect all the urine you pass in the 
container provided. 
At the end of the 24 hours (e.g. the next 
morning at 06:15) you empty your bladder 
collecting that urine too. The collection is now 
complete. You need to take it to your 2nd 
appointment (randomization). 
Measured GFR test 
Shortly before your randomization visit the study 
nurse will arrange for you to have a test to 




The appointment for your randomization 
visit at the study clinic is:  
 
_______________________________________  
On the morning of your appointment please 
collect a sample of the urine you pass first thing, 
and bring it to your appointment in the small 
specimen pot provided.  
1 month visit 
The appointment for 1 month visit to the 
study clinic is:  
_____________________________________  
On the morning of your appointment please 
collect a sample of the urine you pass first 
thing, and bring it to your appointment in the 
small specimen pot provided.  
 
After this study clinic visit if your blood tests 
are satisfactory and you are not experiencing 
any problems you will continue to take one 
tablet from Bottle X twice a day and two 
capsules from Bottle Y once a day.  
3 month visit 
The appointment for your 3 month to the 
study clinic is:  
_____________________________________ 
On the morning of your appointment collect a 
sample of the urine you pass first thing, and 
bring it to your appointment in the small 
specimen pot provided.  
Please do not take your study tablets on 
the morning of this appointment.  
Instead take the tablets to the clinic with you. 
The study nurse will be taking a blood test, 
after which you will be able to take your 
tablets. 
If your blood tests are satisfactory and you are 
not experiencing any problems the study nurse 
will issue you with a new supply of tablets and 
collect the first set of bottles.  You will 
continue to take  one tablet from Bottle X 
twice a day and two capsules from Bottle Y 
once a day. 
Appendix 8:  
UK HARP-III trial study participation card. 







UK HARP-III PPC V3.0_2015-05-11 
This patient is participating in UK HARP-III. This involves 
taking either LCZ696 200mg (an angiotensin receptor-
neprilysin inhibitor) twice daily and placebo irbesartan once 
daily, or placebo LCZ696 twice daily and active irbesartan 150-
300mg, once daily. Participation in the study will be for about 
13 months. The study started in 2014. 
 
Enquiries to: UK HARP-III Coordinating Centre (CTSU) 
Richard Doll Building, University of Oxford, 
Old Road Campus, Oxford, OX3 7LF 
24-hour Freefone: 0800 585323 
UK HARP-III 
UK Heart and Renal Protection III 
UK HARP-III 
UK Heart and Renal Protection III 
Appendix 9:  
UK HARP-III trial approvals (Ethics, MHRA, ARSAC). 
 
NRES Committee East Midlands - Nottingham 2 
The Old Chapel 




Telephone:   
Facsimile:  
05 December 2013 
 
Dr Richard Haynes 
Clinical Research Fellow 
Clinical Trial Service Unit, Oxford University 
CTSU, Richard Doll Building, Old Road Campus 




Dear Dr Haynes, 
 
Study title: Randomized multicentre pilot study of LCZ696 versus 
irbesartan in patients with chronic kidney disease: UK 
Heart and Renal Protection (HARP)-III 
REC reference: 13/EM/0434 
Protocol number: CTSUHARP3 
EudraCT number: 2013-004205-89 
IRAS project ID: 135727 
 
The Research Ethics Committee reviewed the above application at the meeting held on 25 
November 2013. Thank you for attending to discuss the application.  
 
We plan to publish your research summary wording for the above study on the NRES website, 
together with your contact details, unless you expressly withhold permission to do so. 
Publication will be no earlier than three months from the date of this favourable opinion letter. 
Should you wish to provide a substitute contact point, require further information, or wish to 





The chair introduced himself and the committee and thanked the researchers for attending the 
meeting 
  
The committee asked the researchers if participants call for advice who is the named contact 
person for participants to contact as the Patient Information Sheet, does not provide a named 
contact. The researchers advised that the generic contact number links to a core of advisors 
who will have a basic knowledge of the trial and the procedures. They will be in a position to 
provide support to participants if required. The Chief Investigator will be available to support if 
necessary  
 
The committee advised the researchers that the process for the wash out needs to be made 
clearer to participants within the Participant Information Sheet. The researchers advised that 
participants will be requested to stop any current ACE inhibitors, angiotensin receptor blockers 
or direct renin inhibitor therapy. Once the participant has gone through the wash out period then 
placebo drugs are given to try out for a period of four to seven weeks. The committee queried if 
participants would be at risk during this process and the researchers advised that only the blood 
pressure may be of concern.  Consequently regular blood pressure measurements will be 
taken and an alternative blood pressure drug could be given 
  
The committee asked the researcher if other organisations would be reviewing the participants 
data as reflected in section A36 in the IRAS application form. The researchers advised that data 
will be shared but participants data will not be identified  
 
The committee discussed the need for the Consent Form to request permission to inform the 
GP. The researchers advised that due to the nature of the trial then the GP would be informed 
and the section on the Consent Form enables the research team to confirm that they have 
discussed with the participant that the GP will be kept up to date 
  
The committee asked the researcher who will be sending the invitation letter out to potential 
participants. The researchers advised that the letter will be send from either the participants GP 
or from their local health trust and that the local investigator will be a signatory on the letter  
 
The committee discussed with the researcher the option of using a reply slip. The researchers 
acknowledged that this was a good idea but advised the committee that they did not have a 
postage budget so are unable to offer this service  
 
The committee praised the researchers for the Participant Information Sheet which was felt to 
be well written in lay terms and very readable. 
 
The members of the Committee present gave a favourable ethical opinion of the above research 
on the basis described in the application form, protocol and supporting documentation, subject 
to the conditions specified below. 
 
Ethical review of research sites 
 
Non NHS sites 
 
The Committee has not yet been notified of the outcome of any site-specific assessment (SSA) 
for the non-NHS research site(s) taking part in this study. The favourable opinion does not 
therefore apply to any non-NHS site at present. I will write to you again as soon as one 
Research Ethics Committee has notified the outcome of a SSA. In the meantime no study 
procedures should be initiated at non-NHS sites. 
 
Conditions of the favourable opinion 
 




The Participant Information Sheet  
 
1. Insert PALS contact details to include the Invitation letter  
2. Page 2, “what will happen to me if I take part” 3rd paragraph, change the sentence to 
read, “This will allow you and the UK HARPIII doctors and nurses to be sure the routine 
of taking these particular tablets suits you” 
3. Study Timetable – Early Phase, insert – “During this period you have the chance to try 




You should notify the REC in writing once all conditions have been met (except for site 
approvals from host organisations) and provide copies of any revised documentation 
with updated version numbers. The REC will acknowledge receipt and provide a final list 
of the approved documentation for the study, which can be made available to host 
organisations to facilitate their permission for the study. Failure to provide the final 
versions to the REC may cause delay in obtaining permissions.  
 
Management permission or approval must be obtained from each host organisation prior to the 
start of the study at the site concerned. 
 
Management permission (“R&D approval”) should be sought from all NHS organisations 
involved in the study in accordance with NHS research governance arrangements. 
 
Guidance on applying for NHS permission for research is available in the Integrated Research 
Application System or at http://www.rdforum.nhs.uk.   
 
Where a NHS organisation’s role in the study is limited to identifying and referring potential 
participants to research sites (“participant identification centre”), guidance should be sought 
from the R&D office on the information it requires to give permission for this activity. 
 
For non-NHS sites, site management permission should be obtained in accordance with the 
procedures of the relevant host organisation.  
 
Sponsors are not required to notify the Committee of approvals from host organisations 
 
Registration of Clinical Trials 
 
All clinical trials (defined as the first four categories on the IRAS filter page) must be registered 
on a publically accessible database within 6 weeks of recruitment of the first participant (for 
medical device studies, within the timeline determined by the current registration and publication 
trees).   
 
There is no requirement to separately notify the REC but you should do so at the earliest 
opportunity e.g when submitting an amendment.  We will audit the registration details as part of 
the annual progress reporting process. 
 
To ensure transparency in research, we strongly recommend that all research is registered but 
for non clinical trials this is not currently mandatory. 
 
If a sponsor wishes to contest the need for registration they should contact Catherine Blewett 
( ), the HRA does not, however, expect exceptions to be made. 
Guidance on where to register is provided within IRAS. 
 
Clinical trial authorisation must be obtained from the Medicines and Healthcare products 
Regulatory Agency (MHRA). 
 
The sponsor is asked to provide the Committee with a copy of the notice from the MHRA, either 




It is responsibility of the sponsor to ensure that all the conditions are complied with 




The documents reviewed and approved at the meeting were: 
  
Document    Version    Date    
Advertisement  1.0  28 October 2013  
Covering Letter    05 November 2013  
Evidence of insurance or indemnity    01 August 2013  
GP/Consultant Information Sheets    28 October 2013  
Investigator CV    02 October 2013  
Investigator's Brochure  11  13 March 2012  
Letter from Sponsor    05 November 2013  
Letter of invitation to participant  1.0  28 October 2013  
Other: Summary of Product Characteristics - Irbesartan 
(Approvel)  
  14 August 2013  
Participant Consent Form  1.0  28 October 2013  
Participant Information Sheet  1.0  28 October 2013  
Protocol  1.0  28 October 2013  
REC application  135727/521797/1/3
26  
04 November 2013  
Sample Diary/Patient Card  1.0  28 October 2013  
 
Membership of the Committee 
 
The members of the Ethics Committee who were present at the meeting are listed on the 
attached sheet. 
 
Statement of compliance  
 
This Committee is recognised by the United Kingdom Ethics Committee Authority under the 
Medicines for Human Use (Clinical Trials) Regulations 2004, and is authorised to carry out the 
ethical review of clinical trials of investigational medicinal products. 
 
The Committee is fully compliant with the Regulations as they relate to ethics committees and 
the conditions and principles of good clinical practice. 
 
The Committee is constituted in accordance with the Governance Arrangements for Research 
Ethics Committees and complies fully with the Standard Operating Procedures for Research 
Ethics Committees in the UK. 
 




The attached document “After ethical review – guidance for researchers” gives detailed 
guidance on reporting requirements for studies with a favourable opinion, including: 
 
 Notifying substantial amendments 
 Adding new sites and investigators 
 Notification of serious breaches of the protocol 
 Progress and safety reports 
 Notifying the end of the study 
 
The NRES website also provides guidance on these topics, which is updated in the light of 




You are invited to give your view of the service that you have received from the National 
Research Ethics Service and the application procedure.  If you wish to make your views known 
please use the feedback form available on the website. 
 
Further information is available at National Research Ethics Service website > After Review 
 
13/EM/0434 Please quote this number on all correspondence 
 
We are pleased to welcome researchers and R & D staff at our NRES committee members’ 
training days – see details at http://www.hra.nhs.uk/hra-training/  
 






Dr Martin Hewitt 
Chair 
 





List of names and professions of members who were present at the 
meeting and those who submitted written comments 




Copy to: Ms Heather House 
 
NRES Committee East Midlands - Nottingham 2 
 
Attendance at Committee meeting on 25 November 2013 
 
  
Committee Members:  
 
Name   Profession   Present    Notes    
Ms Gill Bumphrey  Clinical Trials Pharmacist  Yes    
Miss Shamim Byrne  Gynaecologist/Obstetrici
an  
Yes    
Dr Frances Game  Consultant Physician  No    
Dr Martin Hewitt (Chair) Consultant Paediatric 
Oncologist  
Yes    
Dr Asam Latif  Research Pharmacist  No    
Mrs Veronica Lyon  Lay member  Yes    
Dr Simon Roe  Consultant Nephrologist  Yes    
Dr John Shaw  Lay Member  Yes    
Miss Catherine Shenton  Lay Member   Yes    
Mrs Sally Ann Smith  Retired Audit Manager  Yes    
Ms Margret Vince  Translator  Yes    
  
Also in attendance:  
 
Name   Position (or reason for attending)   







NRES Committee East Midlands - Nottingham 2 
The Old Chapel 




Telephone:  0115 8839697 
17 December 2013 
 
Dr Richard Haynes 
Clinical Research Fellow 
Clinical Trial Service Unit, Oxford University 
CTSU, Richard Doll Building, Old Road Campus 




Dear Dr Haynes, 
 
Study title: Randomized multicentre pilot study of LCZ696 versus 
irbesartan in patients with chronic kidney disease: UK Heart 
and Renal Protection (HARP)-III 
REC reference: 13/EM/0434 
Protocol number: CTSUHARP3 
EudraCT number: 2013-004205-89 
IRAS project ID: 135727 
 
Thank you for your letter of 16th December 2013.  I can confirm the REC has received the 
documents listed below and that these comply with the approval conditions detailed in our letter 




The documents received were as follows: 
  
Document    Version    Date    




The final list of approved documentation for the study is therefore as follows: 
  
Document    Version    Date    
Advertisement  1.0  28 October 2013  
Covering Letter    05 November 2013  
Evidence of insurance or indemnity    01 August 2013  
GP/Consultant Information Sheets    28 October 2013  
Investigator CV    02 October 2013  
Investigator's Brochure  11  13 March 2012  
Letter from Sponsor    05 November 2013  
Letter of invitation to participant  1.0  28 October 2013  
Other: Summary of Product Characteristics - Irbesartan 
(Approval)  
  14 August 2013  
Participant Consent Form  1.0  28 October 2013  
Participant Information Sheet  1.1  09 December 2013  
Protocol  1.0  28 October 2013  
REC application  135727/521797/1/326  04 November 2013  
Sample Diary/Patient Card  1.0  28 October 2013  
 
You should ensure that the sponsor has a copy of the final documentation for the study.  It is 
the sponsor's responsibility to ensure that the documentation is made available to R&D offices 
at all participating sites. 
 







E-mail:  NRESCommittee.EastMidlands-Nottingham2@nhs.net 
 
 





From: ARSAC  
Sent: 03 January 2014 08:23 
To: ctrg@admin.ox.ac.uk 
Cc: EAST MIDLANDS - NOTTINGHAM 2 (NRESCommittee.eastmidlands-nottingham2@nhs.net) 
Subject: ARSAC PRA approval - IRAS ID 135727, REC Ref 13/EM/0434 
  
I am writing regarding your Preliminary Research Assessment (PRA) form date 04 11 13 entitled: 
Randomized multicentre pilot study of LCZ696 versus irbesartan in patients with chronic kidney disease: UK Heart 
and Renal Protection (HARP)-III 
This has been approved by the ARSAC and certificate(s) for this study will be issued following receipt of complete 
applications from the site(s) involved.  
If you should have any queries, then please do not hesitate to contact me at this email address, quoting the IRAS ID 
on all correspondence. 
Yours sincerely 
Elaine Gilder 
ARSAC Support Unit 
Centre for Radiation, Chemical and Environmental Hazards 
Public Health England 
Chilton, Didcot, Oxfordshire OX11 0RQ 
arsac@phe.gov.uk 





The information contained in the EMail and any attachments is confidential and intended solely and for 
the attention and use of the named addressee(s). It may not be disclosed to any other person without the 
express authority of Public Health England, or the intended recipient, or both. If you are not the intended 
recipient, you must not disclose, copy, distribute or retain this message or any part of it. This footnote also 
confirms that this EMail has been swept for computer viruses by Symantec.Cloud, but please re-sweep any 
attachments before opening or saving. http://www.gov.uk/PHE 
************************************************************************** 
Appendix 10:  
UK HARP-III trial main results publication and Supplementary data: 
Haynes R, Judge PK, Staplin N, Herrington WG, Storey BC, Bethel A, Bowman L, 
Brunskill N, Cockwell P, Hill M, Kalra PA, McMurray JJV, Taal M, Wheeler DC, 
Landray MJ, Baigent C. Effects of Sacubitril/Valsartan Versus Irbesartan in Patients 
With Chronic Kidney Disease. Circulation 2018;138(15):1505-1514. 
Circulation. 2018;138:1505–1514. DOI: 10.1161/CIRCULATIONAHA.118.034818 October 9, 2018 1505
Key Words: chronic kidney disease  
◼ neprilysin inhibition ◼ renin-angiotensin 
system
Sources of Funding, see page 1513
Editorial, see p 1515
BACKGROUND: Sacubitril/valsartan reduces the risk of cardiovascular mortality 
among patients with heart failure with reduced ejection fraction, but its effects 
on kidney function and cardiac biomarkers in people with moderate to severe 
chronic kidney disease are unknown.
METHODS: The UK HARP-III trial (United Kingdom Heart and Renal 
Protection-III), a randomized double-blind trial, included 414 participants with 
an estimated glomerular filtration rate (GFR) 20 to 60 mL/min/1.73 m2 who were 
randomly assigned to sacubitril/valsartan 97/103 mg twice daily versus irbesartan 
300 mg once daily. The primary outcome was measured GFR at 12 months 
using ANCOVA with adjustment for each individual’s baseline measured GFR. All 
analyses were by intention to treat. 
RESULTS: In total, 207 participants were assigned to sacubitril/valsartan and 
207 to irbesartan. Baseline measured GFR was 34.0 (SE, 0.8) and 34.7 (SE, 
0.8) mL/min/1.73 m2, respectively. At 12 months, there was no difference 
in measured GFR: 29.8 (SE 0.5) among those assigned sacubitril/valsartan 
versus 29.9 (SE, 0.5) mL/min/1.73 m2 among those assigned irbesartan; 
difference, ‒0.1 (0.7) mL/min/1.73 m2. Effects were similar in all prespecified 
subgroups. There was also no significant difference in estimated GFR at 3, 6, 
9, or 12 months and no clear difference in urinary albumin:creatinine ratio 
between treatment arms (study average difference, ‒9%; 95% CI, ‒18 to 1). 
However, compared with irbesartan, allocation to sacubitril/valsartan reduced 
study average systolic and diastolic blood pressure by 5.4 (95% CI, 3.4–7.4) 
and 2.1 (95% CI, 1.0–3.3) mm Hg and levels of troponin I and N terminal of 
prohormone brain natriuretic peptide (tertiary end points) by 16% (95% CI, 
8–23) and 18% (95% CI, 11–25), respectively. The incidence of serious adverse 
events (29.5% versus 28.5%; rate ratio, 1.07; 95% CI, 0.75–1.53), nonserious 
adverse reactions (36.7% versus 28.0%; rate ratio, 1.35; 95% CI, 0.96–1.90), 
and potassium ≥5.5 mmol/L (32% versus 24%, P=0.10) was not significantly 
different between randomized groups.
CONCLUSIONS: Over 12 months, sacubitril/valsartan has similar effects on 
kidney function and albuminuria to irbesartan, but it has the additional effect of 
lowering blood pressure and cardiac biomarkers in people with chronic kidney 
disease.
CLINICAL TRIAL REGISTRATION: URL: http://www.isrctn.com. Unique identifier: 
ISRCTN11958993.
© 2018 The Authors. Circulation is 
published on behalf of the American 
Heart Association, Inc., by Wolters 
Kluwer Health, Inc. This is an open 
access article under the terms of the 
Creative Commons Attribution Non-
Commercial License, which permits 
use, distribution, and reproduction in 
any medium, provided that the original 
work is properly cited and is not used 
for commercial purposes.
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Patients with chronic kidney disease (CKD) are at increased risk of both progression to end-stage renal disease and cardiovascular events compared 
with patients with normal kidney function.1–3 Random-
ized controlled trials have shown that renin-angiotensin 
system (RAS) inhibitors slow the progression of dia-
betic and nondiabetic proteinuric CKD,4–7 and lower-
ing low-density lipoprotein cholesterol reduces the risk 
of atherosclerotic vascular events.8 However, despite 
such treatments, a significant risk of progression to 
end-stage renal disease and cardiovascular events re-
mains. In particular, patients with CKD are at increased 
risk of events related to structural heart disease (such 
as heart failure and arrhythmias), with many dying of 
cardiovascular disease before they reach end-stage re-
nal disease.9
Natriuretic peptides have a range of potentially 
beneficial effects, including natriuresis, diuresis, vaso-
dilatation, and inhibition of RAS.10,11 Neprilysin (NEP 
or neutral endopeptidase) is the key enzyme respon-
sible for degrading natriuretic peptides and other va-
soactive peptides, such as angiotensin II, bradykinin, 
endothelin, and substance P.10,12 Although inhibition 
of NEP (NEPi) raises concentrations of circulating na-
triuretic peptides, it also leads to reflex RAS activation 
and inhibits angiotensin II breakdown, counteracting 
any potentially beneficial effects, so NEPi must be 
combined with RAS inhibition. Combinations of NEPi 
and angiotensin-converting enzyme inhibitors are as-
sociated with a high risk of angioedema (because of 
excessive inhibition of bradykinin degradation),13 so 
the chosen method of RAS inhibition for use with 
NEPi is an angiotensin receptor blocker. Sacubitril/
valsartan, which combines an angiotensin receptor 
blocker (valsartan) with a NEPi (sacubitril), was the 
first angiotensin receptor–neprilysin inhibitor to be 
developed.
The PARADIGM-HF trial (Prospective Comparison of 
an Angiotensin Receptor–Neprilysin Inhibitor With An-
giotensin-Converting Enzyme Inhibitors to Determine 
Impact on Global Mortality and Morbidity in Heart Fail-
ure) showed that sacubitril/valsartan reduced the risk of 
cardiovascular mortality among patients with heart fail-
ure with reduced ejection fraction when compared with 
the angiotensin-converting enzyme inhibitor enalapril 
(hazard ratio, 0.80; 95% CI, 0.71–0.89).14 Several trials 
in populations with heart failure, including PARADIGM-
HF, suggest that sacubitril/valsartan slows the decline in 
kidney function compared with RAS inhibition alone, 
but that it slightly increased albuminuria.15–17 Animal 
studies have shown that combining NEP and RAS inhi-
bition can reduce proteinuria and histological evidence 
of kidney damage.18–21 The UK HARP-III trial (United 
Kingdom Heart and Renal Protection-III) aimed to com-
pare the effects of sacubitril/valsartan versus irbesartan 
(a licensed angiotensin receptor blocker for diabetic ne-
phropathy) on kidney function and other outcomes in 
people with CKD.
METHODS
Trial Design and Participants
The data, analytic methods, and study materials will be made 
available to other researchers for purposes of reproducing the 
results from the Richard Doll Centenary Archive according to 
the Nuffield Department for Population Health’s Data Sharing 
Policy.22 Details of the UK HARP-III trial objectives, design, and 
methods have been reported previously.23 Ethical (Nottingham 
Research Ethics Committee 2 [13/EM/0434]) and regulatory 
approvals were obtained before the enrollment of any study 
participants. Participants ≥18 years of age were eligible to 
participate if they had CKD with either (1) an estimated glo-
merular filtration rate (eGFR) of ≥45 and <60 mL/min/1.73 m2 
and a urine albumin:creatinine ratio (uACR) >20 mg/mmol 
(177 mg/g), or (2) an eGFR of ≥20 and <45 mL/min/1.73 m2 
(regardless of uACR).
Potentially eligible participants attended a screening visit 
at which medical history and eligibility criteria were checked, 
written informed consent was obtained, and blood and urine 
samples were taken for local laboratory analysis. Any current 
RAS inhibitor was stopped, and the participant entered the 4- 
to 7-week single-blind prerandomization run-in phase, during 
which they took 1 placebo sacubitril/valsartan tablet and 1 
placebo irbesartan capsule daily. The aims of the run-in phase 
were to (1) enable a washout of any angiotensin-converting 
enzyme inhibitors before introduction of NEPi (to reduce the 
risk of angioedema), (2) allow a comparison of the acute 
effects of the study treatments on eGFR, and (3) identify and 
exclude those less likely to adhere to study treatment and 
Clinical Perspective
What Is New?
• The UK HARP-III trial (United Kingdom Heart and 
Renal Protection-III) has demonstrated that, in a 
wide range of people with proteinuric chronic kid-
ney disease, adding neprilysin inhibition to angio-
tensin II receptor blockade has no additional effect 
on kidney function or albuminuria compared with 
irbesartan.
• The tolerability and safety profiles of the 2 treat-
ments were not different. However, compared with 
irbesartan, sacubitril/valsartan further reduces both 
blood pressure and biomarkers of cardiovascular 
risk (troponin I and N-terminal pro-B-type natri-
uretic peptide).
What Are the Clinical Implications?
• UK HARP-III raises the hypothesis that sacubitril/
valsartan could be an acceptable treatment to 
reduce cardiovascular risk in people with chronic 
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trial procedures before randomization to maintain statistical 
sensitivity.24,25
Randomization and Masking
At the end of the run-in period, glomerular filtration rate 
(GFR) was measured, and willing and eligible participants 
were randomized 1:1 to sacubitril/valsartan or irbesartan 
by an internet-based system with minimized randomization 
(which helped ensure balance for categories of age, sex, sys-
tolic blood pressure, previous diabetes mellitus, eGFR, and 
uACR).23 Treatment allocation was concealed, so investigators, 
clinicians, and patients had no foreknowledge of the upcom-
ing treatment allocation.26 A double-dummy approach was 
used to ensure participants and study staff remained blind 
to treatment allocation: participants were issued 2 bottles of 
study treatments, 1 containing sacubitril/valsartan 97/103 mg 
or placebo tablets and the other containing irbesartan 150 
mg or placebo capsules.27
Procedures
After randomization, participants were initially instructed 
to take 1 tablet and 1 capsule daily of study treatment (ie, 
either sacubitril/valsartan 97/103 mg or irbesartan 150 mg); 
this dosage was increased to sacubitril/valsartan 97/103 mg 
twice daily or irbesartan 300 mg once daily after 2 weeks 
unless potassium or change in kidney function precluded 
a dose increase. Study visits were scheduled at 1, 3, 6, 9, 
and 12 months after randomization (and additional visits 
arranged where necessary to monitor participant safety). 
At each follow-up, study staff sought information on all 
serious adverse events and any nonserious adverse events 
considered with reasonable probability to be related to 
study treatment. Compliance with study treatments was 
assessed by self-report, and blood pressure and weight were 
measured at every visit. Blood and urine samples were col-
lected at every study visit for local analysis of creatinine, 
potassium, liver function tests (bilirubin, liver transaminase, 
and alkaline phosphatase), and uACR. Central laboratory 
assays of creatinine, uACR, and cardiac biomarkers (tropo-
nin I and NT-proBNP [N-terminal pro-B-type natriuretic pep-
tide]) were conducted at randomization, 6 months, and 12 
months. Additionally, participants were advised not to take 
their morning dose of study treatment on the day of their 
3-month visit so that creatinine, uACR, and trough blood lev-
els of sacubitril, sacubitrilat (the primary metabolite of sacu-
bitril), and valsartan could be collected. GFR was measured 
at or just before the 12-month visit, and paper results of all 
GFR measurements were sent to the coordinating center for 
verification blind to treatment allocation. If participants were 
unwilling or no longer able to attend follow-up visits, infor-
mation was obtained by telephone or from relatives or care-
givers wherever possible. The original protocol specified that 
360 participants would be followed for 6 months; before the 
completion of recruitment (and blind to any interim results), 
the steering committee decided to extend follow-up to 12 
months (because of results from other trials suggesting that 
the effect on kidney function may take ≥9 months to fully 
emerge) and to increase the sample size to ≥400 participants 
(to increase the statistical power).
Laboratory Methods
GFR was measured in the study centers using 51Cr-EDTA, 99mTc-
DTPA (diethylenetriaminepentaacetic acid), or iohexol methods 
depending on local practice (with each center using the same 
method at baseline and 12 months). Creatinine was assayed in 
the central laboratory on a Beckman Coulter AU680 analyzer 
using a kinetic alkaline picrate method and calibrated using 
material traceable to isotope dilution mass spectrometry (using 
the National Institute of Standards and Technology Standard 
Reference Material 967); troponin I was measured by immuno-
assay on an Architect system and NT-proBNP by immunoassay 
on an Elecsys system.
Statistical Analysis
The primary outcome was measured GFR (mGFR), and 
ANCOVA was used to compare mean mGFR at 12 months 
between patients allocated sacubitril/valsartan and irbesar-
tan patients, with adjustment for each individual’s baseline 
mGFR.28 Assuming a between-person SD in mGFR of 15 mL/
min/1.73 m2 and a correlation between an individual’s base-
line and follow-up mGFR of 0.8, randomization of 400 par-
ticipants would provide ≥80% power (at P=0.05) to detect a 
difference in mGFR at the final follow-up (adjusted for base-
line values) of 3 mL/min/1.73 m2, even if 15% of participants 
discontinued allocated study treatment.
All analyses were performed according to the intention-
to-treat principle among all randomized participants.29,30 
Comparisons of continuous outcomes were performed using 
ANCOVA adjusted for each participant’s baseline value, after 
appropriate transformation if required. Multiple imputation 
methods were used to account for missing data.31 Time-to-event 
analyses used log-rank methods to calculate event rate ratios, 
95% CIs, and associated 2-sided P values.29,30 Pharmacokinetic 
analyses involved multiple linear regression of each sacubitril/
valsartan metabolite against a number of prespecified baseline 
variables, adjusted for time since the last dose of sacubitril/
valsartan. The primary pharmacokinetic analysis restricted the 
dataset to those participants assigned sacubitril/valsartan who 
had last taken the drug 10 to 16 hours before the sample being 
collected. Further details (including secondary and tertiary out-
comes) are available in the prespecified data analysis plan.23 
Analyses were done using SAS version 9.3 (SAS Institute) and R 
version 3.3.3 (www.R-Project.org).
RESULTS
Between November 1, 2014, and January 31, 2016, 
620 participants attended screening visits, and 566 
(91%) entered the prerandomization run-in (Figure 1). 
In total, 414 participants were randomized: 207 to sa-
cubitril/valsartan and 207 to irbesartan. The mean age 
was 62.8 years (SD, 13.7), 298 (72%) were male, and 
the mean blood pressure was 146/81 mm Hg (Table 1). 
Mean eGFR at baseline was 35.5 (10.9) mL/min/1.73 
m2, and the median uACR was 54 (interquartile range, 
11–153) mg/mmol (Table 1).
By 12 months, similar proportions of participants 
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of those assigned sacubitril/valsartan and 34 [16%] of 
those assigned irbesartan), and the reasons for stop-
ping full dose study treatment were similar. There was 
no excess of discontinuations because of serious ad-
verse events, nonserious adverse reactions, or other 
reasons in those allocated sacubitril/valsartan (Table I in 
the online-only Data Supplement).
At 12 months, the mean (SE) mGFR was 29.8 (0.5) 
mL/min/1.73 m2 among those assigned to the sacu-
bitril/valsartan group compared with 29.9 (0.5) mL/
min/1.7 3m2 among those assigned irbesartan, a 
nonsignificant difference of 0.1 (0.7) mL/min/1.73 m2 
(P=0.86) (Table  2). Neither a prespecified complete 
case analysis (ie, without imputation: difference ‒0.4 
[0.7] mL/min/1.73 m2) nor an “on-treatment” analysis 
(difference ‒0.5 [0.7] mL/min/1.73 m2) materially af-
fected this finding. There was no evidence that the dif-
ference between sacubitril/valsartan and irbesartan in 
effect on mGFR differed by age (χ1
2=0.45, P=0.50), sex 
(χ1
2=0.70, P=0.4), baseline mGFR (χ1
2=0.42, P=0.52), 
baseline uACR (χ1
2=0.76, P=0.38), cause of kidney 
disease (χ6
2=2.24, P=0.90), or any other prespecified 
baseline characteristic (Figure I in the online-only Data 
Supplement).
Compared with irbesartan, allocation to sacubitril/
valsartan was not associated with any significant ef-
fect on eGFR at any time point (Figure  2). The rate 
of change in eGFR did not differ significantly be-
tween arms, whether measured from randomization 
to 12 months, from randomization to 3 months, or 
from 3 to 12 months (Table II in the online-only Data 
Supplement).
Allocation to sacubitril/valsartan produced a non-
significant 9% (‒18% to 1%, P=0.08) reduction in 
study-average uACR (Table  3) and was associated 
with a reduction in blood pressure compared with 
irbesartan. Overall, the mean systolic blood pressure 
was 5.4 (95% CI, ‒7.4 to ‒3.4) mm Hg lower, and 
the mean diastolic blood pressure was 2.1 (95% CI, 
‒3.3 to ‒1.0) mm Hg lower among those allocated to 
sacubitril/valsartan (Table 3). Exploratory analyses did 
not show any differences in the intensity of nonstudy 
antihypertensive agents between the treatment arms 
during follow-up.
Figure 1. Flow of participants. 
*Participants could report >1 reason. †Duration 
of the trial was increased from 6 to 12 months, 
and 9 participants did not consent to this exten-
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Allocation to sacubitril/valsartan was associated with 
significant reductions in levels of cardiac biomarkers 
compared with irbesartan. Study average NT-proBNP 
concentrations were 18% (‒25 to ‒11%) lower and tro-
ponin I levels were 16% (‒23% to ‒8%) lower among 
participants assigned sacubitril/valsartan (Table 3).
Using data from 87 participants who had taken 
their last dose of sacubitril/valsartan 10 to 16 hours 
previously, no significant determinants of sacubitril 
or valsartan concentration were identified (Table III 
in the online-only Data Supplement). However, kid-
ney function was a major determinant of sacubitrilat 
  No 34 (16%) 41 (20%)
CKD-EPI estimated glomerular filtration rate at randomization, mL/min/1.73 m2
  Mean (SD) 35.4 (11.0) 35.5 (11.0)
  <30 79 (38%) 77 (37%)
  ≥30 to <45 86 (42%) 91 (44%)
  ≥45 41 (20%) 39 (19%)
  Not available 1 0
Urine albumin:creatinine ratio at randomization, mg/mmol
  Geometric mean (≈SE) 34 (5) 34 (5)
  Median (IQR) 52 (11–162) 56 (11–146)
  <3 30 (14%) 28 (14%)
  ≥3 to <30 43 (21%) 45 (22%)
  ≥30 134 (65%) 134 (65%)
Cause of kidney disease
  Glomerular disease 60 (29%) 51 (25%)
  Tubulointerstitial disease* 18 (9%) 32 (15%)
  Diabetic kidney disease† 36 (17%) 47 (23%)
  Hypertensive/renovascular 
disease†
18 (9%) 24 (12%)
  Other systemic diseases 
affecting the kidneys†
1 (0%) 2 (1%)
  Familial/hereditary 
nephropathies
30 (14%) 13 (6%)
  Other known causes‡ 5 (2%) 4 (2%)
  Unknown‡ 39 (19%) 34 (16%)
24-h urinary sodium excretion during run-in, mg/24 h
  Geometric mean (≈SE) 2245 (183) 2585 (187)
  Median (IQR) 2484 (1794–3795) 2875 (1932–
4232)
  Not available 100 110
Values are n (%), mean (SD), geometric mean (≈SE), or median (IQR). CKD-EPI 
indicates Chronic Kidney Disease Epidemiology Collaboration; ERA-EDTA, European 
Renal Association-European Dialysis and Transplant Association; IQR, interquartile 
range; LDL, low-density lipoprotein; and RAS, renin–angiotensin system. 
*Includes obstructive renal diseases. 
†All considered systemic diseases affecting the kidney by the ERA-EDTA 
registry. 













Age at randomization, y
  Mean age (SD) 62.0 (14.1) 63.6 (13.4)
  <50 37 (18%) 36 (17%)
  ≥50 to <70 97 (47%) 99 (48%)
  ≥70 73 (35%) 72 (35%)
Sex
  Male 148 (71%) 150 (72%)
  Female 59 (29%) 57 (28%)
Ethnicity
  White 186 (90%) 191 (92%)
  Black 3 (1%) 4 (2%)
  South Asian 11 (5%) 7 (3%)
  Other 7 (3%) 5 (2%)
Self-reported prior disease
  Coronary heart disease 21 (10%) 33 (16%)
  Cerebrovascular disease 16 (8%) 15 (7%)
  Peripheral vascular disease 22 (11%) 22 (11%)
  Heart failure 8 (4%) 7 (3%)
  Diabetes mellitus 81 (39%) 83 (40%)
Systolic blood pressure at randomization (mm Hg)
  Mean systolic blood pressure (SD) 146 (16) 146 (16)
  <140 76 (37%) 85 (41%)
  ≥140 to <160 93 (45%) 84 (41%)
  ≥160 38 (18%) 38 (18%)
Diastolic blood pressure at randomization (mm Hg)
  Mean diastolic blood pressure 
(SD)
81 (11) 80 (11)
  <80 96 (46%) 105 (51%)
  ≥80 to <90 68 (33%) 58 (28%)
  ≥90 43 (21%) 44 (21%)
Body mass index, kg/m2
  Mean body mass index (SD) 30 (6) 31 (6)
  <25 35 (17%) 33 (16%)
  ≥25 to <30 74 (36%) 73 (35%)
  ≥30 95 (46%) 100 (48%)
  Not available 3 1
Medication
  Antiplatelet therapy 64 (31%) 75 (36%)
  Oral anticoagulant 13 (6%) 15 (7%)
  Diuretic 79 (38%) 85 (41%)
  Calcium channel blocker 104 (50%) 103 (50%)
  β-Blocker 50 (24%) 62 (30%)
  α-Blocker 58 (28%) 55 (27%)
  LDL-lowering agent 126 (61%) 137 (66%)
Use of RAS blockade at screening visit
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concentration, with each 10 mL/min lower mGFR be-
ing associated with a 1485 (572–2397) ng/mL higher 
sacubitrilat concentration (Table III in the online-only 
Data Supplement).
Allocation to sacubitril/valsartan had no significant 
effect on fatal serious adverse events (1 [0.5%] versus 
1 [0.5%]) or on any nonfatal serious adverse events (61 
[29.5%] versus 59 [28.5%]; rate ratio, 1.07; 95% CI, 
0.75–1.53; P=0.70) (Table IV in the online-only Data 
Supplement). One case of angioedema occurred in a 
participant allocated sacubitril/valsartan, but the partici-
pant did not attend hospital or require any specific treat-
ment. There was no difference overall in the number 
of nonserious adverse reactions (76 [36.7%] versus 58 
[28.0%]; rate ratio, 1.35; 95% CI, 0.96–1.90; P=0.08) 
(Table IV in the online-only Data Supplement). Alloca-
tion to sacubitril/valsartan was associated with higher 
rates of nonserious hypotension (17 [8.2%] versus 7 
[3.4%]; rate ratio, 2.36; 95% CI, 1.06–5.26; P=0.04). 
There was no difference between treatments in the 
number of participants experiencing hyperkalemia (66 
[32%] versus 50 [24%], P=0.10) or in the proportion 
experiencing a significant decline in eGFR (defined as 
≥25% reduction; 71 [34%] versus 67 [32%], P=0.75) 
(Table 4). There were no cases of significant liver injury.
DISCUSSION
The UK HARP-III trial has shown that, compared with 
irbesartan, 12 months of treatment with sacubitril/
valsartan did not significantly affect kidney function in 
people with CKD. Sacubitril/valsartan had no additional 
effect on albuminuria compared with irbesartan and 
was as well tolerated, with no major safety concerns 
identified. Sacubitril/valsartan was also found to reduce 
blood pressure and biomarkers of cardiovascular risk 
(troponin I and NT-proBNP) compared with irbesartan.
The kidney function results from the UK HARP-III 
trial do not confirm findings from the analyses of kid-
ney disease progression outcomes from other NEPi 
trials among patients with heart failure. In a trial 
among patients with heart failure with preserved 
ejection fraction, kidney function declined more 
slowly with sacubitril/valsartan compared with valsar-
tan.15 In the large PARADIGM-HF trial, a marginally 
Table 2. Effect of Allocation to Sacubitril/Valsartan Versus Irbesartan 
on Measured Glomerular Filtration Rate at 12 Months
Follow-Up 
Visit








Randomization 34.0 (0.8) 34.7 (0.8)   
12 mo 29.8 (0.5) 29.9 (0.5) –0.1 (0.7) 0.86
Where the difference between mGFR and central eGFR at the corresponding 
time point was more extreme than the first or 99th percentile of the distribution 
of differences, the value of mGFR was set to missing. Ten missing mGFR values 
at randomization had eGFR values at randomization imputed, and 41 missing 
mGFR values at 12 mo were imputed with the use of multiple imputation. For 
the 2 patients who commenced chronic dialysis during the study, a value of 
0 was imputed for their 12-mo mGFR. eGFR indicates estimated glomerular 
filtration rate; and mGFR, measured glomerular filtration rate.
*Values are absolute differences in arithmetic means (SE). The 12-mo 
estimates and P values were derived from ANCOVA with adjustment for the 
randomization value.
Figure 2. Effect of allocation to sacubitril/
valsartan versus irbesartan on estimated 
glomerular filtration rate (eGFR). 
Creatinine measured in the central laboratory 
except for 1- and 9-month visits when creati-
nine was measured in the local laboratory. Error 




 http://ahajournals.org by on N
ovem
ber 21, 2019
Haynes et al Effects of Sacubitril/Valsartan in Chronic Kidney Disease
Circulation. 2018;138:1505–1514. DOI: 10.1161/CIRCULATIONAHA.118.034818 October 9, 2018 1511
ORIGINAL RESEARCH 
ARTICLE
slower decline in eGFR was also observed with sacu-
bitril/valsartan compared with enalapril (‒1.3 [95% 
CI, ‒1.2 to ‒1.4] versus ‒1.8 [95% CI, ‒1.8 to ‒1.7] 
mL/min/1.73 m2 per year; P<0.0001).16 The lack of 
any additional effect of sacubitril/valsartan on kidney 
function in the UK HARP-III trial may reflect differing 
determinants of kidney disease progression in a pro-
teinuric CKD population compared with heart failure 
populations. If cardiac function is a more important 
determinant of kidney function in a heart failure 
population than in proteinuric CKD, then a treatment 
that improves cardiac function, such as sacubitril/val-
sartan, might be more likely to affect kidney function 
in a heart failure population.
Studies using animal models of established kidney 
disease have found that combinations of NEP and 
Table 3. Effect of Allocation to Sacubitril/Valsartan Versus Irbesartan on Urinary Albumin:Creatinine Ratio, 
Systolic and Diastolic Blood Pressure, and Cardiac Biomarkers
Follow-Up Visit
Mean (SE)*
Difference in Means 
(95% CI)† P Value
Sacubitril/ 
Valsartan (n=207) Irbesartan (n=207)
Urinary albumin:creatinine ratio, mg/mmol
  Randomization 34.1 (4.6) 33.9 (4.5)   
  3 mo 17.0 (1.0) 17.8 (1.0) ‒4% (‒19 to 12)  
  6 mo 15.6 (1.0) 18.4 (1.1) ‒15% (‒28 to 0)  
  12 mo 16.4 (1.2) 17.6 (1.3) ‒6% (‒23 to 14)  
  Study average 16.3 (0.6) 17.9 (0.7) ‒9% (‒18 to 1) 0.08
Systolic blood pressure, mm Hg
  Randomization 146 (1.1) 146 (1.1)   
  1 mo 129 (1.1) 132 (1.1) ‒3.5 (‒6.5 to ‒0.6)  
  3 mo 129 (1.1) 137 (1.1) ‒7.3 (‒10.3 to ‒4.3)  
  6 mo 128 (1.1) 135 (1.1) ‒6.9 (‒10.0 to ‒3.7)  
  9 mo 130 (1.2) 134 (1.2) ‒4.0 (‒7.3 to ‒0.8)  
  12 mo 128 (2.5) 133 (2.2) ‒4.4 (‒10.9 to 2.1)  
  Study average 129 (0.8) 134 (0.7) ‒5.4 (‒7.4 to ‒3.4) <0.001
Diastolic blood pressure, mm Hg
  Randomization 81 (0.8) 80 (0.8)   
  1 mo 73 (0.6) 74 (0.6) ‒0.8 (‒2.5 to 0.9)  
  3 mo 73 (0.6) 76 (0.6) ‒2.6 (‒4.3 to ‒0.9)  
  6 mo 72 (0.6) 75 (0.6) ‒2.5 (‒4.2 to ‒0.8)  
  9 mo 73 (0.6) 74 (0.6) ‒1.8 (‒3.6 to ‒0.1)  
  12 mo 72 (1.6) 75 (1.3) ‒2.2 (‒6.2 to 1.9)  
  Study average 73 (0.5) 75 (0.4) ‒2.1 (‒3.3 to ‒1.0) <0.001
N-terminal pro-B-type natriuretic peptide, ng/L
  Randomization 254.5 (22) 250.9 (22)   
  6 mo 175.6 (7.2) 219.7 (8.9) ‒20% (‒29 to ‒11)  
  12 mo 210.2 (11) 247.5 (12) ‒15% (‒26 to ‒2)  
  Study average 188.7 (6.0) 230.4 (7.3) ‒18% (‒25 to ‒11) <0.001
Troponin I, ng/L
  Randomization 7.3 (0.5) 7.5 (0.5)   
  6 mo 5.4 (0.2) 6.6 (0.2) ‒19% (‒27 to ‒10)  
  12 mo 6.3 (0.4) 7.1 (0.4) ‒11% (‒24 to 4)  
  Study average 5.7 (0.2) 6.8 (0.2) ‒16% (‒23 to ‒8) <0.001
Any missing data were imputed with the use of multiple imputation. 
*Geometric means (≈SE) are presented for urinary albumin:creatinine ratio and cardiac biomarkers, and arithmetic means 
(SE) are presented for blood pressure. 
†Values are percentage changes in geometric means (95% CI) for urinary albumin:creatinine ratio and cardiac biomarkers, 
and absolute differences in arithmetic means (95% CI) for blood pressure. The estimates and P values at each follow-up visit 
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RAS inhibition are not associated with significant dif-
ferences in GFR compared with isolated RAS inhibi-
tion.18,19,21,32 However, histology results from these ani-
mals demonstrated that combined NEP/RAS inhibition 
was associated with greater reductions in histological 
markers of CKD progression (glomerulosclerosis and 
tubulointerstitial fibrosis), compared with isolated RAS 
inhibition.12,18–20 It should be noted that the largest de-
cline in eGFR was observed during the first month, 
likely attributable to the known glomerular hemody-
namic effects of RAS inhibition. In the remaining 11 
months of observation, eGFR decline was slow in both 
groups, implying that a longer observation period may 
have been necessary to observe the full effect on kid-
ney function.
Allocation to sacubitril/valsartan did not increase al-
buminuria, in contrast with trials among patients with 
heart failure, among whom sacubitril/valsartan causes 
statistically significant (but clinically modest) increases 
in albuminuria (from a much lower baseline).15 If similar 
increases in albuminuria had developed in people with 
proteinuric CKD, this would have been of concern be-
cause albuminuria is associated with an increased risk 
of progression to end-stage renal disease (although 
whether this association is directly causal remains un-
certain).33–35 Nonetheless, the lack of effect on albu-
minuria despite the observed blood pressure difference 
raises the possibility that the effect on systemic blood 
pressure does not lead to a reduction in intraglomerular 
pressure.
Sacubitril/valsartan lowered blood pressure com-
pared with irbesartan. Similar additional reductions 
in blood pressure compared with RAS inhibition have 
been shown in populations with heart failure or hy-
pertension.14,36–39 These differences were observed in 
the context of a median of 1 other antihypertensive 
medication being used in addition to study treatment 
in both groups. It remains uncertain whether lowering 
blood pressure reduces the rate of progression of kid-
ney disease,40,41 but there is strong evidence that it re-
duces the risk of cardiovascular events.41 Patients with 
CKD are at increased risk of cardiovascular events.42 
Indeed, most patients with CKD are at higher risk of 
cardiovascular mortality than progression to end-
stage kidney disease (ie, dialysis or transplantation).9 
As kidney function declines, the nature of cardiovas-
cular disease changes from a typical atherosclerotic 
phenotype to one of structural heart disease, which 
becomes increasingly prevalent such that 80% of pa-
tients starting dialysis have evidence of it.43,44 The find-
ing that NT-proBNP (an indicator of cardiac wall stress 
and not a substrate of neprilysin) and troponin levels 
(a marker of cardiomyocyte necrosis) were both lower 
among participants assigned sacubitril/valsartan com-
pared with irbesartan has also been observed among 
patients with heart failure.39,45,46 Recent animal data 
also demonstrated that sacubitril/valsartan attenuates 
cardiac hypertrophy and fibrosis in an animal model of 
CKD.47 These findings raise the hypothesis that sacubi-
tril/valsartan may have cardiovascular benefits among 
patients with advanced CKD and provides a rationale 
for a clinical outcome trial.
Sacubitril/valsartan was generally well tolerated, 
and no major hazards were observed; although there 
were numerically more nonserious adverse reactions in 
the sacubitril/valsartan group, this difference was not 
statistically significant. These randomized comparisons 
follow a placebo run-in during which 152/566 (26%) 
of participants withdrew, mostly for nonmedical rea-
sons.23 Compared with those allocated to irbesartan, 
participants allocated sacubitril/valsartan reported more 
symptoms of hypotension, which is expected given its 
larger blood pressure-lowering effect. Because kidney 
function is a major determinant of sacubitrilat concen-
tration, it is possible that higher concentrations of sa-
cubitrilat in this population contributed to this excess 
in hypotension. Both treatments had similar effects on 
the incidence of hyperkalemia, and no cases of signifi-
cant liver injury were observed despite high blood con-
centrations of sacubitrilat resulting from reduced renal 
excretion. One participant allocated sacubitril/valsartan 
developed angioedema but did not require medical in-
tervention, and it resolved spontaneously.
Study limitations include the short duration of fol-
low-up and the sample size, which was not sufficiently 
large to test the effect of sacubitril/valsartan on clini-
cal outcomes. The choice of comparator (irbesartan) 
also might have an effect on the interpretation of 
the results because it has a different pharmacological 
profile from valsartan and may provide more intense 
angiotensin receptor blockade.48 This would suggest 
that the additional BP reduction and effects on cardiac 
biomarkers are an underestimate of the effect of ne-
prilysin inhibition.
Table 4. Effect of Allocation to Sacubitril/Valsartan Versus Irbesartan 







  ≥5.5 to <6.0 44 (21%) 38 (18%)  
  ≥6.0 to <6.5 20 (10%) 7 (3%)  
  ≥6.5 2 (1%) 5 (2%)  
Total: Any potassium 
≥5.5 mmol/L
66 (32%) 50 (24%) 0.10
Estimated glomerular filtration rate
  ≥25% reduction in 
CKD-EPI eGFR*
71 (34%) 67 (32%) 0.75
Based on local laboratory measurements. CKD-EPI indicates Chronic 
kidney Disease Epidemiology Collaboration; and eGFR, estimated glomerular 
filtration rate.
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In conclusion, over 12 months in people with CKD, the 
combination of sacubitril and valsartan is well tolerated 
and has similar effects on kidney function and albumin-
uria to irbesartan, but it has additional blood pressure– 
and cardiac biomarker–lowering effects.
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Supplementary Table 1:  Reasons for completely stopping randomized treatment, overall and by
different types of adverse events
Reason for stopping Sacubitril/valsartan (n=207) Irbesartan (n=207) p-value
Serious adverse event
Angiooedema 1 (0%) 0 (0%)
Hyperkalaemia 0 (0%) 1 (0%)
Acute kidney injury 1 (0%) 1 (0%)
Gastrointestinal disorders 1 (0%) 0 (0%)
Infections and infestations 1 (0%) 0 (0%)
Pregnancy, puerperium and perinatal conditions 0 (0%) 1 (0%)
Renal and urinary disorders 0 (0%) 1 (0%)
Respiratory, thoracic and mediastinal disorders 0 (0%) 1 (0%)
Surgical and medical procedures 0 (0%) 2 (1%)
Subtotal: Any serious adverse event 4 (2%) 7 (3%) 0.54
Non-serious adverse reaction
Hypotensive disorder 2 (1%) 2 (1%)
Hyperkalaemia 4 (2%) 0 (0%)
Acute kidney injury 1 (0%) 3 (1%)
Abnormal liver function test 0 (0%) 0 (0%)
Cardiac disorders 0 (0%) 1 (0%)
Gastrointestinal disorders 3 (1%) 1 (0%)
General disorders and administration site conditions 1 (0%) 2 (1%)
Metabolism and nutrition disorders 1 (0%) 0 (0%)
Musculoskeletal and connective tissue disorders 1 (0%) 0 (0%)
Nervous system disorder 3 (1%) 2 (1%)
Respiratory, thoracic and mediastinal disorders 0 (0%) 1 (0%)
Skin and subcutaneous tissue disorders 2 (1%) 0 (0%)
Subtotal: Any non-serious adverse reaction 18 (9%) 12 (6%) 0.34
Other reason
Unable to attend clinic 2 (1%) 1 (0%)
Concerns about tablets 0 (0%) 1 (0%)
Doctor advice 3 (1%) 4 (2%)
Withdrew consent 5 (2%) 6 (3%)
Participants wishes 1 (0%) 2 (1%)
Subtotal: Any other reason 11 (5%) 15 (7%) 0.54
Total: stopped for any reason 33 (16%) 34 (16%) 1.00
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Supplementary Table 2: Effect of allocation to sacubitril/valsartan versus irebsartan on rate of
change in estimated glomerular filtration rate
Time period
No. with
value* Sacubitril/valsartan (n=207) Irbesartan (n=207) p value
Randomisation to 12 months 409 -0.22 (0.03) -0.25 (0.03) 0.42
Randomisation to 3 months 410 -0.68 (0.12) -0.61 (0.10) 0.63
3 months to 12 months 409 -0.11 (0.05) -0.16 (0.04) 0.44
CKD-EPI=Chronic kidney disease Epidemiology Collaboration. eGFR=estimated glomerular filtration rate. Central creatinine measurements were only available at randomisation, 3,
6 and 12 months so local creatinine measurements were used at 1 and 9 months, after correction for the mean bias observed between local and central creatinine values. *Missing
values of eGFR were imputed with the use of multiple imputation and participants with the most poorly fitting slopes (defined as participants with the mean deviation from their own
fitted slope in the top 1% of the distribution [of mean deviations across all participants]) were excluded.
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(95% CI) p value
Absolute change in
ng/mL (95% CI) p value
Percentage change
(95% CI) p value
Age, per decade higher 22% (1 to 48%) 0.04 889 (-30 to 1808) 0.06 14% (-2 to 33%) 0.09
Race* 0.78 0.71 0.22
Black -60% (-95 to 252%) -4856 (-15440 to 5729) -63% (-94 to 112%)
Other -44% (-89 to 175%) 539 (-7208 to 8286) 5% (-71 to 276%)
South Asian 7% (-71 to 297%) 1947 (-3684 to 7578) -59% (-84 to 5%)
Sex† -25% (-67 to 71%) 0.48 -4413 (-8444 to -381) 0.03 -37% (-67 to 23%) 0.18
Body surface area, per 0.1 m² higher -32% (-64 to 31%) 0.25 -3327 (-6500 to -154) 0.04 -23% (-54 to 31%) 0.34
Weight, per 5 kg higher 20% (-20 to 78%) 0.37 1915 (-25 to 3854) 0.05 13% (-18 to 56%) 0.44
mGFR (unadjusted for BSA), per 10 mL/min/1.73m² lower -17% (-32 to 1%) 0.06 1485 (572 to 2397) 0.002 -3% (-17 to 13%) 0.65
Log albumin:creatinine ratio, per 5-fold increase -7% (-24 to 13%) 0.44 -622 (-1590 to 346) 0.21 -14% (-27 to 1%) 0.07
mGFR=measured glomerular filtration rate. BSA=body surface area. Models adjusted for all characteristics shown in table and additionally for time since last dose. *White ethnicity used as reference category. Race was not prespecified for inclusion in the
models. †Males used as reference category. Values for sacubitril and valsartan were log tranformed due to skewed distributions.
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Supplementary Table 4: Effect of allocation to sacubitril/valsartan versus irbesartan on serious






(95% CI) p value
Any fatal serious adverse event 1 (0.5%) 1 (0.5%)
Non-fatal serious adverse events
Angiooedema 1 (0.5%) 0 (0.0%)
Hypotension 1 (0.5%) 1 (0.5%)
Dialysis 2 (1.0%) 3 (1.4%)
Other non-fatal SAEs (by MedDRA System, Organ, Class [SOC] category)
Respiratory, thoracic and mediastinal disorders 6 (2.9%) 6 (2.9%)
Infection and infestations 16 (7.7%) 15 (7.2%)
Blood and lymphatics system 2 (1.0%) 2 (1.0%)
Cardiac disorders 6 (2.9%) 5 (2.4%)
Gastrointestinal disorders 5 (2.4%) 6 (2.9%)
Metabolism and nutrition disorders
Diabetes/glucose 3 (1.4%) 1 (0.5%)
Other metabolism/nutrition 7 (3.4%) 6 (2.9%)
Cancer 4 (1.9%) 5 (2.4%)
Neoplasms benign, malignant and unspecified (incl. cysts and polyps) 2 (1.0%) 3 (1.4%)
Nervous system disorders 3 (1.4%) 3 (1.4%)
Renal and urinary disorders 10 (4.8%) 5 (2.4%)
Other medical 30 (14.5%) 29 (14.0%)
Investigations 8 (3.9%) 13 (6.3%)
Surgical and medical procedures (excluding dialysis) 18 (8.7%) 14 (6.8%)
Miscellaneous medical* 13 (6.3%) 8 (3.9%)
Non-medical (including trauma) 7 (3.4%) 5 (2.4%)
Total: Any non-fatal serious adverse event 61 (29.5%) 59 (28.5%) 1.07 (0.75-1.53) 0.70
Total: Any serious adverse event 61 (29.5%) 59 (28.5%) 1.07 (0.75-1.53) 0.70
Non-serious adverse reactions
Hypotension 17 (8.2%) 7 (3.4%) 2.36 (1.06-5.26) 0.04
Hyperkalaemia 6 (2.9%) 1 (0.5%) 4.23 (0.96-18.61) 0.06
Acute kidney injury 3 (1.4%) 6 (2.9%) 0.51 (0.14-1.90) 0.32
Other NSAR (by MedDRA System, Organ, Class [SOC] category)
Respiratory, thoracic and mediastinal disorders 4 (1.9%) 4 (1.9%)
Gastrointestinal disorders 18 (8.7%) 10 (4.8%)
Metabolism and nutrition disorders (excluding hyperkalaemia) 3 (1.4%) 1 (0.5%)
Musculoskeletal and connective tissue disorders 6 (2.9%) 5 (2.4%)
Nervous system disorders 20 (9.7%) 18 (8.7%)
Renal and urinary disorders (excluding acute kidney injury) 2 (1.0%) 2 (1.0%)
Reproductive system and breast disorders 2 (1.0%) 3 (1.4%)
Skin and subcutaneous tissue disorders (excluding angiooedema) 18 (8.7%) 6 (2.9%)
Other medical 6 (2.9%) 7 (3.4%)
Investigations 3 (1.4%) 1 (0.5%)
Miscellaneous medical** 8 (3.9%) 12 (5.8%)
Total: Any non-serious adverse reaction*** 76 (36.7%) 58 (28.0%) 1.35 (0.96-1.90) 0.08
SAE=serious adverse event. NSAR=non-serious adverse reaction. *Made up of SOC categories: Ear disorders, Endocrine disorders, Eye disorders, Hepatobiliary disorders,
Immune system disorders, Musculoskeletal and connectivetissue disorders, Psychriatric disorders, Reproductive system and breast disorders, Skin and subcutaneous tissue
disorders (excluding angiooedema), Vascular disorders (excluding hypotension), Congenital, familialand genetic disorders, General disorders and administration site conditions, and
Pregnancy, puerperium and perinatal conditions. **Made up of SOC categories: Infection and infestations, Blood and lymphatics system,Cardiac disorders, Ear disorders,
Endocrine disorders, Eye disorders, Hepatobiliary disorders, Immune system disorders, Cancer, Neoplasms benign, malignant and unspecified (incl. cysts and polyps),
Psychriatricdisorders, Skin and subcutaneous tissue disorders (excluding angiooedema), Vascular disorders (excluding hypotension), Surgical and medical procedures, Congenital,
familial and genetic disorders, General disordersand administration site conditions, and Pregnancy, puerperium and perinatal conditions. ***Excluding angioodema.
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Supplementary figure 1: Effect of allocation to sacubitril/valsartan on measured
glomerular filtration rate at 12 months in different types of participants




Sacubitril/valsartan better Irbesartan better
Age (χ1
2 = 0.45; p=0.50)
≤60 years 29.9 (0.8) 29.5 (0.8) 0.5 (−1.7 to 2.7)
>60 years 29.7 (0.6) 30.2 (0.6) −0.4 (−2.0 to 1.2)
Sex (χ1
2 = 0.70; p=0.40)
Male 29.6 (0.5) 30.1 (0.5) −0.5 (−2.0 to 1.0)
Female 30.3 (0.9) 29.5 (0.9) 0.8 (−1.7 to 3.3)
Prior diabetes ( χ1
2 = 0.10; p=0.76)
Yes 29.2 (0.8) 29.1 (0.7) 0.1 (−2.0 to 2.2)
No 30.2 (0.6) 30.5 (0.6) −0.3 (−1.9 to 1.3)
Prior vascular disease ( χ1
2 = 0.15; p=0.69)
Yes 29.0 (1.0) 29.6 (0.8) −0.6 (−3.1 to 1.9)
No 30.1 (0.5) 30.1 (0.5) 0.0 (−1.5 to 1.5)
Systolic blood pressure ( χ1
2 = 0.16; p=0.69)
≤140 mmHg 30.5 (0.8) 30.9 (0.7) −0.4 (−2.4 to 1.7)
>140 mmHg 29.4 (0.6) 29.3 (0.6) 0.2 (−1.5 to 1.8)
Diastolic blood pressure ( χ1
2 = 1.29; p=0.26)
≤80 mmHg 29.1 (0.7) 30.0 (0.6) −0.9 (−2.7 to 1.0)
>80 mmHg 30.5 (0.6) 29.8 (0.7) 0.6 (−1.2 to 2.4)
Body mass index ( χ1
2 = 0.00; p=0.99)
≤30 kg/m2 30.1 (0.6) 30.2 (0.6) −0.1 (−1.9 to 1.7)
>30 kg/m2 29.8 (0.7) 29.9 (0.7) −0.1 (−2.0 to 1.8)
Baseline mGFR ( χ1
2 = 0.42; p=0.52)
≤30 mL/min/1.73m2 22.4 (0.7) 22.0 (0.7) 0.4 (−1.5 to 2.3)
>30 mL/min/1.73m2 35.1 (0.6) 35.5 (0.6) −0.5 (−2.2 to 1.3)
Baseline uACR ( χ1
2 = 0.76; p=0.38)
≤30 mg/mmol 29.1 (0.8) 30.0 (0.8) −0.9 (−3.1 to 1.4)
>30 mg/mmol 30.3 (0.6) 29.9 (0.6) 0.3 (−1.3 to 2.0)
Baseline 24 hour urinary sodium excretion ( χ1
2 = 0.76; p=0.38)
≤2680 mg/24 hours 29.9 (0.8) 31.0 (1.0) −1.1 (−3.6 to 1.3)
>2680 mg/24 hours 31.8 (0.9) 31.5 (0.9) 0.4 (−2.0 to 2.8)
Use of RAS blockade at screening ( χ1
2 = 2.09; p=0.15)
Yes 30.0 (0.5) 29.7 (0.5) 0.3 (−1.1 to 1.7)
No 28.8 (1.2) 30.9 (1.0) −2.2 (−5.2 to 0.9)
Cause of kidney disease ( χ1
2 = 2.24; p=0.90)
Glomerular disease 30.3 (0.9) 30.8 (0.9) −0.4 (−2.9 to 2.0)
Tubulointerstitial disease* 28.6 (1.6) 29.7 (1.2) −1.1 (−5.0 to 2.8)
Diabetic kidney disease† 28.1 (1.1) 27.6 (0.9) 0.5 (−2.4 to 3.4)
Hypertensive/renovascular disease† 31.0 (1.6) 31.5 (1.4) −0.5 (−4.6 to 3.6)
Familial/hereditary nephropathies 28.5 (1.2) 31.0 (1.9) −2.4 (−6.9 to 2.0)
Other known causes‡§ 32.6 (2.8) 29.8 (2.6) 2.8 (−4.7 to 10.3)
Unknown‡ 31.2 (1.1) 30.7 (1.1) 0.5 (−2.6 to 3.6)
All participants 29.8 (0.5) 29.9 (0.5) −0.1 (−1.4 to 1.2)
mGFR = measured glomerular filtration rate. uACR=urinary albumin:creatinine ratio. RAS=renin−angiotensin system. *Includes obstructive renal diseases.
†All considered 'Systemic diseases affecting the kidney' by the ERA−EDTA registry. ‡All considered 'Miscellaneous renal disorders' by the ERA−EDTA
registry.§Includes other systemic kidney diseases.
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ABSTRACT
Despite current practice, patients with chronic kidney
disease (CKD) are at increased risk of progression to end-
stage renal disease and cardiovascular events. Neprilysin in-
hibition (NEPi) is a new therapeutic strategy with potential
to improve outcomes for patients with CKD. NEPi enhances
the activity of natriuretic peptide systems leading to natri-
uresis, diuresis and inhibition of the renin–angiotensin
system (RAS), which could act as a potentially beneficial
counter-regulatory system in states of RAS activation such as
chronic heart failure (HF) and CKD. Early NEPi drugs were
combined with angiotensin-converting enzyme inhibitors
but were associated with unacceptable rates of angioedema
and, therefore, withdrawn. However, one such agent (oma-
patrilat) showed promise of NEP/RAS inhibition in treating
CKD in animal models, producing greater reductions in pro-
teinuria, glomerulosclerosis and tubulointerstitial fibrosis
compared with isolated RAS inhibition. A new class of drug
called angiotensin receptor neprilysin inhibitor (ARNi) has
been developed. One such drug, LCZ696, has shown sub-
stantial benefits in trials in hypertension and HF. In CKD,
HF is common due to a range of mechanisms including
hypertension and structural heart disease (including left ven-
tricular hypertrophy), suggesting that ARNi could benefit pa-
tients with CKD by both retarding the progression of CKD
(hence delaying the need for renal replacement therapy) and
reducing the risk of cardiovascular disease. LCZ696 is now
being studied in a CKD population.
Keywords: cardiovascular disease, chronic kidney disease,
heart failure, hypertension, neprilysin inhibition
INTRODUCTION
Patients with chronic kidney disease (CKD) face many
hazards including increased risk of progression to end-stage
renal disease (ESRD) and premature mortality from cardiovas-
cular disease (CVD) [1, 2]. Whereas a minority of patients
with CKD will reach ESRD, CVD is much more common. A
variety of processes contribute to this excess risk including
atherosclerosis, arteriosclerosis, hypertension, sympathetic
hyperactivity and structural heart disease [including left ven-
tricular (LV) hypertrophy], which may manifest clinically as
heart failure (HF) [2]. As CKD progresses, the contribution of
atherosclerosis becomes proportionally smaller and arterio-
sclerosis and structural heart disease predominate, potentially
explaining the high incidence of sudden cardiac death in pa-
tients with advanced CKD [2]. The similarities in the mani-
festation of CVD observed in patients with advanced CKD
and that in patients with HF raises the hypothesis that treat-
ments proven to be effective in the HF population may also be
beneficial in patients with advanced CKD. However, such pa-
tients have not been studied in randomized cardiological trials.
Randomized trials have shown that renin–angiotensin sys-
tem (RAS) inhibitors [RASi; angiotensin-converting enzyme in-
hibitors (ACEi) and angiotensin receptor blockers (ARB)] reduce
the risk of ESRD in patients with diabetic and non-diabetic protei-
nuric CKD [3–6]. In the general population, RASi reduce cardio-
vascular events, and meta-analyses suggest that the mechanism of
this benefit is not simply blood pressure (BP) reduction [7, 8].
However, trials of RASi in patients with advanced CKD have not
shown benefits on cardiovascular outcomes, although this may be
because they were not large enough to do so [9].
Although dual ACEi/ARB therapy reduces albuminuria
more than either agent alone, trials have shown that this does
not translate into either cardiovascular benefit or additional© The Author 2014. Published by Oxford University Press on behalf of ERA-
EDTA. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/4.0/),
which permits unrestricted reuse, distribution, and reproduction in any medium,
provided the original work is properly cited.
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renal protection [10–13]. Indeed, in those trials, dual therapy
was associated with increased risk of adverse effects including
hyperkalaemia and acute kidney injury [11–13]. Similar out-
comes were observed when RASi was combined with a direct
renin inhibitor (aliskiren) as an alternative approach to dual
RASi [14].
The lack of benefit associated with dual RAS blockade high-
lights the need for new therapeutic strategies in CKD. The
natriuretic peptide (NP) system is a neurohormonal system
that counter-regulates the RAS. Therefore, enhancing the ac-
tivity of NPs may be beneficial in states of RAS activation,
such as cardiovascular and kidney disease.
NP SYSTEM AND NEPRILYSIN
NPs are a family of three peptides that include atrial, brain and
c-type NPs (ANP, BNP and CNP, respectively) [15]. ANP and
BNP are predominantly synthesized and released from cardiac
myocytes in response to atrial stretch due to raised venous
pressure. ANP precursor expression in the kidney produces a
subtype called urodilatin from distal tubular cells, whereas CNP
is predominantly expressed in endothelial cells [15, 16]. All
three NPs are formed as pre-pro-peptides and undergo several
cleavage steps to form active peptides. NPs exert physiological
effects via NP receptors (NPRs). ANP and BNP act via NPR-A
(guanylate cyclase-A) and CNP via NPR-B (guanylate cyclase-
B) [17]. These receptors are coupled to cyclic guanosine mono-
phosphate (cGMP)-dependent signalling (Figure 1) [15–17].
ANP and BNP have a range of renal and cardiovascular
effects contributing to natriuresis, diuresis and BP regulation
[16, 17]. CNP is a vasoactive peptide with marked cardiovas-
cular effects but minimal renal actions [16, 17]. Both ANP and
urodilatin regulate renal sodium and water excretion by
inhibition of angiotensin II- and aldosterone-dependent
sodium and water reabsorption and inhibition of antidiuretic
hormone [17]. Natriuresis results from afferent arteriolar vaso-
dilatation and efferent arteriolar vasoconstriction, increasing
renal vascular resistance and glomerular filtration. ANP also
causes relaxation of mesangial cells, further increasing the capil-
lary surface area for filtration and hence diuresis [18]. In add-
ition, ANP inhibits endothelin production, proliferation of
smooth muscle cells and myocardial hypertrophy [17, 18].
Animal models lacking the proANP gene develop salt-
sensitive hypertension [19]. Gene delivery of ANP to mice with
salt-sensitive hypertension reduces BP, cardiac hypertrophy,
stroke and renal injury [20, 21]. Recently, two single nucleotide
polymorphisms rs5068 and rs1938358 in the ANP and BNP
genes have been found to be associated with both increased
levels of NT-proANP and NT-proBNP, respectively, and with
lower BP and an improved metabolic profile [22]. These genetic
data suggest that augmenting NP concentrations could lead to
improved clinical outcomes.
Neprilysin
Neprilysin [also known as neutral endopeptidase (NEP)] is
the key enzyme responsible for degradation of NPs [17]. NEP
is a membrane-bound zinc-containing metalloproteinase with
widespread tissue distribution including the brain, vascular
endothelial cells, smooth muscle cells, cardiac myocytes and
neutrophils, but has greatest abundance in the brush border of
proximal renal tubular cells [16, 23]. NEP is also responsible
for processing and catabolism of a range of other vasoactive
peptides including bradykinin, substance P, angiotensin II and
endothelin [23].
The broad range of potential therapeutic actions of NPs led
to development of agents that inhibit NEP. Neprilysin inhib-
ition (NEPi) results in potent natriuresis and vasodilation; in




















the kidney, this vasodilatory effect reduces intraglomerular
pressure and proteinuria [24, 25]. Chronic isolated NEPi does
not translate into clinically meaningful BP reductions as NEPi
impairs breakdown of angiotensin II and any BP effects are
offset by up-regulation of RAS and sympathetic nervous
system activity. The beneficial renal and cardiovascular effects
of NEPi are enhanced when combined with RASi and this has
led to development of dual NEPi/RASi [16].
DUAL NEPi /ACE i (VASOPEPTIDASE
INHIBITORS)
Dual NEPi/ACEi are also known as vasopeptidase inhibitors
(VPIs). Many compounds have been produced and trialled in
humans (Table 1). Omapatrilat was the most studied VPI.
Omapatrilat was well tolerated in studies of healthy volun-
teers among whom it significantly increased urinary excretion
of ANP and cGMP (i.e. markers of NEPi). Omapatrilat also
produced potent ACE inhibition with decreased levels of
angiotensin II and reduced systemic BP. Renal effects of oma-
patrilat included marked increases in renal blood flow without
associated change in glomerular filtration rate (GFR) and de-
creased filtration fraction. This haemodynamic profile could
translate into renal protection and slower progression of CKD,
as discussed further below [24, 25].
VPIs and angioedema
Despite the promising cardiorenal and neurohormonal
findings seen with VPIs, omapatrilat was associated with
excess rates of angioedema. In 723 patients with CVD, omapa-
trilat reduced BP but six cases of angioedema occurred [26]. In
the Omapatrilat Cardiovascular Treatment versus Enalapril
(OCTAVE) trial, angioedema occurred with greater severity
and frequency with omapatrilat than enalapril [274/12 609
(2.17%) versus 86/12 557 (0.68%); relative risk 3.17; 95% confi-
dence interval (95% CI) 2.52–4.12; P < 0.005] [27]. Two of the
participants experienced airway compromise, one of whom re-
quired mechanical ventilation. The mechanism of angioedema
was found to be related to increased bradykinin activity with
combined NEPi and ACEi (described below).
Angioedema is an uncommon complication of ACEi therapy
which is seen in 0.1–0.3% of treated patients and can occur at
any interval after starting these drugs [28]. It can very rarely
cause laryngeal oedema and asphyxiation leading to death [16].
ACE inhibitor-induced angioedema is thought to be mediated
by decreased bradykinin breakdown resulting in increased
bradykinin levels (Figure 2) [28, 29]. In an acute episode of an-
gioedema, bradykinin concentrations can rise >10-fold [28].
Given the low incidence of angioedema associated with
ACEi, it is thought that individuals are only affected if they
have an additional risk factor, such as smoking (due to
reduced NEP and dipeptidyl peptidase IV activity in smokers),
black race (due to ACE gene polymorphisms) or hereditary an-
gioedema (for example due to C1 inhibitor deficiency) [29,
30]. With ACE inhibition, bradykinin degradation becomes
dependent on secondary enzymes (including NEP) for its
breakdown and hence combined NEPi/ACEi had an additive
effect on bradykinin levels. Following the results of the
OCTAVE trial, the Food and Drug Administration review
board did not approve omapatrilat and it was withdrawn from
development by the manufacturer [16].
DUAL NEP/ARB INHIBIT ION
Whilst ACEi induce RAS blockade by inhibiting the conver-
sion of angiotensin I to angiotensin II, angiotensin II receptor
blockers (ARBs) elicit similar effects by blocking the activation
of angiotensin II Type 1 receptors by angiotensin II. However,
ARBs have minimal effect on bradykinin activity and, there-
fore, are much less likely to cause angioedema. This led to the
development of dual-acting angiotensin receptor neprilysin in-
hibitors (ARNi), which combine the beneficial effects of ARBs
and NEPi without excess risk of angioedema (Figure 3).
LCZ696 was the first ARNi to be developed. It combines two
drugs: an ARB moiety (valsartan) and an NEP inhibitor pro-
drug (AHU377) in a 1:1 molar complex. Oral administration
of LCZ696 delivers systemic exposure to the two separate moi-
eties. AHU377 has a relatively short half-life and undergoes
further rapid conversion by enzymatic cleavage of its ethyl
ester to form the active NEPi compound, LBQ657 [31, 32].
In studies of healthy volunteers, AHU377 reached peak
plasma concentrations in 0.5–1.1 h and the active moiety
LBQ657 in 1.8–3.5 h [32]. LCZ696 was associated with in-
creases in plasma cGMP, renin and angiotensin II levels. Sys-
temic exposure to valsartan following dosing with LCZ696
demonstrated bioequivalence [e.g. 400 mg LCZ696 (maximum
Table 1. VPIs produced and studied in humans
VPI Situation studied Year
MDL-100240 Healthy volunteers 2000
Sampatrilat Hypertension 1998–99
Fasidotril Hypertension 2000
Omapatrilat (BMS-186716) Hypertension, HF and CVD 1999–2004





















dose) is equivalent to 320 mg of valsartan] [32]. The drug was
well tolerated in these participants [32, 33].
NEPi IN HYPERTENSION
NEPi was originally studied using VPIs in a range of animal
models of hypertension including salt-sensitive hypertension,
stroke-prone spontaneous hypertensive rats and renovascular
hypertension.
In the OCTAVE trial involving 25 302 hypertensive patients
[27], compared with enalapril, at 8 weeks omapatrilat reduced
systolic BP (SBP) by 3.6 mmHg (95% CI 2.6–4.6; P<0.001)
and by 24 weeks fewer participants required adjunctive anti-
hypertensive therapies (19 versus 27%, P < 0.001) [27].
A trial of 1328 hypertensive patients compared increasing
doses of LCZ696 (100, 200 and 400 mg), valsartan (80, 160
and 320 mg), AHU377 (200 mg) or placebo [33]. The primary
end point was mean change from baseline in mean sitting dia-
stolic BP (DBP) between LCZ696 and valsartan during the 8-
week treatment period. At the end of 8 weeks, the three
LCZ696 doses had superior DBP lowering (mean reduction
2.17 mmHg; 95% CI 1.06–3.28; P < 0.0001) compared with the
appropriate comparator dose of valsartan [33]. Single-dose
pairwise comparisons showed that each dose of LCZ696 had
greater SBP and DBP lowering than its equivalent dose of val-
sartan, and that the proportional reduction in SBP and of DBP
increased with increasing LCZ696 dosage [results for mean
change in SBP and DBP for LCZ696 (LCZ) 400 mg versus val-
sartan (Val) 320 mg are shown in Figure 4].
Plasma ANP and cGMP levels increased significantly with
LCZ696. LCZ696 reduced albuminuria more than placebo, but
not more than the equivalent dose of valsartan [33]. However,
baseline albuminuria was low (geometric mean between 1.1
and 1.5 mg/mmol in all treatment groups). LCZ696 was well
tolerated and no cases of angioedema occurred [33].
A recent trial has demonstrated similar efficacy in Asian pa-
tients (from Japan, China, Korea, Taiwan and Thailand) with
hypertension, who are generally less responsive to isolated
RASi [34]. The Prospective comparison of Angiotensin Recep-
tor neprilysin inhibitor with Angiotensin receptor blocker
MEasuring arterial sTiffness in the eldERly (PARAMETER)
study is assessing the efficacy of LCZ696 versus olmesartan on
central aortic haemodynamics and aortic stiffness in 432 pa-
tients (aged >60 years) [35]. The results are expected in 2015.
NEPi IN HEART FAILURE
In early HF, NP levels increase to counteract salt and water re-
tention. Over time the effects of NPs are negated by up-regula-
tion of neurohormonal pathways, including RAS and the
sympathetic nervous system, which cause further salt and
water retention. Increasing levels of NPs with NEPi may help
counteract up-regulation of these pathogenic pathways, when
combined with RAS blockade.
The Omapatrilat Versus Enalapril Randomized Trial of
Utility in Reducing Events (OVERTURE) trial randomized
5770 patients with New York Heart Association (NYHA)
Classes II–IV HF to either omapatrilat or enalapril [36]. Non-
significantly fewer patients treated with omapatrilat died or
were hospitalized for HF compared with enalapril [914/2886
(32%) versus 973/2884 (34%); HR 0.94; 95% CI 0.86–1.03; P =
0.187] [36]. Angioedema was again more frequent with oma-
patrilat (0.8%) than enalapril (0.5%) but was less severe than
in other trials [36].
The Prospective comparison of ARNi with ARB on Man-
agement Of heart failUre with preserved ejectioN fracTion
(PARAMOUNT) trial randomized 301 patients with HF with
preserved ejection fraction (HFpEF) to maximum tolerated
daily doses of LCZ696 or valsartan [37]. The primary end
point was change in NT-proBNP (as a marker of LV wall
stress) from baseline to 12 weeks. NT-proBNP is a useful
marker to study as it is not degraded by NEP, so any changes
in NT-proBNP levels can still be used to assess disease sever-
ity in HF with NEPi [38]. In PARAMOUNT, greater reduc-
tions in NT-proBNP were seen with LCZ696 (ratio of change
from baseline to 12 weeks 0.77; 95% CI 0.64–0.92; P = 0.005),
in addition to improved NYHA class, BP and left atrial size.
The drug was well tolerated, and although one case of angio-
edema occurred, it did not require hospitalization [37].
F IGURE 3 : Mechanism of action of ARNi.





















The Prospective comparison of ARNi with ACEi to Deter-
mine Impact on Global Mortality and morbidity in Heart
Failure trial (PARADIGM-HF), the largest ever trial in HF
with reduced ejection fraction (NYHA Classes II–IV) rando-
mized 8436 patients to maximum daily tolerated doses of
LCZ696 or enalapril [31, 39]. The primary outcome was a
composite of time to first occurrence of either cardiovascular
death or hospitalization for HF. Mean BP (mmHg) at baseline
was 121/74 and LV ejection fraction 29% [39]. Mean serum
creatinine at baseline was 99 μmol/L [mean estimated GFR
(eGFR) 68 mL/min/1.73 m2] and 37% of participants had an
eGFR <60 mL/min/1.73 m2 at enrolment [39].
The trial was closed early on the recommendation of the
Data Monitoring Committee, having met the primary end point
with overwhelming efficacy in favour of LCZ696 [40]. The full
results of the trial are expected in the summer of 2014.
The Prospective comparison of ARni with Arb Global Out-
comes in heart failure with preserved ejection fraction
(PARAGON-HF) will soon start recruiting about 4300 patients
with HFpEF and compare LCZ696 with valsartan. The primary
outcome will be a composite of cardiovascular death and total
(first and recurrent) hospitalizations for HF [38].
NEPi IN CKD
The evidence for a potential role of NEPi in CKD comes from
the study of NEPi in animal models of renal disease and the
results of renal outcomes from trials in HF. However, no large-
scale human trials have been conducted with this class of
agents in a CKD cohort.
In an animal model of hypertension, long-term administra-
tion of omapatrilat led to dose-dependent reductions in BP
and proteinuria that halted progression of glomerulosclerosis,
tubulointerstitial fibrosis and renal injury [24]. In a 5/6 neph-
rectomy model, the anti-hypertensive and renoprotective
effects of the VPI AVE7688 were compared with enalapril.
Treatment was started once proteinuria and hypertension de-
veloped. AVE7688 greatly reduced proteinuria, glomerulo-
sclerosis and tubulointerstitial fibrosis on renal biopsy [23].
Similar findings have also been observed in models of diabetic
nephropathy [41]. AVE7688 increased renal synthesis of nitric
oxide and decreased synthesis of endothelin-1 with reduced
renal vasoconstriction and increased tubular ANP release [23].
In another 5/6 nephrectomy model, omapatrilat was adminis-
tered at various time points following surgery [25]. Micro-
puncture studies demonstrated that omapatrilat led to greater
reductions in SBP and capillary glomerular pressure [25]. The
study also demonstrated reduced proteinuria and greater pro-
tection from renal injury with reduced glomerulosclerosis and
delayed progression of renal disease with omapatrilat com-
pared with ACEi-alone, which is likely to result from the effect
on glomerular capillary pressure [25].
Candoxatrilat, an isolated NEPi, was compared with
placebo in 24 patients with normal, moderately or severely
reduced GFR in a cross-over study [42]. Compared with the
placebo infusion, plasma ANP and urinary cGMP rose signifi-
cantly after a 100-mg intravenous bolus of candoxatrilat. A
marked natriuresis and diuresis occurred in all groups without
changes in GFR or systemic BP [42].
In the Inhibition of Metallo Protease by Omapatrilat in a
Randomized Exercise and Symptoms Study of Heart Failure
(IMPRESS) trial (comparing omapatrilat with lisinopril), cre-
atinine levels were reported as being raised more frequently in
patients treated with lisinopril than omapatrilat (6.1 versus
1.8%, respectively; P = 0.009) [43]. Similarly, in the OVER-
TURE trial, worsening renal impairment occurred less fre-
quently with omapatrilat (6.8 versus 10.1% with enalapril),
despite including patients with moderate renal impairment
(eligibility required serum creatinine <221 μmol/L at baseline)
[36]. Over 36 weeks of follow-up of the PARAMOUNT trial
(comparing LCZ696 with valsartan), eGFR declined to a lesser
degree in the LCZ696 group (LCZ696, –1.6 mL/min/1.73 m²
versus valsartan, –5.2 mL/min/1.73 m²; P = 0.007) [37]. However,
albuminuria increased by 1 mg/mmol with LCZ696 compared
with no change with valsartan (P = 0.02), but was very low at
baseline [mean urine albumin:creatinine ratio (ACR) 2.0 mg/
mmol] [37]. The PARADIGM-HF protocol includes renal-
specific secondary end points: time to the composite of (i)
50% decline in eGFR relative to baseline, (ii) >30 mL/min/
1.73 m² decline in eGFR relative to baseline eGFR of <60 mL/
min/1.73 m² or (iii) progression to ESRD [31].
These studies highlight the potential advantages of combined
NEPi/RASi in slowing the progression of CKD. However, the
current data are indirect as they are based on animal models or
HF populations. The UK Heart And Renal Protection III (UK
HARP-III) trial (ISRCTN11958993) will compare LCZ696
against irbesartan in 360 patients with proteinuric CKD (urine
ACR >20 mg/mmol and eGFR ≥20 <60 mL/min/1.73 m2). The
trial will be the first test of an ARNi in a proteinuric population,
and will assess the short-term safety and efficacy of LCZ696 in
CKD with a primary outcome of the difference in change in
measured GFR from baseline to 6 months between the two arms.
CONCLUSION
NPs act as a potentially beneficial counter-regulatory system in
states of excess RAS activation such as seen in hypertension,
HF and CKD. In hypertension and HF, inhibition of neprilysin
with LCZ696 has been shown to provide substantial clinical
benefit. For patients with CKD, NEPi could be beneficial for
two reasons: first, it may reduce the risk of CVD; second, it
may retard the progression of CKD itself and delay the need
for renal replacement therapy. A large randomized trial of an
ARNi in a CKD population will be required to investigate this
potential, but—if positive—such a trial would have a substan-
tial impact on clinical practice.
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A B S T R A C T
Patients with chronic kidney disease are at increased risk of cardio-
vascular disease and this often manifests clinically like heart failure.
Conversely, patients with heart failure frequently have reduced
kidney function. The links between the kidneys and cardiovascular
system are being elucidated, with blood pressure being a key risk
factor. Patients with heart failure have benefitted from many trials
which have now established a strong evidence based on which to
base management. However, patients with advanced kidney dis-
ease have often been excluded from these trials. Nevertheless, there
is little evidence that the benefits of such treatments are modified
by the presence or absence of kidney disease, but more direct evi-
dence among patients with advanced kidney disease is required.
Neprilysin inhibition is the most recent treatment to be shown to
improve outcomes among patients with heart failure. The UK
HARP-III trial assessed whether neprilysin inhibition improved
kidney function in the short- to medium-term and its effects on
cardiovascular biomarkers. Although no effect (compared to irbe-
sartan control) was found on kidney function, allocation to nepri-
lysin inhibition (sacubitril/valsartan) did reduce cardiac bio-
markers more than irbesartan, suggesting that this treatment
might improve cardiovascular outcomes in this population. Larger
clinical outcomes trials are needed to test this hypothesis.
Keywords: blood pressure, cardiovascular, CKD, heart failure,
renin-angiotensin system
C K D A N D S T R U C T U R A L H E A R T D I S E A S E A R E
C L O S E L Y A S S O C I A T E D
Chronic kidney disease (CKD) and heart failure (HF) fre-
quently coexist and both are associated with high morbidity
and mortality [1, 2]. Numerous studies have shown that there
is an inverse association between kidney function and cardio-
vascular risk [3, 4]. Structural heart disease, which may
manifest clinically as HF, is a leading cause of cardiovascular
disease in CKD patients and its prevalence increases with de-
clining kidney function [2, 5]. A cross-sectional echocardio-
graphic observational study reported an increasing prevalence
of left ventricular hypertrophy (LVH) with decreasing esti-
mated glomerular filtration rate (eGFR) (from 32% among
patients with eGFR 60 mL/min/1.73 m2 to 75% among
patients with eGFR <30 mL/min/1.73 m2) [6, 7]. Studies using
cardiac magnetic resonance imaging with gadolinium en-
hancement have found that diffuse late gadolinium enhance-
ment is associated with the degree of LVH [8] and indicates
myocyte disarray and interstitial fibrosis histologically [9].
Although overt systolic dysfunction is not common (affecting
only 8% of patients in the above cross-sectional echocardio-
graphic study) and not clearly associated with kidney function
[7], more subtle disturbances in ventricular function (such as
reduced left ventricular deformation, early myocardial relaxa-
tion velocity or reduction in global longitudinal strain that
may contribute to diastolic dysfunction) are more common
and are present even in the early stages of CKD [10, 11].
These abnormalities provide the anatomical substrate for the
excess risk of symptomatic HF, arrhythmia and sudden car-
diac death observed among patients with advanced CKD.
Conversely, in large HF registries, 20–68% of patients with HF
have moderate to severe kidney disease [1]. The presence of
CKD is associated with poor prognosis in HF and can be used
to stratify the risk of patients with HF [6, 12, 13].
P A T H O P H Y S I O L O G Y O F H F I N C K D
The pathophysiological relationship between the heart and the
kidneys involves many different pathways. CKD may disturb
homoeostasis in ways that may be directly damaging to the car-
diovascular system [i.e. ‘direct’ risk factors such as high blood
pressure (BP) or vascular calcification] or the kidneys and
VC The Author(s) 2019. Published by Oxford University Press on behalf of ERA-EDTA.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which
















xford user on 21 O
ctober 2019
circulation may both be subject to ‘indirect’ risk factors (e.g. di-
abetes mellitus and smoking). In addition, HF may worsen
CKD by decreasing renal perfusion, causing renal venous con-
gestion and activation of the sympathetic nervous system and
renin–angiotensin–aldosterone system (RAS, which may in
turn cause inflammation and oxidative stress). Treatment for
HF in CKD can be divided into two broad types: (i) treatments
that intervene on pathophysiological links between CKD and
HF to prevent HF and (ii) treatments known to improve prog-
nosis in established HF among people without CKD.
T R E A T M E N T T O P R E V E N T H F I N C K D
CKD is commonly associated with high BP, due to salt and wa-
ter retention, activation of the sympathetic nervous and other
neurohormonal systems and accumulation of endogenous vas-
opressors [14]. Studies of living kidney donors suggest that re-
ducing GFR by 10 mL/min as a consequence of donor
nephrectomy leads to a 5 mmHg increase in systolic BP [15].
BP is positively associated with the risk of death from HF [16]
and randomized trials have demonstrated that this association
is causal [17]. Meta-analysis of all the major BP-lowering trials
has shown that a 10 mmHg reduction in systolic BP lowers the
risk of HF by 28% [95% confidence interval (CI) 22–33] [18].
Most classes of antihypertensive treatments have similar effects,
with the exception of calcium channel blockers (which may
have a smaller benefit) and diuretics (which may have a larger
benefit) [18]. A subgroup analysis within this meta-analysis
(which included 13 trials involving nearly 38 000 participants,
of whom 6000 had CKD) suggested that the effect of BP lower-
ing on HF was larger among patients without CKD [relative
risk (RR) 0.48 (95% CI 0.38–0.62)] than among patients with
CKD [RR 0.95 (95% CI 0.70–1.04); P for interaction <0.001]
[18]. Nevertheless, the benefits of lowering BP on other cardio-
vascular outcomes remain clear even among patients with
CKD.
Anaemia is a well-recognized complication of CKD and has
been proposed as a direct cause of HF in patients with CKD fol-
lowing observational and non-randomized interventional stud-
ies, suggesting that anaemia is associated with LVH and
correcting the anaemia reverses the LVH [19, 20]. However,
randomized trials have shown that full or partial correction of
anaemia with erythropoiesis-stimulating agents (ESAs) does
not reduce left ventricular mass nor the risk of HF and may
even increase the risk of other cardiovascular outcomes such as
stroke [21].
Reducing parathyroid hormone concentrations with calci-
mimetic therapy might reduce the risk of non-atherosclerotic
cardiovascular events (such as HF) among haemodialysis
patients [22, 23]. Such treatment also reduces fibroblast growth
factor 23 (FGF23; see below). Unfortunately, the randomized
data on other interventions that target CKD-specific mecha-
nisms of HF are much less robust. For example, although there
is evidence that hyperphosphataemia (i) can cause vascular
smooth muscle cells to adopt an osteoblastic phenotype and
cause vascular calcification (which in turn increases cardiac
afterload) [24] and (ii) is associated with LVH [25], no
sufficiently large trials of phosphate reduction have been con-
ducted to elucidate whether these associations are causal.
Although FGF23 has been found to induce LVH after direct in-
tracardiac injection in mice [26], the totality of the observa-
tional evidence does not suggest that FGF23 is a cause of
cardiovascular disease (and no trials of FGF23 reduction in
CKD exist) [27].
T R E A T M E N T T O I M P R O V E P R O G N O S I S I N
E S T A B L I S H E D H F I N T H E G E N E R A L
P O P U L A T I O N
The main objectives of HF therapy in CKD (as well as in non-
CKD) patients are to decrease the preload and afterload and to
reduce LVH, treat myocardial ischaemia and inhibit neurohu-
moral hyperactivity, especially the sympathetic nervous system
and RAS [28]. However, the optimum treatment of HF in
patients with CKD remains unclear, as there is little direct evi-
dence to support any recommendations. Most of the pivotal
randomized trials that guide the management of HF define
CKD as a baseline eGFR <60 mL/min/1.73 m2 but have ex-
cluded patients with more advanced stages of CKD (i.e. eGFR
<30 mL/min/1.73 m2).
Many pharmacological and device treatments are recom-
mended for HF with reduced ejection fraction (HFrEF) [29].
The mainstays of such treatment are angiotensin-converting
enzyme inhibitors (ACEis) and b-blockers. The largest trial of
ACEis in HFrEF was Studies of Left Ventricular Dysfunction
(SOLVD)-Treatment, which compared enalapril 10 mg twice
daily with placebo among 2569 patients with HFrEF and dem-
onstrated a 16% (95% CI 5–26) reduction in mortality (primary
outcome) [30]. This effect was similar in patients with and with-
out CKD [31]. Similarly, in the four large trials of b-blockers in
HFrEF, there was no good evidence that the benefits of b-
blocker therapy were modified by baseline kidney function. The
results of these trials (and their published effects by baseline
kidney function) are summarized in Table 1.
For patients with HFrEF [with a left ventricular ejection
fraction (LVEF) <35%] who remain symptomatic after opti-
mization of ACEi and b-blocker therapy, guidelines recom-
mend a mineralcorticoid receptor antagonist (MRA). This
recommendation follows two large trials (see Table 1). Again,
the effect of treatment on the primary outcome was not mod-
ified by baseline kidney function. However, these trials high-
light the importance of safety as a consideration in the
treatment of patients with CKD. Patients with CKD are at
higher risk of hyperkalaemia (due to the reduced ability of
their kidneys to excrete potassium), which is associated with
an increased risk of hospitalization and death [43]. The trials
had stringent monitoring of serum potassium and developed
criteria for reducing the dose or stopping the MRA, such that
there was no excess death due to hyperkalaemia in the trials.
The importance of such monitoring is highlighted by
population-based studies, which demonstrate increased rates
of hospitalization for hyperkalaemia since the publication of
these trials [44]. Device therapies [implantable cardioverter
defibrillators (ICDs) and cardiac resynchronization therapy
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(CRT)] also improve prognosis in selected patients with
HFrEF). A meta-analysis of the trials of ICDs has raised
the hypothesis that worse kidney function might attenu-
ate the benefit of these devices [45], but this is not the
case for CRT devices. Intravenous iron has been shown
to improve functional capacity among patients with
HFrEF and results of clinical outcomes trials are needed
[46]. Indeed, the PIVOTAL trial among haemodialysis
patients suggests that intravenous iron may reduce car-
diovascular morbidity in this population [47]. This find-
ing may alter the interpretation of the placebo-controlled
ESA trials in which participants allocated to placebo re-
ceived more iron.
However, as noted above, few patients with CKD have
HFrEF, whereas structural substrates for diastolic dysfunction
are common among patients with CKD. In contrast with
HFrEF, no treatment has yet demonstrated convincing benefit
(in terms of morbidity and mortality) in patients with HF with
moderately reduced EF (HFmrEF: LVEF 40–<50%) or HF
with preserved EF (HFpEF: LVEF 50%). The Treatment of
Preserved Cardiac Function Heart Failure with an Aldosterone
Antagonist trial tested spironolactone (15–45 mg daily) versus
placebo in 3445 patients with LVEF45% and observed a non-
significant 11% (95% CI 4–23) reduction in the primary out-
come of cardiovascular death, aborted cardiac arrest or hospi-
talization for HF [37]. There was again no modification of the
treatment effect by baseline kidney function. However, post hoc
analyses have suggested that patients recruited from certain
geographic regions had significantly worse adherence to
treatment (when measured biochemically), which may have
made the overall result a ‘false negative’ [48].
N E P R I L Y S I N I N H I B I T I O N
Neprilysin [also known as neutral endopeptidase (NEP)]
degrades natriuretic and other vasoactive peptides (including
bradykinin, substance P, endothelin and angiotensin II) and
therefore neprilysin inhibition (NEPi) enhances the activity of
the natriuretic peptide system leading to natriuresis, diuresis,
BP reduction and inhibition of RAS and the sympathetic ner-
vous system [49]. Isolated NEPi causes reflex activation of the
RAS, so development of NEPi has always been combined with
ACEi or ARB. The potential of NEPi in HFrEF was suggested in
the Omapatrilat versus Enalapril Randomized Trial of Utility in
Reducing Events trial, which compared omapatrilat (a com-
bined ACEi and NEPi) to enalapril in 5770 patients with HF
and found a non-significant 6% (95% CI 3–14) reduction in
the primary outcome of all-cause mortality or hospitalization
for HF [50]. However, development of omapatrilat was stopped
when the Omapatrilat Cardiovascular Treatment Assessment
Versus Enalapril trial (in 25 302 patients with hypertension)
found an excess risk of angioedema compared with enalapril
(2.17 versus 0.68%; P< 0.005) [51]. This was thought to be due
to excessive bradykinin concentrations (as both ACE and NEP
degrade bradykinin) and led to the development of a new class
of drug called an angiotensin receptor neprilysin inhibitor


































FIGURE 1: Effects of sacubitril/valsartan on vasoactive peptides.
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Sacubitril/valsartan is a first-in-class ARNI that is rapidly
metabolized after ingestion to the NEPi pro-drug sacubitril and
the ARB valsartan. Sacubitril/valsartan reduces BP more than
equivalent doses of valsartan alone [52]. The Prospective
Comparison of ARNI with ACEi to Determine Impact on
Global Mortality and Morbidity in Heart Failure
(PARADIGM-HF) trial randomized 8442 participants with
HFrEF to treatment with sacubitril/valsartan or enalapril and
was terminated earlier than planned based on the recommen-
dation by the Data Monitoring Committee after interim effi-
cacy analysis showed overwhelming evidence of benefit at a
median follow-up duration of 27 months. Compared with
those assigned to enalapril, participants assigned to sacubitril/
valsartan in PARADIGM-HF experienced a 20% (95% CI 13–
27) reduction in the primary composite endpoint of cardiovas-
cular death or HF hospitalization. This effect was again similar
among participants with and without CKD. Sacubitril/valsar-
tan is now recommended in the European Society of
Cardiology guidelines as a replacement for ACEi (or ARB) in
patients who have symptomatic HF with a reduced LVEF
35% and who remain symptomatic despite maximum-
tolerated evidence-based treatment [29, 40].
Sacubitril/valsartan has also been tested among patients with
HFpEF. The PARAMOUNT trial compared sacubitril/valsartan
with valsartan in 301 patients with change in NT-proBNP as
the primary outcome [53]. At 12 weeks, among participants
assigned sacubitril/valsartan, NT-proBNP was 23% (95% CI 8–
36) lower compared with participants assigned valsartan. The
PARAGON-HF trial has recruited 4822 participants with
HFpEF to compare sacubitril/valsartan with valsartan and is
scheduled to be completed in mid-2019 [54]. The primary out-
come is the composite of cardiovascular death and total (first
and recurrent) hospitalizations for HF.
In addition to its known benefits in HFrEF (and potential for
benefit in HFpEF), NEPi might also have beneficial effects on the
kidney. Experiments using 5/6 nephrectomy models suggested that
NEPi reduces proteinuria and histological markers of kidney dam-
age more than ACE inhibition alone [55, 56]. In addition, sacubi-
tril/valsartan appeared to slow the deterioration of kidney function
in the PARADIGM-HF [57] and PARAMOUNT trials [58].
However, it also modestly increased albuminuria in both trials (al-
though baseline levels were very low in these HF populations) [59].
The UK Heart and Renal Protection (HARP)-III trial was
designed to investigate the short- to medium-term effects of
sacubitril/valsartan 97/103 mg twice daily versus irbesartan
300 mg once daily on kidney function among patients with
established CKD [60]. Patients were eligible for the UK HARP-
III trial if either their eGFR was 20–<45 mL/min/1.73 m2 or
their eGFR was 45–<60 mL/min/1.73 m2 and the urine albu-
min:creatinine ratio was >20 mg/mmol. Other pre-specified
outcomes included albuminuria, BP and cardiac biomarkers. A
total of 414 participants were randomized and the average
eGFR was 35 mL/min/1.73 m2 and median urine albumin:crea-
tinine ratio was 54 mg/mmol. Only 4 and 13% reported HF and
coronary heart disease, respectively, at baseline.
The primary outcome of measured GFR at 12 months did
not differ between the two groups: the difference in means was
0.1 (standard error 0.7) mL/min/1.73 m2 [61]. Albuminuria
was not significantly reduced [9% (95% CI 1–18) among
those assigned sacubitril/valsartan] despite an additional 5.4/2.1
(both P< 0.001) mmHg reduction in BP. Despite the apparent
lack of an effect on short to medium-term kidney function, allo-
cation to sacubitril/valsartan did reduce both NT-proBNP and
troponin I compared with allocation to irbesartan. Study aver-
age concentations of NT-proBNP and troponin I were 18%
(95% CI 11–25) and 16% (95% CI 8–23) lower, respectively.
Although the effects on kidney function are not encouraging,
they do not exclude a benefit on long-term progression of CKD
(although any effect would not be large). However, the effects
on BP and cardiac biomarkers support the hypothesis that sacu-
bitril/valsartan might reduce the risk of cardiovascular events
(and in particular those related to HF) among patients with
CKD, irrespective of whether they have known cardiac disease.
The neutral effects on tolerability and safety outcomes in the
UK HARP-III trial would also support further investigation of
this hypothesis.
C O N C L U S I O N
The burden of HF among patients with CKD is considerable
and contributes significantly to the excess of cardiovascular
morbidity and mortality observed in this growing population.
The anatomical substrates of HF develop early in the progres-
sion of CKD and strategies to prevent it have not been rigor-
ously tested in the CKD population. Furthermore, trials among
patients with known HF have usually excluded patients with
moderate or advanced CKD, so the efficacy and—
importantly—the safety of these treatments in the CKD popula-
tion are uncertain. NEPi looks promising as a treatment that
could reduce the risk of HF safely among patients with CKD,
but clinical outcome trials are required. Newer treatments for
HF, such as sodium glucose co-transporter-2 inhibitors, are be-
ing tested in large trials in both HF and CKD populations [62–
64] and may be the first treatments that have proven efficacy
for HF among patients with a wide-spectrum of kidney disease.
Nevertheless, further trials of established and future interven-
tions are required that allow doctors to confidently reduce ex-
cess risk of cardiovascular disease in CKD.
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Appendix 13:  
Publication: observational epidemiology of blood pressure and vascular outcomes 
from the SHARP trial: 
Herrington W, Staplin N, Judge PK, Mafham M, Emberson J, Haynes R, Wheeler DC, 
Walker R, Tomson C, Agodoa L, Wiecek A, Lewington S, Reith CA, Landray MJ, 
Baigent C, SHARP Collaborative Group. Evidence for Reverse Causality in the 
Association Between Blood Pressure and Cardiovascular Risk in Patients with 
Chronic Kidney Disease. Hypertension. 2017;69(2):314-322. 
314
In apparently healthy adults, each 20 mm Hg increase in long-term average—usual—systolic blood pressure (SBP) 
or 10 mm Hg higher usual diastolic blood pressure (DBP) is 
associated with about a doubling in the risk of death from 
ischemic heart disease, stroke, or heart failure, with no thresh-
old level below which lower SBP is not associated with lower 
risk (at least down to 115/75 mm Hg).1 Meta-analyses of ran-
domized trials have demonstrated that lowering SBP reduces 
cardiovascular risk, confirming that the relationship between 
blood pressure (BP) and cardiovascular risk is one of the cause 
and effect.2,3
Chronic kidney disease (CKD) is a cause of hypertension 
and is associated with a high risk of cardiovascular disease.4 
Most patients with CKD die before reaching end-stage renal 
disease, and cardiovascular disease is the single largest cause 
of death among such patients.4 However, in contrast to studies 
in apparently healthy people, observational studies of people 
with CKD have not consistently yielded a positive association 
between BP and cardiovascular risk, and at low–normal BP, 
some studies have indicated an increased risk of cardiovascu-
lar disease.5–10 It has been suggested that this observation may 
be attributable to reverse causality, whereby long-standing 
Abstract—Among those with moderate-to-advanced chronic kidney disease, the relationship between blood pressure (BP) 
and cardiovascular disease seems U shaped but is loglinear in apparently healthy adults. The SHARP (Study of Heart 
and Renal Protection) randomized 9270 patients with chronic kidney disease to ezetimibe/simvastatin versus matching 
placebo and measured BP at each follow-up visit. Cox regression was used to assess the association between BP and 
risk of cardiovascular disease among (1) those with a self-reported history of cardiovascular disease and (2) those with 
no such history and, based on plasma troponin-I concentration, a low probability of subclinical cardiac disease. A total 
of 8666 participants had a valid baseline BP and troponin-I measurement, and 2188 had at least 1 cardiovascular event 
during follow-up. After adjustment for relevant confounders, the association between systolic BP and cardiovascular 
events was U shaped, but among participants without evidence of previous cardiovascular disease, there was a positive 
loglinear association throughout the range of values studied. Among those with the lowest probability of subclinical 
cardiac disease, each 10 mm Hg higher systolic BP corresponded to a 27% increased risk of cardiovascular disease (hazard 
ratio, 1.27; 95% confidence interval, 1.11–1.44). In contrast, the relationship between diastolic BP and cardiovascular 
risk remained U shaped irrespective of cardiovascular disease history or risk of subclinical disease. In conclusion, the lack 
of a clear association between systolic BP and cardiovascular risk in this population seems attributable to confounding, 
suggesting that more intensive systolic BP reduction may be beneficial in such patients.
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hypertension causes changes in cardiac structure and function 
which lower BP while also increasing cardiovascular risk.11,12
If such a mechanism is indeed responsible, then it may be 
hypothesized that a positive association between BP and car-
diovascular disease might be present among selected patients 
with CKD but without cardiac disease. Among patients with 
advanced CKD (ie, stages 4–5), at least 50% have echocar-
diographic evidence of abnormal cardiac structure,13,14 many 
without any obvious clinical manifestations.15 A potential 
surrogate measure of subclinical cardiac disease is provided 
by plasma troponin concentration, which correlates positively 
with left ventricular mass,16,17 correlates negatively with car-
diac function,18 and predicts development of heart failure 
in unselected populations19,20 and in people with CKD.21 
We hypothesized that there would be a trend toward a more 
strongly positive association between BP and cardiovascular 
events among those with the lowest baseline troponin-I con-
centrations (and hence the lowest risk of subclinical cardiac 
disease) in SHARP (Study of Heart and Renal Protection), 
a randomized trial comparing the combination of ezetimibe 
plus simvastatin versus placebo among 9270 patients with 
CKD.22
Methods
The trial methods and results have been published previously.22 
Patients aged 40 years or over were eligible to participate if they 
had at least 2 previous measurements of serum or plasma creatinine 
≥150 µmol/L (≥1.7 mg/dL) in men or ≥130 µmol/L (≥1.5 mg/dL) in 
women or were receiving maintenance dialysis. Individuals with a 
previous history of myocardial infarction or coronary revasculariza-
tion were excluded, but individuals with a history of angina, periph-
eral vascular disease, stroke, or diabetes mellitus were eligible. In the 
current analyses, baseline information refers to information that was 
recorded at randomization to ezetimibe/simvastatin versus placebo 
(or shortly before). Baseline information included sociodemographic 
characteristics (age, sex, ethnicity, and highest attained educational 
achievement), anthropometric measurements, self-reported medical 
history, current medication (including antihypertensive treatments, 
but not their doses), and lifestyle behaviors (alcohol consumption and 
smoking).
At each study clinic visit, using a suitably sized cuff attached to 
an automated digital sphygmomanometer (UA-767; A&D Company, 
Ltd, Tokyo, Japan), trained research nurses recorded a single BP read-
ing after the patient had been seated for 5 minutes.
Baseline samples of nonfasting blood and urine were collected 
and stored at or below −40°C before transfer to the accredited cen-
tral laboratory. Creatinine was measured using a kinetic alkaline pic-
rate method calibrated using material traceable to National Institute 
of Standards and Technology Standard Reference Material 914a, 
and estimated glomerular filtration rate (eGFR) calculated using 
the CKD-EPI study (CKD Epidemiology Collaboration) equation.23 
Troponin-I was measured by chemiluminescent immunoassay on an 
ACCESS2 analyzer using AccuTnI reagent and calibrator (Beckman 
Coulter Inc) and Liquichek Cardiac Markers Plus Controls (Bio-Rad 
Laboratories Ltd). Assay linearity and functional sensitivity was veri-
fied down to at least 0.01 ng/mL.
After randomization, participants were followed up at 2 and 
6 months and then at 6 monthly intervals for at least 4 years. 
Wherever possible, follow-up of patients who were unable to at-
tend clinics was conducted by telephone. At each follow-up, infor-
mation on all serious adverse events (including all hospitalizations) 
was sought, and further supporting documentation collected on 
events that might have represented a study outcome. These docu-
ments were sent for central adjudication by trained clinicians blind 
to randomized treatment allocation using prespecified criteria. 
For the purpose of the present analyses, we defined the following 
outcomes (1) atherosclerotic cardiovascular event (myocardial in-
farction, coronary death, unstable angina, ischemic heart failure, 
coronary revascularization, nonhemorrhagic stroke, transient isch-
emic attack, and peripheral arterial disease diagnosis, including 
noncoronary revascularization), (2) nonatherosclerotic cardiovas-
cular event (other cardiac death, nonischemic heart failure, ar-
rhythmia, valvular heart disease, and hemorrhagic stroke), and (3) 
any cardiovascular event (atherosclerotic and nonatherosclerotic 
cardiovascular events combined). Analyses of nonvascular mortal-
ity were included for comparison.
Statistical Analysis
The relationship between baseline troponin-I (≤0.01 ng/mL; >0.01 
but ≤0.03 ng/mL; and >0.03 ng/mL) and risk of cardiovascular 
events in the SHARP trial was assessed in Cox models adjusting for 
age, sex, ethnicity (white, black, Asian, and other), country, high-
est attained educational achievement (university, secondary school, 
vocational qualification, other, and unrecorded), smoking (never, for-
mer, and current), self-reported diabetes mellitus, body mass index, 




Figure 1. Association between troponin-I (TnI) and risk of 
cardiovascular events (A) overall and (B) by renal replacement 
therapy status. Analyses restricted to those without previous 
cardiovascular disease at baseline. The reference group in A is 
those with a TnI ≤0.01 ng/mL and in B, it is those not on dialysis 
at baseline with a TnI ≤0.01 ng/mL. Hazard ratios adjusted for 
age, sex, ethnicity, country, education, smoking status, previous 
diabetes mellitus, estimated glomerular filtration rate, renal 
replacement therapy status (A only), body mass index, treatment 
allocation, and blood pressure are quoted (above squares) with 
number of events (below squares). CI indicates confidence 
interval.
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  Baseline systolic, mm Hg 116 (10) 138 (5) 163 (14) <0.0001 127 (20) 138 (18) 152 (20) <0.0001
  Baseline diastolic, mm Hg 72 (10) 80 (10) 86 (12) <0.0001 65 (6) 79 (3) 93 (7) <0.0001
  Usual systolic, mm Hg 128 (4) 136 (2) 143 (4) <0.0001 132 (7) 136 (6) 140 (6) <0.0001
  Usual diastolic, mm Hg 74 (4) 77 (4) 80 (5) <0.0001 71 (3) 77 (1) 82 (2) <0.0001
  Any antihypertensive  
medication (%)‡
81 85 87 <0.0001 83 84 86 0.0038
Demographics
  Age at randomization, y 60 (12) 62 (12) 63 (12) <0.0001 66 (12) 62 (11) 58 (11) <0.0001
  Men (%) 57 63 68 <0.0001 59 62 67 <0.0001
Previous disease
  Evidence of previous 
cardiovascular disease, 
including Troponin-I >0.01 (%)‡
49 51 59 <0.0001 56 52 52 0.0031
  Self-reported history of 
cardiovascular disease (%)
15 16 17 0.03 18 15 14 0.0002
  Troponin-I, ng/mL (%)    <0.0001    0.05
   ≤0.01 58 56 47  52 55 54  
    >0.01, ≤0.03 33 34 39  37 35 35  
   >0.03, ≤0.1 7 8 11  9 9 9  
   >0.1 2 2 2  2 2 1  
  Diabetes mellitus (%)‡ 18 22 28 <0.0001 28 22 17 <0.0001
  Renal replacement therapy status (%)‡
   Not on dialysis 66 70 66 0.0008 59 70 72 <0.0001
   On dialysis 34 30 34 0.0007 41 30 27 <0.0001
Renal function
   CKD-EPI–estimated GFR, mL/min/1.73m2‡§
  Mean (SD) 26.2 (12.8) 25.3 (12.7) 24.5 (12.8) 0.0001 25.1 (13.0) 25.5 (12.7) 25.4 (12.9) 0.60
   ≥60 (%) 2 2 <1  1 2 1  
    ≥30, <60 (%) 33 30 31  30 32 31  
    ≥15, <30 (%) 46 44 43  45 43 45  
   <15 (%) 20 24 26  23 23 23  
  Urinary albumin:creatinine ratio, mg/g§
  Geometric mean  
(approximate SE)
94 (4) 173 (7) 302 (13) <0.0001 118 (5) 171 (7) 240 (10) <0.0001
   <30 (%) 27 19 12  26 18 15  
    ≥30, ≤300 (%) 44 38 32  38 42 34  
   >300 (%) 28 42 55  35 40 51  
Mean (SD); % or, geometric mean (SE) are shown. There were 9270 participants randomized, but 604 had missing values of SBP, DBP, or previous cardiovascular 
disease at baseline and are excluded from all analyses. Among the 5854 included participants not on dialysis at baseline, 32 (0.5%) and 471 (8%) had missing 
values for baseline estimated GFR and urine albumin:creatinine ratio, respectively. CKD-EPI indicates chronic kidney disease Epidemiology Collaboration; DBP, 
diastolic blood pressure; GFR, glomerular filtration rate; and SBP, systolic blood pressure.
*Test of heterogeneity between SBP categories.
†Test of heterogeneity between DBP categories.
‡Adjusted for age, sex, and ethnicity.
§For participants not on dialysis.
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Assumptions about the nature and direction of any causal or ef-
fect modifying relationships between baseline characteristics, BP, 
and outcomes were formulated a priori (see directed acyclic graph in 
Figure S1 in the online-only Data Supplement).24 SBP, DBP, and their 
difference (pulse pressure [PP]) as continuous variables were related 
to the risk of cardiovascular events using Cox proportional hazards 
regression adjusted for previous cardiovascular disease and the same 
variables used in the troponin model above. Because our a priori as-
sumption was that urinary albumin excretion is a mediating variable 
(ie, BP influences risk partly through its effects on urinary albumin 
excretion; Figure S1), we did not adjust for this variable in our pri-
mary model, although we did so in exploratory analyses. To adjust 
for variation in BP, we applied a standard correction for regression 
dilution bias.25 Such adjustment allows the relevance of long-term 
average—usual—BP to be quantified but does not affect the statis-
tical assessment of nonlinearity (Methods in the online-only Data 
Supplement; Figure S2).26 To test for nonlinear associations, models 
for the main analyses were additionally fitted with a quadratic BP 
function. A quadratic function was retained if the difference in twice 
the log-likelihood statistic between 2 nested models (one with and 
the other without the quadratic function) provided statistical evidence 
for improvement in model fit (ie, there was evidence of a nonlinear 
association), and the P value for this comparison referred to as the 
test for nonlinearity. Heterogeneity testing was performed to assess 
whether associations differed between participants by the selected 
subgroups (reported cardiovascular disease versus none; and among 
those with no such report, by troponin-I ≤0.01 versus >0.01 ng/mL) 
using an analogous method, including where relevant an additional 
interaction term between evidence of previous cardiovascular disease 
and a quadratic function of BP.
In figures displaying associations between BP and risk, for each 
subgroup, hazard ratios (HRs) were presented for 3 groups con-
taining an equal numbers of events with regression lines calculated 
from regression models using BP as a continuous variable, and these 
plotted against the mean BP value at the study midpoint accompa-
nied by a confidence interval (CI) derived only from the variance of 
the log risk in that 1 group. Hence, each HR, including that for the 
reference group, was associated with a group-specific CI that reflects 
the amount of data only in that 1 group, thereby allowing appropriate 
statistical comparisons to be made between any 2 groups.27
Values for the small number of missing eGFR and urinary 
albumin:creatinine ratio were imputed using multiple imputation, 
with the results across imputations combined using the methods of 
Rubin.28 In sensitivity analyses, the main analyses were repeated sep-
arately among participants on dialysis and those not, and among those 
above and below the study’s median age. The proportional hazard 
assumption was tested through examination of the time dependency 
of the Schoenfeld partial residuals. Analyses used SAS v9.3 (SAS 
Institute, Cary, NY) and R v2.14.2.
Results
A total of 604 participants were excluded from analyses due 
either to a missing baseline measurement of BP (n=25 indi-
viduals) or a missing troponin-I measurement (n=579). Of the 
remaining 8666 participants, 7278 reported no previous his-
tory of cardiovascular disease, and among this group, a higher 
baseline troponin-I was associated with male sex, higher SBP, 
older age, more diabetes mellitus, and worse renal function 
(with a larger proportion of such patients on dialysis; Table 
S1). After adjustment for these differences, increasing base-
line troponin-I was strongly associated with future cardiovas-
cular risk. Compared with those with a troponin-I ≤0.01 ng/
mL, those with troponin-I concentration >0.01 but ≤0.03 ng/
mL, and >0.03 ng/mL were at 61% (HR, 1.61; 95% CI, 1.43–
1.81) and 182% (HR, 2.82; 95% CI, 2.42–3.28) increased car-
diovascular risk, respectively (Figure 1A). A higher troponin-I 
was associated with increased cardiovascular risk in both dial-
ysis and nondialysis patients (Figure 1B).
Mean baseline SBP ranged from 116 mm Hg in the lowest 
third to 163 mm Hg in the highest third. Compared with those 
A B
C
Figure 2. Association between (A) systolic 
blood pressure (SBP), (B) diastolic blood 
pressure (DBP), and (C) pulse pressure 
(PP) and cardiovascular events overall. For 
each plot, categories of blood pressure 
contain similar numbers of events. Hazard 
ratios (HRs) adjusted for age, sex, ethnicity, 
country, education, smoking status, previous 
cardiovascular disease, previous diabetes 
mellitus, estimated glomerular filtration rate, 
renal replacement therapy status, body 
mass index, and treatment allocation are 
quoted (above squares) with numbers of 
events (below). Exclusions as per Table.*HRs 
per 10 mm Hg higher usual blood pressure 
are presented for associations where there 
is no evidence of deviation from a loglinear 
relationship. CI indicates confidence interval.
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in the lowest third, those in the highest third of SBP were more 
often male, were older, and reported more diabetes mellitus and 
previous cardiovascular disease, and nondialysis patients had 
lower eGFR (Table; Table S2). Mean baseline DBP ranged from 
65 mm Hg in the lowest third to 93 mm Hg in the highest third. 
Compared with those in the lowest third of DBP, and in contrast 
to the baseline characteristics by SBP, those with higher DBP 
were younger, less likely to report diabetes mellitus, previous 
cardiovascular disease, or to be on dialysis (Table; Table S2). 
The majority of participants were taking at least 1 antihyper-
tensive agent, ranging from 87% in the highest third of baseline 
SBP to 81% in the lowest third, and from 86% to 83% in the 
highest and lowest thirds of DBP, respectively (Table). Over 
one half of participants were taking at least 2 agents (Table S2).
Overall, 2188 participants experienced at least 1 cardio-
vascular event during a median of 4.9 years of follow-up 
(annual rate 6.7% per year).
SBP and Vascular Risk
The adjusted association between SBP and cardiovascular risk 
was U shaped (Figure 2A; test against the linearity assump-
tion [nonlinearity] P=0.003). But, among the 7278 partici-
pants who reported no previous history of cardiovascular 
disease, there was a positive loglinear association throughout 
the range studied (Figure 3A; nonlinearity P=0.35). After 
adjusting for regression dilution, each 10 mm Hg higher usual 
SBP was associated with 16% higher cardiovascular risk 
(HR, 1.16; 95% CI, 1.08–1.25). Among this group, there was 
a steeper association in those with lower baseline troponin 
(heterogeneity test P=0.01; Figure 3B). Among those at low-
est probability of cardiac disease (no self-reported previous 
cardiovascular disease and troponin-I ≤0.01 ng/mL), each 10 
mm Hg higher usual SBP was associated with 27% higher car-
diovascular risk (HR, 1.27; 95% CI, 1.11–1.44; Figure 3B). 
Additional adjustment for baseline urinary albumin:creatinine 
ratio had little impact on this estimated HR (1.23; 95% CI, 
1.08–1.40).
The magnitude of association between SBP and risk of 
cardiovascular events was similar for atherosclerotic (HR per 
10 mm Hg usual SBP, 1.25; 95% CI, 1.06–1.48) and nonath-
erosclerotic events (HR per 10 mm Hg usual SBP, 1.31; 95% 
CI, 1.09–1.57; Figure 4A and 4B). Within the low cardiac risk 
group, there were apparently similar loglinear associations 
between SBP and risk of cardiovascular events among those 
on dialysis and those not (HRs per 10 mm Hg higher SBP 
1.36; 95% CI, 1.16–1.60 and 1.18; 95% CI, 0.95–1.47; hetero-
geneity P=0.31; Figure 5A and 5B), although these analyses 
were constrained by the small numbers of events. Likewise, 
there were apparently similar loglinear associations in those 
younger than 62 and those aged 62 years or over (HRs, 1.37; 
95% CI, 1.14–1.66; 1.20; 95% CI, 1.00–1.43; heterogeneity 
P=0.31; Figure S3A and S3B).
DBP and Vascular Risk
Overall, there was a U-shaped association between DBP and 
cardiovascular events (nonlinearity P=0.0008; Figure 2B). 
This association was U shaped irrespective of a recorded his-






Figure 3. Association between systolic blood pressure (SBP), diastolic blood pressure (DBP), and pulse pressure (PP) and cardiovascular 
events, subdivided by self-reported history of previous cardiovascular disease (A, C, E) and by baseline troponin-I concentration (B, D, F).  
For each plot, categories of blood pressure contain similar numbers of events. Hazard ratios adjusted for age, sex, ethnicity, country, 
education, smoking status, previous diabetes mellitus, estimated glomerular filtration rate, renal replacement therapy status, body mass 
index, and treatment allocation are quoted (above squares) with numbers of events (below). Exclusions as per Table. *Hazard ratios per 
10 mm Hg higher usual SBP/PP are presented for associations where there is no evidence of deviation from a log–linear relationship. CI 
indicates confidence interval; CVD, self-reported history of cardiovascular disease; HR, hazard ratio; and TnI, troponin-I (ng/mL).
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disease in those without such a history (Figure 3C and 3D) 
and was similar for both atherosclerotic and nonatheroscle-
rotic events (Figure 4C and 4D), in dialysis and nondialysis 
(Figure 5C and 5D), and in younger and older patients (Figure 
S3C and S3D).
PP and Vascular Risk
Overall, the adjusted association between PP and risk of car-
diovascular events was loglinear (HR per 10 mm Hg higher 
usual PP, 1.12; 95% CI, 1.06–1.19; Figure 2C) but was U 
shaped among those with a history of cardiovascular disease 
and loglinear among those without such a history (HR per 10 
mm Hg higher usual PP, 1.18; 95% CI, 1.10–1.26; Figure 3E). 
Among those in the lowest category of troponin-I, each 10 
mm Hg higher usual PP was associated with 24% higher car-
diovascular risk (HR, 1.24; 95% CI, 1.11–1.39; Figure 3F), 
with similar relationships for atherosclerotic and nonathero-
sclerotic cardiovascular events considered separately (HRs 
per 10 mm Hg higher usual PP 1.21; 95% CI, 1.05–1.40 and 
1.33; 95% CI, 1.14–1.55, respectively; Figure 4E and 4F). 
Among those at lowest cardiac risk, the HRs per 10 mm Hg 
higher PP were similar among dialysis and nondialysis 
(Figure 5E and 5F) and in younger and older patients (Figure 
S3E and S3F).
BP and Nonvascular Mortality
There were 1196 nonvascular deaths during follow-up (3.2% 
per year). For SBP, there was some evidence for a U-shaped 
association (nonlinearity P=0.03) with nonvascular mortality, 
while the relationship with DBP appeared flat (nonlinearity 
P=0.24; HR per 5 mm Hg usual DBP, 1.00; 95% CI, 0.94–1.06) 
and was similar irrespective of baseline troponin-I (Figure S4).
Discussion
A U-shaped association between BP and cardiovascular 
risk has been observed in many studies of populations with 
advanced CKD,5–10 which is in contrast to the positive loglin-
ear relationships with ischemic heart disease, stroke, and heart 
failure mortality observed among apparently healthy adults.1 
The presence of a clear positive loglinear relationship between 
SBP (or PP) and cardiovascular events in patients with CKD at 
lowest risk of cardiac disease in SHARP suggests that reverse 
causality is a plausible explanation for previously observed 
U-shaped associations among patients with moderate-to-
advanced CKD.5–10 A loglinear relationship between SBP (or 
PP) and the risk of cardiovascular events was present in both 
dialysis and nondialysis patients, suggesting that BP remains 
a cause of cardiovascular disease irrespective of the severity 
of CKD, and hence that the absolute benefits of lowering BP 
among dialysis patients may be larger than those achievable at 
an earlier stage of CKD.
We did not observe a positive association between DBP 
and cardiovascular risk in this population. Myocardial per-
fusion is dependent on diastolic blood flow, and it has been 
suggested that a hypertrophied left ventricle (a key feature 
of structural heart disease in CKD13,14) may be more likely to 
become ischemic at low levels of DBP than a normal ven-
tricle.29 Because PP is the difference between SBP and DBP, 
our finding of a positive association between PP and cardio-







Figure 4. Association between (A) systolic blood pressure (SBP), (C) diastolic blood pressure (DBP), and (E) pulse pressure (PP) and 
atherosclerotic cardiovascular events and association between (B) SBP, (D) DBP, and (F) PP and nonatherosclerotic cardiovascular 
events, subdivided by evidence of previous cardiovascular disease. Conventions as per Figure 3. CI indicates confidence interval; CVD, 
self-reported history of cardiovascular disease; HR, hazard ratio; and TnI, troponin-I (ng/mL).
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the finding of a positive relationship for SBP and a U-shaped 
relationship for DBP. Vascular calcification is accelerated in 
CKD and reduces vascular recoil, thereby increasing SBP and 
decreasing DBP, that is, widening PP.30 If present, vascular 
calcification may increase the risk of cardiovascular events,31 
and the present analyses suggest that widening PP is associ-
ated with an increased risk of both atherosclerotic and nonath-
erosclerotic cardiovascular events in this population.
Among people with cardiovascular disease, randomized tri-
als have shown that lowering BP is effective at reducing car-
diovascular risk,32 in spite of U-shaped associations between 
BP and cardiovascular risk being commonly observed in such 
populations.29,33–35 Similarly, lowering BP is effective in elderly 
people,36,37 in whom some prospective studies have also failed 
to demonstrate a positive association between BP and cardio-
vascular disease.29 Comparatively few people with moderate-to-
advanced CKD have been studied in trials of antihypertensive 
therapy, but about 10 000 people with some evidence of reduced 
renal function were included in a recent meta-analysis.3 In this 
study, each 5 mm Hg SBP reduction lowered cardiovascular 
risk by 14%, with no heterogeneity in this risk reduction among 
different categories of eGFR.3 Similar benefits were observed 
in a separate meta-analysis of trials conducted among people on 
dialysis.38 However, although BP lowering seems beneficial in 
CKD, the optimum BP target for people with CKD is unknown, 
with current guideline recommendations ranging from <130/80 
to <150/90 mm Hg (Table S3).
There have been 2 negative trials of intensive versus stan-
dard BP lowering in CKD populations, but these lacked sta-
tistical power to detect the magnitude of benefit suggested by 
our analyses.39,40 The recent SPRINT (Systolic Blood Pressure 
Intervention Trial) demonstrated clearly that an SBP target 
of 120 mm Hg (achieved SBP 121 mm Hg) was superior to 
a target of 140 mm Hg (achieved SBP 136 mm Hg) in high-
risk adults.37 These data, taken together with the evidence of 
reverse causality in the present analysis in the SHARP trial, 
suggest that trials of lower BP targets in patients with CKD are 
indicated. Such trials would also be able to assess the poten-
tial hazards of lower BP targets—for example, in SPRINT, 
the more intensive BP regimen was associated with an excess 
of acute kidney injury (204/4678 [4.4%] versus 120/4683 
[2.6%]; P<0.001)37—and the somewhat uncertain benefits of 
intensive BP lowering on renal progression.
Our study has the advantage of a large sample size, 
detailed adjudication of cardiovascular events, and the ability 
to select those at lowest risk of cardiac disease through the 
measurement of baseline troponin (which has not been pos-
sible in previous studies5–10). The most important limitation is 
that, because no cardiac imaging was performed in SHARP, 
the correlation between troponin-I concentration and preexist-
ing structural cardiac disease cannot be formally confirmed 
in this cohort. Nevertheless, the use of troponin as a tool to 
identify those at higher risk of subclinical cardiac disease is 
supported by other studies,16–21,41 and baseline troponin-I was 
a strong independent predictor of cardiovascular risk in both 
dialysis and nondialysis patients in SHARP. A further limi-
tation is that SHARP only had a single measurement of BP 
at each clinic visit, which means short-term variability in BP 
was not assessed. This may also lead to underestimates of the 







Figure 5. Association between systolic blood pressure (SBP), diastolic blood pressure (DBP), and pulse pressure (PP) and cardiovascular 
events, subdivided by evidence of previous cardiovascular disease, for those not on dialysis (A, C, E) and on dialysis (B, D, F). Conventions 
as per Figure 3. CI indicates confidence interval; CVD, self-reported history of cardiovascular disease; HR, hazard ratio; and TnI, troponin-I 
(ng/mL).
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risk, particularly because BP exhibits marked day-to-day 
variability among people on dialysis in whom out-of-dialysis 
unit SBP readings give better estimates of average BP than 
measurements taken before or after dialysis.42,43 This limita-
tion was partially offset by our adjustment for regression 
dilution bias. Such adjustment is well established in studies 
of apparently healthy individuals25 because the magnitude of 
reductions in cardiovascular risk produced by antihyperten-
sive therapy in randomized trials2,3 is better predicted by asso-
ciations between usual, rather than a single measure of BP in 
observational studies.1–3
Perspectives
In summary, a U-shaped association between SBP and cardio-
vascular risk in CKD populations, as observed in many previ-
ous studies, may be attributable to reverse causality because of 
subclinical cardiac disease. When adjustment is made for such 
confounding, the observed association between SBP and both 
atherosclerotic and nonatherosclerotic cardiovascular risk is 
positive and loglinear, consistent with BP being a causal risk 
factor for both forms of cardiovascular disease in patients with 
CKD, as it is in other populations. Randomized trials of more 
intensive BP reduction should be a priority in patients with 
moderate-to-advanced CKD.
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What Is New?
•	Observational studies have found that the association between systolic 
blood pressure (SBP) and cardiovascular risk in chronic kidney disease 
(CKD) populations is U shaped. We have shown that the U-shaped rela-
tionship is confined to patients with a known history of cardiovascular 
disease or a high probability of such disease, whereas among patients 
with a lower probability of subclinical cardiovascular disease, there is a 
loglinear association between SBP (or pulse pressure) and both athero-
sclerotic and nonatherosclerotic cardiovascular diseases.
What Is Relevant?
•	These observations indicate that confounding by disease is the chief 
explanation for the apparent weakening and reversal of the association 
between SBP and cardiovascular risk in moderate-to-advanced CKD and 
suggest that such confounding masks a causal association between 
blood pressure and risk in patients with CKD with established cardio-
vascular disease. They support the need for randomized trials of more 
versus less intensive blood pressure reduction among patients with 
moderate-to-advanced CKD, including hemodialysis and peritoneal di-
alysis patients.
Summary
This study examined the association between blood pressure and 
risk of cardiovascular disease among CKD patients with (1) no self-
reported history of cardiovascular disease and (2) no such history 
and, based on plasma troponin-I concentration, a low probability of 
subclinical cardiac disease. Overall, the association between SBP 
and cardiovascular events was U shaped, but among participants 
without evidence of previous cardiovascular disease, there was 
a positive loglinear association with SBP throughout the range of 
values studied. Among those with the lowest probability of subclini-
cal cardiac disease, each 10 mm Hg higher SBP corresponded to a 
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Detailed Statistical Methods: Estimation of “Usual” Blood Pressure 
 
To ensure natural blood pressure variation and any measurement error was accounted for, a 
standard correction for such regression-dilution bias was made. (Supplemental Figure 2).1,2 
Each individual's usual systolic blood pressure, S, was estimated using linear regression 
models with blood pressure at the study midpoint (2.5 years) as the outcome and their 
baseline value, s, as the explanatory variable. It was found that there was a quadratic 
relationship between baseline and follow-up blood pressure, so usual systolic blood pressure 
was estimated using the formula: 
 
S=136.1 + 0.316(s - 138.9) - 0.001(s - 138.9)2. 
 
Similarly, each individual's usual diastolic blood pressure, D, was calculated from their 
baseline value, d, using the formula:  
 
D=77.1 + 0.396(d - 79.1) - 0.0018(d - 79.1)2. 
 
A similar method of estimation of usual blood pressure has been used previously in the 
analyses of the influence of blood pressure on vascular disease risk performed by the 
Prospective Studies Collaboration.3 
 
The following hazard ratios demonstrate how the use of a single blood pressure 
measurement or the average of 3 readings over 6 months would underestimate the 
relevance of SBP to vascular risk (among those who reported no previous history of 
cardiovascular disease and a baseline troponin-I ≤0.01ng/mL) compared to using the usual 
SBP described above. 
 
 Hazard ratio (95% CI) per 
10 mmHg higher SBP  
“Usual” SBP 1.29 (1.12-1.48)* 
Average SBP of 3 readings over 6 months 1.11 (1.05-1.16) 
Single baseline measure of SBP 1.08 (1.04-1.13) 
SBP = systolic blood pressure. *The hazard ratio quoted here for “usual” SBP differs to that 
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Table S1: Baseline characteristics and laboratory measurements subdivided by self-reported 




Self-reported history of previous cardiovascular disease 
and baseline troponin-I concentration 
No CVD  
CVD (n=1388) TnI≤0.01 (n=4070) TnI>0.01 (n=3208) 
Blood pressure    
Baseline systolic (mmHg) 136 (20) 142 (23) 141 (23) 
Baseline diastolic (mmHg) 80 (12) 79 (13) 76 (13) 
Usual systolic (mmHg) 135 (6) 136 (7) 136 (7) 
Usual diastolic (mmHg) 77 (5) 77 (5) 76 (5) 
Any antihypertensive medication 3405 (84%) 2722 (85%) 1194 (86%) 
Demographics    
Age at randomization (years) 59 (11) 64 (12) 67 (11) 
Men 2338 (57%) 2193 (68%) 910 (66%) 
Ethnicity    
White 2985 (73%) 2222 (69%) 1033 (74%) 
Black 73 (2%) 104 (3%) 41 (3%) 
Asian 908 (22%) 786 (25%) 272 (20%) 
Other 104 (3%) 96 (3%) 42 (3%) 
Education    
University 569 (14%) 307 (10%) 120 (9%) 
Secondary school 1377 (34%) 1016 (32%) 435 (31%) 
Vocational qualifications 891 (22%) 768 (24%) 366 (26%) 
Primary school or no formal education 651 (16%) 647 (20%) 287 (21%) 
Not specified 582 (14%) 470 (15%) 180 (13%) 
Current smoker 560 (14%) 387 (12%) 207 (15%) 
Prior disease    
Self-reported history of cardiovascular disease 0 (0%) 0 (0%) 1388 (100%) 
Troponin-I (ng/mL)    
0.01 4070 (100%) 0 (0%) 527 (38%) 
>0.01 to 0.03 0 (0%) 2502 (78%) 551 (40%) 
>0.03 to 0.1 0 (0%) 591 (18%) 186 (13%) 
>0.1 0 (0%) 115 (4%) 40 (3%) 
Diabetes 621 (15%) 859 (27%) 506 (36%) 
Renal status    
Not on dialysis 3187 (78%) 1731 (54%) 926 (67%) 
On dialysis 878 (22%) 1474 (46%) 460 (33%) 
Measurements    
CKD-EPI-estimated GFR (mL/min/1.73m²)*    
Mean (SD) 26.6 (13.3) 23.2 (12.0) 25.0 (13.0) 
60 49 (1%) 20 (1%) 13 (1%) 
30 to <60 1127 (28%) 426 (13%) 263 (19%) 
15 to <30 1375 (34%) 790 (25%) 411 (30%) 
<15 639 (16%) 498 (16%) 211 (15%) 
Urinary albumin:creatinine ratio (mg/g)*    
Median (IQR) 175 (37-645) 253 (60-896) 224 (49-979) 
<30 648 (16%) 267 (8%) 153 (11%) 
30 to 300 1159 (28%) 596 (19%) 293 (21%) 
>300 1152 (28%) 752 (23%) 363 (26%) 
Body-mass index (kg/m²) 27.0 (5.3) 27.0 (5.7) 27.4 (5.6) 
Treatment allocation    
Randomized to simvastatin plus ezetimibe 2014 (49%) 1630 (51%) 709 (51%) 
Mean (SD) or n (%) shown. GFR=glomerular filtration rate. CVD = self-reported history of cardiovascular disease. TnI=troponin-I. 
*For participants not on dialysis. Missing data as described in Table. 
Table S2: Additional baseline characteristics and laboratory measurements by tertiles of baseline blood pressure
















White 74% 74% 67% 74% 72% 69%
Black 3% 2% 3% 3% 3% 3%
Asian 20% 21% 26% 21% 23% 24%
Other 3% 3% 3% 3% 3% 4%
Education <0.0001 0.21
University 13% 12% 10% 11% 12% 12%
Secondary school 32% 34% 31% 32% 34% 33%
Vocational qualifications 22% 23% 24% 24% 22% 23%
Primary school or no formal education 17% 17% 21% 19% 18% 19%
Not specified 15% 14% 14% 15% 14% 14%
Current smoker 12% 13% 14% 0.07 13% 12% 14% 0.03
Medications
Number of antihypertensive medications <0.0001 0.01
None 19% 15% 13% 17% 17% 14%
One 26% 23% 23% 23% 25% 24%
Two 24% 26% 25% 23% 25% 28%
Three or more 30% 36% 38% 38% 33% 34%
Type of antihypertensive medication
ACE inhibitor or ARB 53% 55% 55% 0.12 54% 54% 55% 0.42
Beta blocker 36% 38% 39% 0.03 38% 36% 39% 0.03
Calcium channel blocker 32% 43% 48% <0.0001 40% 41% 43% 0.09
Diuretic 41% 41% 42% 0.50 45% 40% 39% <0.0001
Other co-medication
Antiplatelet therapy 23% 22% 23% 0.88 27% 21% 19% <0.0001
Oral anticoagulant therapy 4% 3% 3% 0.0021 4% 3% 3% 0.03
Erythropoiesis stimulating agent 26% 26% 29% 0.01 31% 26% 25% <0.0001
Sevelamer 9% 7% 8% 0.17 10% 7% 7% <0.0001
Table S2: Additional baseline characteristics and laboratory measurements by tertiles of baseline blood pressure















Body-mass index (kg/m²) 26.8 (5.4) 27.0 (5.4) 27.4 (5.4) 0.0005 27.1 (5.5) 27.2 (5.4) 27.0 (5.5) 0.44
Total cholesterol (mmol/L) 4.83 (1.15) 4.91 (1.15) 4.91 (1.16) 0.01 4.75 (1.17) 4.89 (1.14) 5.02 (1.16) <0.0001
LDL cholesterol (mmol/L) 2.74 (0.86) 2.80 (0.86) 2.78 (0.86) 0.02 2.68 (0.87) 2.78 (0.85) 2.86 (0.87) <0.0001
HDL cholesterol (mmol/L) 1.11 (0.33) 1.12 (0.33) 1.13 (0.33) 0.09 1.08 (0.33) 1.12 (0.33) 1.15 (0.33) <0.0001
Triglycerides (mmol/L) 2.31 (1.73) 2.34 (1.72) 2.32 (1.73) 0.81 2.38 (1.75) 2.28 (1.72) 2.31 (1.75) 0.07
Phosphate (mmol/L) 1.26 (0.44) 1.27 (0.44) 1.30 (0.44) 0.0008 1.30 (0.44) 1.26 (0.44) 1.27 (0.44) 0.0015
Hemoglobin (g/dL) 12.28 (1.66) 12.17 (1.65) 12.05 (1.64) <0.0001 11.90 (1.66) 12.24 (1.63) 12.37 (1.67) <0.0001
Albumin (g/L) 40.1 (3.7) 40.2 (3.7) 40.0 (3.7) 0.04 39.9 (3.8) 40.2 (3.7) 40.1 (3.8) 0.0028
C-reactive protein (mg/L) [geometric mean
(approximate SE)] 3.1 (0.1) 2.9 (0.1) 3.1 (0.1) 0.09 3.3 (0.1) 2.9 (0.1) 3.0 (0.1) 0.0004
Treatment allocation
Randomized to simvastatin plus ezetimibe 50% 51% 50% 0.52 50% 50% 50% 0.91
Mean (SD) or % shown, all characteristics adjusted for age, sex and ethnicity, with the exception of ethnicity. ACE=angiotensin-converting enzyme. ARB=angiotensin-II receptor blocker.
LDL=low-density lipoprotein. HDL=high-density lipoprotein. *P value for test of heterogeneity between SBP categories. †P value for test of heterogeneity beween DBP categories.
Table S3: Guideline recommendations for management of blood pressure in chronic kidney disease 
 
CKD = chronic kidney disease; eGFR = estimated glomerular filtration rate; mGFR = measured glomerular filtration rate. 
* 
CKD defined using the National Kidney Foundation Kidney Disease 
Outcomes Quality Initiative (NFK KDOQI) definition as; either kidney damage (defined as pathological abnormalities or markers of damage, including abnormalities in blood or urine tests or imaging 
studies) or GFR <60 mL/min/1.73m
2
 for ≥3 months; 
† 
Microalbuminuria defined as urine albumin excretion ≥30-300 mg/d;
 ‡ 
Macroalbuminuria defined as urine albumin excretion >300 mg/d; 
§ 
Albuminuria defined as >30 mg/g at any age and at any level of GFR; 
║ 
If ≥70 years, treatment should be individualised, taking into consideration factors such as frailty, comorbidities and 
albuminuria; 
¶ 
CKD includes those with reduced renal function and/or the detection of elevated urinary excretion of albumin, staged according to eGFR; 
# 
Overt proteinuria defined as >300 mg/d; 
** 
Albuminuria defined as albumin:creatinine ratio ≥30 mg/mmol; 
††
 Albuminuria defined as albumin:creatinine ratio ≥70 mg/mmol; 
‡‡
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Figure S1: Causal diagram showing the assumed associations between baseline blood












RRT=renal replacement therapy. *Age, sex, ethnicity, country, education, smoking status at
screening, previous cardiovascular disease, previous diabetes mellitus and body mass index.
Analyses were adjusted for the confounders enclosed by boxes in the causal diagram. No
adjustment was made for antihypertensive use as it was assumed that any effect on outcomes
was mediated through its effect on blood pressure.
†The a priori assumption was that urinary albumin excretion lies on the causal pathway between
blood pressure and vascular outcomes and is not a confounder, however sensitivity analyses
including adjustment for urinary albumin excretion were conducted.
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Figure S2: Mean blood pressure over follow−up in categories defined by
quintiles of baseline measurement
SBP=systolic blood pressure. DBP=diastolic blood pressure. Excludes 4161 participants with missing BP values at



































Less than 62 years old
Figure S3: Association between systolic blood pressure, diastolic blood pressure and pulse pressure and cardiovascular



































62 years or over
SBP=systolic blood pressure. DBP=diastolic blood pressure. PP=pulse pressure. CVD=self−reported history of cardiovascular disease. TnI=troponin−I (ng/mL). HR=hazard ratio. For each plot,
categories of blood pressure contain similar numbers of events. Hazard ratios adjusted for age, sex, ethnicity, country, education, smoking status, previous diabetes mellitus, renal replacement
therapy status, eGFR, body−mass index and treatment allocation are quoted (above squares) with numbers of events (below). Exclusions as per Table. *Hazard ratios per 10 mmHg higher usual
SBP/PP are presented for associations where there is no evidence of deviation from a log−linear relationship.
Test for difference in association by age


































































































Test for difference in association by age
























Figure S4: Association between (A) systolic blood pressure, (C) diastolic blood pressure and (E) pulse pressure and
non−vascular mortality overall, and association between (B) systolic blood pressure, (E) diastolic blood pressure and





































SBP=systolic blood pressure. DBP=diastolic blood pressure. PP=pulse pressure. HR=hazard ratio. CVD=self−reported history of cardiovascular disease. TnI=troponin−I (ng/mL). For each plot,
categories of blood pressure contain similar numbers of events. Hazard ratios adjusted for age, sex, ethnicity, country, education, smoking status, previous cardiovascular disease (panels A, C
and E only), previous diabetes mellitus, renal replacement therapy status, eGFR, body−mass index and treatment allocation are quoted (above squares) with numbers of events (below).
Exclusions as per Table. *Hazard ratios per 10 mmHg higher usual SBP/PP and †hazard ratios per 5 mmHg higher usual DBP are presented for associations where there is no evidence of










































































Test for difference in association: p=0.27
HR* (95% CI):
0.88 (0.76−1.03) 
HR* (95% CI):
0.97 (0.90−1.06)
CVD or
TnI > 0.01
No CVD and
TnI ≤ 0.01
F
